

(19) **DANMARK**



Patent- og
Varemærkestyrelsen

(10) **DK/EP 3122375 T3**

(12) **Oversættelse af
europæisk patentskrift**

-
- (51) Int.Cl.: **A 61 K 39/00 (2006.01)** **A 61 K 48/00 (2006.01)** **C 12 N 15/00 (2006.01)**
- (45) Oversættelsen bekendtgjort den: **2021-05-25**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2021-03-03**
- (86) Europæisk ansøgning nr.: **15768124.8**
- (86) Europæisk indleveringsdag: **2015-03-27**
- (87) Den europæiske ansøgnings publiceringsdag: **2017-02-01**
- (86) International ansøgning nr.: **US2015023161**
- (87) Internationalt publikationsnr.: **WO2015149016**
- (30) Prioritet: **2014-03-28 US 201461972176 P**
- (84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**
- (73) Patenthaver: **University of Washington through its Center for Commercialization, 4311 11th Avenue NE , Suite 500, Seattle, WA 98105, USA**
- (72) Opfinder: **DISIS, Mary, L., 17850 SE 192nd Drive, Renton, WA 98058, USA**
CECIL, Denise, 19224 15th Avenue NW, Shoreline, WA 98177, USA
SLOTA, Meredith, c/o University of Washington, 4545 Roosevelt Way NE, Suite 400, Seattle, WA 98105, USA
- (74) Fuldmægtig i Danmark: **Zacco Denmark A/S, Arne Jacobsens Allé 15, 2300 København S, Danmark**
- (54) Benævnelse: **Vacciner mod bryst- og ovariecancer**
- (56) Fremdragne publikationer:
WO-A1-00/50590
WO-A1-2008/073660
WO-A2-01/02556
US-A1- 2007 083 334
US-A1- 2009 170 767
US-A1- 2010 150 918
US-A1- 2011 008 347
US-A1- 2012 128 584
US-A1- 2012 135 033
US-A1- 2013 034 566
VIEHL CARSTEN T ET AL: "Generation of mammaglobin-A-specific CD4 T cells and identification of candidate CD4 epitopes for breast cancer vaccine strategies", BREAST CANCER RESEARCH AND TREATMENT, vol. 109, no. 2, May 2008 (2008-05), pages 305-314, XP002776779, ISSN: 0167-6806
SEON ET AL.: 'Endoglin-Targeted Cancer Therapy.' CURR DRUG DELIV vol. 8, no. 1, January 2011, pages 135 - 143, XP055096084
Meredith Slota ET AL: "Identification of Immunogenic Epitopes From Cancer Stem Cell Antigens for the Design

Fortsættes ...

of Multi-epitope TH1 CD4+T Cell Vaccines Against Breast Cancer" In: "SITC 27th Annual Meeting Poster Abstract Book", 26 October 2012 (2012-10-26), XP055251491, page 79,

DESCRIPTION

BACKGROUND

[0001] Cancer therapy has conventionally been accomplished by surgical reduction of a tumor mass and subsequent chemo- and/or radiotherapy. This strategy can reduce the tumor and, in less advanced stages, often results in complete remission. Unfortunately, the prognosis for more advanced tumors has changed little over the past 50 years and a significant proportion of cancer-related deaths are caused by subsequent metastases. New prophylactic and therapeutic treatments are needed to combat the increasing occurrence of cancer.

[0002] Over 1 million people are diagnosed with breast cancer each year worldwide and more than 400,000 people die of breast cancer each year. It is estimated that one in eight women will be diagnosed with breast cancer at some point in her lifetime. Preventing the development of breast cancer could have significant health and economic benefits for all individuals. Billions of dollars would be saved if people did not need to receive expensive cancer-related surveillance and therapeutic interventions. New approaches for the prevention and treatment of breast cancer are needed.

[0003] WO0102556A2 describes agents for the diagnosis, prognosis, and treatment of malignant disease.

[0004] WO0050590A1 describes a MDM interaction interacting protein and methods of use thereof.

[0005] WO2008073660A1 describes molecules and methods for the treatment and detection of cancer.

[0006] US2009170767A1 describes soluble endoglin compounds for the treatment and prevention of cancer.

[0007] US2012135033A1 describes multiple delivery systems for heterologous antigens.

[0008] US2007083334A1 describes methods and systems for annotating biomolecular sequences.

[0009] US2012128584A1 describes anti-CDH3 antibodies labelled with radioisotopes and uses thereof.

[0010] US2013034566A1 describes anti-CDH3 antibodies and uses thereof.

[0011] US2010150918A1 describes a cross-species specific binding domain.

[0012] US2011008347A1 describes cancer-related protein kinases.

[0013] Viehl et al., (Breast Cancer Res Treat (2008) 109: 305) describes the generation of mammaglobin-A-specific CD4 T cells and identification of candidate CD4 epitopes for breast cancer vaccine strategies.

[0014] Seon et al., (Curr Drug Deliv, (20110100), vol. 8, no. 1) describes endoglin-targeted cancer therapy.

SUMMARY

[0015] The present invention provides a composition comprising a nucleotide sequence encoding a fusion peptide of 5 epitopes, wherein the nucleotide sequence encodes an amino acid sequence that has at least 90% sequence identity to the amino acid sequence of SEQ ID NO 39, wherein the composition is effective to elicit an immune response in a subject.

[0016] The compositions described herein include, in some aspects, a composition comprising: a first plasmid comprising a first nucleotide sequence, the first nucleotide sequence encoding a first epitope of a first antigen expressed by cells associated with breast cancer; and a second nucleotide sequence, the second nucleotide sequence encoding a second epitope of a second antigen expressed by cells associated with breast cancer, wherein the first nucleotide sequence and the second nucleotide sequence are located in one or more plasmids.

[0017] In other aspects, the disclosure includes a composition comprising: a first plasmid comprising a first nucleotide sequence, the first nucleotide sequence encoding a first epitope of a first antigen, the first epitope is a portion of an HIF-1 α peptide, wherein the first nucleotide sequence is located in a plasmid. In yet other aspects, the disclosure includes a

composition comprising: a first plasmid comprising a first nucleotide sequence, the first nucleotide sequence encoding a first epitope of a first antigen; and a second nucleotide sequence, the second nucleotide sequence encoding a second epitope of a second antigen, wherein the first and the second epitopes are portions of an HIF-1 α peptide, wherein the first nucleotide sequence and the second nucleotide sequence are located in one or more plasmids.

[0018] The compositions described herein include, in some aspects, a composition comprising: a first plasmid comprising a first nucleotide sequence, the first nucleotide sequence encoding a first epitope of a first antigen, the first epitope is a portion of a peptide selected from: CD105, Yb-1, SOX-2, CDH3 or MDM2, wherein the first nucleotide sequence is located in a plasmid. In other aspects, the disclosure includes a composition comprising: a first plasmid comprising a first nucleotide sequence, the first nucleotide sequence encoding a first epitope of a first antigen; and a second nucleotide sequence, the second nucleotide sequence encoding a second epitope of a second antigen, wherein the first and the second epitopes are independently selected from: CD105, Yb-1, SOX-2, CDH3 or MDM2, wherein the first nucleotide sequence and the second nucleotide sequence are located in one or more plasmids.

[0019] The compositions described herein include, in some aspects, a composition comprising: a first plasmid comprising a first nucleotide sequence, the first nucleotide sequence encoding a first epitope of a first antigen, the first epitope is a portion of a peptide selected from: IGFBP-2, HER-2, IGF-1R, wherein the first nucleotide sequence is located in a plasmid. In yet some other aspects, the disclosure includes a composition comprising: a first plasmid comprising a first nucleotide sequence, the first nucleotide sequence encoding a first epitope of a first antigen; and a second nucleotide sequence, the second nucleotide sequence encoding a second epitope of a second antigen, wherein the first and the second epitopes are independently selected from: IGFBP-2, HER-2 or IGF-1R, wherein the first nucleotide sequence and the second nucleotide sequence are located in one or more plasmids.

[0020] The compositions described herein include, in some aspects, a composition comprising: a first epitope of a first antigen expressed by cells associated with breast cancer; and a second epitope of a second antigen expressed by cells associated with breast cancer.

[0021] In other aspects, the disclosure includes a composition comprising: at least a first epitope of a first antigen, the first epitope is a portion of a peptide from HIF-1 α . In yet other aspects, the disclosure includes, a composition comprising: at least a first epitope of a first antigen, at least a second epitope of a second antigen, the first and the second epitopes are from HIF-1 α .

[0022] In other aspects, the disclosure includes a composition comprising: at least a first epitope of a first antigen, the first epitope is a portion of a peptide selected from: CD105, Yb-1, SOX-2, CDH3 or MDM2. In yet other aspects, the disclosure includes a composition comprising: at least a first epitope of a first antigen, at least a second epitope of a second antigen, the first and the second epitopes are independently selected from: CD105, Yb-1, SOX-2, CDH3 or MDM2.

[0023] In some instances, the disclosure includes a composition that comprises an isolated and purified plasmid comprising a nucleotide sequence encoding a polypeptide, wherein the polypeptide comprises a plurality of epitopes; and an excipient. Sometimes, the plurality of epitopes comprises one or more epitopes comprising at least 90% sequence identity to an amino acid sequence selected from SEQ ID NOs: 1, 6, 8-10, 14-16, 20, 25-28, 32-34, 46-56, 60-62, 66-75, 82-85, and 87.

[0024] Sometimes, the isolated and purified plasmid may further comprise a first nucleotide sequence encoding a first epitope of a first antigen expressed by cells associated with breast cancer. In some cases, the composition further comprises a second nucleotide sequence encoding a second epitope of a second antigen expressed by cells associated with breast cancer. The first nucleotide sequence and the second nucleotide sequence may be located in one or more isolated and purified plasmids. The first epitope and the second epitope may independently be selected from a portion of an HIF-1 α peptide comprising at least 90% sequence identity to an amino acid sequence selected from SEQ ID NOs: 82-84. The first and the second epitopes may independently be selected from: CD105, Yb-1, SOX-2, CDH3 or MDM2, wherein the first nucleotide sequence and the second nucleotide sequence are located in one or more isolated and purified plasmids. The first and the second epitopes may independently be selected from: IGFBP-2, HER-2 or IGF-1R, wherein the first nucleotide sequence and the second nucleotide sequence are located in one or more isolated and purified plasmids. The first and the second nucleic acid sequences may be located on the first isolated and purified plasmid. The second nucleic acid sequence may be located on a second isolated and purified plasmid.

[0025] In some cases, the disclosure includes a composition that comprises a first epitope of a first antigen expressed by cells associated with breast cancer or ovarian cancer; and a second epitope of a second antigen expressed by cells associated with breast cancer or ovarian cancer; wherein the first and the second epitopes independently comprise at least 90% sequence identity to an amino acid sequence selected from SEQ ID NOs: 1, 6, 8-10, 14-16, 20, 25-28, 32-34, 46-56, 60-62, 66-75, 82-85, and 87.

[0026] In some instances, the disclosure includes a composition that comprises a plasmid comprising at least one nucleotide sequence encoding a polypeptide comprising at least 70% sequence identity to an epitope sequence selected from SEQ ID NOs: 54, 73, 85, and 87; and an excipient.

[0027] In some cases, the disclosure includes a composition that comprises a plasmid comprising four nucleotide sequences, wherein each of the four nucleotide sequences independently encodes a polypeptide comprising at least 70% sequence identity to an epitope sequence selected from SEQ ID NOs: 54, 73, 85, and 87; and an excipient.

[0028] Sometimes, the disclosure includes a composition that comprises a plasmid comprising a nucleotide sequence encoding a polypeptide comprising at least 80% sequence identity to SEQ ID NO: 89; and an excipient.

[0029] Sometimes, the disclosure includes a composition that comprises a polypeptide comprising at least 80% sequence identity to SEQ ID NO: 89.

[0030] In some instances, a method of administering one or more of the compositions described herein to a subject is disclosed herein. Sometimes, the subject may be in need thereof of one or more of the composition.

[0031] Sometimes, a method of preventing breast cancer or ovarian cancer in a subject is described herein, in which the method comprises administering a composition described herein to the subject. Sometimes, the cancer may be ovarian cancer. The cancer may be breast cancer. A method of preventing breast cancer in a subject is described herein, in which the method comprises administering a composition described herein to the subject.

[0032] Sometimes, a method of treating breast cancer or ovarian cancer in a subject is described herein, in which the method comprises administering a composition described herein to the subject. Sometimes, the cancer may be ovarian cancer. The cancer may be breast cancer. A method of treating breast cancer in a subject is described herein, in which the method comprises administering a composition described herein to the subject.

[0033] Sometimes, the administering further comprises delivery of at least one dose of a composition described herein to the subject. Sometimes, the administering further comprises delivery of a composition described herein to the subject by subcutaneous injection, intradermal injection, intramuscular injection, intravascular injection, topical application or inhalation.

[0034] In some instances, a method of producing an immune response in a subject having a breast cancer or ovarian cancer is described herein, which comprises administering to the subject a composition described herein.

[0035] The disclosure further includes an isolated and purified plasmid comprising at least one nucleotide sequence encoding a polypeptide comprising at least 90% sequence identity to an epitope sequence selected from SEQ ID NOs: 82-84. The isolated and purified plasmid may comprise a set of two or more nucleotide sequences in which each of the two or more nucleotide sequences independently encodes a polypeptide comprising at least 90% sequence identity selected from SEQ ID NOs: 82-84. The isolated and purified plasmid may comprise a set of two or more nucleotide sequences in which each of the two or more nucleotide sequences encodes a polypeptide comprising at least 90% sequence identity selected from SEQ ID NOs: 82-84; and each of the nucleotides are not identical within the set of two or more nucleotide sequences.

[0036] The disclosure may also include an isolated and purified plasmid comprising at least one nucleotide sequence encoding a polypeptide comprising at least 90% sequence identity to an epitope sequence selected from SEQ ID NOs: 1, 6, 8-10, 14-16, 20, 25-28, and 32-34. The isolated and purified plasmid may comprise a set of two or more nucleotide sequences in which each of the two or more nucleotide sequences independently encodes a polypeptide comprising at least 90% sequence identity selected from SEQ ID NOs: 1, 6, 8-10, 14-16, 20, 25-28, and 32-34. The isolated and purified plasmid may comprise a set of two or more nucleotide sequences in which each of the two or more nucleotide sequences encodes a polypeptide comprising at least 90% sequence identity selected from SEQ ID NOs: 1, 6, 8-10, 14-16, 20, 25-28, and 32-34; and each of the nucleotides are not identical within the set of two or more nucleotide sequences.

[0037] The disclosure may include an isolated and purified plasmid comprising at least one nucleotide sequence encoding a polypeptide comprising at least 90% sequence identity to an epitope sequence selected from SEQ ID NOs: 46-56, 60-62, or 66-75. The isolated and purified plasmid may comprise a set of two or more nucleotide sequences in which each of the two or more nucleotide sequences independently encodes a polypeptide comprising at least 90% sequence identity selected from SEQ ID NOs: 46-56, 60-62, or 66-75. The isolated and purified plasmid may comprise a set of two or more nucleotide sequences in which each of the two or more nucleotide sequences encodes a polypeptide comprising at least 90% sequence identity selected from SEQ ID NOs: 46-56, 60-62, or 66-75; and each of the nucleotides are not identical within the set of two

or more nucleotide sequences.

[0038] Sometimes, the disclosure may further include an isolated and purified plasmid comprising at least one nucleotide sequence encoding a polypeptide comprising at least 70% sequence identity to an epitope sequence selected from SEQ ID NOs: 54, 73, 85, and 87.

BRIEF DESCRIPTION OF THE DRAWINGS

[0039] The features of the disclosure are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present disclosure will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the disclosure are utilized, and the accompanying drawings of which:

FIG. 1 demonstrates that Th1 and Th2 epitopes vary in functional avidity.

FIG. 2 shows that Th2 abrogates the anti-tumor efficacy of Th1.

FIG. 3 depicts antigen specific IgG immunity.

FIG. 4 shows population based epitope screening.

FIG. 5 demonstrates characteristics of breast cancer subjects.

FIG. 6 depicts antigen specific IPN γ responses for stem cell/EMT proteins.

FIG. 7 depicts antigen specific IL-10 responses for stem cell/EMT proteins

FIG. 8 shows that peptides in extended sequences validate as native epitopes with the CD105 extended epitope (52aa) QNGTWPREVLLVLSVNS SVFLHL QALGI PLHLAYNSSLVTFQEPPGVNTTEL (SEQ ID NO: 1).

FIG. 9 shows extended epitopes for Yb-1 based on IPN γ /IL-10 activity ratio.

FIG. 10 shows magnitude and incidence of IFN γ predominant. IPN γ /IL-10 activity ratios for the CDH3 antigen.

FIG. 11 shows magnitude and incidence of IFN γ predominant. IPN γ /IL-10 activity ratios for the HIF1 α antigen.

FIG. 12 depicts a chart of simultaneous *in vivo* evaluation in mice.

FIG. 13 shows immunogenicity and efficacy of an exemplary Yb-1 plasmid based vaccine in mice.

FIG. 14 depicts a map, immunogenicity and exemplary sequence of a composition described herein. SEQ ID NO: 39 is illustrated in Fig. 14.

FIG. 15A shows an exemplary validation of peptide specific T-cells as native epitopes.

FIG. 15B depicts a timeline for a clinical trial using a composition described herein.

FIG. 15C depicts a study schema for Phase I of a clinical trial using a composition described herein.

FIG. 16 shows a Western blot analysis of HIF1 α expression in a single plasmid, pHIF1 α and a plasmid encoding 5 antigens, BCMA5.

FIG. 17 shows magnitude and incidence of IFN γ predominant. IPN γ /IL-10 activity ratios for the CD105 antigen.

FIG. 18 shows magnitude and incidence of IFN γ predominant. IPN γ /IL-10 activity ratios for the MDM-2 antigen.

FIG. 19 shows magnitude and incidence of IFN γ predominant. IPN γ /IL-10 activity ratios for the SOX-2 antigen.

FIG. 20 shows magnitude and incidence of IFN γ predominant. IPN γ /IL-10 activity ratios for the Yb-1 antigen.

FIG. 21 depicts HIF1 α peptide and plasmid vaccine immunogenicity and efficacy in mice.

FIG. 22 depicts CD105 peptide and plasmid vaccine immunogenicity and efficacy in mice.

FIG. 23 depicts CDH3 peptide and plasmid vaccine immunogenicity and efficacy in mice.

FIG. 24 depicts SOX2 peptide and plasmid vaccine immunogenicity and efficacy in mice.

FIG. 25 depicts MDM2 peptide and plasmid vaccine immunogenicity and efficacy in mice.

FIG. 26 shows the mass of mice three months after the last vaccine.

FIG. 27 shows the mass of mice ten days after the last vaccine.

FIG. 28 demonstrates that the IGFBP-2 C-terminus is enriched for epitopes that induce IL-10-secreting T-cells as compared to the N-terminus.

FIG. 29 shows that the N-terminus, but not C-terminus, IGFBP-2 vaccine both stimulates Type I immunity and inhibits tumor growth.

FIG. 30 shows that the IGFBP-2 vaccine-induced Th2 abrogates the anti-tumor effect of IGFBP-2-specific Th1.

FIG. 31 demonstrates that HER2 Th1 epitope based vaccines may increase survival which is associated with epitope spreading in advanced stage HER2+breast cancer patients.

FIG. 32 demonstrates that extended Th plasmid based vaccines are more effective than peptide based vaccine in generating tumor antigen specific Th1 immunity.

FIG. 33 shows that persistent HER2 ICD specific immunity >1 year after plasmid DNA based vaccination has ended.

FIG. 34 shows IGF-1R epitopes screened for IPN γ and IL-10 T-cell secretion by ELISPOT.

FIG. 35 demonstrates that multi-epitope IGF-1R vaccine inhibits the growth of implanted breast cancer.

FIG. 36 shows that multiantigen ployepitope vaccines prevent the development of breast cancer in mice.

FIG. 37 shows exemplary cytokine secretion patterns induced by HER2 vaccination.

FIG. 38 depicts a ROC analysis of stem cell/EMT antigens.

FIG. 39 depicts candidate proteins overexpressed in stem cells and/or EMT.

FIG. 40 illustrates a cartoon representation of a construct described herein.

FIG. 41 shows a Western Blot image of IGFBP-2, Survivin, HIF-1A, and IGF-IR expression.

FIG. 42A-Fig. 42D show the anti-tumor effects of a multi-antigen vaccine in ID8 ovarian cancer implant model. Mice were imaged on an IVIS Bioluminescent Imager three weeks after implant of ID8-Luc. Total flux (photons/second) were measure in Primary implant (Fig. 42A) and metastatic sites (Fig. 42B). Representative animals are shown as adjuvant alone (Fig. 42C), and Tri-antigen vaccinated (Fig. 42D).

Fig. 43A and Fig. 43B illustrate TH1 response as a function of protein sequences. Selective TH1 inducing sequences were identified in the N-terminus of HIF1 α and the C-terminus of survivin. The mean cSPW x incidence per peptide is shown by donor type. IFN- γ cSPW x incidence is shown on the positive y-axis for volunteer donors (n=20) (white) and cancer donors (n=20) (gray). IL-10 cSPW x incidence is shown on the negative y-axis for volunteer donors (solid black) and cancer donors (dotted black). Fig. 43A shows the TH1 response with respect to HIF-1A peptides. Fig. 43B shows the TH1 response with respect to Survivin peptides. Vertical lines show the selected sequences.

Fig. 44A-Fig. 44D show a comparison of IgG antibody expression levels in ovarian cancer patients and volunteers. IgG antibodies specific for candidate antigens are significantly elevated in ovarian cancer patients as compared to volunteer controls. IgG in ug/ml (y-axis) and experimental populations (X-axis) are shown for IGF-IR (Fig. 44A), IGFBP-2 (Fig. 44B), HIF-1A (Fig. 44C), and Survivin (Fig. 44D). Mean and 2 stand dev of volunteer controls (dotted line), *p<0.05; **p<0.01; ***p<0.001.

DETAILED DESCRIPTION

[0040] This disclosure provides compositions of breast cancer vaccines and ovarian cancer vaccines, often for the prevention or treatment of breast cancer or ovarian cancer. Also disclosed are methods of administering breast cancer vaccines or ovarian cancer vaccines to a subject. The compositions provided herein may be used in combination with the disclosed methods for the prevention or treatment of breast cancer or ovarian cancer.

[0041] In some cases, the compositions may include; sequences of nucleic acids encoding epitopes of breast cancer or ovarian cancer antigens, the epitopes may elicit an immunogenic response in a subject, plasmids containing the sequences described herein, an adjuvant, a pharmaceutical carrier and, inert chemicals suitable for use with pharmaceutical compositions. The breast cancer or ovarian cancer antigens may be at least one of any antigen expressed in a subject that may have or may develop breast cancer or ovarian cancer. Often, the breast cancer or ovarian cancer antigens are expressed by breast cancer cells, ovarian cancer cells, and/or tissues such as breast cancer or ovarian cancer stem cells (CSC)s. CSCs may exhibit capable of self renewal, unregulated growth, and drug resistance. In some cases, CSCs may express proteins (e.g., antigens) and for example, the level of expression of proteins (e.g., antigens) by CSCs may be upregulated (e.g., increased expression relative to a given amount) or downregulated (e.g., decreased expression relative to a given amount). In some cases, proteins that are upregulated by CSCs compared to normal tissue or cells may be involved in the development and/or progression of breast cancer or ovarian cancer. For example, the proteins may be identified and epitopes of antigens targeted using the compositions and methods described herein.

[0042] In some cases, one epitope of a breast cancer or ovarian cancer antigen may be used in the composition. In other cases, more than one epitope of a breast cancer or ovarian cancer antigen may be used in the composition. In other cases, more than two antigens, more than three, more than four, more than five, more than six, more than seven, more than eight, more than nine, more than ten, more than 15, more than 20, more than 25 or more than 30 breast cancer or ovarian cancer antigens may be used in the composition. In some cases, the antigens may be the same. In other cases, the antigens may be different. The compositions of breast cancer or ovarian cancer vaccines described herein could be formulated for the prevention of breast cancer or ovarian cancer. For example, prevention compositions may eliminate cells (e.g., CSCs such as breast CSCs or ovarian CSCs) with abnormal (e.g., upregulated) expression of proteins to prevent breast cancer or ovarian cancer.

[0043] In some cases, the epitope and/or epitopes may be on the same breast cancer or ovarian cancer antigen or the epitope and/or epitopes may be on a different breast cancer or ovarian cancer antigen. In some cases, one epitope on a breast cancer or ovarian cancer antigen may be used in the composition. In other cases, more than one epitope on a breast cancer or ovarian cancer antigen, more than two antigens, more than three, more than four, more than five, more than six, more than seven, more than eight, more than nine, more than ten, more than 15, more than 20, more than 25 or more than 30 epitope on a breast cancer or ovarian cancer antigens may be used in the composition.

[0044] The compositions and methods described herein may elicit an immune response in a subject. The immune response may be an immune response to the epitopes of the antigens in the composition (e.g., vaccine). Vaccines arm the immune system of the subject such that the immune system may detect and destroy that which contains the antigens of the vaccines in the subject. The compositions and methods described herein may elicit a Type 1 (Th1) immune response in the subject. Th1 immune responses may include secretion of inflammatory cytokines (e.g., IFN γ , TNF α) by a subset of immune cells (e.g., antigen specific T-cells). In some cases, the inflammatory cytokines activate another subtype of immune cells (e.g., cytotoxic T-cells) which may destroy that which contains the antigen in the subject.

[0045] Using the screening methods described herein to identify epitopes and binding peptides from tumor antigens, epitopes of a plurality of antigens may be screened for induction of a Th1 immune responses. For example, the methods of screening may identify epitopes from at least one tumor antigen that elicit a Th1 response (e.g., preferentially cause secretion of Th1 cytokines) to breast cancer or ovarian cancer antigens, including CSC (e.g., breast CSC, or ovarian CSC) antigens as described herein.

[0046] In some cases, the epitopes and/or antigens used in the compositions and methods described herein may be recognized by the immune system of a subject to elicit a Th1 immune response and release Type I cytokines. The Th1 response may be initiated by the interaction between the epitope and the T-cell, more specifically, the major histocompatibility complex (MHC) expressed by the T-cell. For example, high affinity binding of an epitope to an MHC receptor may stimulate a Th1 response. MHC receptors may be at least one of a plurality of types of MHC receptors. The MHC receptors engaged on a T-cell may vary across individuals in a population.

[0047] The compositions described herein may include additional components in addition to nucleic acids encoding epitopes of antigens. In some cases, the compositions may include at least one adjuvant. In some cases, the composition may include at least one pharmaceutical carrier. In some cases, the composition may include at least one inert chemical suitable for use with pharmaceutical compositions. In some cases, the composition may include at least one adjuvant and at least one pharmaceutical carrier. In some cases, the composition may include at least one adjuvant and at least one inert chemical suitable for use with pharmaceutical compositions. In some cases, the composition may include at least one inert chemical suitable for use with pharmaceutical compositions and a pharmaceutical carrier. In some cases, the composition may contain a plurality of adjuvants, a plurality of pharmaceutical carriers and a plurality of inert chemicals suitable for use with

pharmaceutical compositions.

[0048] In some cases, one adjuvant may be used in the composition. In other cases, more than one adjuvant, more than two adjuvants, more than three adjuvants, more than four adjuvants, more than five adjuvants, more than six adjuvants, more than seven adjuvants, more than eight adjuvants, more than nine adjuvants or more than ten adjuvants may be used in the composition. In some cases, one pharmaceutical carrier may be used in the composition. In other cases, more than one pharmaceutical carrier, more than two pharmaceutical carriers, more than three pharmaceutical carriers, more than four adjuvants, more than five pharmaceutical carriers, more than six pharmaceutical carriers, more than seven pharmaceutical carriers, more than eight pharmaceutical carriers, more than nine pharmaceutical carriers or more than ten pharmaceutical carriers may be used in the composition. In some cases, one chemical may be used in the composition. In other cases, more than one chemical, more than two chemicals, more than three chemicals, more than four chemicals, more than five chemicals, more than six chemicals, more than seven chemicals, more than eight chemicals, more than nine chemicals or more than ten chemicals may be used in the composition.

[0049] The disclosure further describes methods administering can breast cancer or ovarian cancer vaccines to a subject. In some cases, the methods may include constructing a plasmid based vaccine that targets those antigens and determining whether administration of the vaccine is safe, immunogenic, and effective to prevent the development of breast cancer. For example, the composition may be a multiantigen Th1 polyepitope plasmid based vaccine. In some cases, the method may include conducting at least one clinical trial to determine the safety and immunogenicity of the plasmid based vaccine in subjects with breast cancer or ovarian cancer. For example, antigens may be expressed by or associated with CSCs (e.g., breast CSCs or ovarian CSCs) and/or the transition of a cell from an epithelial cell to a mesenchymal cell (EMT). In some cases, epitopes of the compositions may be derived from antigens wherein the epitopes may elicit a Th1 immune response in the subject. For example, the Th1 immune response may include immune cells, often CD4+ T-cells. In some cases, the composition may be a nucleic acid (e.g., plasmid based vaccine) that may include nucleic acids encoding more than one antigen or more than one epitope of an antigen. In some cases, the methods may be used to determine if the compositions described herein prevent the development of breast cancer or ovarian cancer in a plurality of organism, for example, in models of cancer (e.g., breast cancer or ovarian cancer) using genetically similar rodents (e.g., mice), using genetically diverse rodents (e.g., mice), and in subjects which may or may not have breast cancer or ovarian cancer. In some instances, the cancer may be a breast cancer. In some cases, breast cancer may be triple negative breast cancer (TNBC).

Identification of Antigens

[0050] The compositions and methods described herein include the identification and engineering of breast cancer or ovarian cancer antigens in a pharmaceutical composition (e.g., a vaccine). While any techniques known to one of ordinary skill in the art may be used to identify antigens expressed by a subject with breast cancer or ovarian cancer, in an exemplary case, suitable antigens may be identified using the methods described herein. In some cases, the methods may include by screening sera from subjects. In some cases, the screening may be antibody screening. For example, the antibodies screened may be IgG antibodies. In some cases, the sera may be from a subject with breast cancer or ovarian cancer. In other cases, the sera may be from a subject that does not have breast cancer or ovarian cancer.

[0051] Cancer antigens, such as for example breast cancer antigens or ovarian cancer antigens, may be a portion of a protein, a portion of a peptide or a portion of a polyamino acid. In some cases, the portion may be a percentage of a protein, a percentage of a peptide or a percentage of a polyamino acid. In some cases, the percentage may be less than 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of a protein, a peptide or a polyamino acid. In some cases, the portion may be located at the C terminus of a protein, a peptide or a polyamino acid. In other cases, the portion may be located near the C terminus of a protein, a peptide or a polyamino acid. For example, near the C terminus may be within 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50% of the length of the total protein, peptide or polyamino acid from the median. In some cases, the portion may be located at the N terminus of a protein, a peptide or a polyamino acid. In other cases, the portion may be located near the N terminus of a protein, a peptide or a polyamino acid. For example, near the N terminus may be within 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50% of the length of the total protein, peptide or polyamino acid from the median. In some cases, the portion may be located near the middle of a protein, a peptide or a polyamino acid. In other cases, the portion may be located near the middle of a protein, a peptide or a polyamino acid. For example, near the middle may be within 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50% of the length of the total protein, peptide or polyamino acid from the termini.

[0052] At least one antigen may identified and screened for suitability as an antigen in a composition described herein (e.g., a vaccine). In some cases, one antigen may be identified and screened. In other cases, more than one antigen may be identified and screened, more than two antigens may be identified and screened , more than three antigens may be identified and

screened, more than four antigens may be identified and screened, more than five antigens may be identified and screened, more than six antigens may be identified and screened, more than seven antigens may be identified and screened, more than eight antigens may be identified and screened, more than nine antigens may be identified and screened, more than ten antigens may be identified and screened, more than 11 antigens may be identified and screened, more than 12 antigens may be identified and screened, more than 13 antigens may be identified and screened, more than 14 antigens may be identified and screened, more than 15 antigens may be identified and screened, more than 20 antigens may be identified and screened, more than 25 antigens may be identified and screened, more than 30 antigens may be identified and screened, more than 35 antigens may be identified and screened, more than 40 antigens may be identified and screened, more than 45 antigens may be identified and screened or more than 50 antigens may be identified and screened for suitability in a vaccine. In an exemplary case, five antigens may be identified and screened for suitability in a vaccine.

[0053] The antigens screened for suitability in a vaccine may be derived from any protein detected in the sera from a subject with breast cancer or ovarian cancer using the screening techniques known to one of ordinary skill in the art. In some cases, the screening may often be antibody screening. While the proteins may be any protein detected in the sera from a subject with breast cancer or ovarian cancer, in an exemplary case, the proteins from which antigens may be derived may be classified as stem cell proteins and/or EMT proteins. For example, in breast cancer stem cell/EMT proteins may include SOX2, YB1, CD105, MDM2, CDH3+/- and HIF1 α . Often, the antigens may be immunogenic in both breast cancer subjects and subjects without breast cancer.

Mapping Epitopes of Antigens

[0054] The compositions and disclosed methods include mapping of at least one epitope within antigens, such that the epitopes result in a Th1 immune response when administered to a subject. In some cases, the epitope may be administered as a breast cancer vaccine or ovarian cancer vaccine. While any technique known to one of ordinary skill in the art may be used to identify epitopes which may elicit a Th1 immune response by a subject, the methods described herein may be preferably used. In some cases, the epitope may be a portion of an antigen (e.g., identified above). For example, the epitope may be a peptide of an antigenic protein and/or a portion of an antigenic protein.

[0055] In some cases, the epitopes may be human leukocyte antigen (HLA) class I epitopes derived from breast cancer or ovarian cancer antigens. For example, HLA class I epitopes may include epitopes which bind to HLA-A, -B, and -C molecules. In some cases, the epitopes may be class II epitopes derived from breast cancer or ovarian cancer antigens for cancer vaccine (e.g., breast cancer or ovarian cancer) development. For example, HLA class II epitopes may include epitopes which bind to HLA-DP, -DM, -DOA, -DOB, -DQ and -DR molecules. In some cases, in addition to the methods described herein, epitopes may be mapped using the steps of, (1) determining if the epitopes bind MHC (e.g., with high affinity) by at least one HLA allele (e.g., HLA-DR, , i.e., are universal epitopes), (2) determining if the epitopes stimulate IPN γ rather than IL-10 secretion (e.g., from antigen specific T-cells), and (3) determining whether T-cells may recognize peptides (e.g., epitopes) processed by antigen presenting cells (APCs), i.e., are native epitopes. In some cases, T-cell lines may be used. For example, T-cell lines may be epitope-derived T-cell lines. In some cases, the T-cell may be an exogenous T-cell engineered to express a Chimeric Antigen Receptor construct that binds the epitope with high selectivity and avidity. In some cases, the epitopes may be derived from proteins (e.g., recombinant proteins). In other cases, the proteins may be native proteins. In some cases, the proteins may be processed endogenously. In other cases, the proteins may be processed exogenously. In some cases, the proteins may be processed endogenously by autologous APCs. In other cases, the proteins may be processed exogenously by autologous APCs.

[0056] In all cases, the peptides are epitopes mapped from antigens and may be identified using the methods described herein for the selection of peptide epitopes. In some cases, the epitopes may be derived from human proteins that may be used directly in a peptide based vaccine. In other cases, the epitopes may be derived from human proteins and the encoding nucleic acid sequences may be incorporated into a nucleic acid construct designed to induce expression of the epitope in the subject following administration. For example, the nucleic acid construct may allow for the immune response to at least one epitope to be entrained, amplified, attenuated, suppressed, or eliminated to specific sets of self-proteins. In some cases, the peptide or the nucleic acid construct may be optimized into a protein or plasmid-based vaccination to induce, amplify or entrain a Th1 immune response. In some cases, the epitopes may be extended Th1 epitopes. In other cases, the peptide or the nucleic acid construct may be optimized into a protein or plasmid-based vaccination to suppress, attenuate or eliminate a pathological response, in a subject (e.g., human or animal) in need thereof.

[0057] In some cases, the peptides are located within portions of a protein, peptide or polyamino acid such that the protein, peptide or polyamino acid stimulates secretion of IFN γ . In some cases, the peptides are located within portions of a protein,

peptide or polyamino acid such that the protein, peptide or polyamino acid that inhibits secretion of IFN γ . In some cases, the peptides are located within portions of a protein, peptide or polyamino acid such that the protein, peptide or polyamino acid stimulates secretion of IL-10. In some cases, the peptides are located within portions of a protein, peptide or polyamino acid such that the protein, peptide or polyamino acid that inhibits secretion of IL-10. In some cases, the peptide may stimulate secretion of IFN γ and inhibits secretion of IL-10. In other cases, the peptide may stimulate secretion of IL-10 and inhibits secretion of IFN γ . In some cases, the peptide may stimulate secretion of IFN γ and stimulate secretion of IL-10. In other cases, the peptide may inhibit secretion of IL-10 and inhibits secretion of IFN γ .

[0058] In some cases, the amino acids comprising the peptide may be tuned such that the desired effect of the peptide on IFN γ secretion and/or the desired effect of the peptide on IL-10 secretion may be achieved. For example, a peptide which stimulates secretion of both IFN γ and IL-10 may be tuned such that the length of the peptide is shortened to eliminate amino acids which stimulate IL-10 secretion such that the peptide only stimulates secretion of IFN γ .

[0059] In some cases, identified epitopes may be included in vaccine compositions of extended epitope vaccines. In some cases, extended epitopes may be 40-80-mer peptides. In an exemplary case, either the nucleic acid sequences or the peptide sequences are juxtaposed for construction of extended epitope sequences. Juxtaposition (e.g., within 10 amino acids of each other) of selected peptides within the parent protein may allow for the construction of in-tandem extended epitopes that may contain tolerizing and/or suppressive epitopes. For example, the in-tandem extended epitopes may contain short intervening, <10 amino acid sequences. Any of these peptides and/or extended epitopes (embodied either as the peptide itself, or as the corresponding nucleic acid construct) singularly, or in any combination, may be optimized into a protein or plasmid-based vaccination that will specifically induce, amplify or entrain a protective immune response, or alternatively, will suppress, attenuate or eliminate a pathological one, in a subject (human or animal) in need thereof.

[0060] In some cases, the epitopes may be a length of amino acids. In some cases, the epitopes may be less than five amino acids, less than 10 amino acids, less than 15 amino acids, less than 20 amino acids, less than 25 amino acids, less than 30 amino acids, less than 35 amino acids, less than 40 amino acids, less than 45 amino acids, less than 50 amino acids, less than 55 amino acids, less than 60 amino acids, less than 70 amino acids, less than 75 amino acids, less than 80 amino acids, less than 85 amino acids, less than 90 amino acids, less than 95 amino acids, less than 100 amino acids, less than 110 amino acids, less than 120 amino acids, less than 130 amino acids, less than 140 amino acids, less than 150 amino acids, less than 160 amino acids, less than 170 amino acids, less than 180 amino acids, less than 190 amino acids, less than 200 amino acids, less than 210 amino acids, less than 220 amino acids, less than 230 amino acids, less than 240 amino acids, less than 250 amino acids, less than 260 amino acids, less than 270 amino acids, less than 280 amino acids, less than 290 amino acids, less than 300 amino acids, less than 350 amino acids, less than 400 amino acids, less than 450 amino acids or less than 500 amino acids.

[0061] In some instances, the disclosure provides a composition comprising an isolated and purified plasmid comprising a nucleotide sequence encoding a polypeptide, wherein the polypeptide comprises a plurality of epitopes; and an excipient. In some instances, the plurality of epitopes comprises one or more epitopes comprising at least 90% sequence identity to an amino acid sequence selected from SEQ ID NOs: 1, 6, 8-10, 14-16, 20, 25-28, 32-34, 46-56, 60-62, 66-75, 82-85, and 87. In some cases, the plurality of epitopes comprises one or more epitopes comprising at least 90% sequence identity to an amino acid sequence selected from SEQ ID NOs: 82-84. In some cases, the plurality of epitopes comprises one or more epitopes comprising at least 90% sequence identity to an amino acid sequence selected from SEQ ID NOs: 1, 6, 8-10, 14-16, 20, 25-28, or 32-34. In some cases, the plurality of epitopes comprises one or more epitopes comprising at least 90% sequence identity to an amino acid sequence selected from SEQ ID NOs: 46-56, 60-62, or 66-75. In some cases, the plurality of epitopes comprises one or more epitopes comprising at least 90% sequence identity to an amino acid sequence selected from SEQ ID NOs: 54, 73, 85, and 87. In some cases, the plurality of epitopes comprises one or more epitopes selected from SEQ ID NOs: 1, 6, 8-10, 14-16, 20, 25-28, 32-34, 46-56, 60-62, 66-75, 82-85, and 87.

[0062] In some cases, the plurality of epitopes is a plurality of contiguous epitopes. In some cases, the contiguous epitopes further comprise a linker between one or more of the epitope sequences. In some cases, the amino acid sequences of the first and the second epitopes are separated by a sequence of linker amino acids. In some cases, the amino acid sequence of the first epitope is adjacent to the amino acid sequence of the second epitope.

[0063] In some cases, the composition further comprises an additional isolated and purified plasmid comprising an additional nucleotide sequence encoding an additional polypeptide, wherein the additional polypeptide comprises a plurality of epitopes comprising one or more epitopes comprising at least 90% sequence identity to an amino acid sequence selected from SEQ ID NOs: 1, 6, 8-10, 14-16, 20, 25-28, 32-34, 46-56, 60-62, 66-75, 82-85, and 87. Sometimes, the composition further comprises an additional isolated and purified plasmid comprising an additional nucleotide sequence encoding an additional polypeptide, wherein the additional polypeptide comprises a plurality of epitopes selected from SEQ ID NOs: 1, 6, 8-10, 14-16, 20, 25-28,

32-34, 46-56, 60-62, 66-75, 82-85, and 87. In some cases, the sequences of the polypeptide and the additional polypeptide are different.

[0064] In some cases, the immune response is a Type 1 immune response. In some cases, the immune response is characterized by a ratio of Type I cytokine production to Type II cytokine production that is greater than 1. In some cases, the immune response is characterized by a ratio of Type I cytokine production to Type II cytokine production that is less than 1. In some cases, the immune response is characterized by a ratio of IFN γ production to IL-10 production that is greater than 1. In some cases, the immune response is characterized by a ratio of IFN γ production to IL-10 production that is less than 1.

[0065] In some cases, the composition is administered to a subject. In some cases, the subject is in need of administration of the composition. In some cases, the composition is effective to elicit an immune response in a subject. In some cases, the composition is effective to eliminate a number of cells associated with breast cancer or ovarian cancer in a subject. In some cases, the composition may be used to prevent the growth of cells associated with breast cancer or ovarian cancer in a subject.

[0066] In some cases, the cancer is breast cancer. In some instances, the breast cancer is a relapsed or refractory or metastasized breast cancer. In some instances, the cancer is ovarian cancer. In some cases, the ovarian cancer is a relapsed or refractory or metastasized ovarian cancer.

[0067] In some cases, at least the first epitope is contained within a pharmaceutical composition. In some cases, at least the first epitope is contained within a pharmaceutical composition further comprising a pharmaceutical carrier. In some cases, at least the first epitope is contained within a pharmaceutical composition further comprising a pharmaceutical carrier and an adjuvant. In some cases, at least the first epitope is contained within a pharmaceutical composition further comprising an adjuvant. In some cases, the composition further comprises an adjuvant and a pharmaceutical carrier. In some cases, the adjuvant is GM-CSF.

[0068] The disclosure also provides for a kit for preparing the compositions described herein, the kit comprising instructions for preparing the composition. The disclosure also provides for a kit for administering the compositions described herein, the kit comprising instructions for administering the composition.

Compositions Comprising Epitopes for a Breast Cancer Vaccine

[0069] The compositions described herein include a composition comprising: a first plasmid comprising a first nucleotide sequence, the first nucleotide sequence encoding a first epitope of a first antigen expressed by cells associated with breast cancer; and a second nucleotide sequence, the second nucleotide sequence encoding a second epitope of a second antigen expressed by cells associated with breast cancer, wherein the first nucleotide sequence and the second nucleotide sequence are located in one or more plasmids. In some cases, the composition may include nucleic acids which encode epitopes from the following proteins, CD105, HIF1 α , MDM2, Yb1, SOX-2, HER-2, IGFBP2, IGF-1R, CDH3, and Survivin.

[0070] In some cases, the compositions may include a composition comprising: a first plasmid comprising a first nucleotide sequence, the first nucleotide sequence encoding a first epitope of a first antigen, the first epitope is a portion of a peptide selected from: CD105, Yb-1, SOX-2, CDH3 or MDM2, wherein the first nucleotide sequence is located in a plasmid. In other cases, the composition may include a composition comprising: a first plasmid comprising a first nucleotide sequence, the first nucleotide sequence encoding a first epitope of a first antigen; and a second nucleotide sequence, the second nucleotide sequence encoding a second epitope of a second antigen, wherein the first and the second epitopes are independently selected from: CD105, Yb-1, SOX-2, CDH3 or MDM2, wherein the first nucleotide sequence and the second nucleotide sequence are located in one or more plasmids.

[0071] In some cases, the composition may include nucleic acids which encode epitopes from the following proteins, CD105, MDM2, Yb-1, SOX-2, and CDH3. In some cases, the composition may include a nucleic acid sequence encoding an epitope of the peptide CD105 is selected from the group consisting of: a nucleotide sequence having at least 90% sequence identity to the nucleotide sequence of CAGAACGGCACCTGGCCCCGCGAGGTGCTGCTGGTGTGCTGTCCGTGAACCTCCTCCGT GTTCCTGCACCTACAGGCCCTGGGCATCCCCCTGCACCTGGCCTACAACCTCCTCCCT GGTGACCTTCCAGGAGCCCCCGGCGTGAACACCACCGAGCTG (SEQ ID NO: 2); a nucleotide sequence having at least 90% sequence identity to the nucleotide sequence of ACCGTGTTTCATGCGCCTGAACATCATCTCCCCGACCTGTCCGGCTGCACCTCCAAG GGCCTGGTGTGCTGCCCCGCGTGCTGGGCATCACCTTCGGCGCCTTCCTGATCGGCGCC CTGCTGACCGCCGCCCTGTGGTACATCTACTCCACACCCGCTCCCCCTCCAAGCGC

GAGCCCGTGGTGGCCGTGGCCGCCCCCGCCTCCTCCGAGTCCTCCTCCACCAACCAC
TCCATCGGCTCCACCCAGTCCACCCCCTGCTCCACCTCCTCCATGGCC (SEQ ID NO: 3); a nucleotide sequence having at
least 90% sequence identity to the nucleotide sequence of
ACCGTGTCCATGCGCCTGAACATCGTGTCCCCCGACCTGTCCGGCAAGGGCCTGGTG
CTGCCCTCCGTGCTGGGCATCACCTTCGGCGCCTTCCTGATCGGCGCCCTGCTGACC
GCCGCCCTGTGGTACATCTACTCCCACACCCGCGGCCCTCCAAGCGCGAGCCCGTG
GTGGCCGTGGCCGCCCCCGCCTCCTCCGAGTCCTCCTCCACCAACCACTCCATCGGC
TCCACCCAGTCCACCCCCTGCTCCACCTCCTCCATGGCC (SEQ ID NO: 4); a nucleotide sequence having at least 90%
sequence identity to the nucleotide sequence of
ACCGTGTCCATGCGCCTGAACATCGTGTCCCCCGACCTGTCCGGCAAGGGCCTGGTG
CTGCCCTCCGTGCTGGGCATCACCTTCGGCGCCTTCCTGATCGGCGCCCTGCTGACC
GCCGCCCTGTGGTACATCTACTCCCACACCCGCGGCCCTCCAAGCGCGAGCCCGTG
GTGGCCGTGGCCGCCCCCGCCTCCTCCGAGTCCTCCTCCACCAACCACTCCATCGGC
TCCACCCAGTCCACCCCCTGCTCCACCTCCTCCATGGCC (SEQ ID NO: 5); a nucleotide sequence encoding an amino acid
sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of
EARMLNASIVASFVELPL (SEQ ID NO: 6); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence
having at least 90% sequence identity to the amino acid sequence of
QNGTWPREVLLVLSVNSSVFLHLQALGIPLHLAYNSSLVTFQEPGVTTEL (SEQ ID NO: 7); a nucleotide sequence encoding
an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of
TVFMRLNIISPDLSGCTSKGLVLPALGITFGAFLIGALLTAALWYIYSHTRSPSKREPVV
AVAAPASSESSTNHSIGSTQSTPCSTSSMA (SEQ ID NO: 8); a nucleotide sequence encoding an amino acid sequence, the
amino acid sequence having at least 90% sequence identity to the amino acid sequence of
TVSMRLNIVSPDLGKGLVLPVLGITFGAFLIGALLTAALWYIYSHTRGPSKREPVVAV AAPASSESSTNHSIGSTQSTPCSTSSMA
(SEQ ID NO: 9); or a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 90%
sequence identity to the amino acid sequence of
TVSMRLNIVSPDLGKGLVLPVLGITFGAFLIGALLTAALWYIYSHTRAPSKREPVVAV AAPASSESSTNHSIGSTQSTPCSTSSMA
(SEQ ID NO: 10). In some cases, the composition may include a nucleic acid sequence encoding an epitope of the peptide Yb-
1 is selected from the group consisting of: a nucleotide sequence having at least 90% sequence identity to the nucleotide
sequence of GGAGTGCCAGTGCAGGGCTCCAAGTACGCTGCCGACCGCAACCACTACCGCCGCTA
CCCACGCCGTCGCGGCCACCCCGCAACTACCAGCAGAAC (SEQ ID NO: 11); a nucleotide sequence having at least 90%
sequence identity to the nucleotide sequence of
GGCGTGCCCGTGCAGGGCTCCAAGTACGCCGCCGACCGCAACCACTACCGCCGCTA
CCCCCGCCGCGCGGCCCGCCCGCAACTACCAGCAGAAC (SEQ ID NO: 12); a nucleotide sequence having at least 90%
sequence identity to the nucleotide sequence of
GGCGTGCCCGTGCAGGGCTCCAAGTACGCCGCCGACCGCAACCACTACCGCCGCTA
CCCCCGCCGCGCGGCCCGCCCGCAACTACCAGCAGAAC (SEQ ID NO: 13); a nucleotide sequence encoding an amino
acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of
EDVVFHQTAIKNNPRK (SEQ ID NO: 14); a nucleotide sequence encoding an amino acid sequence, the amino acid
sequence having at least 90% sequence identity to the amino acid sequence of YRRNFNYRRRRPEN (SEQ ID NO: 15); or a
nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the
amino acid sequence of GVPVQGSKYAADRNHYRRYPRRRGPPRNYQQN (SEQ ID NO: 16). In some cases, the composition
may include a nucleic acid sequence encoding an epitope of the peptide SOX-2 is selected from the group consisting of: a
nucleotide sequence having at least 90% sequence identity to the nucleotide sequence of
GGCCTCAATGCGCACGGCGCAGCGCAGATGCAGCCCATGCACCGCTACGACGTGAG
CGCCCTGCAGTACAACCTCCATGACCAGCTCGCAGACCTACATGAACGGCTCGCCCA
CCTACAGCATGTCCTACTCGCAGCAGGGCACCCCTGGCATGGCTCTTGGCTCCATGG GTTCGGTG (SEQ ID NO: 17); a
nucleotide sequence having at least 90% sequence identity to the nucleotide sequence of
GGCCTGAACGCCACGGCGCCGCCAGATGCAGCCCATGCACCGCTACGACGTGTC
CGCCCTGCAGTACAACCTCCATGACCTCCTCCCAGACCTACATGAACGGCTCCCCAC
CTACTCCATGTCCTACTCCCAGCAGGGCACCCCGGCATGGCCCTGGGCTCCATGGG CTCCGTG (SEQ ID NO: 18); a
nucleotide sequence having at least 90% sequence identity to the nucleotide sequence of
GGCCTGAACGCCACGGCGCCGCCAGATGCAGCCCATGCACCGCTACGACGTGTC
CGCCCTGCAGTACAACCTCCATGACCTCCTCCCAGACCTACATGAACGGCTCCCCAC
CTACTCCATGTCCTACTCCCAGCAGGGCACCCCGGCATGGCCCTGGGCTCCATGGG CTCCGTG (SEQ ID NO: 19); or a
nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the
amino acid sequence of GLNAHGAAQMMPHRYDVSALQYNSMTSSQTYMNGSPTYMSYSQQGTPGMALGSM GSV (SEQ ID
NO: 20). In some cases, the composition may include, a nucleic acid sequence encoding an epitope of the peptide CDH3 is
selected from the group consisting of: a nucleotide sequence having at least 90% sequence identity to the nucleotide
sequence of AGGTCACTGAAGGAAAGGAATCCATTGAAAATCTTCCCATCCAAACGTATCTTACG

AAGACACAAGAGAGATTGGGTGGTTGCTCCAATATCTGTCCCTGAAAATGGCAAGG
 GTCCCTTCCCACAGAGACTGAATCAGCTCAAGTCTAATAAAGATAGAGACACCAAG
 ATTTTCTACAGCATCACGGGGCCGGGTGCAGACAGCCCACCTGAGGGTGTCTTCGCT GTAGAGAAGGAGACA (SEQ ID NO: 21); a nucleotide sequence having at least 90% sequence identity to the nucleotide sequence of TTGAAAATCTTCCCATCCAAACGTATCTTACGAAGACACAAGAGAGATTGGGTGGT
 TGCTCCAATATCTGTCCCTGAAAATGGCAAGGGTCCCTTCCCACAGAGACTGAATCA
 GCTCAAGTCTAATAAAGATAGAGACACCAAGATTTTCTACAGCATCACGGGGCCGG
 GTGCAGACAGCCCACCTGAGGGTGTCTTCGCTGTAGAGAAGGAGACA (SEQ ID NO: 22); a nucleotide sequence having at least 90% sequence identity to the nucleotide sequence of GCCATGCACTCCCCCCCCACCCGCATCCTGCGCCGCCGCAAGCGCGAGTGGGTGAT
 GCCCCCATCTTCGTGCCCCGAGAACGGCAAGGGCCCCCTTCCCCCAGCGCCTGAACC
 AGCTGAAGTCCAACAAGGACCGCGGCACCAAGATCTTCTACTCCATCACCGGCCCC
 GGCGCCGACTCCCCCCCCGAGGGCGTGTTCACCATCGAGAAGGAGTCC (SEQ ID NO: 23); a nucleotide sequence having at least 90% sequence identity to the nucleotide sequence of GTGATGAACTCCCCCCCCTCCCGCATCCTGCGCCGCCGCAAGCGCGAGTGGGTGAT
 GCCCCCATCTCCGTGCCCCGAGAACGGCAAGGGCCCCCTTCCCCCAGCGCCTGAACC
 AGCTGAAGTCCAACAAGGACCGCGGCACCAAGCTGTTCTACTCCATCACCGGCCCC
 GGCGCCGACTCCCCCCCCGAGGGCGTGTTCACCATCGAGAAGGAGACC (SEQ ID NO: 24); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of RSLKERNPLKIFPSKRILRRHKRDWVAPISVPENGKGPFQRLNQLKSNKDRDTKIFYSI
 TPGADSPPEGVFAVEKET (SEQ ID NO: 25); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of LKIFPSKRILRRHKRDWVAPISVPENGKGPFQRLNQLKSNKDRDTKIFYSI
 TPGADSP PEGVFAVEKET (SEQ ID NO: 26); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of AMHSPPTRILRRRKREWMPPIFVPENGKGPFQRLNQLKSNKDRGTKIFYSI
 TPGADSP PEGVFTIEKES (SEQ ID NO: 27); or a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of VMNSPPSRILRRRKREWMPPISVPENGKGPFQRLNQLKSNKDRGTKIFYSI
 TPGADSP PEGVFTIEKES (SEQ ID NO: 28). In some cases, the composition may include, a nucleic acid sequence encoding an epitope of the peptide MDM2 is selected from the group consisting of: a nucleotide sequence having at least 90% sequence identity to the nucleotide sequence of ACCTACACCATGAAGGAGGTGCTGTTCTACCTGGGCCAGTACATCATGACCAAGCG
 CCTGTACGACGAGAAGCAGCAGCACATCGTGTACTGCTCCAACGACCTGCTGGGCG
 ACCTGTTCTGGCGTGCCCTCCTTCTCCGTGAAGGAGCACCGCAAaATCTACACCATGA
 TCTACCGCAACCTGGTGGTGGTGAACCAGCAGGAGTCTCCGACTCCGGCACCTCC GTGTCC (SEQ ID NO: 29); a nucleotide sequence having at least 90% sequence identity to the nucleotide sequence of ACCTACACCATGAAGGAGATCATCTTCTACATCGGCCAGTACATCATGACCAAGCG
 CCTGTACGACGAGAAGCAGCAGCACATCGTGTACTGCTCCAACGACCTGCTGGGCG
 ACGTGTTCTGGCGTGCCCTCCTTCTCCGTGAAGGAGCACCGCAAGATCTACGCCATGA
 TCTACCGCAACCTGGTGGCGGTGTCCCAGCAGGACTCCGGCACCTCCCTGTCC (SEQ ID NO: 30); a nucleotide sequence having at least 90% sequence identity to the nucleotide sequence of ATCTACACCATGAAGGAGATCATCTTCTACATCGGCCAGTACATCATGACCAAGCG
 CCTGTACGACGAGAAGCAGCAGCACATCGTGTACTGCTCCAACGACCTGCTGGGCG
 ACGTGTTCTGGCGTGCCCTCCTTCTCCGTGAAGGAGCACCGCAAGATCTACGCCATGA
 TCTACCGCAACCTGGTGGTGGTGTCCCAGCAGGACTCCGGCACCTCCCCCTCC (SEQ ID NO: 31); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of TYTMKEVLFLYLGQYIMTKRLYDEKQQHIVYCSNDLLGDLFGVPSFSVKEHRKIYTMIIYR NLVVVNQQESSDSGTSV (SEQ ID NO: 32); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of TYTMKEIFLYIGQYIMTKRLYDEKQQHIVYCSNDLLGDVFGVPSFSVKEHRKIY AMIYRN LVAVSQQDSGTSLS (SEQ ID NO: 33); or a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of IYTMKEIFLYIGQYIMTKRLYDEKQQHIVYCSNDLLGDVFGVPSFSVKEHRKIY AMIYRN LVVVSQQDSGTSPS (SEQ ID NO: 34).

[0072] In an exemplary case, the compositions may include a nucleic acid sequence encoding a fusion peptide of five epitopes is selected from the group consisting of: a nucleotide sequence having at least 90% sequence identity to the nucleotide sequence of ATGGCGGTACCCATGCAACTGTCCTGCTCTAGACAGAACGGCACCTGGCCCCGCGA
 GGTGCTGCTGGTGGTGTCCGTGAACTCCTCCGTGTTCTGACCTACAGGCCCTGGG
 CATCCCCCTGCACCTGGCCTACAACTCCTCCCTGGTGACCTTCCAGGAGCCCCCGG
 CGTGAACACCACCGAGCTGAGATCCACCGGTGGAGTGCCAGTGCCAGGGCTCCAAGT
 ACGTGCCGACCGCAACCACTACCGCCGCTACCCACGCCGTGCGGGCCCCACCCCGC

AACTACCAGCAGAACACGCGTGGCCTCAATGCGCACGGCGCAGCGCAGATGCAGCC
 CATGCACCGCTACGACGTGAGCGCCCTGCAGTACAACTCCATGACCAGCTCGCAGA
 CCTACATGAACGGCTCGCCACCTACAGCATGTCCTACTCGCAGCAGGGCACCCT
 GGCATGGCTCTTGGCTCCATGGGTTGCGTGAGATCCCAATTGAGGTCACTGAAGGA
 AAGGAATCCATTGAAAATCTTCCCATCCAAACGTATCTTACGAAGACACAAGAGAG
 ATTGGGTGGTTGCTCCAATATCTGTCCCTGAAAATGGCAAGGGTCCCTTCCCACAGA
 GACTGAATCAGCTCAAGTCTAATAAAGATAGAGACACCAAGATTTTCTACAGCATC
 ACGGGGCCGGGTGCAGACAGCCACCTGAGGGTGTCTTCGCTGTAGAGAAGGAGAC
 AAGATCCGCCGGCGAAACCTACACCATGAAGGAGGTGCTGTTCTACCTGGGCCAGT
 ACATCATGACCAAGCGCCTGTACGACGAGAAGCAGCAGCACATCGTGTACTGCTCC
 AACGACCTGCTGGGCGACCTGTTGCGCGTGCCCTCCTTCTCCGTGAAGGAGCACCGC
 AAAATCTACACCATGATCTACCGCAACCTGGTGGTGGTGAACCAGCAGGAGTCCTC
 CGACTCCGGCACCTCCGTGTCCAGATCTTAG (SEQ ID NO: 35); a nucleotide sequence having at least 90% sequence
 identity to the nucleotide sequence of ATGGCGGTACCCATGACCGTGTTCATGCGCCTGAACATCATCTCCCCGACCTGTCC
 GGCTGCACCTCCAAGGGCCTGGTGTGCCCCGCGTGCTGGGCATCACCTTCGGCGCC
 TTCCTGATCGGCGCCCTGCTGACCGCCGCCCTGTGGTACATCTACTCCCACACCCGC
 TCCCCCTCCAAGCGCGAGCCCGTGGTGGCCGTGGCCGCCCCCGCCTCCTCCGAGTCC
 TCCTCCACCAACCACTCCATCGGCTCCACCCAGTCCACCCCTGCTCCACCTCCTCC
 ATGGCCACCGGTGGAGTGCCAGTGCAGGGCTCCAAGTACGCTGCCGACCGCAACCA
 CTACCGCCGCTACCCACGCCGTGCGGGCCACCCCGCAACTACCAGCAGAACACGC
 GTGGCCTCAATGCGCACGGCGCAGCGCAGATGCAGCCCATGCACCGCTACGACGTG
 AGCGCCCTGCAGTACAACTCCATGACCAGCTCGCAGACCTACATGAACGGCTCGCC
 CACTACAGCATGTCCTACTCGCAGCAGGGCACCCCTGGCATGGCTCTTGGCTCCAT
 GGGTTCGGTGAGATCCCAATTGTTGAAAATCTTCCCATCCAAACGTATCTTACGAAG
 ACACAAGAGAGATTGGGTGGTTGCTCCAATATCTGTCCCTGAAAATGGCAAGGGTC
 CCTTCCCACAGAGACTGAATCAGCTCAAGTCTAATAAAGATAGAGACACCAAGATT
 TTCTACAGCATCACGGGGCCGGGTGCAGACAGCCACCTGAGGGTGTCTTCGCTGT
 AGAGAAGGAGACAAGATCCGCCGGCGAAACCTACACCATGAAGGAGGTGCTGTTC
 TACCTGGGCCAGTACATCATGACCAAGCGCCTGTACGACGAGAAGCAGCAGCACAT
 CGTGTACTGCTCCAACGACCTGCTGGGCGACCTGTTGCGCGTGCCCTCCTTCTCCGT
 GAAGGAGCACCGCAAAATCTACACCATGATCTACCGCAACCTGGTGGTGGTGAACC
 AGCAGGAGTCCTCCGACTCCGGCACCTCCGTGTCCAGATCTTAG (SEQ ID NO: 36); a nucleotide sequence having at least
 90% sequence identity to the nucleotide sequence of
 ATGGCGGTACCCATGACCGTGTCCATGCGCCTGAACATCGTGTCCCCGACCTGTCC
 GGCAAGGGCCTGGTGTGCCCTCCGTGCTGGGCATCACCTTCGGCGCCTTCCTGATC
 GGCGCCCTGCTGACCGCCGCCCTGTGGTACATCTACTCCCACACCCGCGGCCCTCC
 AAGCGCGAGCCCGTGGTGGCCGTGGCCGCCCCCGCCTCCTCCGAGTCCTCCTCCACC
 AACCCTCCATCGGCTCCACCCAGTCCACCCCTGCTCCACCTCCTCCATGGCCACC
 GGTGGCGTGCCCGTGCAGGGCTCCAAGTACGCCGCCGACCGCAACCACTACCGCCG
 CTACCCCGCCGCGCGGCCGCCCCCGCAACTACCAGCAGAACACGCGTGGCCTGA
 ACGCCACGGCGCCGCCCAGATGCAGCCCATGCACCGCTACGACGTGTCCGCCCTG
 CAGTACAACTCCATGACCTCCTCCCAGACCTACATGAACGGCTCCCCACCTACTCC
 ATGTCCTACTCCCAGCAGGGCACCCCGGCATGGCCCTGGGCTCCATGGGCTCCGTG
 AGATCCCAATTGGCCATGCACTCCCCCCCCACCCGCATCCTGCGCCGCCGCAAGCGC
 GAGTGGGTGATGCCCCCATCTTCGTGCCCCGAGAACGGCAAGGGCCCCTTCCCCCA
 GCGCCTGAACCAGCTGAAGTCCAACAAGGACCGCGGCACCAAGATCTTCTACTCCA
 TCACCGGCCCGGCGCCGACTCCCCCCCCGAGGGCGTGTTACCATCGAGAAGGAG
 TCCAGATCCGCCGGCGAAACCTACACCATGAAGGAGATCATCTTCTACATCGGCCA
 GTACATCATGACCAAGCGCCTGTACGACGAGAAGCAGCAGCACATCGTGTACTGCT
 CCAACGACCTGCTGGGCGACGTGTTGCGCGTGCCCTCCTTCTCCGTGAAGGAGCACC
 GCAAGATCTACGCCATGATCTACCGCAACCTGGTGGCCGTGTCCAGCAGGACTCC GGCACCTCCCTGTCCAGATCTTAG
 (SEQ ID NO: 37); a nucleotide sequence having at least 90% sequence identity to the nucleotide sequence of
 ATGGCGGTACCCATGACCGTGTCCATGCGCCTGAACATCGTGTCCCCGACCTGTCC
 GGCAAGGGCCTGGTGTGCCCTCCGTGCTGGGCATCACCTTCGGCGCCTTCCTGATC
 GGCGCCCTGCTGACCGCCGCCCTGTGGTACATCTACTCCCACACCCGCGGCCCTCC
 AAGCGCGAGCCCGTGGTGGCCGTGGCCGCCCCCGCCTCCTCCGAGTCCTCCTCCACC
 AACCCTCCATCGGCTCCACCCAGTCCACCCCTGCTCCACCTCCTCCATGGCCACC
 GGTGGCGTGCCCGTGCAGGGCTCCAAGTACGCCGCCGACCGCAACCACTACCGCCG
 CTACCCCGCCGCGCGGCCGCCCCCGCAACTACCAGCAGAACACGCGTGGCCTGA
 ACGCCACGGCGCCGCCCAGATGCAGCCCATGCACCGCTACGACGTGTCCGCCCTG
 CAGTACAACTCCATGACCTCCTCCCAGACCTACATGAACGGCTCCCCACCTACTCC
 ATGTCCTACTCCCAGCAGGGCACCCCGGCATGGCCCTGGGCTCCATGGGCTCCGTG
 AGATCCCAATTGGCCATGCACTCCCCCCCCACCCGCATCCTGCGCCGCCGCAAGCGC
 GAGTGGGTGATGCCCCCATCTTCGTGCCCCGAGAACGGCAAGGGCCCCTTCCCCCA
 GCGCCTGAACCAGCTGAAGTCCAACAAGGACCGCGGCACCAAGATCTTCTACTCCA
 TCACCGGCCCGGCGCCGACTCCCCCCCCGAGGGCGTGTTACCATCGAGAAGGAG
 TCCAGATCCGCCGGCGAAACCTACACCATGAAGGAGATCATCTTCTACATCGGCCA
 GTACATCATGACCAAGCGCCTGTACGACGAGAAGCAGCAGCACATCGTGTACTGCT
 CCAACGACCTGCTGGGCGACGTGTTGCGCGTGCCCTCCTTCTCCGTGAAGGAGCACC
 GCAAGATCTACGCCATGATCTACCGCAACCTGGTGGCCGTGTCCAGCAGGACTCC GGCACCTCCCTGTCCAGATCTTAG
 (SEQ ID NO: 37); a nucleotide sequence having at least 90% sequence identity to the nucleotide sequence of
 ATGGCGGTACCCATGACCGTGTCCATGCGCCTGAACATCGTGTCCCCGACCTGTCC
 GGCAAGGGCCTGGTGTGCCCTCCGTGCTGGGCATCACCTTCGGCGCCTTCCTGATC
 GGCGCCCTGCTGACCGCCGCCCTGTGGTACATCTACTCCCACACCCGCGGCCCTCC
 AAGCGCGAGCCCGTGGTGGCCGTGGCCGCCCCCGCCTCCTCCGAGTCCTCCTCCACC
 AACCCTCCATCGGCTCCACCCAGTCCACCCCTGCTCCACCTCCTCCATGGCCACC
 GGTGGCGTGCCCGTGCAGGGCTCCAAGTACGCCGCCGACCGCAACCACTACCGCCG
 CTACCCCGCCGCGCGGCCGCCCCCGCAACTACCAGCAGAACACGCGTGGCCTGA

ACGCCCACGGCGCCGCCAGATGCAGCCCATGCACCGCTACGACGTGTCCGCCCTG
 CAGTACAACCTCCATGACCTCCTCCCAGACCTACATGAACGGCTCCCCACCTACTCC
 ATGTCCTACTCCCAGCAGGGCACCCCCGGCATGGCCCTGGGCTCCATGGGCTCCGTG
 AGATCCCAATTGGTGATGAACTCCCCCCCCCTCCCGCATCCTGCGCCGCCGCAAGCGC
 GAGTGGGTGATGCCCCCATCTCCGTGCCCCGAGAACGGCAAGGGCCCCTTCCCCCA
 GCGCCTGAACCAGCTGAAGTCCAACAAGGACCGCGGCACCAAGCTGTTCTACTCCA
 TCACCGGCCCCGGCGCCGACTCCCCCCCCGAGGGCGTGTTACCATCGAGAAGGAG
 ACCAGATCCGCCGGCGAAATCTACACCATGAAGGAGATCATCTTCTACATCGGCCA
 GTACATCATGACCAAGCGCCTGTACGACGAGAAGCAGCAGCACATCGTGTACTGCT
 CCAACGACCTGCTGGGCGACGTGTTCCGGCGTGCCCTCCTTCTCCGTGAAGGAGCACC
 GCAAGATCTACGCCATGATCTACCGCAACCTGGTGGTGGTGTCCCAGCAGGACTCC GGCACCTCCCCCTCCAGATCTTAG
 (SEQ ID NO: 38); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 90%
 sequence identity to the amino acid sequence of
 MAVPMLQLSCSRQNGTWPREVLLVLSVNSSVFLHLQALGIPLHLAYNSSLVTFQEPPGVN
 TTELIRSTGGVPVQGSKYAADRNHYRRYPRRRGPPRNYQQNTRGLNAHGAAQMMPMH
 RYDVSALQYNSMTSSQTYMNGSPTYSMSYSQQGTPGMALGSMGSVRSQRLRSLKERNP
 LKIFPSKRILRRHKRDWVAPISVPENGKGPFPPQRLNQLKSNKDRDTKIFYISITGPGADSP
 PEGVFAVEKETRSAGETYTMKEVLFYLGQYIMTKRLYDEKQQHIVYCSNDLLGDLFGV
 PSFSVKEHRKIYTMIRNLVVVNQQESSDSGTSVSRS (SEQ ID NO: 39); a nucleotide sequence encoding an amino acid
 sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of
 MAVPMTVMRLNIISPDLGCTSKGLVLPVAVLGITFGAFLIGALLTAALWYIYSHTRSPS
 KREPVVAVAAPASSESSSTNHSIGSTQSTPCSTSSMATGGVPVQGSKYAADRNHYRRYP
 RRRGPPRNYQQNTRGLNAHGAAQMMPMHRYDVSALQYNSMTSSQTYMNGSPTYSMS
 YSQQGTPGMALGSMGSVRSQLLKIFPSKRILRRHKRDWVAPISVPENGKGPFPPQRLNQ
 LKSNKDRDTKIFYISITGPGADSPPEGVFAVEKETRSAGETYTMKEVLFYLGQYIMTKRL
 YDEKQQHIVYCSNDLLGDLFGVPSFSVKEHRKIYTMIRNLVVVNQQESSDSGTSVSRS (SEQ ID NO: 40); a nucleotide sequence
 encoding an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid
 sequence of MAVPMTVMRLNIVSPDLGKGLVLPVAVLGITFGAFLIGALLTAALWYIYSHTRGPSKRE
 PVVAVAAPASSESSSTNHSIGSTQSTPCSTSSMATGGVPVQGSKYAADRNHYRRYP
 GPPRNYQQNTRGLNAHGAAQMMPMHRYDVSALQYNSMTSSQTYMNGSPTYSMSYSQ
 QGTPGMALGSMGSVRSQLAMHSPTRILRRRKREWWMPPIFVPENGKGPFPPQRLNQLK
 SNKDRGTKIFYISITGPGADSPPEGVFTIEKESRSAGETYTMKEIFYIGQYIMTKRLYDEK
 QQHIVYCSNDLLGDVFGVPSFSVKEHRKIYAMIYRNLVAVSQQDSGTSLSRS (SEQ ID NO: 41); or a nucleotide sequence
 encoding an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid
 sequence of MAVPMTVMRLNIVSPDLGKGLVLPVAVLGITFGAFLIGALLTAALWYIYSHTRAPSKRE
 PVVAVAAPASSESSSTNHSIGSTQSTPCSTSSMATGGVPVQGSKYAADRNHYRRYP
 GPPRNYQQNTRGLNAHGAAQMMPMHRYDVSALQYNSMTSSQTYMNGSPTYSMSYSQ
 QGTPGMALGSMGSVRSQLVMSPPSRILRRRKREWWMPPIFVPENGKGPFPPQRLNQLKS
 NKDRGTKLFYSITGPGADSPPEGVFTIEKETRSAGE
 IYTMKEIFYIGQYIMTKRLYDEKQQHIVYCSNDLLGDVFGVPSFSVKEHRKIYAMIYRN LVVVSQQDSGTSVSRS (SEQ ID NO: 42).

[0073] In some cases, the composition may include nucleic acids which encode epitopes from the following proteins, HER-2, IGFBP2 and IGF-1R. In some cases, the composition may comprise a first plasmid comprising a first nucleotide sequence, the first nucleotide sequence encoding a first epitope of a first antigen, the first epitope is a portion of a peptide selected from: IGFBP-2, HER-2, IGF-1R, wherein the first nucleotide sequence is located in a plasmid. In some cases, the composition may comprise: a first plasmid comprising a first nucleotide sequence, the first nucleotide sequence encoding a first epitope of a first antigen; and a second nucleotide sequence, the second nucleotide sequence encoding a second epitope of a second antigen, wherein the first and the second epitopes are independently selected from: IGFBP-2, HER-2 or IGF-1R, wherein the first nucleotide sequence and the second nucleotide sequence are located in one or more plasmids. In some cases, the compositions may comprise a nucleic acid sequence encoding an epitope of the peptide IGFBP-2 is selected from the group consisting of: a nucleotide sequence having at least 90% sequence identity to the nucleotide sequence of
 ATGCTGCCGAGAGTGGGCTGCCCCGCGCTGCCGCTGCCGCCGCCGCCGCTGCTGCC
 GCTGCTGCCGCTGCTGCTGCTGCTACTGGGCGCGAGTGGCGGGCGGGCGGGGCGC
 GCGCGGAGGTGCTGTTCCGCTGCCCGCCCTGCACACCCGAGCGCCTGGCCGCCTGC
 GGGCCCCCGCCGGTTGCGCCGCCCGCCGCGGTGGCCGCAAGTGGCCGGAGGCGCCCCG
 CATGCCATGCGCGGAGCTCGTCCGGGAGCCGGGCTGCGGCTGCTGCTCGGTGTGCG
 CCCGGCTGGAGGGCGAGGCGTGCGGCGTCTACACCCCGCGCTGCGGCCAGGGGCTG
 CGCTGCTATCCCCACCCGGGCTCCGAGCTGCCCTGCAGGCGCTGGTCATGGGCGA
 GGGCACTTGTGAGAAGCGCCGGGACGCCGAGTATGGCGCCAGCCCGGAGCAGGTT

GCAGACAATGGCGATGACCACTCAGAAGGAGGCCTGGTGGAG (SEQ ID NO: 43); a nucleotide sequence having at least 90% sequence identity to the nucleotide sequence of

ATGCTGCCCCGCCTGGGCGGCCCGCCCTGCCCTGCTGCTGCCCTCCCTGCTGCTG
 CTGCTGCTGCTGGGCGCCGGCGGCTGCGGCCCGGCGTGCGCGCCGAGGTGCTGTT
 CCGCTGCCCCCCTGCACCCCGAGCGCCTGGCCGCTGCGGCCCGCCCGACGC
 CCCCTGCGCCGAGCTGGTGC GCGAGCCCGGCTGCGGCTGCTGCTCCGTGTGCGCCC
 GCCAGGAGGGCGAGGCCTGCGGCGTGACATCCCCGCTGCGCCCAGACCCTGCGC
 TGCTACCCCAACCCCGGCTCCGAGCTGCCCCTGAAGGCCCTGGTGACCGGCGCCGG
 CACCTGCGAGAAGCGCCGCGTGGGCACCACCCCGAGCAGGTGGCCGACTCCGACG
 ACGACCACTCCGAGGGCGGCCTGGTGGAG (SEQ ID NO: 44); a nucleotide sequence having at least 90% sequence identity to the nucleotide sequence of

ATGCTGCCCCGCCTGGGCGGCCCGCCCTGCCCTGCTGCTGCCCTCCCTGCTGCTG
 CTGCTGCTGCTGGGCGCCGGCGGCTGCGGCCCGGCGTGCGCGCCGAGGTGCTGTT
 CCGCTGCCCCCCTGCACCCCGAGCGCCTGGCCGCTGCGGCCCGCCCGACGC
 CCCCTGCGCCGAGCTGGTGC GCGAGCCCGGCTGCGGCTGCTGCTCCGTGTGCGCCC
 GCCAGGAGGGCGAGGCCTGCGGCGTGACATCCCCGCTGCGCCCAGACCCTGCGC
 TGCTACCCCAACCCCGGCTCCGAGCTGCCCCTGAAGGCCCTGGTGACCGGCGCCGG
 CACCTGCGAGAAGCGCCGCGTGGGCACCACCCCGAGCAGGTGGCCGACTCCGAGG
 ACGACCACTCCGAGGGCGGCCTGGTGGAG (SEQ ID NO: 45); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of NHVDSTMNMLGGGS (SEQ ID NO: 46); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of ELAVFREKVTEQHRQ (SEQ ID NO: 47), a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of LGLEEPKKLRPPPAR (SEQ ID NO: 48); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of DQVLERISTMRLPDE (SEQ ID NO: 49); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of GPLEHLYSLHIPNCD (SEQ ID NO: 50); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of KHGLYNLKQCKMSLN (SEQ ID NO: 51); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of PNTGKLIQGAPTIRG (SEQ ID NO: 52); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of PECHLFYNEQQEARG (SEQ ID NO: 53); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of MLPRVGCPALPLPPPPLPLPLLLLLLLGASGGGGGARAELVFRCPPTPERLAACGPPP VAPPAVAAVAGGARMPCAELVREPGCGCCSVCARLEGEACGVYTPRCGQGLRCYPH PGSELPLQALVMGEGTCEKRRDAEYGASPEQVADNGDDHSEGLVE (SEQ ID NO: 54); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of MLPRLGGPALPLLLPSLLLLLLGAGGCGPGVRAEVLFRCPPTPERLAACGPPPDAPCA ELVREPGCGCCSVCARQEGEACGVYIPRCAQTLRCYPNPGSELPLKALVTGAGTCEKRR VGTPPQQVADSDDDHSEGLVE (SEQ ID NO: 55); and a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of

MLPRLGGPALPLLLPSLLLLLLGAGGCGPGVRAEVLFRCPPTPERLAACGPPPDAPCA
 ELVREPGCGCCSVCARQEGEACGVYIPRCAQTLRCYPNPGSELPLKALVTGAGTCEKRR VGATPQQVADSEDDHSEGLVE (SEQ ID NO: 56). In some cases, the compositions may comprise a nucleic acid sequence encoding an epitope of the peptide HER-2 is selected from the group consisting of: a nucleotide sequence having at least 90% sequence identity to the nucleotide sequence of

ACGATGCGGAGACTGCTGCAGGAAACGGAGCTGGTGGAGCCGCTGACACCTAGCG
 GAGCGATGCCCAACCAGGCGCAGATGCGGATCCTGAAAGAGACGGAGCTGAGGAA
 GGTGAAGGTGCTTGATCTGGCGCTTTTGGCACAGTCTACAAGGGCATCTGGATCCC
 TGATGGGGAGAATGTGAAAATTCCAGTGGCCATCAAAGTGTTGAGGGAAAACACAT
 CCCCCAAAGCCAACAAAGAAATCTTAGACGAAGCATACGTGATGGCTGGTGTGGGC
 TCCCCATATGTCTCCCGCCTTCTGGGCATCTGCCTGACATCCACGGTGACAGCTGGTG
 ACACAGCTTATGCCCTATGGCTGCCTCTTAGACCATGTCCGGGAAAACCGCGGACG
 CCTGGGCTCCCAGGACCTGCTGAACTGGTGTATGCAGATTGCCAAGGGGATGAGCT
 ACCTGGAGGATGTGCGGCTCGTACACAGGGACTTGGCCGCTCGGAACGTGCTGGTC
 AAGAGTCCCAACCATGTCAAATTACAGACTTCGGGCTGGCTCGGCTGCTGGACAT
 TGACGAGACAGAGTACCATGCAGATGGGGGCAAGGTGCCCATCAAGTGGATGGCG
 CTGGAGTCCATTCTCCGCCGGCGGTTACCCACCAGAGTGATGTGTGGAGTTATGGT
 GTGACTGTGTGGGAGCTGATGACTTTTGGGGCCAAACCTTACGATGGGATCCCAGC
 CCGGGAGATCCCTGACCTGCTGGAAAAGGGGGAGCGGCTGCCCCAGCCCCCATCT
 GCACCATTGATGTCTACATGATCATGGTCAAATGTTGGATGATTGACTCTGAATGTC
 GGCCAAGATTCCGGGAGTTGGTGTCTGAATTCTCCCGCATGGCCAGGGACCCCCAG

CGCTTTGTGGTCATCCAGAATGAGGACTTGGCTCCCGGAGCTGGCGGCATGGTGCA
CCACAGGCACCGCAGCTCATCTCCTCTGCCTGCTGCCCCGACCTGCTGGTGCCACTCT
GGAAAGGCCCAAGACTCTCTCCCCAGGGAAGAATGGGGTCGTCAAAGACGTTTTTG
CCTTTGGGGGTGCCGTGGAGAACCCCGAGTACTTG (SEQ ID NO: 57); a nucleotide sequence having at least 90%
sequence identity to the nucleotide sequence of
ACCATGCGCCGCCTGCTGCAGGAGACCGAGCTGGTGGAGCCCCTGACCCCCTCCGG
CGCCGTGCCCAACCAGGCCAGATGCGCATCCTGAAGGAGACCGAGCTGCGCAAGC
TGAAGGTGCTGGGCTCCGGCGCCTTCGGCACCCTGTACAAGGGCATCTGGATCCCC
GACGGCGAGAACGTGAAGATCCCCGTGGCCATCAAGGTGCTGCGCGAGAACACCTC
CCCCAAGGCCAACAAAGGAGATCCTGGACGAGGCCTACGTGATGGCCGGCGTGGGCT
CCCCCTACGTGTCCCGCCTGCTGGGCATCTGCCTGACCTCCACCGTGCAGCTGGTGA
CCCAGCTGATGCCCTACGGCTGCCTGCTGGACCACGTGCGCGAGCACCGCGGCCGC
CTGGGCTCCCAGGACCTGCTGAACTGGTGCCTGCGATCGCCAAGGGCATGTCCTA
CCTGGAGGAGGTGCGCCTGGTGCACCGCGACCTGGCCGCCCGCAACGTGCTGGTGA
AGTCCCCCAACCACGTGAAGATCACCGACTTCGGCCTGGCCCGCCTGCTGGACATC
GACGAGACCGAGTACCACGCCGACGGCGGCAAGGTGCCCATCAAGTGGATGGCCCT
GGAGTCCATCCTGCGCCGCCGCTTCACCCACAGTCCGACGTGTGGTCTACGGCGT
GACCGTGTGGGAGCTGATGACCTTCGGCGCCAAGCCCTACGACGGCATCCCCGCC
GCGAGATCCCCGACCTGCTGGAGAAGGGCGAGCGCCTGCCCCAGCCCCCATCTGC
ACCATCGACGTGTACATGATCATGGTGAAGTGCTGGATGATCGACTCCGAGTGCCG
CCCCCGCTTCCGCGAGCTGGTGTCCGAGTTCTCCCGCATGGCCCGCGACCCCCAGCG
CTTCGTGGTGTATCCAGAACGAGGACCTGGCCCTGGGCACCGGCTCCACCGCCCACC
GCCGCCACCGCTCCTCCTCCCCCCCCCCCCCATCCGCCCGCCGGCGCCACCCTGG
AGCGCCCCAAGACCCTGTCCCCCGGCAAGAACGGCGTGGTGAAGGACGTGTTCCGC
TTCGGCGGCGCCGTGGAGAACCCCGAGTACCTG (SEQ ID NO: 58); a nucleotide sequence having at least 90% sequence
identity to the nucleotide sequence of ACCATGCGCCGCCTGCTGCAGGAGACCGAGCTGGTGGAGCCCCTGACCCCCTCCGG
CGCCATGCCCAACCAGGCCAGATGCGCATCCTGAAGGAGACCGAGCTGCGCAAGG
TGAAGGTGCTGGGCTCCGGCGCCTTCGGCACCCTGTACAAGGGCATCTGGATCCCC
GACGGCGAGAACGTGAAGATCCCCGTGGCCATCAAGGTGCTGCGCGAGAACACCTC
CCCCAAGGCCAACAAAGGAGATCCTGGACGAGGCCTACGTGATGGCCGGCGTGGGCT
CCCCCTACGTGTCCCGCCTGCTGGGCATCTGCCTGACCTCCACCGTGCAGCTGGTGA
CCCAGCTGATGCCCTACGGCTGCCTGCTGGACCACGTGCGCGAGCACCGCGGCCGC
CTGGGCTCCCAGGACCTGCTGAACTGGTGCCTGCGATCGCCAAGGGCATGTCCTA
CCTGGAGGACGTGCGCCTGGTGCACCGCGACCTGGCCGCCCGCAACGTGCTGGTGA
AGTCCCCCAACCACGTGAAGATCACCGACTTCGGCCTGGCCCGCCTGCTGGACATC
GACGAGACCGAGTACCACGCCGACGGCGGCAAGGTGCCCATCAAGTGGATGGCCCT
GGAGTCCATCCTGCGCCGCCGCTTCACCCACAGTCCGACGTGTGGTCTACGGCGT
GACCGTGTGGGAGCTGATGACCTTCGGCGCCAAGCCCTACGACGGCATCCCCGCC
GCGAGATCCCCGACCTGCTGGAGAAGGGCGAGCGCCTGCCCCAGCCCCCATCTGC
ACCATCGACGTGTACATGATCATGGTGAAGTGCTGGATGATCGACTCCGAGTGCCG
CCCCCGCTTCCGCGAGCTGGTGTCCGAGTTCTCCCGCATGGCCCGCGACCCCCAGCG
CTTCGTGGTGTATCCAGAACGAGGACCTGACCCCGGCACCGGCTCCACCGCCCACC
GCCGCCACCGCTCCTCCTCCCCCCTGCCCCCGTGCGCCCGCCGGCGCCACCCTGG
AGCGCCCCAAGACCCTGTCCCCCGGCAAGAACGGCGTGGTGAAGGACGTGTTCCGC
TTCGGCGGCGCCGTGGAGAACCCCGAGTACCTG (SEQ ID NO: 59); a nucleotide sequence encoding an amino acid
sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of
TMRRLQETELVEPLTPSGAMPNQAQMRILKETELRKVKVLGSGAFGTVYKGIWIPDGE
NVKIPVAIKVIRENTSPKANKEILDEAYVMAGVGSPLYVSRLLGICLTSTVQLVTQLMPY
GCLLDHVRENRRGLGSQDLLNWCMQIAKGMSYLEDVRLVHRDLAARNVLVKSPNHV
KITDFGLARLLDIDETEHADGGKVPIKWMALESILRRRFTHQSDVWSYGVTVWELMT
FGAKPYDGIPAREIPDLLEKGERLPQPPICTIDVYMIMVKCWMIDSECRPRFRELVEFSR
MARDPQRFVVIQNEIDLAPGAGGMVHHRHRSSSPLPAARPAGATLERPKTLPKNGV KDVFAFGGAVENPEYL (SEQ ID NO:
60); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 90% sequence
identity to the amino acid sequence of TMRRLQETELVEPLTPSGAVPNQAQMRILKETELRKLKVLGSGAFGTVYKGIWIPDGE
NVKIPVAIKVIRENTSPKANKEILDEAYVMAGVGSPLYVSRLLGICLTSTVQLVTQLMPY
GCLLDHVREHRRGLGSQDLLNWCVQIAKGMSYLEEVRLVHRDLAARNVLVKSPNHVK
ITDFGLARLLDIDETEHADGGKVPIKWMALESILRRRFTHQSDVWSYGVTVWELMTF
GAKPYDGIPAREIPDLLEKGERLPQPPICTIDVYMIMVKCWMIDSECRPRFRELVEFSR
MARDPQRFVVIQNEIDLALGTGSTAHRHRSSSPPIRPAATLERPKTLPKNGVVK DVFAFGGAVENPEYL (SEQ ID NO: 61);

and a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of TMRRLQETELVEPLTPSGAMPNQAQMRILKETELRKVKVLGSGAFGTVYKGIWMPDGE NVKIPVAIKVLRENTSPKANKEILDEAYVMAGVGSPYVSRLLGICLTSTVQLVTQLMPY GCLLDHVREHRGRLGSQDLLNWCVQIAKGMSYLEDVRLVHRDLAARNVLVKSPNHV KITDFGLARLLDIDETEHADGGKVPIKWMMALESILRRRFTHQSDVWSYGVTVWELMT FGAKPYDGIPAREIPDLLLEKGERLPQPPICTIDVYMIMVKCWMIDSECRPRFRELVEFSR MARDPQRFVVIQNEDLTPGTGSTAHRHRHSSSPLPPVRPAGATLERPKTLPSPGKNGVVK DVFAFGGAVENPEYL (SEQ ID NO: 62). In some cases, the compositions may comprise a nucleic acid sequence encoding an epitope of the peptide IGF-1R is selected from the group consisting of: a nucleotide sequence having at least 90% sequence identity to the nucleotide sequence of TGGTCCTTCGGCGTGGTGCTGTGGGAGATCGCCACCCTGGCCGAGCAGCCCTACCA GGGCCTGTCCAACGAGCAGGTGCTGCGCTTCGTGATGGAGGGCGGCCTGCTGGACA AGCCCGACAACCTGCCCCGACATGCTGTTTCGAGCTGATGCGCATGTGCTGGCAGTAC AACCCCAAGATGCGCCCCCTCCTTCCTGGAGCACAAGGCCGAGAACGGCCCCGGCCC CGGCGTGCTGGTGCTGCGCGCCTCCTTCGACGAGCGCCAGCCCTACGCCACATGA ACGGAGGCCGCAAGAACGAGCGCGCCCTGCCC (SEQ ID NO: 63); a nucleotide sequence having at least 90% sequence identity to the nucleotide sequence of TGGTCCTTCGGCGTGGTGCTGTGGGAGATCGCCACCCTGGCCGAGCAGCCCTACCA GGGCCTGTCCAACGAGCAGGTGCTGCGCTTCGTGATGGAGGGCGGCCTGCTGGACA AGCCCGACAACCTGCCCCGACATGCTGTTTCGAGCTGATGCGCATGTGCTGGCAGTAC AACCCCAAGATGCGCCCCCTCCTTCCTGGAGCACAAGGCCGAGAACGGCCCCGGCCC CGGCGTGCTGGTGCTGCGCGCCTCCTTCGACGAGCGCCAGCCCTACGCCACATGA ACGGCGGCCGCGCCAACGAGCGCGCCCTGCCC (SEQ ID NO: 64); a nucleotide sequence having at least 90% sequence identity to the nucleotide sequence of TGGTCCTTCGGCGTGGTGCTGTGGGAGATCGCCACCCTGGCCGAGCAGCCCTACCA GGGCCTGTCCAACGAGCAGGTGCTGCGCTTCGTGATGGAGGGCGGCCTGCTGGACA AGCCCGACAACCTGCCCCGACATGCTGTTTCGAGCTGATGCGCATGTGCTGGCAGTAC AACCCCAAGATGCGCCCCCTCCTTCCTGGAGCACAAGGCCGAGAACGGCCCCGGCGT GCTGGTGCTGCGCGCCTCCTTCGACGAGCGCCAGCCCTACGCCACATGAACGGCG GCCGCGCCAACGAGCGCGCCCTGCCC (SEQ ID NO: 65); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of DYRSYRFPKLTVITE (SEQ ID NO: 66); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of IRGWKLFYNYALVIF (SEQ ID NO: 67); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of VVTGYVKIRHSHALV (SEQ ID NO: 68); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of FFYVQAKTGYENFIH (SEQ ID NO: 69); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of LIIALPVAVLLIVGG (SEQ ID NO: 70); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of LVIMLYVFHRKRNN (SEQ ID NO: 71); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of NCHHVVRLLGVVSQG (SEQ ID NO: 72); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of WSFGVVLWEIATLAEQPYQGLSNEQVLRFMVEGGLLDKPDNCPDMLFELMRMCWQY NPKMRPSFLEHKAENGPGLVLRASFDERQPYAHMNGGRKNERALP (SEQ ID NO: 73); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of WSFGVVLWEIATLAEQPYQGLSNEQVLRFMVEGGLLDKPDNCPDMLFELMRMCWQY NPKMRPSFLEHKAENGPGLVLRASFDERQPYAHMNGGRANERALP (SEQ ID NO: 74); and a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of WSFGVVLWEIATLAEQPYQGLSNEQVLRFMVEGGLLDKPDNCPDMLFELMRMCWQY NPKMRPSFLEHKAENGPGLVLRASFDERQPYAHMNGGRANERALP (SEQ ID NO: 75). In some cases, the compositions may comprise a nucleic acid sequence encoding a fusion protein of three epitopes is selected from the group consisting of: a nucleotide sequence having at least 90% sequence identity to the nucleotide sequence of ATGGCGGTACCAATGCTGCCGAGAGTGGGCTGCCCCGCGCTGCCGCTGCCGCGGCC GCCGCTGCTGCCGCTGCTGCCGCTGCTGCTGCTGCTACTGGGCGCGAGTGGCGGCG GCGGCGGGGCGCGCGCGGAGGTGCTGTTCCGCTGCCCGCCCTGCACACCCGAGCGC CTGGCCGCCTGCGGGCCCCCGCCGTTGCGCCGCCCGCCGCGGTGGCCGCAGTGGC CGGAGGCGCCCGCATGCCATGCGCGGAGCTCGTCCGGGAGCCGGGCTGCGGCTGCT GCTCGGTGTGCGCCCGGCTGGAGGGCGAGGCGTGCGGCGTCTACACCCCGCGCTGC GGCCAGGGGCTGCGCTGCTATCCCCACCCGGGCTCCGAGCTGCCCCTGCAGGCGCT GGTATGGGCGAGGGCACTTGTGAGAAGCGCCGGGACGCCGAGTATGGCGCCAGC CCGGAGCAGGTTGCAGACAATGGCGATGACCACTCAGAAGGAGGCCTGGTGAGC AATTGACGATGCGGAGACTGCTGCAGGAAACGGAGCTGGTGAGCCGCTGACACCT

AGCGGAGCGATGCCCAACCAGGCGCAGATGCGGATCCTGAAAGAGACGGAGCTGA
GGAAGGTGAAGGTGCTTGGATCTGGCGCTTTTGGCACAGTCTACAAGGGCATCTGG
ATCCCTGATGGGGAGAATGTGAAAATTCCAGTGGCCATCAAAGTGTTGAGGGAAAA
CACATCCCCCAAAGCCAACAAAGAAATCTTAGACGAAGCATACGTGATGGCTGGTG
TGGGCTCCCCATATGTCTCCCGCCTTCTGGGCATCTGCCTGACATCCACGGTGCAGC
TGGTGACACAGCTTATGCCCTATGGCTGCCTCTTAGACCATGTCCGGGAAAACCGCG
GACGCCTGGGCTCCCAGGACCTGCTGAACTGGTGTATGCAGATTGCCAAGGGGATG
AGCTACCTGGAGGATGTGCGGCTCGTACACAGGGACTTGGCCGCTCGGAACGTGCT
GGTCAAGAGTCCCAACCATGTCAAATTACAGACTTCGGGCTGGCTCGGCTGCTGG
ACATTGACGAGACAGAGTACCATGCAGATGGGGGCAAGGTGCCCATCAAGTGGAT
GGCGCTGGAGTCCATTCTCCGCCGGCGGTTACCCACCAGAGTGATGTGTGGAGTT
ATGGTGTGACTGTGTGGGAGCTGATGACTTTTGGGGCCAAACCTTACGATGGGATC
CCAGCCCGGGAGATCCCTGACCTGCTGGAAAAGGGGGAGCGGCTGCCCCAGCCCC
CATCTGCACCATTGATGTCTACATGATCATGGTCAAATGTTGGATGATTGACTCTGA
ATGTCGGCCAAGATTCCGGGAGTTGGTGTCTGAATTCTCCCGCATGGCCAGGGACC
CCCAGCGCTTTGTGGTCATCCAGAATGAGGACTTGGCTCCCGGAGCTGGCGGCATG
GTGCACCACAGGCACCGCAGCTCATCTCCTCTGCCTGCTGCCCCGACCTGCTGGTGCC
ACTCTGGAAAGGCCCAAGACTCTCTCCCCAGGGAAGAATGGGGTCGTCAAAGACGT
TTTTGCCTTTGGGGGTGCCGTGGAGAACCCCGAGTACTTGGGCCGGCCGGTACCTTG
GTCCTTCGGCGTGGTGTGTGGGAGATCGCCACCCTGGCCGAGCAGCCCTACCAGG
GCCTGTCCAACGAGCAGGTGCTGCGCTTCGTGATGGAGGGCGGCCTGCTGGACAAG
CCCGACAACCTGCCCCGACATGCTGTTTCGAGCTGATGCGCATGTGCTGGCAGTACAA
CCCCAAGATGCGCCCCCTCCTTCCTGGAGCACAAGGCCGAGAACGGCCCCGGCCCCG
GCGTGCTGGTGTGCTGCGCGCCTCCTTCGACGAGCGCCAGCCCTACGCCACATGAAC
GGAGGCCGCAAGAACGAGCGCGCCCTGCCCGCGGCCGCATAG (SEQ ID NO: 76); a nucleotide sequence having at least
90% sequence identity to the nucleotide sequence of
ATGGCGGTACCAATGCTGCCCCGCCTGGGCGGCCCGCCCTGCCCTGCTGCTGCCC
TCCCTGCTGCTGCTGCTGCTGCTGGGCGCCGGCGGCTGCGGCCCGGCGTGCGCGCC
GAGGTGCTGTTCCGCTGCCCCCCTGCACCCCGAGCGCCTGGCCGCCTGCGGCCCC
CCCCCGACGCCCCCTGCGCCGAGCTGGTGCAGCAGCCGGCTGCGGCTGCTGCTC
CGTGTGCGCCCGCCAGGAGGGCGAGGCCTGCGGCGTGATACATCCCCGCTGCGCCC
AGACCCTGCGCTGCTACCCCAACCCCGGCTCCGAGCTGCCCTGAAGGCCCTGGTG
ACGGCGCCGGCACCTGCGAGAAGCGCCGCGTGGGCACCACCCCCAGCAGGTGGC
CGACTCCGACGACGACCACTCCGAGGGCGGCCTGGTGGAGCAATTGACCATGCGCC
GCCTGCTGCAGGAGACCGAGCTGGTGGAGCCCCTGACCCCTCCGGCGCCGTGCCC
AACCAGGCCCAGATGCGCATCCTGAAGGAGACCGAGCTGCGCAAGCTGAAGGTGCT
GGGCTCCGGCGCCTTCGGCACCGTGTACAAGGGCATCTGGATCCCCGACGGCGAGA
ACGTGAAGATCCCCGTGGCCATCAAGGTGCTGCGCGAGAACACCTCCCCAAGGCC
AACAAGGAGATCCTGGACGAGGCCTACGTGATGGCCGGCGTGGGCTCCCCCTACGT
GTCCCGCCTGCTGGGCATCTGCCTGACCTCCACCGTGCAGCTGGTGACCCAGCTGAT
GCCCTACGGCTGCCTGCTGGACCACGTGCGCGAGCACCGCGGCCGCTGGGCTCCC
AGGACCTGCTGAACTGGTGCCTGCAGATCGCCAAGGGCATGTCTACCTGGAGGAG
GTGCGCCTGGTGCACCGCGACCTGGCCGCCCGCAACGTGCTGGTGAAGTCCCCAA
CCACGTGAAGATCACCGACTTCGGCCTGGCCCGCCTGCTGGACATCGACGAGACCG
AGTACCACGCCGACGGCGGCAAGGTGCCCATCAAGTGGATGGCCCTGGAGTCCATC
CTGCGCCGCCGCTTCACCCACCAGTCCGACGTGTGGTCTACGGCGTGACCGTGTGG
GAGCTGATGACCTTCGGCGCCAAGCCCTACGACGGCATCCCCGCCCGGAGATCCC
CGACCTGCTGGAGAAGGGCGAGCGCCTGCCCCAGCCCCCATCTGCACCATCGACG
TGTACATGATCATGGTGAAGTGCTGGATGATCGACTCCGAGTGCCGCCCCCGCTTCC
GCGAGCTGGTGTCCGAGTTCTCCCGCATGGCCCGCGACCCCGAGCGCTTCGTGGTGA
TCCAGAACGAGGACCTGGCCCTGGGCACCGGCTCCACCGCCACCGCCGCCACCGC
TCCTCCTCCCCCCCCCCCCCATCCGCCCGCCGGCGCCACCCTGGAGCGCCCCAAG
ACCCTGTCCCCCGGCAAGAACGGCGTGGTGAAGGACGTGTTGCTTCGGCGGGCGC
CGTGGAGAACCCCGAGTACCTGGGCCGGCCGGTACCTTGGTCTTCGGCGTGGTGC
TGTGGGAGATCGCCACCCTGGCCGAGCAGCCCTACCAGGGCCTGTCCAACGAGCAG
GTGCTGCGCTTCGTGATGGAGGGCGGCCTGCTGGACAAGCCCGACAACCTGCCCGA
CATGCTGTTTCGAGCTGATGCGCATGTGCTGGCAGTACAACCCCAAGATGCGCCCCCTC
CTTCCTGGAGCACAAGGCCGAGAACGGCCCCGGCCCCGGCGTGCTGGTGTGCTGCGCG
CCTCCTTCGACGAGCGCCAGCCCTACGCCACATGAACGGCGGCCGCGCCAACGAG

CGCGCCCTGCCCCGCGGCCGCATAG (SEQ ID NO: 77); a nucleotide sequence having at least 90% sequence identity to the nucleotide sequence of ATGGCGGTACCAATGCTGCCCCGCCTGGGCGGCCCGCCCTGCCCCTGCTGCTGCCC TCCCTGCTGCTGCTGCTGCTGCTGGGCGCCGGCGGGCTGCGGCCCGGCGGTGCGCGCC GAGGTGCTGTTCCGCTGCCCCCCCCTGCACCCCCGAGCGCCTGGCCGCCTGCGGCCCC CCCCCGACGCCCCCTGCGCCGAGCTGGTGC GCGAGCCCCGGCTGCGGCTGCTGCTC CGTGTGCGCCCGCCAGGAGGGCGAGGCCTGCGGCGTGACATCCCCCGCTGCGCCC AGACCCTGCGCTGCTACCCCAACCCCGGCTCCGAGCTGCCCCTGAAGGCCCTGGTG ACCGGCGCCGGCACCTGCGAGAAGCGCCGCGTGGGCGCCACCCCCAGCAGGTGGC CGACTCCGAGGACGACCACTCCGAGGGCGGCCTGGTGGAGCAATTGACCATGCGCC GCCTGCTGCAGGAGACCGAGCTGGTGGAGCCCCCTGACCCCCCTCCGGCGCCATGCCC AACCAGGCCCAGATGCGCATCCTGAAGGAGACCGAGCTGCGCAAGGTGAAGGTGC TGGGCTCCGGCGCCTTCGGCACCGTGTACAAGGGCATCTGGATCCCCGACGGCGAG AACGTGAAGATCCCCGTGGCCATCAAGGTGCTGCGCGAGAACACCTCCCCCAAGGC CAACAAGGAGATCCTGGACGAGGCCTACGTGATGGCCGGCGTGGGCTCCCCCTACG TGTCCCGCCTGCTGGGCATCTGCCTGACCTCCACCGTGCAGCTGGTGACCCAGCTGA TGCCCTACGGCTGCCTGCTGGACCACGTGCGCGAGCACCGCGGCCCGCCTGGGCTCC CAGGACCTGCTGAAGTGGTGCCTGCGAGATCGCCAAGGGCATGTCTACCTGGAGGA CGTGCGCCTGGTGCACCGCGACCTGGCCGCCCGCAACGTGCTGGTGAAGTCCCCCA ACCACGTGAAGATCACCGACTTCGGCCTGGCCCCGCTGCTGGACATCGACGAGACC GAGTACCACGCGGACGGCGGCAAGGTGCCCATCAAGTGGATGGCCCTGGAGTCCAT CCTGCGCCGCGCTTCACCCACCAGTCCGACGTGTGGTCTACGGCGTGACCGTGTG GGAGCTGATGACCTTCGGCGCCAAGCCCTACGACGGCATCCCCGCCCGCGAGATCC CCGACCTGCTGGAGAAGGGCGAGCGCCTGCCCCAGCCCCCATCTGCACCATCGAC GTGTACATGATCATGGTGAAGTGCTGGATGATCGACTCCGAGTGCCGCCCCCGCTTC CGCGAGCTGGTGTCCGAGTTCTCCCGCATGGCCCGCGACCCCCAGCGCTTCGTGGTG ATCCAGAACGAGGACCTGACCCCCGGCACCGGCTCCACCGCCACCGCCGCCACCG CTCCTCCTCCCCCCTGCCCCCGTGCGCCCCGCGGCGCCACCCTGGAGCGCCCCAA GACCCTGTCCCCCGCAAGAACGGCGTGGTGAAGGACGTGTTGCTTCGGCGGCG CCGTGGAGAACCCCGAGTACCTGGGCCGGCCGGTACCTTGGTCTTCGGCGTGGTG CTGTGGGAGATCGCCACCCTGGCCGAGCAGCCCTACCAGGGCCTGTCCAACGAGCA GGTGCTGCGCTTCGTGATGGAGGGCGGCCTGCTGGACAAGCCCGACAACCTGCCCCG ACATGCTGTTGAGCTGATGCGCATGTGCTGGCAGTACAACCCCAAGATGCGCCCC TCCTTCTGGAGCACAAGGCCGAGAACGGCCCCGGCGTGCTGGTGTGCTGCGCGCCTC CTTGACGAGCGCCAGCCCTACGCCACATGAACGGCGGCCGCGCCAACGAGCGCG CCCTGCCCCGCGGCCGCATAG (SEQ ID NO: 78); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of MAVPMLPRVGCPALPLPPPLLLPLLLLLLLLGGASGGGGGARA EVLFRCPPTPERLAAC GPPPVAAPAAVAAGGARMPCAEVREPGCGCCSVCARLEGEACGVYTPRCGQGLR CYPHPGSELPLQALVMGEGTCEKRRDAEYGASPEQVADNGDDHSEGLVEQLTMRRL LQETELVEPLTPSGAMPNQAQMRILKETELRKVKVLGSGAFGTVYKGIWIPDGENVKIP VAIKVLRENTSPKANKEILDEAYVMAGVGSPYVSRLLGICLTSTVQLVTQLMPYGCLLD HVRENRGRLGSQDLLNWCMIKMSYLEDVRLVHRDLAARNVLVKSPNHVKITDFG LARLLDIDETEHADGGKVPIKWMALLESILRRRFTHQSDVWSYGVTVWELMTFGAKPY DGIPAREIPDLLEKGERLPQPICTIDVYMIMVKCWMIDSECRPRFRELVSF SRMARDP QRFVVIQNEIDLAPGAGGMVHHRHRSSSPLPAARPAGATLERPKTLSPGKNGVVKDVFA FGGAVENPEYLGRPVPWSFGVVLWEIATLAEQPYQGLSNEQVLRFMEGGLLDKPDNC PDMLFELMRMCWQYNPKMRPSFLEHKAENGP GPGVLVLRASFDERQPYAHMNGGRK NERALPAAA (SEQ ID NO: 79); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of MAVPMLPRLGGPALPLLLPSLLLLLLLLGAGGCGPGVRAEVLFRCPPTPERLAACGPPP DAPCAELVREPGCGCCSVCARQEGEACGVYIPRCAQTLRCYPNPGSELPLKALVTGAGT CEKRRVGTTQQVADSDDHSEGLVEQLTMRRLQETELVEPLTPSGAVPNQAQMRI LKETELRKLKVLGSGAFGTVYKGIWIPDGENVKIPVAIKVLRENTSPKANKEILDEAYV MAGVGSPYVSRLLGICLTSTVQLVTQLMPYGCLLDHVREHRGRLGSQDLLNWCMIKMS YLEEVRLVHRDLAARNVLVKSPNHVKITDFGLARLLDIDETEHADGGKVPIKWM ALLESILRRRFTHQSDVWSYGVTVWELMTFGAKPYDGIPAREIPDLLEKGERLPQPICTI DVYMIMVKCWMIDSECRPRFRELVSF SRMARDPQRFVVIQNEIDLALGTGSTAHRHR SSSPPPIRPAGATLERPKTLSPGKNGVVKDVFAFGGAVENPEYLGRPVPWSFGVVLWEI ATLAEQPYQGLSNEQVLRFMEGGLLDKPDNCPDMLFELMRMCWQYNPKMRPSFLEH KAENGP GPGVLVLRASFDERQPYAHMNGGRANERALPAAA (SEQ ID NO: 80); and a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of

MAVPMLPRLGGPALPLLLPSLLLLLLLGAGGCGPGVRAEVLFRCPCTPERLAACGPPP
DAPCAELVREPGCGCCSVCARQEGEACGVYIPRCAQTLRCYPNPGSELPLKALVTGAGT
CEKRRVGATPQQVADSEDDHSEGLVEQLTMRLLQETELVEPLTPSGAMPNQAQMRI
LKETELRKVKVLGSGAFGTVYKGIWIPDGENVKIPVAIKVLRENTSPKANKEILDEAYV
MAGVGSPYVSRLLGICLTSTVQLVTQLMPYGCLLDHVREHRGRLGSQDLLNWCVQIAK
GMSYLEDVRLVHRDLAARNVLVKSPNHVKITDFGLARLLDIDETEHADGGKVPIKW
MALESILRRRFTHQSDVWSYGVTVWELMTFGAKPYDGIPAREIPDLLEKGERLPQPPICT
IDVYMIMVKCWMIDSECRPRFRELVSFARMARDPQRFVVIQNEDLTPGTGSTAHRHR
SSSPLPPVRPAGATLERPKTLPKGKNGVVKDVFAFGGAVENPEYLGRPVPWSFGVVLW
EIATLAEQPYQGLSNEQVLRFVMEGGLLDKPDNCPDMLFELMRMCWQYNPKMRPSFL
EHKAENGPGLVLRASFDERQPYAHMNGGRANERLPAALPAA(SAQ ID NO: 81).

[0074] In some cases, the compositions may comprise a first and a second epitope independently selected from: CD105, Yb-1, SOX-2, CDH3 or MDM2. In some cases, the compositions may comprise a third epitope, the first, second and third epitopes independently selected from: CD105, Yb-1, SOX-2, CDH3 or MDM2. In some cases, the compositions may comprise a third and a fourth epitope, the first, second, third and fourth epitopes independently selected from: CD105, Yb-1, SOX-2, CDH3 or MDM2. In some cases, the compositions may comprise a third, a fourth and a fifth epitope, the first, second, third, fourth and fifth epitopes independently selected from: CD105, Yb-1, SOX-2, CDH3 or MDM2.

[0075] In some cases, the compositions may comprise a first and a second epitope independently selected from: IGFBP2, HER-2 or IGF-1R. In some cases, the compositions may comprise a third epitope, the first, second and third epitopes independently selected from: IGFBP2, HER-2 or IGF-1R.

[0076] In some cases, the compositions may be capable of being administered to a subject. In some cases, the subject is in need of administration of the composition. In some cases, the composition is effective to elicit an immune response in a subject. In some cases, the composition is effective to eliminate a number of cells associated with breast cancer in a subject. In some cases, the composition can be used to prevent the growth of cells associated with breast cancer in a subject.

[0077] In some cases, the first and the second nucleic acid sequences are located on the first plasmid. In some cases, the second nucleic acid sequence is located on a second plasmid.

[0078] In some cases, the cells associated with breast cancer are selected from: breast cells expressing atypical features, pre-neoplastic breast cells, breast cancer cells, pre-invasive breast cancer cells, breast cancer stem cells, epithelial cells, mesenchymal cells, stromal cells, or a combination thereof.

[0079] In some cases, the first and the second nucleic acid sequences are purified to at least 70% purity. In some cases, the first and the second nucleic acid sequences are located on the first plasmid and are separated by a sequence of linker nucleic acids. In some cases, the first nucleic acid sequence is adjacent to the second nucleic acid sequence on the first plasmid.

[0080] In some cases, at least the first plasmid is contained within a pharmaceutical composition. In some cases, at least the first plasmid is contained within a pharmaceutical composition further comprising a pharmaceutical carrier. In some cases, at least the first plasmid is contained within a pharmaceutical composition further comprising a pharmaceutical carrier and an adjuvant. In some cases, at least the first plasmid is contained within a pharmaceutical composition further comprising an adjuvant. In some cases, the composition further comprises an adjuvant and a pharmaceutically acceptable carrier. In some cases, the adjuvant is GM-CSF.

[0081] In some cases, a subject is selected from: a human with breast cancer, a mouse with breast cancer or a rat with breast cancer. In some cases, a subject is selected from: a human without breast cancer, a mouse without breast cancer or a rat without breast cancer.

[0082] In some cases, the immune response is a Type 1 immune response. In some cases, the first nucleic acid sequence is a species selected from: human, mouse or rat. In some cases, the second nucleic acid sequence is a species selected from: human, mouse or rat. In some cases, the immune response is characterized by a ratio of Type I cytokine production to Type II cytokine production that is greater than 1. In some cases, the immune response is characterized by a ratio of Type I cytokine production to Type II cytokine production that is less than 1. In some cases, the immune response is characterized by a ratio of IFN γ production to IL-10 production that is greater than 1. In some cases, the immune response is characterized by a ratio of IFN γ production to IL-10 production that is less than 1.

[0083] In some cases, the compositions include a composition comprising: a first plasmid comprising a first nucleotide

sequence, the first nucleotide sequence encoding a first epitope of a first antigen, the first epitope is a portion of an HIF-1 α peptide, wherein the first nucleotide sequence is located in a plasmid. In other cases, the compositions include a composition comprising: a first plasmid comprising a first nucleotide sequence, the first nucleotide sequence encoding a first epitope of a first antigen; and a second nucleotide sequence, the second nucleotide sequence encoding a second epitope of a second antigen, wherein the first and the second epitopes are portions of an HIF-1 α peptide, wherein the first nucleotide sequence and the second nucleotide sequence are located in one or more plasmids.

[0084] The nucleic acid sequences which encode epitopes from the following proteins, CD105, HIF1 α , MDM2, Yb1, SOX-2, HER-2, IGFBP2, IGF-1R and CDH3 may differ from those listed herein. In some cases, nucleic acid sequences which are greater than 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55% or greater than 50% homologous to those disclosed herein may be used in the compositions described herein.

[0085] The compositions described herein, in some cases, may include a composition comprising: a first epitope of a first antigen expressed by cells associated with breast cancer; and a second epitope of a second antigen expressed by cells associated with breast cancer.

[0086] In some cases, the composition may comprise: at least a first epitope of a first antigen, the first epitope is a portion of a peptide selected from: CD105, Yb-1, SOX-2, CDH3 or MDM2. In some cases, the composition may comprise: at least a first epitope of a first antigen, at least a second epitope of a second antigen, the first and the second epitopes are independently selected from: CD105, Yb-1, SOX-2, CDH3 or MDM2. In some cases, at least a first epitope of the peptide CD105 is selected from the group consisting of: an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of EARM LNASIVASFVELPL (SEQ ID NO: 6); an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of QNGTWPREVLLVLSVNSSVFLHLQALGIPLHLAYNSSLVTFQEPPGVNTTEL (SEQ ID NO: 1); an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of TVFMRLNIISPDL SGCTSKGLVLPV LGITFGAFLIGALLTAALWYIYSHTRSPSKREPVV AVAAPASSESSSTNHSIGSTQSTPCSTSSMA (SEQ ID NO: 8); an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of TVSMRLNIVSPDL SGKGLVLPV LGITFGAFLIGALLTAALWYIYSHTRGPSKREPVVAV AAPASSESSSTNHSIGSTQSTPCSTSSMA (SEQ ID NO: 9); or an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of TVSMRLNIVSPDL SGKGLVLPV LGITFGAFLIGALLTAALWYIYSHTRAPSKREPVVAV AAPASSESSSTNHSIGSTQSTPCSTSSMA (SEQ ID NO: 10). In some cases, at least a first epitope of the peptide Yb-1 is selected from the group consisting of: an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of EDVFVHQTAIKNNPRK (SEQ ID NO: 14); an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of YRRNFNYRRRRPEN (SEQ ID NO: 15); or an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of GVPVQGSKYAADRNHYRRYPRRRGPPRNYQQN (SEQ ID NO: 16). In some cases, at least a first epitope of the peptide SOX-2 is selected from the group consisting of: an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of GLNAHGAAQM QPMHRYDVSALQYNSMTSSQTYMNGSPTYMSYSQQGTPGMALGSM GSV (SEQ ID NO: 20). In some cases, at least a first epitope of the peptide CDH3 is selected from the group consisting of: an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of RSLKERNPLKIFPSKRILRRHKRDWWAPISVPENGKGPFQRLNQLKSNKDRDTKIFYSI TGP GADSPPEGVFAVEKET (SEQ ID NO: 25); an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of LKIFPSKRILRRHKRDWWAPISVPENGKGPFQRLNQLKSNKDRDTKIFY SITGP GADSP PEGVFAVEKET (SEQ ID NO: 26); an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of AMHSPPTRILRRRKREWWMPPIFVPENGKGPFQRLNQLKSNKDRGTKIFY SITGP GADS PPEGVFTIEKES (SEQ ID NO: 27); or an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of VMNSPPSRILRRRKREWWMPPIFVPENGKGPFQRLNQLKSNKDRGTKLFY SITGP GADS PPEGVFTIEKET (SEQ ID NO: 28). In some cases, at least a first epitope of the peptide MDM-2 is selected from the group consisting of: an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of TYTMKEVLFYLGQYIMTKRLYDEKQQHIVYCSNDLLGDVFGVPSFSVKEHRKIY TMIYR NLVVVNQQESSDSGTSV (SEQ ID NO: 32); an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of TYTMKEIFYIGQYIMTKRLYDEKQQHIVYCSNDLLGDVFGVPSFSVKEHRKIY AMIYRN LVAVSQQDSGTSLS (SEQ ID NO: 33); or an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of IYTMKEIFYIGQYIMTKRLYDEKQQHIVYCSNDLLGDVFGVPSFSVKEHRKIY AMIYRN LVVVSQQDSGTSPS (SEQ ID NO: 34).

[0087] In some cases, the compositions described herein include an amino acid sequence of a fusion peptide of five epitopes is selected from the group consisting of: an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of MAVPMLSCSRQNGTWPREVLLVLSVNSSVFLHLQALGIPLHLAYNSSLVTFQEPPGVN

TTELRSTGGVPVQGSKYAADRNHYRRYPRRRGPPRNYQQNTRGLNAHGAAQMOPMH
 RYDVSALQYNSMTSSQTYMNGSPTYSMSYSQQGTPGMALGSMGVSQRSLSLKERNP
 LKIFPSKRILRRHKRDWWVAPISVPENGKGPFQRLNQLKSNKDRDTKIFYSTGPGADSP
 PEGVFAVEKETRSAGETYTMKEVLFYLGQYIMTKRLYDEKQQHIVYCSNDLLGDLFGV
 PSFSVKEHRKIYTMIRNLVVVNQQESSDSGTSVSRS (SEQ ID NO: 39); an amino acid sequence, the amino acid sequence
 having at least 90% sequence identity to the amino acid sequence of
 MAVPMTVMRLNIISPDLGCTSKGLVLPVGLITFGAFLIGALLTAALWYIYSHTRSPS
 KREPVVAAAPASSESSSTNHSIGSTQSTPCSTSSMATGGVPVQGSKYAADRNHYRRYP
 RRRGPPRNYQQNTRGLNAHGAAQMOPMHRYDVSALQYNSMTSSQTYMNGSPTYSMS
 YSQGTPGMALGSMGVSQRSLLKIFPSKRILRRHKRDWWVAPISVPENGKGPFQRLNQ
 LKSNKDRDTKIFYSTGPGADSPPEGVFAVEKETRSAGETYTMKEVLFYLGQYIMTKRL
 YDEKQQHIVYCSNDLLGDLFGVPSFSVKEHRKIYTMIRNLVVVNQQESSDSGTSVSRS (SEQ ID NO: 40); an amino acid
 sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of
 MAVPMTVSMRLNIVSPDLGKGLVLPVGLITFGAFLIGALLTAALWYIYSHTRGPSKRE
 PVVAAAPASSESSSTNHSIGSTQSTPCSTSSMATGGVPVQGSKYAADRNHYRRYP
 GPPRNYQQNTRGLNAHGAAQMOPMHRYDVSALQYNSMTSSQTYMNGSPTYSMSYSQ
 QGTPGMALGSMGVSQRSQLAMHSPTRILRRRKREWMPPIFVPENGKGPFQRLNQLK
 SNKDRGTKIFYSTGPGADSPPEGVFTIEKESRSAGETYTMKEIFYIGQYIMTKRLYDEK
 QQHIVYCSNDLLGDVFGVPSFSVKEHRKIYAMIYRNLVAVSQQDSGTSLSRS (SEQ ID NO: 41); or an amino acid sequence, the
 amino acid sequence having at least 90% sequence identity to the amino acid sequence of
 MAVPMTVSMRLNIVSPDLGKGLVLPVGLITFGAFLIGALLTAALWYIYSHTRAPSKRE
 PVVAAAPASSESSSTNHSIGSTQSTPCSTSSMATGGVPVQGSKYAADRNHYRRYP
 GPPRNYQQNTRGLNAHGAAQMOPMHRYDVSALQYNSMTSSQTYMNGSPTYSMSYSQ
 QGTPGMALGSMGVSQRSQVMNSPPSRILRRRKREWMPPISVPENGKGPFQRLNQLKS
 NKDRGTLKFYSTGPGADSPPEGVFTIEKETRSAGEIYTMKEIFYIGQYIMTKRLYDEKQ
 QHIVYCSNDLLGDVFGVPSFSVKEHRKIYAMIYRNLVVVSQQDSGTSPSRS (SEQ ID NO: 42).

[0088] The compositions described herein may further include a composition comprising: a first plasmid comprising a first nucleotide sequence, the first nucleotide sequence encoding a first epitope of a first antigen, the first epitope is a portion of a peptide selected from: IGFBP-2, HER-2 or IGF-1R, wherein the first nucleotide sequence is located in a plasmid. In some cases, the composition may comprise: a first plasmid comprising a first nucleotide sequence, the first nucleotide sequence encoding a first epitope of a first antigen; and a second nucleotide sequence, the second nucleotide sequence encoding a second epitope of a second antigen, wherein the first and the second epitopes are independently selected from: IGFBP-2, HER-2 or IGF-1R, wherein the first nucleotide sequence and the second nucleotide sequence are located in one or more plasmids. In some cases, at least a first epitope of the peptide IGFBP-2 is selected from the group consisting of: an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of NHVDSTMNMLGGGGS (SEQ ID NO: 46); an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of ELAVFREKVTEQHRQ (SEQ ID NO: 47); an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of LGLEEPKKLRPPPAR (SEQ ID NO: 48); an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of DQVLERISTMRPDE (SEQ ID NO: 49); an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of GPLEHLYSLHIPNCD (SEQ ID NO: 50); an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of KHGLYNLKQCKMSLN (SEQ ID NO: 51); an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of PECHLFYNEQQEARG (SEQ ID NO: 53); an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of MLPRVGCPALPLPPPPLLPPLLLLLLGGAGGGGGGARAELVFRCPPTPERLAACGPPP VAPPAVAAGGARMPCAEVREPGCGCCSVCARLEGEACGVYTPRCGQGLRCYPH PGSELPLQALVMGEGTCEKRRDAEYGASPEQVADNGDDHSEGGGLVE (SEQ ID NO: 54); an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of MLPRLGGPALPLLLPSLLLLLLGAGGCGPGVRAEVLFRCPPTPERLAACGPPPDAPCA ELVREPGCGCCSVCARQEGEACGVYIPRCAQTLRCYPNPGSELPLKALVTGAGTCEKRR VGTTPQQVADSDDHSEGGGLVE (SEQ ID NO: 55); or an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of MLPRLGGPALPLLLPSLLLLLLGAGGCGPGVRAEVLFRCPPTPERLAACGPPPDAPCA ELVREPGCGCCSVCARQEGEACGVYIPRCAQTLRCYPNPGSELPLKALVTGAGTCEKRR VGATPQQVADSEDDHSEGGGLVE (SEQ ID NO: 56). In some cases, at least a first epitope of the peptide HER-2 is selected from the group consisting of: a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of TMRRLLQETELVEPLTPSGAMPNQAQMRILKETELRKVKVLGSGAFGTVYKGIWPDGE NVKIPVAIKVLRENTSPKANKEILDEAYVMAGVGSPYVSRLLGICLTSTVQLVTQLMPY GCLLDHVRENRGRLGSQDLLNWCMQIAKGMSYLEDVRLVHRDLAARNVLVKSPNHV

KITDFGLARLLDIDETEHADGGKVPIKWMMALESILRRRFTHQSDVWSYGVTVWELMT
FGAKPYDGIPAREIPDLLEKGERLPQPPICTIDVYMIMVKCWMIDSECRPRFRELVEFSR
MARDPQRFVVIQNEIDLAPGAGGMVHHRHRSSSPLPAARPAGATLERPKTLSPGKNGVV KDVFAFGGAVENPEYL (SEQ ID NO: 60); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of TMRLLQETELVEPLTPSGAVPNQAQMRILKETELRKLVKVLGSGAFGTVYKGIWMPDGE NVKIPVAIKVLRENTSPKANKEILDEAYVMAGVGSPYVSRLLGICLTSTVQLVTQLMPY GCLLDHVREHRGRLGSQDLLNWCVQIAKGMSYLEEVRLVHRDLAARNVLVKSPNHVK ITDFGLARLLDIDETEHADGGKVPIKWMMALESILRRRFTHQSDVWSYGVTVWELMTF GAKPYDGIPAREIPDLLEKGERLPQPPICTIDVYMIMVKCWMIDSECRPRFRELVEFSR MARDPQRFVVIQNEIDLALGTGSTAHRHRSSSPPIRPAGATLERPKTLSPGKNGVVK DVFAFGGAVENPEYL (SEQ ID NO: 61); or a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of TMRLLQETELVEPLTPSGAMPNQAQMRILKETELRKVKVLGSGAFGTVYKGIWMPDGE NVKIPVAIKVLRENTSPKANKEILDEAYVMAGVGSPYVSRLLGICLTSTVQLVTQLMPY GCLLDHVREHRGRLGSQDLLNWCVQIAKGMSYLEEDVRLVHRDLAARNVLVKSPNHV KITDFGLARLLDIDETEHADGGKVPIKWMMALESILRRRFTHQSDVWSYGVTVWELMT FGAKPYDGIPAREIPDLLEKGERLPQPPICTIDVYMIMVKCWMIDSECRPRFRELVEFSR MARDPQRFVVIQNEIDLTPGTGSTAHRHRSSSPLPPVRPAGATLERPKTLSPGKNGVVK DVFAFGGAVENPEYL (SEQ ID NO: 62). In some cases, a nucleic acid sequence encoding an epitope of the peptide IGF-1R is selected from the group consisting of: an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of DYRSYRFPKLTVITE (SEQ ID NO: 66); an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of IRGWKLFYNYALVIF (SEQ ID NO: 67); an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of VVTGYVKIRHSHALV (SEQ ID NO: 68); an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of FFYVQAKTGYENFIH (SEQ ID NO: 69); an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of LIALPVAVLLIVGG (SEQ ID NO: 70); an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of LVIMLYVFHRKRNN (SEQ ID NO: 71); an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of NCHHVRLLGVSQG (SEQ ID NO: 72); an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of WSFGVWLWEIATLAEQPYQGLSNEQVLRVFMEGGLLDKPDNCPDMLFELMRMCWQY NPKMRPSFLEHKAENGPGPGVLVLRASFDERQPYAHMNGGRKNERALP (SEQ ID NO: 73); an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of WSFGVWLWEIATLAEQPYQGLSNEQVLRVFMEGGLLDKPDNCPDMLFELMRMCWQY NPKMRPSFLEHKAENGPGPGVLVLRASFDERQPYAHMNGGRANERALP (SEQ ID NO: 74); or an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of WSFGVWLWEIATLAEQPYQGLSNEQVLRVFMEGGLLDKPDNCPDMLFELMRMCWQY NPKMRPSFLEHKAENGPGVLVLRASFDERQPYAHMNGGRANERALP (SEQ ID NO: 75).

[0089] The compositions described herein may further include a nucleic acid sequence encoding a fusion protein of three epitopes is selected from the group consisting of: an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of MAVPMLPRVGCPALPLPPPPLPLPLLLLLLGGAGGGGGARAEVLFRCPPCTPERLAAC GPPPVPAPAAVAAGGARMPCAEVLRPGCGCCSVCARLEGEACGVYTPRCGQGLR CYPHPGSELPLQALVMGEGTCEKRRDAEYGASPEQVADNGDDHSEGGLVEQLTMRRLLQETELVEPLTPSGAMPNQAQMRILKETELRKVKVLGSGAFGTVYKGIWIPDGENVKIP VAIKVLRENTSPKANKEILDEAYVMAGVGSPYVSRLLGICLTSTVQLVTQLMPYGCCLLD HVRENRLGRLGSQDLLNWCQIAKGMSYLEEDVRLVHRDLAARNVLVKSPNHVKITDFGLARLLDIDETEHADGGKVPIKWMMALESILRRRFTHQSDVWSYGVTVWELMTFGAKPY DGIPAREIPDLLEKGERLPQPPICTIDVYMIMVKCWMIDSECRPRFRELVEFSRMARDP QRFVVIQNEIDLAPGAGGMVHHRHRSSSPLPAARPAGATLERPKTLSPGKNGVVKDVFA FGGAVENPEYLGRPVPWSFGVWLWEIATLAEQPYQGLSNEQVLRVFMEGGLLDKPDNC PDMLFELMRMCWQYNPKMRPSFLEHKAENGPGPGVLVLRASFDERQPYAHMNGGRKNERALPAAA (SEQ ID NO: 79); an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of MAVPMLPRLGGPALPLLLPSLLLLLLGGAGCGPGVRAEVLFRCPPCTPERLAACGPPP DAPCAELVREPGCGCCSVCARQEGEACGVYIPRCAQTLRCYPNPGSELPLKALVTGAGT CEKRRVGTTTPQQVADSDDHSEGGLVEQLTMRRLLQETELVEPLTPSGAVPNQAQMRI LKETELRKLVKVLGSGAFGTVYKGIWIPDGENVKIPVAIKVLRENTSPKANKEILDEAYV MAGVGSPYVSRLLGICLTSTVQLVTQLMPYGCCLLDHVREHRGRLGSQDLLNWCVQIAK GMSYLEEVRLVHRDLAARNVLVKSPNHVKITDFGLARLLDIDETEHADGGKVPIKWM ALESILRRRFTHQSDVWSYGVTVWELMTFGAKPYDGIPAREIPDLLEKGERLPQPPICTI

DVYMIMVKCWMIDSECRPRFRELVSEFSRMARDPQRFVVIQNEIDLALGTGSTAHRHR
 SSSPPPIRPAGATLERPKTLSPGKNGVVKDVFAFGGAVENPEYLGRPVPWSFGVWLWEI
 ATLAEQPYQGLSNEQVLRVMEGGLLDKPDNCPDMLFELMRMCWQYNPKMRPSFLEH
 KAENGP GPGVLVLRASFDERQPYAHMNGGRANERALPAAA (SEQ ID NO: 80); or an amino acid sequence, the amino acid
 sequence having at least 90% sequence identity to the amino acid sequence of
 MAVPMLPRLGGPALPLLLPSLLLLLLLGAGGCGPGVRAEVLFRCPCTPERLAACGPPP
 DAPCAELVREPGCGCCSVCARQEGEACGVYIPRCAQTLRCYPNPGSELPLKALVTGAGT
 CEKRRVGATPQQVADSEDDHSEGLVEQLTMRLLQETELVEPLTPSGAMPNQAQMRI
 LKETELRKVKVLGSGAFGTVYKGIWPDGENVKIPVAIKVLRENTSPKANKEILDEAYV
 MAGVGSPYVSRLLGICLTSTVQLVTQLMPYGCLLDHVREHRGRLGSQDLLNWCVQIAK
 GMSYLEDVRLVHRDLAARNVLVKSPNHVKITDFGLARLLDIDETEHADGGKVPIKW
 MALESILRRRFTHQSDVWSYGVTVWELMTFGAKPYDGIPAREIPDLLEKGERLPQPPICT
 IDVYMIMVKCWMIDSECRPRFRELVSEFSRMARDPQRFVVIQNEIDLTPGTGSTAHRHR
 SSSPLPPVRPAGATLERPKTLSPGKNGVVKDVFAFGGAVENPEYLGRPVPWSFGVWLW
 EIATLAEQPYQGLSNEQVLRVMEGGLLDKPDNCPDMLFELMRMCWQYNPKMRPSFL
 EHKAENGP GVLVLRASFDERQPYAHMNGGRANERALPAAA (SEQ ID NO: 81).

[0090] In some cases, the composition comprises a first and a second epitope independently selected from: CD105, Yb-1, SOX-2, CDH3 or MDM2. In some cases, the composition further comprises a Third epitope, the first, second and Third epitopes independently selected from: CD105, Yb-1, SOX-2, CDH3 or MDM2. In some cases, the composition further comprises a Third and a fourth epitope, the first, second, Third and fourth epitopes independently selected from: CD105, Yb-1, SOX-2, CDH3 or MDM2. In some cases, the composition further comprises a Third, a fourth and a fifth epitope, the first, second, Third, fourth and fifth epitopes independently selected from: CD105, Yb-1, SOX-2, CDH3 or MDM2.

[0091] In some cases, the composition comprises a first and a second epitope independently selected from: IGFBP2, HER-2 or IGF-1R. In some cases, the composition further comprises a Third epitope, the first, second and Third epitopes independently selected from: IGFBP2, HER-2 or IGF-1R.

[0092] In some cases, a composition may comprise: at least a first epitope of a first antigen, the first epitope is a portion of a peptide from HIF-1 α . In some cases, a composition may comprise: at least a first epitope of a first antigen, at least a second epitope of a second antigen, the first and the second epitopes are from HIF-1 α .

[0093] In some cases, the compositions may include a nucleic acid sequence encoding an epitope of the peptide HIF-1 α is selected from the group consisting of: a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of
 DSKTFLSRHSLDMKF SYCDERITELMGYEPEELLGRSIYEYHALDSDHLTKTHHDMFT
 KGQVTTGQYRMLAKRGGYVWVETQATVIYN (SEQ ID NO: 82); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of
 SDNVNKYMGLTQFELTGHSVDFDTHP (SEQ ID NO: 83); and a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of GGYVWVETQATVIYNTKNSQ (SEQ ID NO: 84).

[0094] In some cases, the composition may include at least a first epitope of the peptide HIF-1 α is selected from the group consisting of: an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of
 DSKTFLSRHSLDMKF SYCDERITELMGYEPEELLGRSIYEYHALDSDHLTKTHHDMFT
 KGQVTTGQYRMLAKRGGYVWVETQATVIYN (SEQ ID NO: 82); an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of SDNVNKYMGLTQFELTGHSVDFDTHP (SEQ ID NO: 83); and an amino acid sequence, the amino acid sequence having at least 90% sequence identity to the amino acid sequence of GGYVWVETQATVIYNTKNSQ (SEQ ID NO: 84).

[0095] The amino acid sequences of the epitopes from the following proteins, CD105, HIF1 α , MDM2, Yb1, SOX-2, HER-2, IGFBP2, IGF-1R and CDH3 may differ from those listed herein. In some cases, amino acid sequences which are greater than 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55% or greater than 50% homologous to those disclosed herein may be used in the compositions described herein.

[0096] In some cases, the first amino acid sequences are selected from a group of species consisting of, human, mouse and rat. In some cases, the second amino acid sequences are selected from a group of species consisting of, human, mouse and rat.

[0097] In some cases, the first and the second nucleic acid sequences are located on the first plasmid. In some cases, the second nucleic acid sequence is located on a second plasmid. In some cases, the amino acid sequences of the first and the second epitopes are separated by a sequence of linker amino acids. In some cases, the amino acid sequence of the first epitope is adjacent to the amino acid sequence of the second epitope.

[0098] In some cases, the immune response is a Type 1 immune response. In some cases, the immune response is characterized by a ratio of Type I cytokine production to Type II cytokine production that is greater than 1. In some cases, the immune response is characterized by a ratio of Type I cytokine production to Type II cytokine production that is less than 1. In some cases, the immune response is characterized by a ratio of IFN γ production to IL-10 production that is greater than 1. In some cases, the immune response is characterized by a ratio of IFN γ production to IL-10 production that is less than 1.

[0099] In some cases, the composition is administered to a subject. In some cases, the subject is in need of administration of the composition. In some cases, the composition is effective to elicit an immune response in a subject. In some cases, the composition is effective to eliminate a number of cells associated with breast cancer in a subject. In some cases, the composition may be used to prevent the growth of cells associated with breast cancer in a subject.

[0100] In some cases, a subject is selected from the group consisting of a human with breast cancer, a mouse with breast cancer and a rat with breast cancer. In some cases, a subject is selected from the group consisting of a human without breast cancer, a mouse without breast cancer and a rat without breast cancer.

[0101] In some cases, the cells associated with breast cancer are selected from: breast cells expressing atypical features, pre-neoplastic breast cells, breast cancer cells, pre-invasive breast cancer cells, breast cancer stem cells, epithelial cells, mesenchymal cells, stromal cells, or a combination thereof.

[0102] In some cases, at least the first epitope is contained within a pharmaceutical composition. In some cases, at least the first epitope is contained within a pharmaceutical composition further comprising a pharmaceutical carrier. In some cases, at least the first epitope is contained within a pharmaceutical composition further comprising a pharmaceutical carrier and an adjuvant. In some cases, at least the first epitope is contained within a pharmaceutical composition further comprising an adjuvant. In some cases, the composition further comprises an adjuvant and a pharmaceutical carrier. In some cases, the adjuvant is GM-CSF.

[0103] In some cases, the composition may be administered to a subject. In some cases, the subject is in need thereof. Disclosed herein are methods for preventing breast cancer in a subject, the method comprising administering the compositions described herein to a subject. Also disclosed are methods for treating breast cancer in a subject, the method comprising administering the compositions described herein to a subject. In some cases, administering further comprises delivery of at least one dose of the composition described herein to the subject. In some cases, the administering further comprises delivery of the compositions described herein to the subject by subcutaneous injection, intradermal injection, intramuscular injection, intravascular injection, topical application or inhalation. In some cases, the subject is selected from the group consisting of a human with breast cancer, a mouse with breast cancer and a rat with breast cancer. In some cases, the subject is selected from the group consisting of a human without breast cancer, a mouse without breast cancer and a rat without breast cancer.

[0104] The disclosure also provides for a kit for preparing the compositions described herein, the kit comprising instructions for preparing the composition. The disclosure also provides for a kit for administering the compositions described herein, the kit comprising instructions for administering the composition.

Compositions Comprising Epitopes Selected From Survivin, HIF-1 α , IGFBP-2, and IGF-1R

[0105] The compositions described herein include a plasmid comprising at least one nucleotide sequence encoding a polypeptide comprising at least 70% sequence identity to an epitope sequence selected from SEQ ID NOs: 54, 73, 85, and 87; and an excipient. The composition may include a plasmid which comprises at least one nucleotide sequence encoding a polypeptide comprising at least 80% sequence identity to an epitope sequence selected from SEQ ID NOs: 54, 73, 85, and 87. The composition may include a plasmid which comprises at least one nucleotide sequence encoding a polypeptide comprising at least 90% sequence identity to an epitope sequence selected from SEQ ID NOs: 54, 73, 85, and 87. The composition may include a plasmid which comprises at least one nucleotide sequence encoding a polypeptide comprising at least 95% sequence identity to an epitope sequence selected from SEQ ID NOs: 54, 73, 85, and 87. The composition may include a plasmid which comprises at least one nucleotide sequence encoding a polypeptide comprising at least 99% sequence identity to an epitope sequence selected from SEQ ID NOs: 54, 73, 85, and 87. The composition may include a plasmid which comprises at least one nucleotide sequence encoding a polypeptide comprising 100% sequence identity to an epitope

sequence selected from SEQ ID NOs: 54, 73, 85, and 87. The composition may include a plasmid which comprises at least one nucleotide sequence encoding a polypeptide consisting of 100% sequence identity to the full length of an epitope sequence selected from SEQ ID NOs: 54, 73, 85, and 87.

[0106] Sometimes, the at least one nucleotide sequence may encode a polypeptide comprising at least 70% sequence identity to at least 20 contiguous amino acids of SEQ ID NO: 85. The at least one nucleotide sequence may encode a polypeptide comprising at least 80% sequence identity to at least 20 contiguous amino acids of SEQ ID NO: 85. The at least one nucleotide sequence may encode a polypeptide comprising at least 90% sequence identity to at least 20 contiguous amino acids of SEQ ID NO: 85. The at least one nucleotide sequence may encode a polypeptide comprising at least 95% sequence identity to at least 20 contiguous amino acids of SEQ ID NO: 85. The at least one nucleotide sequence may encode a polypeptide comprising at least 99% sequence identity to at least 20 contiguous amino acids of SEQ ID NO: 85. The at least one nucleotide sequence may encode a polypeptide comprising at least 100% sequence identity to at least 20 contiguous amino acids of SEQ ID NO: 85.

[0107] Sometimes, the at least one nucleotide sequence may encode a polypeptide comprising at least 70% sequence identity to at least 60 contiguous amino acids of SEQ ID NO: 87. The at least one nucleotide sequence may encode a polypeptide comprising at least 80% sequence identity to at least 60 contiguous amino acids of SEQ ID NO: 87. The at least one nucleotide sequence may encode a polypeptide comprising at least 90% sequence identity to at least 60 contiguous amino acids of SEQ ID NO: 87. The at least one nucleotide sequence may encode a polypeptide comprising at least 95% sequence identity to at least 60 contiguous amino acids of SEQ ID NO: 87. The at least one nucleotide sequence may encode a polypeptide comprising at least 99% sequence identity to at least 60 contiguous amino acids of SEQ ID NO: 87. The at least one nucleotide sequence may encode a polypeptide comprising at least 100% sequence identity to at least 60 contiguous amino acids of SEQ ID NO: 87.

[0108] In some instances, the composition comprises an isolated plasmid which comprises at least four nucleotide sequences. Sometimes, each of the at least four nucleotide sequences independently encodes a polypeptide comprising at least 60%, 70%, 80%, 90%, 95%, 99%, or 100% sequence identity to an epitope sequence selected from SEQ ID NOs: 54, 73, 85, and 87. Sometimes, the isolated plasmid may comprise four nucleotide sequences. Sometimes, each of the four nucleotide sequences may independently encode a polypeptide comprising at least 60%, 70%, 80%, 90%, 95%, 99%, or 100% sequence identity to an epitope sequence selected from SEQ ID NOs: 54, 73, 85, and 87. Other times, each of the four nucleotide sequences may encode a different polypeptide. Sometimes, each of the different polypeptide may comprise at least 60%, 70%, 80%, 90%, 95%, 99%, or 100% sequence identity to an epitope sequence selected from SEQ ID NOs: 54, 73, 85, and 87.

[0109] Sometimes, one of the four nucleotide sequences may encode a polypeptide comprising at least 70% sequence identity to at least 20 contiguous amino acids of SEQ ID NO: 85. One of the four nucleotide sequences may encode a polypeptide comprising at least 80% sequence identity to at least 20 contiguous amino acids of SEQ ID NO: 85. One of the four nucleotide sequences may encode a polypeptide comprising at least 90% sequence identity to at least 20 contiguous amino acids of SEQ ID NO: 85. One of the four nucleotide sequences may encode a polypeptide comprising at least 95% sequence identity to at least 20 contiguous amino acids of SEQ ID NO: 85. One of the four nucleotide sequences may encode a polypeptide comprising at least 100% sequence identity to at least 20 contiguous amino acids of SEQ ID NO: 85.

[0110] Sometimes, one of the four nucleotide sequences may encode a polypeptide comprising at least 70% sequence identity to at least 60 contiguous amino acids of SEQ ID NO: 87. One of the four nucleotide sequences may encode a polypeptide comprising at least 80% sequence identity to at least 60 contiguous amino acids of SEQ ID NO: 87. One of the four nucleotide sequences may encode a polypeptide comprising at least 90% sequence identity to at least 60 contiguous amino acids of SEQ ID NO: 87. One of the four nucleotide sequences may encode a polypeptide comprising at least 95% sequence identity to at least 60 contiguous amino acids of SEQ ID NO: 87. One of the four nucleotide sequences may encode a polypeptide comprising at least 100% sequence identity to at least 60 contiguous amino acids of SEQ ID NO: 87.

[0111] In some cases, the four nucleotide sequences are positioned in tandem within the plasmid. The four nucleotide sequences may be separated by a sequence of linker nucleic acids. The sequence of linker nucleic acids may be from about 1 to about 150, from about 5 to about 100, or from about 10 to about 50 nucleic acids in length. In some instances, the nucleic acids may encode one or more amino acid residues. Sometimes, the amino acid sequence of the linker may be from about 1 to about 50, or from about 5 to about 25 amino acid residues in length. Sometimes the linker may include a linker (SEQ ID NO: 14) as shown as underlined in Fig. 14.

[0112] Sometimes, the composition may further comprise at least one additional isolated plasmid. Sometimes, the composition may further comprise at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, or more additional isolated plasmid.

[0113] In some cases, the at least one additional isolated plasmid comprises a nucleotide sequence encoding a polypeptide comprising at least 70% sequence identity to an epitope sequence selected from SEQ ID NOs: 54, 73, 85, and 87. The at least one additional isolated plasmid may comprise a nucleotide sequence encoding a polypeptide comprising at least 80% sequence identity to an epitope sequence selected from SEQ ID NOs: 54, 73, 85, and 87. The at least one additional isolated plasmid may comprise a nucleotide sequence encoding a polypeptide comprising at least 90% sequence identity to an epitope sequence selected from SEQ ID NOs: 54, 73, 85, and 87. The at least one additional isolated plasmid may comprise a nucleotide sequence encoding a polypeptide comprising at least 95% sequence identity to an epitope sequence selected from SEQ ID NOs: 54, 73, 85, and 87. The at least one additional isolated plasmid may comprise a nucleotide sequence encoding a polypeptide comprising at least 99% sequence identity to an epitope sequence selected from SEQ ID NOs: 54, 73, 85, and 87. The at least one additional isolated plasmid may comprise a nucleotide sequence encoding a polypeptide comprising 100% sequence identity to an epitope sequence selected from SEQ ID NOs: 54, 73, 85, and 87.

[0114] A composition described herein may include a composition comprising: a plasmid comprising a nucleotide sequence encoding a polypeptide comprising at least 80% sequence identity to SEQ ID NO: 89; and an excipient. The composition may include a plasmid which comprises a nucleotide sequence encoding a polypeptide comprising at least 90% sequence identity to SEQ ID NO: 89. The composition may include a plasmid which comprises a nucleotide sequence encoding a polypeptide comprising at least 95% sequence identity to SEQ ID NO: 89. The composition may include a plasmid which comprises a nucleotide sequence encoding a polypeptide comprising 100% sequence identity to SEQ ID NO: 89. The composition may include a plasmid which comprises a nucleotide sequence encoding a polypeptide consisting of 100% sequence identity to SEQ ID NO: 89.

[0115] A composition described herein may include a composition that comprises a polypeptide comprising at least 80% sequence identity to SEQ ID NO: 89. The composition may include a polypeptide which comprises at least 90% sequence identity to SEQ ID NO: 89. The composition may include a polypeptide which comprises at least 95% sequence identity to SEQ ID NO: 89. The composition may include a polypeptide which comprises 100% sequence identity to SEQ ID NO: 89. The composition may include a polypeptide which consists of 100% sequence identity to SEQ ID NO: 89.

[0116] The composition may be formulated for the treatment of breast cancer or ovarian cancer in a subject. The breast cancer may be a relapsed or refractory breast cancer. The ovarian cancer may be a relapsed or refractory ovarian cancer. The breast cancer may be a metastasized breastcancer. The ovarian cancer may be a metastasized ovarian cancer.

[0117] The composition may elicits an immune response. The immune response may be characterized by a ratio of Type I cytokine production to Type II cytokine production that is greater than 1. The immune response may be characterized by a ratio of Type I cytokine production to Type II cytokine production that is less than 1. The immune response may be characterized by a ratio of IFN- γ production to IL-10 production that is greater than 1. The immune response may be characterized by a ratio of IFN- γ production to IL-10 production that is less than 1.

[0118] Sometimes the composition may further comprises an adjuvant. Sometimes, the adjuvant is GM-CSF.

[0119] The composition may further comprises an excipient. The excipient may be a pharmaceutically acceptable carrier.

[0120] Often, the composition may be formulated for subcutaneous, intramuscular, or intradermal administration.

[0121] The disclosure also provides for a kit for preparing the compositions described herein, the kit comprising instructions for preparing the composition. The disclosure also provides for a kit for administering the compositions described herein, the kit comprising instructions for administering the composition.

Plasmids for Pharmaceutical Compositions

[0122] In some cases, the epitopes may be derived from human proteins that may be used directly in a peptide based vaccine. In other cases, the epitopes may be derived from human proteins and the encoding nucleic acid sequences encoding the epitopes may be incorporated into a nucleic acid construct designed to induce expression of the epitope in a subject following administration. For example, epitopes encoded from the nucleic acid construct may allow for the immune response to at least one epitope to be entrained, amplified, attenuated, suppressed, or eliminated to specific sets of proteins (e.g., self-proteins). In some cases, the peptide or the nucleic acid construct may be optimized into a protein or plasmid-based vaccination to induce, amplify or entrain a Th1 immune response. In some cases, the epitopes may be extended Th1 epitopes. In other cases, the

peptide or the nucleic acid construct may be optimized into a protein or plasmid-based vaccination to suppress, attenuate or eliminate a pathological response, in a subject (e.g., human or animal) in need thereof.

[0123] The compositions described herein may include plasmids which contain nucleic acid sequences to express at least one epitope in a subject following administration of the composition (e.g., vaccine). Any plasmid backbones (e.g., vectors) known to one of ordinary skill in the art suitable for pharmaceutical use for expression of a nucleic sequence may be used in the compositions described herein. In some cases, commercially available plasmid backbones may be used. For example, the plasmid pUMVC3 may be used. In some cases, commercially available plasmid backbones may be modified, mutated, engineered or cloned prior to use. In other cases, non-commercially available plasmid backbones may be used.

[0124] Prior to inserting the nucleic acid sequence of at least one epitope, the plasmid backbone may be less than about 500bp, about 1.0 kB, about 1.2 kB, about 1.4 kB, about 1.6 kB, about 1.8 kB, about 2.0 kB, about 2.2 kB, about 2.4 kB, about 2.6 kB, about 2.8 kB, about 3.0 kB, about 3.2 kB, about 3.4 kB, about 3.6 kB, about 3.8 kB, about 4.0 kB, about 4.2 kB, about 4.4 kB, about 4.6 kB, about 4.8 kB, about 5.0 kB, about 5.2 kB, about 5.4 kB, about 5.6 kB, about 5.8 kB, about 6.0 kB, about 6.2 kB, about 6.4 kB, about 6.6 kB, about 6.8 kB, about 7.0 kB, about 7.2 kB, about 7.4 kB, about 7.6 kB, about 7.8 kB, about 8.0 kB, about 8.2 kB, about 8.4 kB, about 8.6 kB, about 8.8 kB, about 9.0 kB, about 9.2 kB, about 9.4 kB, about 9.6 kB, about 9.8 kB, about 10.0 kB, about 10.2 kB, about 10.4 kB, about 10.6 kB, about 10.8 kB, about 11.0 kB, about 11.2 kB, about 11.4 kB, about 11.6 kB, about 11.8 kB, about 12.0 kB, about 12.2 kB, about 12.4 kB, about 12.6 kB, about 12.8 kB, about 13.0 kB, about 13.2 kB, about 13.4 kB, about 13.6 kB, about 13.8 kB, about 14 kB, about 14.5 kB, about 15 kB, about 15.5 kB, about 16 kB, about 16.5 kB, about 17 kB, about 17.5 kB, about 18 kB, about 18.5 kB, about 19 kB, about 19.5 kB, about 20 kB, about 30 kB, about 40 kB, about 50 kB, about 60 kB, about 70 kB, about 80 kB, about 90 kB, about 100 kB, about 110 kB, about 120 kB, about 130 kB, about 140 kB, about 150 kB, about 160 kB, about 170 kB, about 180 kB, about 190 kB or about 200 kB in length. In an exemplary case, the plasmid is about 4 kB in length prior to addition of the nucleic acid sequence encoding at least one epitope.

[0125] In some cases, the compositions described herein may include one plasmid. In other cases, the compositions described herein may include more than one plasmid. For example, the compositions described herein may include two plasmids, three plasmids, four plasmids, five plasmids, six plasmids, seven plasmids, eight plasmids, nine plasmids, ten plasmids, 11 plasmids, 12 plasmids, 13 plasmids, 14 plasmids, 15 plasmids, 16 plasmids, 17 plasmids, 18 plasmids, 19 plasmids, 20 plasmids or more than 20 plasmids.

[0126] In some cases, the nucleic acids which encode at least one epitope of a plasmid may be deoxyribonucleic acids. For example, the deoxyribonucleic acids may be single stranded, double stranded or complementary. The deoxyribonucleic acids may be derived from genomic, mitochondrial or plasmid deoxyribonucleic acids. In other cases, the nucleic acids of a plasmid may be ribonucleic acids. For example, the ribonucleic acids may be single stranded or double stranded. In some cases, the ribonucleic acids may be micro, antisense, short hairpin, small interfering, messenger, transfer, ribosomal, or the like. In some cases, the nucleic acids of the plasmids may be a portion of deoxyribonucleic acids and a portion of ribonucleic acids.

[0127] The nucleic acids which encode at least one epitope of a plasmid may be derived from any species such that the epitope expressed from the nucleic acids results in an immune response in a subject. In some cases, the subject may be a rodent, a non-human primate or a human. The nucleic acids encoding the epitope of the plasmid may be isolated from any source of nucleic acids using methods and techniques known to one of ordinary skill in the art. The nucleic acids encoding the epitope of the plasmid may be cloned into the plasmid backbone using methods and techniques known to one of ordinary skill in the art.

[0128] In some cases, the nucleic acid sequence encoding the epitope may be an endogenous nucleic acid sequence to the subject. For example, the nucleic acid sequence for CD105 from a human may be used to express CD105 in a human. In other cases, the nucleic acid sequence for the antigenic epitope may be an exogenous nucleic acid sequence to the subject. For example, the nucleic acid sequence for CD105 from a non-human may be used to express CD105 in a human.

[0129] In some cases, the nucleic acid sequences to express the antigenic epitope may be wild-type nucleic acid sequences. For example, the naturally occurring nucleic acid sequence for CD105 in the genome of a species may be used to express CD105 in a subject. In other cases, the nucleic acid sequences encoding the epitope may be synthetic nucleic acid sequences. For example, the naturally occurring nucleic acid sequence for CD105 in the genome of a species may be modified using molecular techniques known to one of ordinary skill in the art and may be used to express CD105 in a subject.

[0130] In some cases, the nucleic acid sequence encoding the epitope may be an endogenous nucleic acid sequence to the subject. For example, the nucleic acid sequence for CD105 from a human may be used to express CD105 in a human. In other cases, the nucleic acid sequence for the antigenic epitope may be an exogenous nucleic acid sequence to the subject.

[0163] In some cases, the nucleic acid sequences to express the antigenic epitope may be wild-type nucleic acid sequences. For example, the naturally occurring nucleic acid sequence for CDH3 in the genome of a species may be used to express CDH3 in a subject. In other cases, the nucleic acid sequences encoding the epitope may be synthetic nucleic acid sequences. For example, the naturally occurring nucleic acid sequence for CDH3 in the genome of a species may be modified using molecular techniques known to one of ordinary skill in the art and may be used to express CDH3 in a subject.

[0164] The compositions described herein include a composition comprising: a first plasmid comprising a first nucleotide sequence, the first nucleotide sequence encoding a first epitope of a first antigen expressed by cells associated with breast cancer; and a second nucleotide sequence, the second nucleotide sequence encoding a second epitope of a second antigen expressed by cells associated with breast cancer, wherein the first nucleotide sequence and the second nucleotide sequence are located in one or more plasmids. In some cases, the composition may include nucleic acids which encode epitopes from the following proteins, CD105, HIF1 α , MDM2, Yb-1, SOX-2, HER-2, IGFBP2, IGF-1R and CDH3.

[0165] In some cases, the compositions may include a composition comprising: a first plasmid comprising a first nucleotide sequence, the first nucleotide sequence encoding a first epitope of a first antigen, the first epitope is a portion of a peptide selected from: CD105, Yb-1, SOX-2, CDH3 or MDM2, wherein the first nucleotide sequence is located in a plasmid. In other cases, the composition may include a composition comprising: a first plasmid comprising a first nucleotide sequence, the first nucleotide sequence encoding a first epitope of a first antigen; and a second nucleotide sequence, the second nucleotide sequence encoding a second epitope of a second antigen, wherein the first and the second epitopes are independently selected from: CD105, Yb-1, SOX-2, CDH3 or MDM2, wherein the first nucleotide sequence and the second nucleotide sequence are located in one or more plasmids.

[0166] In some cases, the composition may include nucleic acids which encode epitopes from the following proteins, CD105, MDM2, Yb-1, SOX-2, and CDH3. In some cases, the composition may include a nucleic acid sequence encoding an epitope of the peptide CD105 is selected from the group consisting of: a nucleotide sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the nucleotide sequence of CAGAACGGCACCTGGCCCCGCGAGGTGCTGCTGGTGTCTCCGTGAACTCCTCCGT GTTCCTGCACCTACAGGCCCTGGGCATCCCCCTGCACCTGGCCTACAACTCCTCCCT GGTGACCTTCCAGGAGCCCCCGCGTGAACACCACCGAGCTG (SEQ ID NO: 2); a nucleotide sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the nucleotide sequence of ACCGTGTTCATGCGCCTGAACATCATCTCCCCGACCTGTCCGGCTGCACCTCCAAG GGCCTGGTGTGCTGCCCCGCGTGTGGGCATCACCTTCGGCGCCTTCCTGATCGGCGCC CTGCTGACCGCCGCCCTGTGGTACATCTACTCCACACCCGCTCCCCCTCCAAGCGC GAGCCCGTGGTGGCCGTGGCCGCCCCCGCCTCCTCCGAGTCCTCCTCCACCAACCAC TCCATCGGCTCCACCCAGTCCACCCCCTGCTCCACCTCCTCCATGGCC (SEQ ID NO: 3); a nucleotide sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the nucleotide sequence of ACCGTGTCCATGCGCCTGAACATCGTGTCCCCGACCTGTCCGGCAAGGGCCTGGTG CTGCCCTCCGTGCTGGGCATCACCTTCGGCGCCTTCCTGATCGGCGCCCTGCTGACC GCCGCCCTGTGGTACATCTACTCCACACCCGCGGCCCTCCAAGCGCGAGCCCGTG GTGGCCGTGGCCGCCCCCGCCTCCTCCGAGTCCTCCTCCACCAACCACTCCATCGGC TCCACCCAGTCCACCCCCTGCTCCACCTCCTCCATGGCC (SEQ ID NO: 4); a nucleotide sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the nucleotide sequence of ACCGTGTCCATGCGCCTGAACATCGTGTCCCCGACCTGTCCGGCAAGGGCCTGGTG CTGCCCTCCGTGCTGGGCATCACCTTCGGCGCCTTCCTGATCGGCGCCCTGCTGACC GCCGCCCTGTGGTACATCTACTCCACACCCGCGGCCCTCCAAGCGCGAGCCCGTG GTGGCCGTGGCCGCCCCCGCCTCCTCCGAGTCCTCCTCCACCAACCACTCCATCGGC TCCACCCAGTCCACCCCCTGCTCCACCTCCTCCATGGCC (SEQ ID NO: 5); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of EARMLNASIVASFVELPL (SEQ ID NO: 6); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of QNGTWPREVLLVLSVNSSVFLHLQALGIPLHLAYNSSLVTFQEPGVTTEL (SEQ ID NO: 1); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of TVFMRLNIISPDLSGCTSKGLVLPVLTGFTGAFLIGALLTAALWYIYSHTRSPSKREPVV AVAAPASSESSSTNHSIGSTQSTPCSTSSMA (SEQ ID NO: 8); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of

TVSMRLNIVSPDL SGKGLVLP SVLGITFGA FLIGALLTAALWYIYSHTRGPSKREPVAV AAPASSESSSTNHSIGSTQSTPCSTSSMA (SEQ ID NO: 9); or a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of TVSMRLNIVSPDL SGKGLVLP SVLGITFGA FLIGALLTAALWYIYSHTRAPSKREPVAV AAPASSESSSTNHSIGSTQSTPCSTSSMA (SEQ ID NO: 10). In some cases, the composition may include a nucleic acid sequence encoding an epitope of the peptide Yb-1 is selected from the group consisting of: a nucleotide sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the nucleotide sequence of GGAGTGCCAGTGCAGGGCTCCAAGTACGCTGCCGACCGCAACCACTACCGCCGCTA CCCACGCCGTGCGGGCCCCACCCCGCAACTACCAGCAGAAC (SEQ ID NO: 11); a nucleotide sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the nucleotide sequence of GGCCTGCCCCGTGCAGGGCTCCAAGTACGCCGCCGACCGCAACCACTACCGCCGCTA CCCCCGCCGCCGCGGGCCCCCCCCCGCAACTACCAGCAGAAC (SEQ ID NO: 12); a nucleotide sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the nucleotide sequence of GGCCTGCCCCGTGCAGGGCTCCAAGTACGCCGCCGACCGCAACCACTACCGCCGCTA CCCCCGCCGCCGCGGGCCCCCCCCCGCAACTACCAGCAGAAC (SEQ ID NO: 12); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of EDVVFVHQTAIKNNPRK (SEQ ID NO: 14); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of YRRNFNYRRRRPEN (SEQ ID NO: 15); or a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of GVPVQGSKYAADRNHYRRYPRRRGPPRNYQQN (SEQ ID NO: 16). In some cases, the composition may include a nucleic acid sequence encoding an epitope of the peptide SOX-2 is selected from the group consisting of: a nucleotide sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the nucleotide sequence of GGCCTCAATGCGCAGCGCGCAGCGCAGATGCAGCCCATGCACCGCTACGACGTGAG CGCCCTGCAGTACAACCTCCATGACCAGCTCGCAGACCTACATGAACGGCTCGCCCA CCTACAGCATGTCCTACTCGCAGCAGGGCACCCCTGGCATGGCTCTTGGCTCCATGGGTTCTGGTG (SEQ ID NO: 17); a nucleotide sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the nucleotide sequence of GGCCTGAACGCCCCACGGCGCCGCCAGATGCAGCCCATGCACCGCTACGACGTGTC CGCCCTGCAGTACAACCTCCATGACCTCCTCCCAGACCTACATGAACGGCTCCCCAC CTACTCCATGTCCTACTCCCAGCAGGGCACCCCGGCATGGCCCTGGGCTCCATGGG CTCCGTG (SEQ ID NO: 18); a nucleotide sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the nucleotide sequence of GGCCTGAACGCCCCACGGCGCCGCCAGATGCAGCCCATGCACCGCTACGACGTGTC CGCCCTGCAGTACAACCTCCATGACCTCCTCCCAGACCTACATGAACGGCTCCCCAC CTACTCCATGTCCTACTCCCAGCAGGGCACCCCGGCATGGCCCTGGGCTCCATGGG CTCCGTG (SEQ ID NO: 18); or a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of GLNAHGAAQMMPMHRYDVSALQYNSMTSSQTYMNGSPTYMSYSQQGTPGMALGSM GSV (SEQ ID NO: 20). In some cases, the composition may include, a nucleic acid sequence encoding an epitope of the peptide CDH3 is selected from the group consisting of: a nucleotide sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the nucleotide sequence of AGGTCACTGAAGGAAAGGAATCCATTGAAAATCTTCCCATCCAAACGTATCTTACG AAGACACAAGAGAGATTGGGTGGTTGCTCCAATATCTGTCCCTGAAAATGGCAAGG GTCCCTTCCCACAGAGACTGAATCAGCTCAAGTCTAATAAAGATAGAGACACCAAG ATTTTCTACAGCATCACGGGGCCGGGTGCAGACAGCCACCTGAGGGTGTCTTCGCT GTAGAGAAGGAGACA (SEQ ID NO: 21); a nucleotide sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the nucleotide sequence of TTGAAAATCTTCCCATCCAAACGTATCTTACGAAGACACAAGAGAGATTGGGTGGT TGCTCCAATATCTGTCCCTGAAAATGGCAAGGGTCCCTTCCCACAGAGACTGAATCA GCTCAAGTCTAATAAAGATAGAGACACCAAGATTTTCTACAGCATCACGGGGCCGG GTGCAGACAGCCACCTGAGGGTGTCTTCGCTGTAGAGAAGGAGACA (SEQ ID NO: 22); a nucleotide sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the nucleotide sequence of GCCATGCACTCCCCCCCCACCCGCATCCTGCGCCGCCGCAAGCGCGAGTGGGTGAT GCCCCCATCTTCGTGCCCCGAGAACGGCAAGGGCCCCCTTCCCCAGCGCCTGAACC AGCTGAAGTCCAACAAGGACCGCGGCACCAAGATCTTCTACTCCATCACCGGCCCC GGCGCCGACTCCCCCCCCGAGGGCGTGTTCACCATCGAGAAGGAGTCC (SEQ ID NO: 23); a nucleotide sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the

nucleotide sequence of GTGATGAACTCCCCCCCCCTCCCGCATCCTGCGCCGCCGCAAGCGCGAGTGGGTGAT
 GCCCCCATCTCCGTGCCCCGAGAACGGCAAGGGCCCCCTTCCCCCAGCGCCTGAACC
 AGCTGAAGTCCAACAAGGACCGCGGCACCAAGCTGTTCTACTCCATCACCGGCCCC
 GGCGCCGACTCCCCCCCCGAGGGCGTGTTACCATCGAGAAGGAGACC (SEQ ID NO: 24); a nucleotide sequence
 encoding an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%,
 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of
 RSLKERNPLKIFPSKRILRRHKRDWVAPISVPENGKGPFQRLNQLKSNKDRDTKIFYSI TPGADSPPEGVFAVEKET (SEQ ID
 NO: 25); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%,
 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of
 LKIFPSKRILRRHKRDWVAPISVPENGKGPFQRLNQLKSNKDRDTKIFYSTPGADSP PEGVFAVEKET (SEQ ID NO: 26); a
 nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%,
 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of
 AMHSPTRILRRRKREWMPPIFVPENGKGPFQRLNQLKSNKDRGTKIFYSTPGADS PEGVFTIEKES (SEQ ID NO: 27); or
 a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%,
 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of
 VMNSPPSRILRRRKREWMPPISVPENGKGPFQRLNQLKSNKDRGTKLFYSTPGADS PEGVFTIEKET (SEQ ID NO: 28). In
 some cases, the composition may include, a nucleic acid sequence encoding an epitope of the peptide MDM2 is selected from
 the group consisting of: a nucleotide sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%,
 97%, 98%, 99%, or 100% sequence identity to the nucleotide sequence of
 ACCTACACCATGAAGGAGGTGCTGTTCTACCTGGGCCAGTACATCATGACCAAGCG
 CCTGTACGACGAGAAGCAGCAGCACATCGTGTACTGCTCCAACGACCTGCTGGGCG
 ACCTGTTCTGGCGTGCCCTCCTTCTCCGTGAAGGAGCACCGCAAaATCTACACCATGA
 TCTACCGCAACCTGGTGGTGGTGAACCAGCAGGAGTCTCCGACTCCGGCACCTCC GTGTCC (SEQ ID NO: 29); a
 nucleotide sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%
 sequence identity to the nucleotide sequence of
 ACCTACACCATGAAGGAGATCATCTTCTACATCGGCCAGTACATCATGACCAAGCG
 CCTGTACGACGAGAAGCAGCAGCACATCGTGTACTGCTCCAACGACCTGCTGGGCG
 ACGTGTTCGGCGTGCCCTCCTTCTCCGTGAAGGAGCACCGCAAGATCTACGCCATGA
 TCTACCGCAACCTGGTGGCCGTGTCCCAGCAGGACTCCGGCACCTCCCTGTCC (SEQ ID NO: 30); a nucleotide sequence
 having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to
 the nucleotide sequence of ATCTACACCATGAAGGAGATCATCTTCTACATCGGCCAGTACATCATGACCAAGCG
 CCTGTACGACGAGAAGCAGCAGCACATCGTGTACTGCTCCAACGACCTGCTGGGCG
 ACGTGTTCGGCGTGCCCTCCTTCTCCGTGAAGGAGCACCGCAAGATCTACGCCATGA
 TCTACCGCAACCTGGTGGTGGTGTCCCAGCAGGACTCCGGCACCTCCCCCTCC (SEQ ID NO: 31); a nucleotide sequence
 encoding an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%,
 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of
 TYTMKEVLFYLGQYIMTKRLYDEKQQHIVYCSNDLLGDLFGVPSFSVKEHRKIYTMIIYR NLVVVNQQESSDSGTSV (SEQ ID NO:
 32); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%,
 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of
 TYTMKEIIFYIGQYIMTKRLYDEKQQHIVYCSNDLLGDVFGVPSFSVKEHRKIYAMIYRN LVAVSQQDSGTSLS (SEQ ID NO: 33); or
 a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%,
 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of
 IYTMKEIIFYIGQYIMTKRLYDEKQQHIVYCSNDLLGDVFGVPSFSVKEHRKIYAMIYRN LVVVSQQDSGTSPS (SEQ ID NO: 34).

[0167] In an exemplary case, the compositions may include a nucleic acid sequence encoding a fusion peptide of five epitopes
 is selected from the group consisting of: a nucleotide sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%,
 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the nucleotide sequence of
 ATGGCGGTACCCATGCAACTGTCCTGCTCTAGACAGAACGGCACCTGGCCCCGCGA
 GGTGCTGCTGGTGCTGTCCGTGAACTCCTCCGTGTTCTGACCTACAGGCCCTGGG
 CATCCCCCTGCACCTGGCCTACAACTCCTCCCTGGTGACCTTCCAGGAGCCCCCGG
 CGTGAACACCACCGAGCTGAGATCCACCGGTGGAGTGCCAGTGCCAGGGCTCCAAGT
 ACGTGCCGACCGCAACCACTACCGCCGCTACCCACGCCGTCGCGGCCACCCCCGC
 AACTACCAGCAGAACACGCGTGGCCTCAATGCGCACGGCGCAGCGCAGATGCAGCC
 CATGCACCGCTACGACGTGAGCGCCCTGCAGTACAACTCCATGACCAGCTCGCAGA
 CCTACATGAACGGCTCGCCACCTACAGCATGTCCTACTCGCAGCAGGGCACCCCT
 GGCATGGCTCTTGGCTCCATGGGTTCCGTGAGATCCCAATTGAGGTCACTGAAGGA
 AAGGAATCCATTGAAAATCTTCCCATCAAACGTATCTTACGAAGACACAAGAGAG
 ATTGGGTGGTTGCTCCAATATCTGTCCCTGAAAATGGCAAGGGTCCCTTCCCACAGA
 GACTGAATCAGCTCAAGTCTAATAAAGATAGAGACACCAAGATTTTCTACAGCATC

ACGGGGCCGGGTGCAGACAGCCACCTGAGGGTGTCTTCGCTGTAGAGAAGGAGAC
AAGATCCGCCGGCGAAACCTACACCATGAAGGAGGTGCTGTTCTACCTGGGCCAGT
ACATCATGACCAAGCGCCTGTACGACGAGAAGCAGCAGCACATCGTGTACTGCTCC
AACGACCTGCTGGGCGACCTGTTGGCGTGCCCTCCTTCTCCGTGAAGGAGCACCGC
AAAATCTACACCATGATCTACCGCAACCTGGTGGTGGTGAACCAGCAGGAGTCCTC
CGACTCCGGCACCTCCGTGTCCAGATCTTAG (SEQ ID NO: 35); a nucleotide sequence having at least 50%, 60%, 70%,
80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the nucleotide sequence of
ATGGCGGTACCCATGACCGTGTTTCATGCGCCTGAACATCATCTCCCCGACCTGTCC
GGCTGCACCTCCAAGGGCCTGGTGTGCCCCGCCGTGCTGGGCATCACCTTCGGCGCC
TTCCTGATCGGCGCCCTGCTGACCGCCGCCCTGTGGTACATCTACTCCCACACCCGC
TCCCCCTCCAAGCGCGAGCCCGTGGTGGCCGTGGCCGCCCGCCCTCCTCCGAGTCC
TCCTCCACCAACCACTCCATCGGCTCCACCCAGTCCACCCCTGCTCCACCTCCTCC
ATGGCCACCGGTGGAGTGCCAGTGCCAGGGCTCCAAGTACGCTGCCGACCGCAACCA
CTACCGCCGCTACCCACGCCGTGCGGGCCACCCCGCAACTACCAGCAGAACACGC
GTGGCCTCAATGCGCACGGCGCAGCGCAGATGCAGCCCATGCACCGCTACGACGTG
AGCGCCCTGCAGTACAACCTCCATGACCAGCTCGCAGACCTACATGAACGGCTCGCC
CACCTACAGCATGTCCTACTCGCAGCAGGGCACCCCTGGCATGGCTCTTGGCTCCAT
GGGTTCCGTGAGATCCCAATTGTTGAAAATCTTCCCATCCAAACGTATCTTACGAAG
ACACAAGAGAGATTGGGTGGTTGCTCCAATATCTGTCCCTGAAAATGGCAAGGGTC
CCTTCCCACAGAGACTGAATCAGCTCAAGTCTAATAAAGATAGAGACACCAAGATT
TTCTACAGCATCACGGGGCCGGGTGCAGACAGCCACCTGAGGGTGTCTTCGCTGT
AGAGAAGGAGACAAGATCCGCCGGCGAAACCTACACCATGAAGGAGGTGCTGTTC
TACCTGGGCCAGTACATCATGACCAAGCGCCTGTACGACGAGAAGCAGCAGCACAT
CGTGTACTGCTCCAACGACCTGCTGGGCGACCTGTTGGCGTGCCCTCCTTCTCCGT
GAAGGAGCACCGCAAAATCTACACCATGATCTACCGCAACCTGGTGGTGGTGAACC
AGCAGGAGTCCTCCGACTCCGGCACCTCCGTGTCCAGATCTTAG (SEQ ID NO: 36); a nucleotide sequence having at least
50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the nucleotide
sequence of ATGGCGGTACCCATGACCGTGTTTCATGCGCCTGAACATCATGTCCCCGACCTGTCC
GGCAAGGGCCTGGTGTGCCCTCCGTGCTGGGCATCACCTTCGGCGCCTTCCTGATC
GGCGCCCTGCTGACCGCCGCCCTGTGGTACATCTACTCCCACACCCGCGGCCCTCC
AAGCGCGAGCCCGTGGTGGCCGTGGCCGCCCGCCCTCCTCCGAGTCCTCCTCCACC
AACCACTCCATCGGCTCCACCCAGTCCACCCCTGCTCCACCTCCTCCATGGCCACC
GGTGGCGTGCCCGTGCAGGGCTCCAAGTACGCCGCCGACCGCAACCACTACCGCCG
CTACCCCGCGCGCGCGGCCCGCCCGCAACTACCAGCAGAACACGCGTGCCCTGA
ACGCCCACGGCGCGCGCCAGATGCAGCCCATGCACCGCTACGACGTGTCCGCCCTG
CAGTACAACCTCCATGACCTCCTCCAGACCTACATGAACGGCTCCCCACCTACTCC
ATGTCCTACTCCCAGCAGGGCACCCCGGCATGGCCCTGGGCTCCATGGGCTCCGTG
AGATCCCAATTGGCCATGCACTCCCCCCCCACCCGCATCCTGCGCCGCCGCAAGCGC
GAGTGGGTGATGCCCCCATCTTCGTGCCCCGAGAACGGCAAGGGCCCCCTTCCCCCA
GCGCCTGAACCAGCTGAAGTCCAACAAGGACCGCGGCACCAAGATCTTCTACTCCA
TCACCGGCCCGGCGCGGACTCCCCCCCCGAGGGCGTGTTACCATCGAGAAGGAG
TCCAGATCCGCCGGCGAAACCTACACCATGAAGGAGATCATCTTCTACATCGGCCA
GTACATCATGACCAAGCGCCTGTACGACGAGAAGCAGCAGCACATCGTGTACTGCT
CCAACGACCTGCTGGGCGACGTGTTCCGGCGTGCCCTCCTTCTCCGTGAAGGAGCACC
GCAAGATCTACGCCATGATCTACCGCAACCTGGTGGCCGTGTCCCAGCAGGACTCC GGCACCTCCCTGTCCAGATCTTAG
(SEQ ID NO: 37); a nucleotide sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,
98%, 99%, or 100% sequence identity to the nucleotide sequence of
ATGGCGGTACCCATGACCGTGTTTCATGCGCCTGAACATCATGTCCCCGACCTGTCC
GGCAAGGGCCTGGTGTGCCCTCCGTGCTGGGCATCACCTTCGGCGCCTTCCTGATC
GGCGCCCTGCTGACCGCCGCCCTGTGGTACATCTACTCCCACACCCGCGGCCCTCC
AAGCGCGAGCCCGTGGTGGCCGTGGCCGCCCGCCCTCCTCCGAGTCCTCCTCCACC
AACCACTCCATCGGCTCCACCCAGTCCACCCCTGCTCCACCTCCTCCATGGCCACC
GGTGGCGTGCCCGTGCAGGGCTCCAAGTACGCCGCCGACCGCAACCACTACCGCCG
CTACCCCGCGCGCGCGGCCCGCCCGCAACTACCAGCAGAACACGCGTGCCCTGA
ACGCCCACGGCGCGCGCCAGATGCAGCCCATGCACCGCTACGACGTGTCCGCCCTG
CAGTACAACCTCCATGACCTCCTCCAGACCTACATGAACGGCTCCCCACCTACTCC
ATGTCCTACTCCCAGCAGGGCACCCCGGCATGGCCCTGGGCTCCATGGGCTCCGTG
AGATCCCAATTGGTGTGAACTCCCCCCCCCTCCCGCATCCTGCGCCGCCGCAAGCGC
GAGTGGGTGATGCCCCCATCTCCGTGCCCCGAGAACGGCAAGGGCCCCCTTCCCCCA

GCGCCTGAACCAGCTGAAGTCCAACAAGGACCGCGGCACCAAGCTGTTCTACTCCA
 TCACCGGCCCCGGCGCCGACTCCCCCCCCGAGGGCGTGTTACCATCGAGAAGGAG
 ACCAGATCCGCGCGCGAAATCTACACCATGAAGGAGATCATCTTCTACATCGGCCA
 GTACATCATGACCAAGCGCCTGTACGACGAGAAGCAGCAGCACATCGTGACTGCT
 CCAACGACCTGCTGGGCGACGTGTTTCGGCGTGCCCTCCTTCTCCGTGAAGGAGCACC
 GCAAGATCTACGCCATGATCTACCGCAACCTGGTGGTGGTGTCCCAGCAGGACTCC GGCACCTCCCCCTCCAGATCTTAG
 (SEQ ID NO: 38); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 50%,
 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid
 sequence of MAVPMLQLSCSRQNGTWPREVLLVLSVNSSVFLHLQALGIPLHLAYNSSLVTFQEPPGVN
 TTELSTGGVPVQGSKYAADRNHYRRYPRRRGPPRNYQQNTRGLNAHGAAQMMPMH
 RYDVSALQYNSMTSSQTYMNGSPTYMSYSQQGTPGMALGSMGVSRSQRLSLKERNP
 LKIFPSKRILRRHKRDWVAPISVPENGKGPFQRLNQLKSNKDRDTKIFYITGPGADSP
 PEGVFAVEKETRSAGETYTMKEVLFFYLGQYIMTKRLYDEKQQHIVYCSNDLLGDLFGV
 PSFSVKEHRKIYTMIRNLVVVNQQESSDSGTSVSRS (SEQ ID NO: 39); a nucleotide sequence encoding an amino acid
 sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%,
 99%, or 100% sequence identity to the amino acid sequence of
 MAVPMTVMRLNIISPDLGCTSKGLVLPVGLITFGAFLIGALLTAALWYIYSHTRSPS
 KREPVAAPASSESSSTNHSIGSTQSTPCSTSSMATGGVPVQGSKYAADRNHYRRYP
 RRRGPPRNYQQNTRGLNAHGAAQMMPMHRYDVSALQYNSMTSSQTYMNGSPTYMS
 YSQGTPGMALGSMGVSRSQLLKIFPSKRILRRHKRDWVAPISVPENGKGPFQRLNQ
 LKSNKDRDTKIFYITGPGADSPPEGVFAVEKETRSAGETYTMKEVLFFYLGQYIMTKRL
 YDEKQQHIVYCSNDLLGDLFGVPSFSVKEHRKIYTMIRNLVVVNQQESSDSGTSVSRS (SEQ ID NO: 40); a nucleotide sequence
 encoding an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%,
 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of
 MAVPMTVMRLNIVSPDLGKGLVLPVGLITFGAFLIGALLTAALWYIYSHTRGPKRE
 PVVAAPASSESSSTNHSIGSTQSTPCSTSSMATGGVPVQGSKYAADRNHYRRYP
 GPPRNYQQNTRGLNAHGAAQMMPMHRYDVSALQYNSMTSSQTYMNGSPTYMSYSQ
 QGTPGMALGSMGVSRSQLAMHSPTRILRRRKREWMPPIFVPENGKGPFQRLNQLK
 SNKDRGTKIFYITGPGADSPPEGVFTIEKESRSAGETYTMKEIFYIGQYIMTKRLYDEK
 QQHIVYCSNDLLGDVFGVPSFSVKEHRKIYAMIYRNLVAVSQQDSGTSLRS (SEQ ID NO: 41); or a nucleotide sequence
 encoding an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%,
 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of
 MAVPMTVMRLNIVSPDLGKGLVLPVGLITFGAFLIGALLTAALWYIYSHTRAPSKRE
 PVVAAPASSESSSTNHSIGSTQSTPCSTSSMATGGVPVQGSKYAADRNHYRRYP
 GPPRNYQQNTRGLNAHGAAQMMPMHRYDVSALQYNSMTSSQTYMNGSPTYMSYSQ
 QGTPGMALGSMGVSRSQVMNSPPSRILRRRKREWMPPISVPENGKGPFQRLNQLKS
 NKDRGTKIFYITGPGADSPPEGVFTIEKETRSAGEIYTMKEIFYIGQYIMTKRLYDEKQ
 QHIVYCSNDLLGDVFGVPSFSVKEHRKIYAMIYRNLVVVSQQDSGTSPSRS (SEQ ID NO: 42).

[0168] In some cases, the composition may include nucleic acids which encode epitopes from the following proteins, HER-2,
 IGFBP2 and IGF-1R. In some cases, the composition may comprise a first plasmid comprising a first nucleotide sequence, the
 first nucleotide sequence encoding a first epitope of a first antigen, the first epitope is a portion of a peptide selected from:
 IGFBP-2, HER-2, IGF-1R, wherein the first nucleotide sequence is located in a plasmid. In some cases, the composition may
 comprise: a first plasmid comprising a first nucleotide sequence, the first nucleotide sequence encoding a first epitope of a first
 antigen; and a second nucleotide sequence, the second nucleotide sequence encoding a second epitope of a second antigen,
 wherein the first and the second epitopes are independently selected from: IGFBP-2, HER-2 or IGF-1R, wherein the first
 nucleotide sequence and the second nucleotide sequence are located in one or more plasmids. In some cases, the
 compositions may comprise a nucleic acid sequence encoding an epitope of the peptide IGFBP-2 is selected from the group
 consisting of: a nucleotide sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%,
 99%, or 100% sequence identity to the nucleotide sequence of
 ATGCTGCCGAGAGTGGGCTGCCCCGCGCTGCCGCTGCCGCCGCCGCCGCTGCTGCC
 GCTGCTGCCGCTGCTGCTGCTGCTACTGGGCGCGAGTGGCGGCGGCGGCGGGGCGC
 GCGCGGAGGTGCTGTTCCGCTGCCCGCCCTGCACACCCGAGCGCCTGGCCGCCTGC
 GGGCCCCCGCGGTTGCGCCGCCCGCCGCGGTGGCCGAGTGGCCGGAGGCGCCCCG
 CATGCCATGCGCGGAGCTCGTCCGGGAGCCGGGCTGCGGCTGCTGCTCGGTGTGCG
 CCCGGCTGGAGGGCGAGGCGTGCGGCGTCTACACCCCGCGCTGCGGCCAGGGGCTG
 CGCTGCTATCCCCACCCGGGCTCCGAGCTGCCCTGCAGGCGCTGGTCATGGGCGA
 GGGCACTTGTGAGAAGCGCCGGGACGCCGAGTATGGCGCCAGCCCGGAGCAGGTT
 GCAGACAATGGCGATGACCACTCAGAAGGAGGCCTGGTGGAG (SEQ ID NO: 43); a nucleotide sequence having at least

50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the nucleotide sequence of ATGCTGCCCCGCCTGGGCGGCCCCGCCCTGCCCTGCTGCTGCCCTCCCTGCTGCTGCTGCTGCTGGGCGCCGGCGGCTGCGGCCCCGGCGTGCGCGCCGAGGTGCTGTTCCGCTGCCCCCCCCTGCACCCCCGAGCGCCTGGCCGCCTGCGGCCCCCCCCCCCCGACGC CCCCTGCGCCGAGCTGGTGC GCGAGCCCGGCTGCGGCTGCTGCTCCGTGTGCGCCC GCCAGGAGGGCGAGGCCTGCGGCGTG TACATCCCCCGCTGCGCCCAGACCCTGCGC TGCTACCCCAACCCCGGCTCCGAGCTGCCCCCTGAAGGCCCTGGTGACCGGCGCCGG CACCTGCGAGAAGCGCCGCGTG GGGACCAACCCCCAGCAGGTGGCCGACTCCGACG ACGACCACTCCGAGGGCGGCCTGGTGGAG (SEQ ID NO: 44); a nucleotide sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the nucleotide sequence of ATGCTGCCCCGCCTGGGCGGCCCCGCCCTGCCCTGCTGCTGCCCTCCCTGCTGCTGCTGCTGCTGGGCGCCGGCGGCTGCGGCCCCGGCGTGCGCGCCGAGGTGCTGTTCCGCTGCCCCCCCCTGCACCCCCGAGCGCCTGGCCGCCTGCGGCCCCCCCCCCCCGACGC CCCCTGCGCCGAGCTGGTGC GCGAGCCCGGCTGCGGCTGCTGCTCCGTGTGCGCCC GCCAGGAGGGCGAGGCCTGCGGCGTG TACATCCCCCGCTGCGCCCAGACCCTGCGC TGCTACCCCAACCCCGGCTCCGAGCTGCCCCCTGAAGGCCCTGGTGACCGGCGCCGG CACCTGCGAGAAGCGCCGCGTG GGGACCAACCCCCAGCAGGTGGCCGACTCCGAGG ACGACCACTCCGAGGGCGGCCTGGTGGAG (SEQ ID NO: 45); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of NHVDSTMNMLGGGS (SEQ ID NO: 46); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of ELAVFREKVTEQHRQ (SEQ ID NO: 47); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of LGLEEPKKLRPPPAR (SEQ ID NO: 48); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of DQVLERISTMRLPDE (SEQ ID NO: 49); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of GPLEHLYSLHIPNCD (SEQ ID NO: 50); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of KHGLYNLKQCKMSLN (SEQ ID NO: 51); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of PNTGKLIQGAPTIRG (SEQ ID NO: 52); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of PECHLFYNEQQEARG (SEQ ID NO: 53); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of MLPRVGC PALPLPPP LLLPL LLLLLL GASGGGGGARA EVLFR CPPCTPERLAACGPPP VAPPA AVAAVAGGARMPCAE LVREPGCGCCSVCARLEGEACGVYTPRCGQGLRCYPH PGSELPLQALVMGEGTCEKRRDAEYGASPEQVADNGDDHSEGLVE (SEQ ID NO: 54); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of MLPRLGGPALPLLLPS LLLLLL LAGGCGPGVRAEVLFR CPPCTPERLAACGPPPDAPCA ELVREPGCGCCSVCARQEGEACGVYIPRCAQTLRCYPNPGSELPLKALVTGAGTCEKRR VGTTTPQQVADSDDDHSEGLVE (SEQ ID NO: 55); and a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of MLPRLGGPALPLLLPS LLLLLL LAGGCGPGVRAEVLFR CPPCTPERLAACGPPPDAPCA ELVREPGCGCCSVCARQEGEACGVYIPRCAQTLRCYPNPGSELPLKALVTGAGTCEKRR VGATPQQVADSEDDHSEGLVE (SEQ ID NO: 56). In some cases, the compositions may comprise a nucleic acid sequence encoding an epitope of the peptide HER-2 is selected from the group consisting of: a nucleotide sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the nucleotide sequence of ACGATGCGGAGACTGCTGCAGGAAACGGAGCTGGTGGAGCCGCTGACACCTAGCG GAGCGATGCCCAACCAGGCGCAGATGCGGATCCTGAAAGAGACGGAGCTGAGGAA GGTGAAGGTGCTTGGATCTGGCGCTTTTGGCACAGTCTACAAGGGCATCTGGATCCC TGATGGGGAGAATGTGAAAATTCCAGTGGCCATCAAAGTGTTGAGGGAAAACACAT CCCCCAAAGCCAACAAAGAAATCTTAGACGAAGCATACGTGATGGCTGGTGTGGGC TCCCCATATGTCTCCCGCCTTCTGGGCATCTGCCTGACATCCACGGTGCAGCTGGTG ACACAGCTTATGCCCTATGGCTGCCTCTTAGACCATGTCCGGGAAAACCGCGGACG

CCTGGGCTCCCAGGACCTGCTGAACTGGTGTATGCAGATTGCCAAGGGGATGAGCT
 ACCTGGAGGATGTGCGGCTCGTACACAGGGACTTGGCCGCTCGGAACGTGCTGGTC
 AAGAGTCCCAACCATGTCAAATTACAGACTTCGGGCTGGCTCGGCTGCTGGACAT
 TGACGAGACAGAGTACCATGCAGATGGGGGCAAGGTGCCCATCAAGTGGATGGCG
 CTGGAGTCCATTCTCCGCCGGCGGTTCACCCACCAGAGTGATGTGTGGAGTTATGGT
 GTGACTGTGTGGGAGCTGATGACTTTTGGGGCCAAACCTTACGATGGGATCCCAGC
 CCGGGAGATCCCTGACCTGCTGGAAAAGGGGGAGCGGCTGCCCCAGCCCCCATCT
 GCACCATTGATGTCTACATGATCATGGTCAAATGTTGGATGATTGACTCTGAATGTC
 GGCCAAGATTCCGGGAGTTGGTGTCTGAATTCTCCCGCATGGCCAGGGACCCCCAG
 CGCTTTGTGGTCATCCAGAATGAGGACTTGGCTCCCGGAGCTGGCGGCATGGTGCA
 CCACAGGCACCGCAGCTCATCTCCTCTGCCTGCTGCCCCGACCTGCTGGTGCCACTCT
 GGAAAGGCCCAAGACTCTCTCCCCAGGGAAGAATGGGGTCGTCAAAGACGTTTTTG
 CCTTTGGGGGTGCCGTGGAGAACCCCGAGTACTTG (SEQ ID NO: 57); a nucleotide sequence having at least 50%, 60%,
 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the nucleotide sequence of
 ACCATGCGCCGCCTGCTGCAGGAGACCGAGCTGGTGGAGCCCCTGACCCCCTCCGG
 CGCCGTGCCCAACCAGGCCAGATGCGCATCCTGAAGGAGACCGAGCTGCGCAAGC
 TGAAGGTGCTGGGCTCCGGCGCCTTCGGCACCGTGTACAAGGGCATCTGGATCCCC
 GACGGCGAGAACGTGAAGATCCCCGTGGCCATCAAGGTGCTGCGCGAGAACACCTC
 CCCCAGGCCAACAAAGGAGATCCTGGACGAGGCCTACGTGATGGCCGGCGTGGGCT
 CCCCCTACGTGTCCCGCCTGCTGGGCATCTGCCTGACCTCCACCGTGCAGCTGGTGA
 CCCAGCTGATGCCCTACGGCTGCCTGCTGGACCACGTGCGCGAGCACCGCGGCCGC
 CTGGGCTCCCAGGACCTGCTGAACTGGTGCCTGCAGATCGCCAAGGGCATGTCCTA
 CCTGGAGGAGGTGCGCCTGGTGCACCGCGACCTGGCCGCCCGCAACGTGCTGGTGA
 AGTCCCCCAACCACGTGAAGATCACCGACTTCGGCCTGGCCCGCCTGCTGGACATC
 GACGAGACCGAGTACCACGCCGACGGCGGCAAGGTGCCCATCAAGTGGATGGCCCT
 GGAGTCCATCCTGCGCCGCCGCTTCACCCACCAGTCCGACGTGTGGTCCTACGGCGT
 GACCGTGTGGGAGCTGATGACCTTCGGCGCCAAGCCCTACGACGGCATCCCCGCCC
 GCGAGATCCCCGACCTGCTGGAGAAGGGCGAGCGCCTGCCCCAGCCCCCATCTGC
 ACCATCGACGTGTACATGATCATGGTGAAGTGCTGGATGATCGACTCCGAGTGCCG
 CCCCCGCTTCCGCGAGCTGGTGTCCGAGTTCTCCCGCATGGCCCGCGACCCCCAGCG
 CTTCTGTGGTATCCAGAACGAGGACCTGGCCCTGGGCACCGGCTCCACCGCCCACC
 GCCGCCACCGCTCCTCCTCCCCCCCCCCCCCATCCGCCCGCCGGCGCCACCCTGG
 AGCGCCCCAAGACCCTGTCCCCCGGCAAGAACGGCGTGGTGAAGGACGTGTTCCGC
 TTCGGCGGCGCCGTGGAGAACCCCGAGTACCTG (SEQ ID NO: 58); a nucleotide sequence having at least 50%, 60%, 70%,
 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the nucleotide sequence of
 ACCATGCGCCGCCTGCTGCAGGAGACCGAGCTGGTGGAGCCCCTGACCCCCTCCGG
 CGCCATGCCCAACCAGGCCAGATGCGCATCCTGAAGGAGACCGAGCTGCGCAAGG
 TGAAGGTGCTGGGCTCCGGCGCCTTCGGCACCGTGTACAAGGGCATCTGGATCCCC
 GACGGCGAGAACGTGAAGATCCCCGTGGCCATCAAGGTGCTGCGCGAGAACACCTC
 CCCCAGGCCAACAAAGGAGATCCTGGACGAGGCCTACGTGATGGCCGGCGTGGGCT
 CCCCCTACGTGTCCCGCCTGCTGGGCATCTGCCTGACCTCCACCGTGCAGCTGGTGA
 CCCAGCTGATGCCCTACGGCTGCCTGCTGGACCACGTGCGCGAGCACCGCGGCCGC
 CTGGGCTCCCAGGACCTGCTGAACTGGTGCCTGCAGATCGCCAAGGGCATGTCCTA
 CCTGGAGGACGTGCGCCTGGTGCACCGCGACCTGGCCGCCCGCAACGTGCTGGTGA
 AGTCCCCCAACCACGTGAAGATCACCGACTTCGGCCTGGCCCGCCTGCTGGACATC
 GACGAGACCGAGTACCACGCCGACGGCGGCAAGGTGCCCATCAAGTGGATGGCCCT
 GGAGTCCATCCTGCGCCGCCGCTTCACCCACCAGTCCGACGTGTGGTCCTACGGCGT
 GACCGTGTGGGAGCTGATGACCTTCGGCGCCAAGCCCTACGACGGCATCCCCGCCC
 GCGAGATCCCCGACCTGCTGGAGAAGGGCGAGCGCCTGCCCCAGCCCCCATCTGC
 ACCATCGACGTGTACATGATCATGGTGAAGTGCTGGATGATCGACTCCGAGTGCCG
 CCCCCGCTTCCGCGAGCTGGTGTCCGAGTTCTCCCGCATGGCCCGCGACCCCCAGCG
 CTTCTGTGGTATCCAGAACGAGGACCTGACCCCCGGCACCGGCTCCACCGCCCACC
 GCCGCCACCGCTCCTCCTCCCCCTGCCCCCGTGCGCCCGCCGGCGCCACCCTGG
 AGCGCCCCAAGACCCTGTCCCCCGGCAAGAACGGCGTGGTGAAGGACGTGTTCCGC
 TTCGGCGGCGCCGTGGAGAACCCCGAGTACCTG (SEQ ID NO: 59); a nucleotide sequence encoding an amino acid
 sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%,
 99%, or 100% sequence identity to the amino acid sequence of
 TMRRLQETELVEPLTPSGAMPNQAQMRILKETELRKVKVLGSGAFGTVYKGIWIPDGE
 NVKIPVAIKVLRENTSPKANKEILDEAYVMAGVGSPPYVSRLLGICLTSTVQLVTQLMPY

GCLLDHVRENRGRLGSQDLLNWCMQIAKGMSYLEDVRLVHRDLAARNVLVKSPNHV
KITDFGLARLLDIDETEHADGGKVPIKWMMALESILRRRFTHQSDVWSYGVTVWELMT
FGAKPYDGIPAREIPDLLEKGERLPQPPICTIDVYMIMVKCWMIDSECRPRFRELVEFSR
MARDPQRFVVIQNEIDLAPGAGGMVHHRHRSSSPLPAARPAGATLERPKTLPSPGKNGV KDVFAFGGAVENPEYL (SEQ ID NO: 60); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of TMRLLQETELVEPLTPSGAVPNQAQMRILKETELRKLKVLGSGAFGTVYKGIWIPDGE
NVKIPVAIKVLRENTSPKANKEILDEAYVMAGVGSPYVSRLLGICLTSTVQLVTQLMPY
GCLLDHVREHRGRLGSQDLLNWCQIAKGMSYLEEVRLVHRDLAARNVLVKSPNHVK
ITDFGLARLLDIDETEHADGGKVPIKWMMALESILRRRFTHQSDVWSYGVTVWELMTF
GAKPYDGIPAREIPDLLEKGERLPQPPICTIDVYMIMVKCWMIDSECRPRFRELVEFSR
MARDPQRFVVIQNEIDLALGTGSTAHRHRSSSPPIRPAGATLERPKTLPSPGKNGVVK DVFAFGGAVENPEYL (SEQ ID NO: 61); and a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of TMRLLQETELVEPLTPSGAMPNQAQMRILKETELRKVKVLGSGAFGTVYKGIWIPDGE
NVKIPVAIKVLRENTSPKANKEILDEAYVMAGVGSPYVSRLLGICLTSTVQLVTQLMPY
GCLLDHVREHRGRLGSQDLLNWCQIAKGMSYLEDVRLVHRDLAARNVLVKSPNHV
KITDFGLARLLDIDETEHADGGKVPIKWMMALESILRRRFTHQSDVWSYGVTVWELMT
FGAKPYDGIPAREIPDLLEKGERLPQPPICTIDVYMIMVKCWMIDSECRPRFRELVEFSR
MARDPQRFVVIQNEIDLTPGTGSTAHRHRSSSPLPPVRPAGATLERPKTLPSPGKNGVVK DVFAFGGAVENPEYL (SEQ ID NO: 62). In some cases, the compositions may comprise a nucleic acid sequence encoding an epitope of the peptide IGF-1R is selected from the group consisting of: a nucleotide sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the nucleotide sequence of TGGTCCTTCGGCGTGGTGCTGTGGGAGATCGCCACCCTGGCCGAGCAGCCCTACCA
GGGCCTGTCCAACGAGCAGGTGCTGCGCTTCGTGATGGAGGGCGGCCTGCTGGACA
AGCCCGACAACGAGCAGGTGCTGCGCTTCGTGATGGAGGGCGGCCTGCTGGACA
AAGCCGACAACGAGCAGGTGCTGCGCTTCGTGATGGAGGGCGGCCTGCTGGACA
CGGCGTGCTGGTGCTGCGCGCCTCCTTCGACGAGCGCCAGCCCTACGCCCACATGA
ACGGAGGCCGCAAGAACGAGCGCGCCCTGCCC (SEQ ID NO: 63); a nucleotide sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the nucleotide sequence of TGGTCCTTCGGCGTGGTGCTGTGGGAGATCGCCACCCTGGCCGAGCAGCCCTACCA
GGGCCTGTCCAACGAGCAGGTGCTGCGCTTCGTGATGGAGGGCGGCCTGCTGGACA
AGCCCGACAACGAGCAGGTGCTGCGCTTCGTGATGGAGGGCGGCCTGCTGGACA
AAGCCGACAACGAGCAGGTGCTGCGCTTCGTGATGGAGGGCGGCCTGCTGGACA
CGGCGTGCTGGTGCTGCGCGCCTCCTTCGACGAGCGCCAGCCCTACGCCCACATGA
ACGGCGGCCGCGCCAACGAGCGCGCCCTGCCC (SEQ ID NO: 64); a nucleotide sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the nucleotide sequence of TGGTCCTTCGGCGTGGTGCTGTGGGAGATCGCCACCCTGGCCGAGCAGCCCTACCA
GGGCCTGTCCAACGAGCAGGTGCTGCGCTTCGTGATGGAGGGCGGCCTGCTGGACA
AGCCCGACAACGAGCAGGTGCTGCGCTTCGTGATGGAGGGCGGCCTGCTGGACA
AAGCCGACAACGAGCAGGTGCTGCGCTTCGTGATGGAGGGCGGCCTGCTGGACA
GCTGGTGCTGCGCGCCTCCTTCGACGAGCGCCAGCCCTACGCCCACATGAACGGCG
GCCGCGCCAACGAGCGCGCCCTGCCC (SEQ ID NO: 65); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of DYRSYRFPKLTVITE (SEQ ID NO: 66); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of IRGWKLFYNYALVIF (SEQ ID NO: 67); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of VVTGYVKIRHSHALV (SEQ ID NO: 68); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of FFYVQAKTGYENFIH (SEQ ID NO: 69); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of LIIALPVAVLLIVGG (SEQ ID NO: 70); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of LVIMLYVFHRKRNN (SEQ ID NO: 71); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of NCHHVRLLGVSQ (SEQ ID NO: 72); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%,

80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of WSFGVVLWEIATLAEQPYQGLSNEQVLRFMVEGGLLDKPDNCPDMLFELMRMCWQY

NPKMRPSFLEHKAENGPGPGVLVLRASFDERQPYAHMNGGRKNERALP (SEQ ID NO: 73); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of WSFGVVLWEIATLAEQPYQGLSNEQVLRFMVEGGLLDKPDNCPDMLFELMRMCWQY

NPKMRPSFLEHKAENGPGPGVLVLRASFDERQPYAHMNGGRANERALP (SEQ ID NO: 74); and a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of WSFGVVLWEIATLAEQPYQGLSNEQVLRFMVEGGLLDKPDNCPDMLFELMRMCWQY

NPKMRPSFLEHKAENGPGVLVLRASFDERQPYAHMNGGRANERALP (SEQ ID NO: 75). In some cases, the compositions may comprise a nucleic acid sequence encoding a fusion protein of three epitopes is selected from the group consisting of: a nucleotide sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the nucleotide sequence of

ATGGCGGTACCAATGCTGCCGAGAGTGGGCTGCCCCGCGCTGCCGCTGCCGCCGCC
GCCGCTGCTGCCGCTGCTGCCGCTGCTGCTGCTGCTACTGGGCGCGAGTGGCGGCG
GCGGCGGGGCGCGCGCGGAGGTGCTGTTCCGCTGCCCCGCCCTGCACACCCGAGCGC
CTGGCCGCCCTGCGGGCCCCCGCCGGTTGCGCCGCCCGCCGCGGTGGCCGCAAGTGGC
CGGAGGCGCCCCGCATGCCATGCGCGGAGCTCGTCCGGGAGCCGGGCTGCGGCTGCT
GCTCGGTGTGCGCCCCGGCTGGAGGGCGAGGCGTGCGGCGTCTACACCCCGCGCTGC
GGCCAGGGGCTGCGCTGCTATCCCCACCCGGGCTCCGAGCTGCCCCCTGCAGGCGCT
GGTCATGGGCGAGGGCACTTGTGAGAAGCGCCGGGACGCCGAGTATGGCGCCAGC
CCGGAGCAGGTTGCAGACAATGGCGATGACCACTCAGAAGGAGGCCTGGTGGAGC
AATTGACGATGCGGAGACTGCTGCAGGAAACGGAGCTGGTGGAGCCGCTGACACCT
AGCGGAGCGATGCCCAACCAGGCGCAGATGCGGATCCTGAAAGAGACGGAGCTGA
GGAAGGTGAAGGTGCTTGGATCTGGCGCTTTTGGCACAGTCTACAAGGGCATCTGG
ATCCCTGATGGGGAGAATGTGAAAATTCCAGTGGCCATCAAAGTGTGAGGGAAAA
CACATCCCCCAAAGCCAACAAAGAAATCTTAGACGAAGCATACTGATGGCTGGTG
TGGGCTCCCCATATGTCTCCCGCCTTCTGGGCATCTGCCTGACATCCACGGTGCAGC
TGGTGACACAGCTTATGCCCTATGGCTGCCTCTTAGACCATGTCCGGGAAAACCGCG
GACGCCTGGGCTCCCAGGACCTGCTGAACTGGTGTATGCAGATTGCCAAGGGGATG
AGCTACCTGGAGGATGTGCGGCTCGTACACAGGGACTTGGCCGCTCGGAACGTGCT
GGTCAAGAGTCCCAACCATGTCAAATTACAGACTTCGGGCTGGCTCGGCTGCTGG
ACATTGACGAGACAGAGTACCATGCAGATGGGGGCAAGGTGCCCATCAAGTGGAT
GGCGCTGGAGTCCATTCTCCGCCGGCGGTTACCCACCAGAGTGATGTGTGGAGTT
ATGGTGTGACTGTGTGGGAGCTGATGACTTTTGGGGCCAAACCTTACGATGGGATC
CCAGCCCCGGGAGATCCCTGACCTGCTGGAAAAGGGGGAGCGGCTGCCCCAGCCCCC
CATCTGCACCATTGATGTCTACATGATCATGGTCAAATGTTGGATGATTGACTCTGA
ATGTCGGCCAAGATTCCGGGAGTTGGTGTCTGAATTCTCCCGCATGGCCAGGGACC
CCCAGCGCTTTGTGGTCATCCAGAATGAGGACTTGGCTCCCGGAGCTGGCGGCATG
GTGCACCACAGGCACCGCAGCTCATCTCCTCTGCCTGCTGCCCCGACCTGCTGGTGCC
ACTCTGGAAAGGCCCAAGACTCTCTCCCCAGGGAAGAATGGGGTCGTCAAAGACGT
TTTTGCCTTTGGGGGTGCCGTGGAGAACCCCGAGTACTTGGGCCGGCCGGTACCTTG
GTCCTTCGGCGTGGTGTGTGGGAGATCGCCACCCTGGCCGAGCAGCCCTACCAGG
GCCTGTCCAACGAGCAGGTGCTGCGCTTCGTGATGGAGGGCGGCCTGCTGGACAAG
CCCGACAACTGCCCCGACATGCTGTTTCGAGCTGATGCGCATGTGCTGGCAGTACAA
CCCCAAGATGCGCCCCCTCCTTCCTGGAGCACAAGGCCGAGAACGGCCCCGGCCCCG
GCGTGCTGGTGTGCTGCGCGCCTCCTTCGACGAGCGCCAGCCCTACGCCACATGAAC
GGAGGCCGCAAGAACGAGCGCGCCCTGCCCGCGGCCGCATAG (SEQ ID NO: 76); a nucleotide sequence having at least

50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the nucleotide sequence of ATGGCGGTACCAATGCTGCCCGCCTGGGCGGCCCCGCCCTGCCCTGCTGCTGCC

TCCCTGCTGCTGCTGCTGCTGCTGGGCGCCGGCGGCTGCGGCCCGGCGTGCGCGCC
GAGGTGCTGTTCCGCTGCCCCCCTGCACCCCCGAGCGCCTGGCCGCCTGCGGCCCC
CCCCCGACGCCCCCTGCGCCGAGCTGGTGCAGGAGCCGGCTGCGGCTGCTGCTC
CGTGTGCGCCCCGCCAGGAGGGCGAGGCCTGCGGCGTGTACATCCCCCGCTGCGCCC
AGACCCTGCGCTGCTACCCCAACCCGGCTCCGAGCTGCCCCCTGAAGGCCCTGGTG
ACCGGCGCCGGCACCTGCGAGAAGCGCCGCGTGGGCACCAACCCCCAGCAGGTGGC
CGACTCCGACGACGACCACTCCGAGGGCGGCCTGGTGGAGCAATTGACCATGCGCC
GCCTGCTGCAGGAGACCGAGCTGGTGGAGCCCCTGACCCCTCCGGCGCCGTGCC

AACCAGGCCCAGATGCGCATCCTGAAGGAGACCGAGCTGCGCAAGCTGAAGGTGCT
 GGGCTCCGGCGCCTTCGGCACCGTGTACAAGGGCATCTGGATCCCCGACGGCGAGA
 ACGTGAAGATCCCCGTGGCCATCAAGGTGCTGCGCGAGAACACCTCCCCAAGGCC
 AACAAAGGAGATCCTGGACGAGGCCTACGTGATGGCCGGCGTGGGCTCCCCCTACGT
 GTCCCGCCTGCTGGGCATCTGCCTGACCTCCACCGTGCAGCTGGTGACCCAGCTGAT
 GCCCTACGGCTGCCTGCTGGACCACGTGCGCGAGCACCGCGGCCGCTGGGCTCCC
 AGGACCTGCTGAACTGGTGCGTGCAGATCGCCAAGGGCATGTCCTACCTGGAGGAG
 GTGCGCCTGGTGACCGCGACCTGGCCGCCCCGCAACGTGCTGGTGAAGTCCCCAA
 CCACGTGAAGATCACCGACTTCGGCCTGGCCCGCCTGCTGGACATCGACGAGACCG
 AGTACCACGCCGACGGCGGCAAGGTGCCCATCAAGTGGATGGCCCTGGAGTCCATC
 CTGCGCCGCCGCTTCACCCACCAAGTCCGACGTGTGGTCTACGGCGTGACCGTGTGG
 GAGCTGATGACCTTCGGCGCCAAGCCCTACGACGGCATCCCCGCCCGCGAGATCCC
 CGACCTGCTGGAGAAGGGCGAGCGCCTGCCCCAGCCCCCATCTGCACCATCGACG
 TGTACATGATCATGGTGAAGTGCTGGATGATCGACTCCGAGTGCCGCCCCCGCTTCC
 GCGAGCTGGTGTCCGAGTTCTCCCGCATGGCCCGCGACCCCCAGCGCTTCGTGGTGA
 TCCAGAACGAGGACCTGGCCCTGGGCACCGGCTCCACCGCCCCACCGCCGCCACCGC
 TCCTCCTCCCCCCCCCCCCCATCCGCCCGCCGGCGCCACCCTGGAGCGCCCCAAG
 ACCCTGTCCCCCGGCAAGAACGGCGTGGTGAAGGACGTGTTGCGCTTCGGCGGGCGC
 CGTGGAGAACCCCGAGTACCTGGGCCGGCCGGTACCTTGGTCCTTCGGCGTGGTGC
 TGTGGGAGATCGCCACCCTGGCCGAGCAGCCCTACCAGGGCCTGTCCAACGAGCAG
 GTGCTGCGCTTCGTGATGGAGGGCGGCCTGCTGGACAAGCCCGACAACCTGCCCCGA
 CATGCTGTTTCGAGCTGATGCGCATGTGCTGGCAGTACAACCCCAAGATGCGCCCCTC
 CTTCTGAGCACAAGGCCGAGAACGGCCCCGGCCCCGGCGTGCTGGTGTGCGCG
 CCTCCTTCGACGAGCGCCAGCCCTACGCCACATGAACGGCGGGCCGCGCCAACGAG
 CGCGCCCTGCCCGCGGCCGCATAG (SEQ ID NO: 77); a nucleotide sequence having at least 50%, 60%, 70%, 80%, 90%,
 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the nucleotide sequence of
 ATGGCGGTACCAATGCTGCCCCGCTGGGCGGCCCGCCCTGCCCTGCTGCTGCCC
 TCCCTGCTGCTGCTGCTGCTGGGCGCCGGCGGCTGCGGCCCGGCGTGCGCGCC
 GAGGTGCTGTTCCGCTGCCCCCCTGCACCCCGAGCGCCTGGCCGCTGCGGCCCC
 CCCCCGACGCCCCCTGCGCCGAGCTGGTGCGCGAGCCCGGCTGCGGCTGCTGCTC
 CGTGTGCGCCCGCCAGGAGGGCGAGGCCTGCGGCGTGATACATCCCCGCTGCGCCC
 AGACCCTGCGCTGCTACCCCAACCCCGGCTCCGAGCTGCCCTGAAGGCCCTGGTG
 ACCGGCGCCGGCACCTGCGAGAAGCGCCGCGTGGGCGCCACCCCCAGCAGGTGGC
 CGACTCCGAGGACGACCACTCCGAGGGCGGCCTGGTGGAGCAATTGACCATGCGCC
 GCCTGCTGCAGGAGACCGAGCTGGTGGAGCCCCTGACCCCTCCGGCGCCATGCCC
 AACCAGGCCCAGATGCGCATCCTGAAGGAGACCGAGCTGCGCAAGGTGAAGGTGC
 TGGGCTCCGGCGCCTTCGGCACCGTGTACAAGGGCATCTGGATCCCCGACGGCGAG
 AACGTGAAGATCCCCGTGGCCATCAAGGTGCTGCGCGAGAACACCTCCCCAAGGC
 CAACAAGGAGATCCTGGACGAGGCCTACGTGATGGCCGGCGTGGGCTCCCCCTACG
 TGTCCTCGCCTGCTGGGCATCTGCCTGACCTCCACCGTGCAGCTGGTGACCCAGCTGA
 TGCCCTACGGCTGCCTGCTGGACCACGTGCGCGAGCACCGCGGCCGCTGGGCTCC
 CAGGACCTGCTGAACTGGTGCGTGCAGATCGCCAAGGGCATGTCCTACCTGGAGGA
 CGTGCGCCTGGTGACCGCGACCTGGCCGCCCCGCAACGTGCTGGTGAAGTCCCCCA
 ACCACGTGAAGATCACCGACTTCGGCCTGGCCCGCCTGCTGGACATCGACGAGACC
 GAGTACCACGCCGACGGCGGCAAGGTGCCCATCAAGTGGATGGCCCTGGAGTCCAT
 CCTGCGCCGCGCCTTCACCCACCAAGTCCGACGTGTGGTCTACGGCGTGACCGTGTG
 GGAGCTGATGACCTTCGGCGCCAAGCCCTACGACGGCATCCCCGCCCGCGAGATCC
 CCGACCTGCTGGAGAAGGGCGAGCGCCTGCCCCAGCCCCCATCTGCACCATCGAC
 GTGTACATGATCATGGTGAAGTGCTGGATGATCGACTCCGAGTGCCGCCCCCGCTTC
 CGCGAGCTGGTGTCCGAGTTCTCCCGCATGGCCCGCGACCCCCAGCGCTTCGTGGTG
 ATCCAGAACGAGGACCTGACCCCGGCACCGGCTCCACCGCCCCACCGCCGCCACCG
 CTCCTCCTCCCCCTGCCCCCGTGCGCCCCGCGGCGCCACCCTGGAGCGCCCCAA
 GACCCTGTCCCCCGGCAAGAACGGCGTGGTGAAGGACGTGTTGCGCTTCGGCGGGCG
 CCGTGGAGAACCCCGAGTACCTGGGCCGGCCGGTACCTTGGTCCTTCGGCGTGGTG
 CTGTGGGAGATCGCCACCCTGGCCGAGCAGCCCTACCAGGGCCTGTCCAACGAGCA
 GGTGCTGCGCTTCGTGATGGAGGGCGGCCTGCTGGACAAGCCCGACAACCTGCCCCG
 ACATGCTGTTTCGAGCTGATGCGCATGTGCTGGCAGTACAACCCCAAGATGCGCCCC
 TCCTTCCTGGAGCACAAGGCCGAGAACGGCCCCGGCGTGCTGGTGTGCGCGCCTC
 CTTTCGACGAGCGCCAGCCCTACGCCACATGAACGGCGGGCCGCGCCAACGAGCGCG CCCTGCCCGCGGCCGCATAG (SEQ

ID NO: 78); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of
MAVPMLPRVGC PALPLPPP LLLPLLLLLLLGASGGGGGARA EVLFR CPPCTPERLAAC
GPPPVAPPAVA AVAGGAR MP CAELVREPGCGCCSV CARLEGEACGVYTPRCGQGLR
CYPHPGSELPLQALVMGEGTCEKRRDAEY GASPEQVADNGDDHSEGGLVEQLTMRRL
LQETELVEPLTPSGAMPNQAQM RILKETELRKVKVLGSGAFGT VYKGIWIPDGENVKIP
VAIKV LRENTSPKANKEILDEAYVMAGV GSPYVSRLLGICLTSTVQLVTQLMPYGCLLD
HVREN RGLGSQDLLNWCMQIAKGMSYLEDVRLVHRDLAARNVLVKSPNHVKITDFG
LARLLDIDET EYHADGGKVPIKWM ALESILRRRFTHQSDVWSYGVTVWELMTFGAKPY
DGIPAREIPDLLEKGERLPQPPICTIDVYMIMVKCWMIDSECRPRFREL VSEFSRMARDP
QRFVVIQNE DLAPGAGGMVHHRHRSSSPLPAARPAGATLERPKTLSPGKNGVVKDVFA
FGGAVENPEYLGRPVPWSFGVVLWEIATLAEQPYQGLSNEQVLR FVMEGGLLDKPDNC
PDMLFELMRMCWQYNPKMRPSFLEHKAENGPGPGVLVLRASFDERQPYAHMNGGRK NERALPAAA (SEQ ID NO: 79); a
nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%,
91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of
MAVPMLPRLGGPALLLLPSLLLLLLL GAGGCGPGVRAEVLFR CPPCTPERLAACGPPP
DAPCAELVREPGCGCCSV CARQEGEACGVYIPRCAQTLRCYPNPGSELPLKALVTGAGT
CEKRRVGTT PQQVADSDDDHSEGGLVEQLTMRRLQETELVEPLTPSGAVPNQAQM RI
LKETELRK LKVLGSGAFGT VYKGIWIPDGENVKIPVAIKV LRENTSPKANKEILDEAYV
MAGVGSPYVSRLLGICLTSTVQLVTQLMPYGCLLDHVREHRGRLGSQDLLNWC VQIAK
GMSYLEEVRLVHRDLAARNVLVKSPNHVKITDFGLARLLDIDET EYHADGGKVPIKWM
ALESILRRRFTHQSDVWSYGVTVWELMTFGAKPYDGIPAREIPDLLEKGERLPQPPICTI
DVYMIMVKCWMIDSECRPRFREL VSEFSRMARDPQRFVVIQNE DLALGTGSTAHRHR
SSSPPPIR PAGATLERPKTLSPGKNGVVKDVFAFGGAVENPEYLGRPVPWSFGVVLWEI
ATLAEQPYQGLSNEQVLR FVMEGGLLDKPDNCPDMLFELMRMCWQYNPKMRPSFLEH
KAENGPGPGVLVLRASFDERQPYAHMNGGRANERALPAAA (SEQ ID NO: 80); and a nucleotide sequence encoding an amino
acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,
98%, 99%, or 100% sequence identity to the amino acid sequence of
MAVPMLPRLGGPALLLLPSLLLLLLL GAGGCGPGVRAEVLFR CPPCTPERLAACGPPP
DAPCAELVREPGCGCCSV CARQEGEACGVYIPRCAQTLRCYPNPGSELPLKALVTGAGT
CEKRRVGATPQQVADSEDDHSEGGLVEQLTMRRLQETELVEPLTPSGAMPNQAQM RI
LKETELRKVKVLGSGAFGT VYKGIWIPDGENVKIPVAIKV LRENTSPKANKEILDEAYV
MAGVGSPYVSRLLGICLTSTVQLVTQLMPYGCLLDHVREHRGRLGSQDLLNWC VQIAK
GMSYLEDVRLVHRDLAARNVLVKSPNHVKITDFGLARLLDIDET EYHADGGKVPIKW
MALESILRRRFTHQSDVWSYGVTVWELMTFGAKPYDGIPAREIPDLLEKGERLPQPPICT
IDVYMIMVKCWMIDSECRPRFREL VSEFSRMARDPQRFVVIQNE DLTPGTGSTAHRHR
SSSPLPPVR PAGATLERPKTLSPGKNGVVKDVFAFGGAVENPEYLGRPVPWSFGVVLW
EIATLAEQPYQGLSNEQVLR FVMEGGLLDKPDNCPDMLFELMRMCWQYNPKMRPSFL
EHKAENGPGVLVLRASFDERQPYAHMNGGRANERALPAAA (SEQ ID NO: 81).

[0169] In some cases, the compositions may comprise a first and a second epitope independently selected from: CD105, Yb-1, SOX-2, CDH3 or MDM2. In some cases, the compositions may comprise a Third epitope, the first, second and Third epitopes independently selected from: CD105, Yb-1, SOX-2, CDH3 or MDM2. In some cases, the compositions may comprise a Third and a fourth epitope, the first, second, Third and fourth epitopes independently selected from: CD105, Yb-1, SOX-2, CDH3 or MDM2. In some cases, the compositions may comprise a Third, a fourth and a fifth epitope, the first, second, Third, fourth and fifth epitopes independently selected from: CD105, Yb-1, SOX-2, CDH3 or MDM2.

[0170] In some cases, the compositions may comprise a first and a second epitope independently selected from: IGFBP2, HER-2 or IGF-1R. In some cases, the compositions may comprise a Third epitope, the first, second and Third epitopes independently selected from: IGFBP2, HER-2 or IGF-1R.

[0171] In some cases, the compositions may be capable of being administered to a subject. In some cases, the subject is in need of administration of the composition. In some cases, the composition is effective to elicit an immune response in a subject. In some cases, the composition is effective to eliminate a number of cells associated with breast cancer in a subject. In some cases, the composition can be used to prevent the growth of cells associated with breast cancer in a subject.

[0172] In some cases, the first and the second nucleic acid sequences are located on the first plasmid. In some cases, the second nucleic acid sequence is located on a second plasmid.

[0173] In some cases, the cells associated with breast cancer are selected from: breast cells expressing atypical features, pre-neoplastic breast cells, breast cancer cells, pre-invasive breast cancer cells, breast cancer stem cells, epithelial cells, mesenchymal cells, stromal cells, or a combination thereof.

[0174] In some cases, the first and the second nucleic acid sequences are purified to at least 70% purity. In some cases, the first and the second nucleic acid sequences are located on the first plasmid and are separated by a sequence of linker nucleic acids. In some cases, the first nucleic acid sequence is adjacent to the second nucleic acid sequence on the first plasmid.

[0175] In some cases, at least the first plasmid is contained within a pharmaceutical composition. In some cases, at least the first plasmid is contained within a pharmaceutical composition further comprising a pharmaceutical carrier. In some cases, at least the first plasmid is contained within a pharmaceutical composition further comprising a pharmaceutical carrier and an adjuvant. In some cases, at least the first plasmid is contained within a pharmaceutical composition further comprising an adjuvant. In some cases, the composition further comprises an adjuvant and a pharmaceutically acceptable carrier. In some cases, the adjuvant is GM-CSF.

[0176] In some cases, a subject is selected from: a human with breast cancer, a mouse with breast cancer or a rat with breast cancer. In some cases, a subject is selected from: a human without breast cancer, a mouse without breast cancer or a rat without breast cancer.

[0177] In some cases, the immune response is a Type 1 immune response. In some cases, the first nucleic acid sequence is a species selected from: human, mouse or rat. In some cases, the second nucleic acid sequence is a species selected from: human, mouse or rat. In some cases, the immune response is characterized by a ratio of Type I cytokine production to Type II cytokine production that is greater than 1. In some cases, the immune response is characterized by a ratio of Type I cytokine production to Type II cytokine production that is less than 1. In some cases, the immune response is characterized by a ratio of IFN γ production to IL-10 production that is greater than 1. In some cases, the immune response is characterized by a ratio of IFN γ production to IL-10 production that is less than 1.

[0178] In some cases, the compositions include a composition comprising: a first plasmid comprising a first nucleotide sequence, the first nucleotide sequence encoding a first epitope of a first antigen, the first epitope is a portion of an HIF-1 α peptide, wherein the first nucleotide sequence is located in a plasmid. In other cases, the compositions include a composition comprising: a first plasmid comprising a first nucleotide sequence, the first nucleotide sequence encoding a first epitope of a first antigen; and a second nucleotide sequence, the second nucleotide sequence encoding a second epitope of a second antigen, wherein the first and the second epitopes are portions of an HIF-1 α peptide, wherein the first nucleotide sequence and the second nucleotide sequence are located in one or more plasmids.

[0179] The nucleic acid sequences which encode epitopes from the following proteins, CD105, HIF1 α , MDM2, Yb-1, SOX-2, HER-2, IGFBP2, IGF-1R and CDH3 may differ from those listed herein. In some cases, nucleic acid sequences which are greater than 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, or greater than 50% homologous to those disclosed herein may be used in the compositions described herein.

[0180] The compositions described herein, in some cases, may include a composition comprising: a first epitope of a first antigen expressed by cells associated with breast cancer; and a second epitope of a second antigen expressed by cells associated with breast cancer.

[0181] In some cases, the composition may comprise: at least a first epitope of a first antigen, the first epitope is a portion of a peptide selected from: CD105, Yb-1, SOX-2, CDH3 or MDM2. In some cases, the composition may comprise: at least a first epitope of a first antigen, at least a second epitope of a second antigen, the first and the second epitopes are independently selected from: CD105, Yb-1, SOX-2, CDH3 or MDM2. In some cases, at least a first epitope of the peptide CD105 is selected from the group consisting of: an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of EARMLNASIVASFVELPL (SEQ ID NO: 6); an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of QNGTWPREVLLVLSVNSSVFLHLQALGIPLHLAYNSSLVTFQEPPGVNTTEL (SEQ ID NO: 1); an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of TVFMRLNIISPDLGCTSKGLVLPVLTGIFGAFLIGALLTAALWYIYSHTRSPSKREPVV AVAAPASSESSSTNHSIGSTQSTPCSTSSMA (SEQ ID NO: 8); an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of TVSMRLNIVSPDLGKGLVLPVLTGIFGAFLIGALLTAALWYIYSHTRGPSKREPVVAV

AAPASSESSSTNHSIGSTQSTPCSTSSMA (SEQ ID NO: 9); or an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of TVSMRLNIVSPDLGKGLVLPVLGITFGAFLIGALLTAALWYIYSHTRAPSKREPVAV AAPASSESSSTNHSIGSTQSTPCSTSSMA (SEQ ID NO: 10). In some cases, at least a first epitope of the peptide Yb-1 is selected from the group consisting of: an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of EDVVFVHQTAIKNNPRK (SEQ ID NO: 14); an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of YRRNFNYRRRRPEN (SEQ ID NO: 15); or an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of GVPVQGSKYAADRNHYRRYPRRRGPPRNYQQN (SEQ ID NO: 16). In some cases, at least a first epitope of the peptide SOX-2 is selected from the group consisting of: an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of GLNAHGAAQMMPMHRYDVSALQYNSMTSSQTYMNGSPTYSMSYSQQGTPGMALGSM GSV (SEQ ID NO: 20). In some cases, at least a first epitope of the peptide CDH3 is selected from the group consisting of: an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of RSLKERNPLKIFPSKRILRRHKRDWVAPISVPENGKGPFQRLNQLKSNKDRDTKIFYSI TGPADSPPEGVFAVEKET (SEQ ID NO: 25); an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of LKIFPSKRILRRHKRDWVAPISVPENGKGPFQRLNQLKSNKDRDTKIFYSITGPADSP PEGVFAVEKET (SEQ ID NO: 26); an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of AMHSPPTRILRRRKREWWMPPIFVPENGKGPFQRLNQLKSNKDRGTKIFYSITGPADS PEGVFTIEKES (SEQ ID NO: 27); or an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of VMNSPPSRILRRRKREWWMPPIFVPENGKGPFQRLNQLKSNKDRGTKIFYSITGPADS PEGVFTIEKET (SEQ ID NO: 28). In some cases, at least a first epitope of the peptide MDM-2 is selected from the group consisting of: an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of TYTMKEVLFLYGQYIMTKRLYDEKQQHIVYCSNDLLGDLFGVPSFSVKEHRKIYTMIR NLVVNQQESSDSGTSV (SEQ ID NO: 32); an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of TYTMKEIIFYIGQYIMTKRLYDEKQQHIVYCSNDLLGDVFGVPSFSVKEHRKIYAMIYRN LVAVSQQDSGTSLS (SEQ ID NO: 33); or an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of IYTMKEIIFYIGQYIMTKRLYDEKQQHIVYCSNDLLGDVFGVPSFSVKEHRKIYAMIYRN LVVVSQQDSGTSPS (SEQ ID NO: 34).

[0182] In some cases, the compositions described herein include an amino acid sequence of a fusion peptide of five epitopes is selected from the group consisting of: an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of MAVPMLSCSRQNGTWPREVLLVLSVNSSVFLHLQALGIPLHLAYNSSLVTFQEPPGVN TTELIRSTGGVPVQGSKYAADRNHYRRYPRRRGPPRNYQQNTRGLNAHGAAQMMPMH RYDVSALQYNSMTSSQTYMNGSPTYSMSYSQQGTPGMALGSMGVSRSQRLSLKERNP LKIFPSKRILRRHKRDWVAPISVPENGKGPFQRLNQLKSNKDRDTKIFYSITGPADSP PEGVFAVEKETRSAGETYTMKEVLFLYGQYIMTKRLYDEKQQHIVYCSNDLLGDLFGV PSFSVKEHRKIYTMIRNLVVNQQESSDSGTSVSRS (SEQ ID NO: 39); an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of MAVPMTVMRLNIISPDLGCTSKGLVLPVAVLGITFGAFLIGALLTAALWYIYSHTRSPS KREPVAVAAAPASSESSSTNHSIGSTQSTPCSTSSMATGGVPVQGSKYAADRNHYRRYPRRRGPPRNYQQNTRGLNAHGAAQMMPMHRYDVSALQYNSMTSSQTYMNGSPTYSMS YSQGTPGMALGSMGVSRSQLLKIFPSKRILRRHKRDWVAPISVPENGKGPFQRLNQ LKSNKDRDTKIFYSITGPADSPPEGVFAVEKETRSAGETYTMKEVLFLYGQYIMTKRL YDEKQQHIVYCSNDLLGDLFGVPSFSVKEHRKIYTMIRNLVVNQQESSDSGTSVSRS (SEQ ID NO: 40); an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of MAVPMTVMRLNIVSPDLGKGLVLPVLGITFGAFLIGALLTAALWYIYSHTRGPSKRE PVVAVAAAPASSESSSTNHSIGSTQSTPCSTSSMATGGVPVQGSKYAADRNHYRRYPRRR GPPRNYQQNTRGLNAHGAAQMMPMHRYDVSALQYNSMTSSQTYMNGSPTYSMSYSQ QGTPGMALGSMGVSRSQLAMHSPPTRILRRRKREWWMPPIFVPENGKGPFQRLNQLK

SNKDRGTKIFYSITGPGADSPPEGVFTIEKESRSAGETYTMKEIFYIGQYIMTKRLYDEK
 QQHIVYCSNDLLGDVFGVPSFSVKEHRKIYAMIYRNLVAVSQQDSGTSLRS (SEQ ID NO: 41); or an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of
 MAVPMTVSMRLNIVSPDLGKGLVPSVLGITFGAFLIGALLTAALWYIYSHTRAPSKRE
 PVVAAAPASSESSSTNHSIGSTQSTPCSTSSMATGGVPVQGSKYAADRNHYRRYPRRR
 GPPRNYQQNTRGLNAHGAAQMMPHRYDVSALQYNSMTSSQTYMNGSPTYMSYSQ
 QGTPGMALGSMGVSRLVMSPPSRILRRRKREWWMPPIVSPENGKGPFPQRLNQLKS
 NKDRGTKLFYSITGPGADSPPEGVFTIEKETRSAGEIYTMKEIFYIGQYIMTKRLYDEKQ
 QHIVYCSNDLLGDVFGVPSFSVKEHRKIYAMIYRNLVAVSQQDSGTSPSRS (SEQ ID NO: 42).

[0183] The compositions described herein may further include a composition comprising: a first plasmid comprising a first nucleotide sequence, the first nucleotide sequence encoding a first epitope of a first antigen, the first epitope is a portion of a peptide selected from: IGFBP-2, HER-2 or IGF-1R, wherein the first nucleotide sequence is located in a plasmid. In some cases, the composition may comprise: a first plasmid comprising a first nucleotide sequence, the first nucleotide sequence encoding a first epitope of a first antigen; and a second nucleotide sequence, the second nucleotide sequence encoding a second epitope of a second antigen, wherein the first and the second epitopes are independently selected from: IGFBP-2, HER-2 or IGF-1R, wherein the first nucleotide sequence and the second nucleotide sequence are located in one or more plasmids. In some cases, at least a first epitope of the peptide IGFBP-2 is selected from the group consisting of: an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of NHVDSTMNMLGGGS (SEQ ID NO: 46); an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of ELAVFREKVTEQHRQ (SEQ ID NO: 47); an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of LGLEEPKKLRPPPAR (SEQ ID NO: 48); an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of DQVLERISTMRPDE (SEQ ID NO: 49); an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of GPLEHLYSLHIPNCD (SEQ ID NO: 50); an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of KHGLYNLKQCKMSLN (SEQ ID NO: 51); an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of PECHLFYNEQEQARG (SEQ ID NO: 53); an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of
 MLPRVGCALPLPPPLPLPLLLLLLGASGGGGGARAELVFRCPPTPERLAACGPPP
 VAPPAVAAGVAGGARMPCAEVREPGCGCCSVCARLEGEACGVYTPRCGQGLRCYPH
 PGSELPLQALVMGEGTCEKRRDAEYGASPEQVADNGDDHSEGLVE (SEQ ID NO: 54); an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of
 MLPRLGGPALPLLLPSLLLLLLLGAGGCGPGVRAEVLFRCPPTPERLAACGPPPDAPCA
 ELVREPGCGCCSVCARQEGEACGVYIPRCAQTLRCYPNPGSELPLKALVTGAGTCEKRR VGTTPQQVADSDDHSEGLVE (SEQ ID NO: 55); or an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of
 MLPRLGGPALPLLLPSLLLLLLLGAGGCGPGVRAEVLFRCPPTPERLAACGPPPDAPCA
 ELVREPGCGCCSVCARQEGEACGVYIPRCAQTLRCYPNPGSELPLKALVTGAGTCEKRR VGATPQQVADSEDDHSEGLVE (SEQ ID NO: 56). In some cases, at least a first epitope of the peptide HER-2 is selected from the group consisting of: a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of
 TMRLLQETELVEPLTPSGAMPNQAQMRILKETELRKVKVLGSGAFGTVYKGIWIPDGE
 NVKIPVAIKVLRENTSPKANKEILDEAYVMAGVGSPYVSRLLGICLTSTVQLVTQLMPY
 GCLLDHVRENRGRLGSQDLLNWCMQIAKGMSYLEDVRLVHRDLAARNVLVKSPNHV
 KITDFGLARLLDIDETEHADGGKVIKWMALLESILRRRFTHQSDVWSYGVTVWELMT
 FGAQPYDGIPAREIPDLLEKGERLPQPPICTIDVYIMVKCWMIDSECRPRFRELVSFESR
 MARDPQRFVVIQNEIDLAPGAGGMVHHRHRSSSPLPAARPAGATLERPKTLSPGKNGVV KDVFAFGGAVENPEYL (SEQ ID NO: 60); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of
 TMRLLQETELVEPLTPSGAVPNQAQMRILKETELRKVKVLGSGAFGTVYKGIWIPDGE
 NVKIPVAIKVLRENTSPKANKEILDEAYVMAGVGSPYVSRLLGICLTSTVQLVTQLMPY

GCLLDHVREHRGRLGSQDLLNWCVQIAKGMSYLEEVRLVHRDLAARNVLVKSPNHVK
ITDFGLARLLDIDETEHADGGKVPIKWMALESILRRRFTHQSDVWSYGVTVWELMTF
GAKPYDGIPAREIPDLLEKGERLPQPPICTIDVYMIMVKCWMIDSECRPRFRELVSEFSR
MARDPQRFVVIQNEIDLALGTGSTAHRHRSSSPPPPIRPAGATLERPKTLSPGKNGVVK DVFAFGGAVENPEYL (SEQ ID NO: 61);
or a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%,
90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of
TMRRLQETELVEPLTPSGAMPNQAQMRILKETELRKVKVLGSGAFGTVYKGIWIPDGE
NVKIPVAIKVLRENTSPKANKEILDEAYVMAGVGSPYVSRLLGICLTSTVQLVTQLMPY
GCLLDHVREHRGRLGSQDLLNWCVQIAKGMSYLEEDVRLVHRDLAARNVLVKSPNHV
KITDFGLARLLDIDETEHADGGKVPIKWMALESILRRRFTHQSDVWSYGVTVWELMT
FGAKPYDGIPAREIPDLLEKGERLPQPPICTIDVYMIMVKCWMIDSECRPRFRELVSEFSR
MARDPQRFVVIQNEIDLTPGTGSTAHRHRSSSPLPPVRPAGATLERPKTLSPGKNGVVK DVFAFGGAVENPEYL (SEQ ID NO:
62). In some cases, a nucleic acid sequence encoding an epitope of the peptide IGF-1R is selected from the group consisting
of: an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%,
96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of DYRSYRFPKLTVITE (SEQ ID NO: 66); an
amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%,
97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of IRGWKLFYNYALVIF (SEQ ID NO: 67); an amino
acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,
98%, 99%, or 100% sequence identity to the amino acid sequence of VVTGYVKIRHSHALV (SEQ ID NO: 68); an amino acid
sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%,
99%, or 100% sequence identity to the amino acid sequence of FFYVQAKTGYENFIH (SEQ ID NO: 69); an amino acid
sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%,
99%, or 100% sequence identity to the amino acid sequence of LIIALPVAVLLIVGG (SEQ ID NO: 70); an amino acid sequence,
the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or
100% sequence identity to the amino acid sequence of LVIMLYVFHRKRNS (SEQ ID NO: 71); an amino acid sequence, the
amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%
sequence identity to the amino acid sequence of NCHHVVRLLGVVSQG (SEQ ID NO: 72); an amino acid sequence, the amino
acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%
sequence identity to the amino acid sequence of
WSFGVVLWEIATLAEQPYQGLSNEQVLRVMEGGLLDKPDNCPDMLFELMRMCWQY
NPKMRPSFLEHKAENGPGPGVLVLRASFDERQPYAHMNGGRKNERALP (SEQ ID NO: 73); an amino acid sequence, the amino
acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%
sequence identity to the amino acid sequence of
WSFGVVLWEIATLAEQPYQGLSNEQVLRVMEGGLLDKPDNCPDMLFELMRMCWQY
NPKMRPSFLEHKAENGPGPGVLVLRASFDERQPYAHMNGGRANERALP (SEQ ID NO: 74); or an amino acid sequence, the
amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%
sequence identity to the amino acid sequence of
WSFGVVLWEIATLAEQPYQGLSNEQVLRVMEGGLLDKPDNCPDMLFELMRMCWQY
NPKMRPSFLEHKAENGPGPGVLVLRASFDERQPYAHMNGGRANERALP (SEQ ID NO: 75).

[0184] The compositions described herein may further include a nucleic acid sequence encoding a fusion protein of three
epitopes is selected from the group consisting of: an amino acid sequence, the amino acid sequence having at least 50%,
60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid
sequence of
MAVPMLPRVGC PALPLPPPLPLLLPLLLLLLGASGGGGGARA EVLFRCPPTPERLAAC
GPPP VAPPAVA AVAGGARMPCAELVREPGCGCCSV CARLEGEACGVYTPRCGQGLR
CYPHPGSELPLQALVMGEGTCEKRRDAEYGASPEQVADNGDDHSEGGLVEQLTMRRL
LQETELVEPLTPSGAMPNQAQMRILKETELRKVKVLGSGAFGTVYKGIWIPDGENVKIP
VAIKVLRENTSPKANKEILDEAYVMAGVGSPYVSRLLGICLTSTVQLVTQLMPYGCLLD
HVREN RGR LGSQDLLNWCMQIAKGMSYLEDVRLVHRDLAARNVLVKSPNHVKITDFG
LARLLDIDETEHADGGKVPIKWMALESILRRRFTHQSDVWSYGVTVWELMTFGAKPY
DGIPAREIPDLLEKGERLPQPPICTIDVYMIMVKCWMIDSECRPRFRELVSEFSRMARDP
QRFVVIQNEIDLAPGAGGMVHHRHRSSSPLPAARPAGATLERPKTLSPGKNGVVKDVFA
FGGAVENPEYLGRPVPWSFGVVLWEIATLAEQPYQGLSNEQVLRVMEGGLLDKPDNC
PDMLFELMRMCWQYNPKMRPSFLEHKAENGPGPGVLVLRASFDERQPYAHMNGGRK NERALPAAA (SEQ ID NO: 79); an
amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%,
97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of
MAVPMLPRLGGPALPLLLPSLLLLLLLGAGGCGPGVRAEVLFRCPPTPERLAACGPPP
DAPCAELVREPGCGCCSVCARQEGEACGVYIPRCAQTLRCYPNPGSELPLKALVTGAGT
CEKRRVGTTPQQVADSDDHSEGGLVEQLTMRRLQETELVEPLTPSGAVPNQAQMRI

LKETELRKLVKLGSGAFGTVYKGIWIPDGENVKIPVAIKVLRENTSPKANKEILDEAYV
MAGVGSPYVSRLLGICLTSTVQLVTQLMPYGCLLDHVREHRGRLGSQDLLNWCVQIAK
GMSYLEEVRLVHRDLAARNVLVKSPNHVKITDFGLARLLDIDETEHADGGKVPIKWM
ALESILRRRFTHQSDVWSYGVTVWELMTFGAKPYDGIPAREIPDLLEKGERLPQPPICTI
DVYMIMVKCWMIDSECRPRFRELVSFSESRMARDPQRFVVIQNEIDLALGTGSTAHRHR
SSSPPPPIRPAGATLERPKTLPSPGKNGVVKDVFAFGGAVENPEYLGRPVPWSFGVVLWEI
ATLAEQPYQGLSNEQVLRVMEGGLLDKPDNCPDMLFELMRMCWQYNPKMRPSFLEH
KAENGGPGVVLVRASFDERQPYAHMNGGRANERALPAAA (SEQ ID NO: 80); or an amino acid sequence, the amino acid
sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence
identity to the amino acid sequence of MAVPMLPRLGGPALPLLLPSLLLLLLGAGGCGPGVRAEVLFRCPPTPERLAACGPPP
DAPCAELVREPGCGCCSVCARQEGEACGVYIPRCAQTLRCYPNPGSELPLKALVTGAGT
CEKRRVGATPQQVADSEDDHSEGLVEQLTMRLLQETELVEPLTPSGAMPNQAQMRI
LKETELRKVKLVGSGAFGTVYKGIWIPDGENVKIPVAIKVLRENTSPKANKEILDEAYV
MAGVGSPYVSRLLGICLTSTVQLVTQLMPYGCLLDHVREHRGRLGSQDLLNWCVQIAK
GMSYLEDVRLVHRDLAARNVLVKSPNHVKITDFGLARLLDIDETEHADGGKVPIKW
MALESILRRRFTHQSDVWSYGVTVWELMTFGAKPYDGIPAREIPDLLEKGERLPQPPICT
IDVYMIMVKCWMIDSECRPRFRELVSFSESRMARDPQRFVVIQNEIDLTPGTGSTAHRHR
SSSPPLPPVRPAGATLERPKTLPSPGKNGVVKDVFAFGGAVENPEYLGRPVPWSFGVVLW
EIALAEQPYQGLSNEQVLRVMEGGLLDKPDNCPDMLFELMRMCWQYNPKMRPSFL
EHKAENGGVVLVRASFDERQPYAHMNGGRANERALPAAA (SEQ ID NO: 81).

[0185] In some cases, the composition comprises a first and a second epitope independently selected from: CD105, Yb-1, SOX-2, CDH3 or MDM2. In some cases, the composition further comprises a Third epitope, the first, second and Third epitopes independently selected from: CD105, Yb-1, SOX-2, CDH3 or MDM2. In some cases, the composition further comprises a Third and a fourth epitope, the first, second, Third and fourth epitopes independently selected from: CD105, Yb-1, SOX-2, CDH3 or MDM2. In some cases, the composition further comprises a Third, a fourth and a fifth epitope, the first, second, Third, fourth and fifth epitopes independently selected from: CD105, Yb-1, SOX-2, CDH3 or MDM2.

[0186] In some cases, the composition comprises a first and a second epitope independently selected from: IGFBP2, HER-2 or IGF-1R. In some cases, the composition further comprises a Third epitope, the first, second and Third epitopes independently selected from: IGFBP2, HER-2 or IGF-1R.

[0187] In some cases, a composition may comprise: at least a first epitope of a first antigen, the first epitope is a portion of a peptide from HIF-1 α . In some cases, a composition may comprise: at least a first epitope of a first antigen, at least a second epitope of a second antigen, the first and the second epitopes are from HIF-1 α .

[0188] In some cases, the compositions may include a nucleic acid sequence encoding an epitope of the peptide HIF-1 α is selected from the group consisting of: a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of DSKTFLSRHSLDMKFSYCDERITELMGYEPEELLGRSIYEYHALDSDHLTKTHHDMFT KGQVTTGQYRMLAKRGGYVWETQATVIYN (SEQ ID NO: 82); a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SDNVNKYMGLTQFELTGHSVDFDTHP (SEQ ID NO: 83); and a nucleotide sequence encoding an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of GGYVWETQATVIYNTKNSQ (SEQ ID NO: 84).

[0189] In some cases, the composition may include at least a first epitope of the peptide HIF-1 α is selected from the group consisting of: an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of DSKTFLSRHSLDMKFSYCDERITELMGYEPEELLGRSIYEYHALDSDHLTKTHHDMFT KGQVTTGQYRMLAKRGGYVWETQATVIYN (SEQ ID NO: 82); an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SDNVNKYMGLTQFELTGHSVDFDTHP (SEQ ID NO: 83); and an amino acid sequence, the amino acid sequence having at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of GGYVWETQATVIYNTKNSQ (SEQ ID NO: 84).

[0190] The compositions described herein may contain short epitopes encoded on a single plasmid backbone. In some cases, the plasmid backbone may encode one short epitope. In other cases, the plasmids described herein may encode more than

one short epitope. For example, the compositions described herein may encode two short epitopes, three short epitopes, four short epitopes, five short epitopes, six short epitopes, seven short epitopes, eight short epitopes, nine short epitopes, ten short epitopes, 11 short epitopes, 12 short epitopes, 13 short epitopes, 14 short epitopes, 15 short epitopes, 16 short epitopes, 17 short epitopes, 18 short epitopes 19 short epitopes, 20 short epitopes or more than 20 short epitopes. In an exemplary case, the plasmid encodes no more than six short epitopes.

[0191] The compositions described herein may contain extended epitopes encoded on a single plasmid backbone. In some cases, the plasmid may encode one extended epitope. In other cases, the compositions may encode more than one extended epitope. For example, the plasmids may encode two extended epitopes, three extended epitopes, four extended epitopes, five extended epitopes, six extended epitopes, seven extended epitopes, eight extended epitopes, nine extended epitopes, ten extended epitopes, 11 extended epitopes, 12 extended epitopes, 13 extended epitopes, 14 extended epitopes, 15 extended epitopes, 16 extended epitopes, 17 extended epitopes, 18 extended epitopes 19 extended epitopes, 20 extended epitopes or more than 20 extended epitopes. In an exemplary case, the plasmid encodes no more than four extended epitopes.

[0192] The compositions of breast cancer vaccines described herein may contain short epitopes and extended epitopes on a single plasmid backbone. In some cases, the plasmid may include one short epitope. In other cases, the compositions of plasmids described herein may include more than one short epitope. For example, the compositions of plasmids described herein may include two short epitopes, three short epitopes, four short epitopes, five short epitopes, six short epitopes, seven short epitopes, eight short epitopes, nine short epitopes, ten short epitopes, 11 short epitopes, 12 short epitopes, 13 short epitopes, 14 short epitopes, 15 short epitopes, 16 short epitopes, 17 short epitopes, 18 short epitopes 19 short epitopes, 20 short epitopes or more than 20 short epitopes.

[0193] In some cases, the plasmid may encode one extended epitope. In other cases, the compositions described herein may encode more than one extended epitope. For example, the compositions described herein may encode two extended epitopes, three extended epitopes, four extended epitopes, five extended epitopes, six extended epitopes, seven extended epitopes, eight extended epitopes, nine extended epitopes, ten extended epitopes, 11 extended epitopes, 12 extended epitopes, 13 extended epitopes, 14 extended epitopes, 15 extended epitopes, 16 extended epitopes, 17 extended epitopes, 18 extended epitopes 19 extended epitopes, 20 extended epitopes or more than 20 extended epitopes.

[0194] Plasmids for the compositions containing more than one sequence encoding an epitope may contain spacers between each epitope sequence. In some cases, sequences of short epitopes may be encoded in tandem without the use of spacers. In some cases, sequences of extended epitopes may be encoded in tandem without the use of spacers. In some cases, sequences of short epitopes may be encoded in tandem with the use of spacers. In some cases, sequences of extended epitopes may be encoded in tandem with the use of spacers.

[0195] In an exemplary case, a composition may be a plasmid-based vaccine containing short and extended antigenic epitopes. The plasmid, or plasmids, of the vaccine may be constructed using a 4 kB plasmid backbone (e.g., pUMVC3 or pNGVL3). Often, the plasmid may contain an antibiotic resistance gene. For example, pUMVC3 contains the kanamycin resistance gene in addition to an origin of replication for selection and propagation in bacteria. In some cases, the multiple cloning site in pUMVC3 may be flanked by eukaryotic transcriptional control elements to promote the expression of inserted sequences (e.g., gene cassettes) in eukaryotic cells. For example, the inserted sequences may be epitopes.

[0196] In an exemplary case, the nucleic acid coding sequence of the antigenic epitope peptides may be assembled with the Kozak consensus translation initiation sequence, a termination codon, and cloning sites in the plasmid backbone. Standard molecular techniques known to one of ordinary skill in the art which include synthetic oligonucleotides, polymerase chain reaction amplification, restriction endonucleases, and nucleic acid ligase (e.g., DNA ligase) may be used to generate nucleic acid (e.g., DNA fragments) and insert the nucleic acid fragments into the plasmid vector backbone.

[0197] In some cases, the plasmid may contain a nucleic acid sequence coding for at least one tag. In some cases, the tag may be translated into a peptide. Any nucleic acid sequence for a tag known to one of ordinary skill in the art may be used with the plasmids described herein. For example, the tag may be a histidine tag with three histidine residues, a histidine tag with four histidine residues, a histidine tag with five histidine residues, or a histidine tag with six histidine residues, or the like. Expression of the tag in a subject may be determined using any suitable technique known to one of ordinary skill in the art.

[0198] In some cases, plasmids may be sequenced using any sequencing technique known to one of ordinary skill in the art such that the results of the sequencing technique provides nucleotide level resolution of the entire plasmid.

[0199] In some aspects, the composition may be a multiantigen breast cancer vaccine. For example, the multiantigen breast cancer vaccine may contain a plurality of antigens. In some cases, expression of one antigen may impact expression of a

different antigen. In some cases, expression of more than one antigen may impact expression of a different antigen. In some cases, expression of one antigen may impact expression of more than one different antigen. In some cases, expression of one antigen may not impact expression of a different antigen. In some cases, expression of more than one antigen may not impact expression of a different antigen. In some cases, expression of one antigen may not impact expression of more than one different antigen. For example, antigenic competition may limit the immunogenicity of multiantigen vaccines. Any techniques known to one of ordinary skill in the art may be used to determine if an immune response elicited following administration of a multiple antigen vaccine is of comparable magnitude to each antigen as a single antigen vaccine. For example, ELISPOT (e.g., for secretion of IPN γ) may determine the magnitude of the immune response. In some cases, the ELISPOT may detect rodent, non-human primate or human peptides.

Plasmids--Survivin, HIF-1A, IGF-1R, and/or IGFBP2

[0200] A composition described herein may include a nucleic acid-based vaccine which comprises a plasmid encoding one or more epitopes selected from Survivin, HIF-1A, IGF-1R, or IGFBP2. Sometimes, the epitopes may be derived from human proteins and the encoding nucleic acid sequences encoding the epitopes may be incorporated into a nucleic acid construct designed to induce expression of the epitope in a subject following administration. For example, epitopes encoded from the nucleic acid construct may allow for the immune response to at least one epitope to be entrained, amplified, attenuated, suppressed, or eliminated to specific sets of proteins (e.g., self-proteins).

[0201] In some instances, the vaccine described herein is a peptide based vaccine. The peptide based vaccine can comprise a plasmid which encodes one or more epitopes selected from Survivin, HIF-1A, IGF-1R, or IGFBP2. The epitopes may be derived from human proteins that may be used directly in a peptide based vaccine.

[0202] In some cases, the peptide or the nucleic acid construct may be optimized into a protein or plasmid-based vaccination to induce, amplify or entrain a TH1 immune response. In some cases, the epitopes may be extended TH1 epitopes. In other cases, the peptide or the nucleic acid construct may be optimized into a protein or plasmid-based vaccination to suppress, attenuate or eliminate a pathological response, in a subject (e.g., human or animal) in need thereof.

[0203] The compositions described herein may include plasmids which contain nucleic acid sequences to express at least one epitope in a subject following administration of the composition (e.g., vaccine).

[0204] Any plasmid backbones (e.g., vectors) known to one of ordinary skill in the art suitable for pharmaceutical use for expression of a nucleic sequence may be used in the compositions described herein.

[0205] The vector can be a circular plasmid or a linear nucleic acid. The circular plasmid or linear nucleic acid can be capable of directing expression of a particular nucleotide sequence in an appropriate subject cell. The vector can have a promoter operably linked to the polypeptideencoding nucleotide sequence, which can be operably linked to termination signals. The vector can also contain sequences required for proper translation of the nucleotide sequence. The vector comprising the nucleotide sequence of interest can be chimeric, meaning that at least one of its components is heterologous with respect to at least one of its other components. The expression of the nucleotide sequence in the expression cassette can be under the control of a constitutive promoter or of an inducible promoter, which can initiate transcription only when the host cell is exposed to some particular external stimulus.

[0206] The vector can be a plasmid. The plasmid can be useful for transfecting cells with nucleic acid encoding the polypeptide, which the transformed host cells can be cultured and maintained under conditions wherein expression of the polypeptide takes place.

[0207] The plasmid can comprise a nucleic acid sequence that encodes one or more of the various polypeptide disclosed herein. A single plasmid can contain coding sequence for a single polypeptide, or coding sequence for more than one polypeptide. Sometimes, the plasmid can further comprise coding sequence that encodes an adjuvant, such as an immune stimulating molecule, such as a cytokine.

[0208] The plasmid can further comprise an initiation codon, which can be upstream of the coding sequence, and a stop codon, which can be downstream of the coding sequence. The initiation and termination codon can be in frame with the coding sequence. The plasmid can also comprise a promoter that is operably linked to the coding sequence, and an enhancer upstream of the coding sequence. The enhancer can be human actin, human myosin, human hemoglobin, human muscle creatine or a viral enhancer such as one from CMV, FMDV, RSV or EBV. Polynucleotide function enhances are described in U.S. Patent Nos. 5,593,972, 5,962,428, and WO94/016737.

[0209] The plasmid can also comprise a mammalian origin of replication in order to maintain the plasmid extrachromosomally and produce multiple copies of the plasmid in a cell. The plasmid can be pVAX1, pCEP4 or pREP4 from Invitrogen (San Diego, CA).

[0210] The plasmid can also comprise a regulatory sequence, which may be well suited for gene expression in a cell into which the plasmid is administered. The coding sequence can comprise a codon that can allow more efficient transcription of the coding sequence in the host cell.

[0211] In some cases, commercially available plasmid backbones may be used. For example, the plasmid pUMVC3 may be used. In some cases, commercially available plasmid backbones may be modified, mutated, engineered or cloned prior to use. In other cases, non-commercially available plasmid backbones may be used.

[0212] Additional plasmids can include pSE420 (Invitrogen, San Diego, Calif), which can be used for protein production in *Escherichia coli* (E.coli). The plasmid can also be pYES2 (Invitrogen, San Diego, Calif), which can be used for protein production in *Saccharomyces cerevisiae* strains of yeast. The plasmid can also be of the MAXBAC™ complete baculovirus expression system (Invitrogen, San Diego, Calif), which can be used for protein production in insect cells. The plasmid can also be pcDNA1 or pcDNA3 (Invitrogen, San Diego, Calif), which can be used for protein production in mammalian cells such as Chinese hamster ovary (CHO) cells.

[0213] The vector can be circular plasmid, which can transform a target cell by integration into the cellular genome or exist extrachromosomally (e.g., autonomous replicating plasmid with an origin of replication). Exemplary vectors include pVAX, pcDNA3.0, or provax, or any other expression vector capable of expressing DNA encoding the antigen and enabling a cell to translate the sequence to an antigen that is recognized by the immune system.

[0214] The nucleic acid based vaccine can also be a linear nucleic acid vaccine, or linear expression cassette ("LEC"), that is capable of being efficiently delivered to a subject via electroporation and expressing one or more polypeptides disclosed herein. The LEC can be any linear DNA devoid of any phosphate backbone. The DNA can encode one or more polypeptides disclosed herein. The LEC can contain a promoter, an intron, a stop codon, and/or a polyadenylation signal. The expression of the polypeptide may be controlled by the promoter. The LEC can not contain any antibiotic resistance genes and/or a phosphate backbone. The LEC can not contain other nucleic acid sequences unrelated to the polypeptide expression.

[0215] The LEC can be derived from any plasmid capable of being linearized. The plasmid can express the polypeptide. Exemplary plasmids include: pNP (Puerto Rico/34), pM2 (New Caledonia/99), VLV009, pVAX, pcDNA3.0, provax, or any other expression vector capable of expressing DNA encoding the antigen and enabling a cell to translate the sequence to an antigen that is recognized by the immune system.

[0216] Prior to inserting the nucleic acid sequence of at least one epitope, the plasmid backbone may be less than about 500bp, about 1.0 kB, about 1.2 kB, about 1.4 kB, about 1.6 kB, about 1.8 kB, about 2.0 kB, about 2.2 kB, about 2.4 kB, about 2.6 kB, about 2.8 kB, about 3.0 kB, about 3.2 kB, about 3.4 kB, about 3.6 kB, about 3.8 kB, about 4.0 kB, about 4.2 kB, about 4.4 kB, about 4.6 kB, about 4.8 kB, about 5.0 kB, about 5.2 kB, about 5.4 kB, about 5.6 kB, about 5.8 kB, about 6.0 kB, about 6.2 kB, about 6.4 kB, about 6.6 kB, about 6.8 kB, about 7.0 kB, about 7.2 kB, about 7.4 kB, about 7.6 kB, about 7.8 kB, about 8.0 kB, about 8.2 kB, about 8.4 kB, about 8.6 kB, about 8.8 kB, about 9.0 kB, about 9.2 kB, about 9.4 kB, about 9.6 kB, about 9.8 kB, about 10.0 kB, about 10.2 kB, about 10.4 kB, about 10.6 kB, about 10.8 kB, about 11.0 kB, about 11.2 kB, about 11.4 kB, about 11.6 kB, about 11.8 kB, about 12.0 kB, about 12.2 kB, about 12.4 kB, about 12.6 kB, about 12.8 kB, about 13.0 kB, about 13.2 kB, about 13.4 kB, about 13.6 kB, about 13.8 kB, about 14 kB, about 14.5 kB, about 15 kB, about 15.5 kB, about 16 kB, about 16.5 kB, about 17 kB, about 17.5 kB, about 18 kB, about 18.5 kB, about 19 kB, about 19.5 kB, about 20 kB, about 30 kB, about 40 kB, about 50 kB, about 60 kB, about 70 kB, about 80 kB, about 90 kB, about 100 kB, about 110 kB, about 120 kB, about 130 kB, about 140 kB, about 150 kB, about 160 kB, about 170 kB, about 180 kB, about 190 kB or about 200 kB in length. In an exemplary case, the plasmid is about 4 kB in length prior to addition of the nucleic acid sequence encoding at least one epitope.

[0217] In some cases, the compositions described herein may include one plasmid. In other cases, the compositions described herein may include more than one plasmid. For example, the compositions described herein may include two plasmids, three plasmids, four plasmids, five plasmids, six plasmids, seven plasmids, eight plasmids, nine plasmids, ten plasmids, 11 plasmids, 12 plasmids, 13 plasmids, 14 plasmids, 15 plasmids, 16 plasmids, 17 plasmids, 18 plasmids, 19 plasmids, 20 plasmids or more than 20 plasmids.

[0218] The nucleic acids which encode at least one epitope of a plasmid may be derived from any species such that the

epitope expressed from the nucleic acids results in an immune response in a subject. In some cases, the subject may be a rodent, a non-human primate or a human. The nucleic acids encoding the epitope of the plasmid may be isolated from any source of nucleic acids using methods and techniques known to one of ordinary skill in the art. The nucleic acids encoding the epitope of the plasmid may be cloned into the plasmid backbone using methods and techniques known to one of ordinary skill in the art.

[0219] In some cases, the nucleic acid sequence encoding the epitope may be an endogenous nucleic acid sequence to the subject. For example, the nucleic acid sequence for Survivin from a human may be used to express Survivin in a human. In other cases, the nucleic acid sequence for the antigenic epitope may be an exogenous nucleic acid sequence to the subject. For example, the nucleic acid sequence for Survivin from a non-human may be used to express Survivin in a human.

[0220] In some cases, the nucleic acid sequences to express the antigenic epitope may be wild-type nucleic acid sequences. For example, the naturally occurring nucleic acid sequence for Survivin in the genome of a species may be used to express Survivin in a subject. In other cases, the nucleic acid sequences encoding the epitope may be synthetic nucleic acid sequences. For example, the naturally occurring nucleic acid sequence for Survivin in the genome of a species may be modified using molecular techniques known to one of ordinary skill in the art and may be used to express Survivin in a subject.

[0221] In some cases, the nucleic acid sequence encoding the epitope may be an endogenous nucleic acid sequence to the subject. For example, the nucleic acid sequence for HIF-1A from a human may be used to express HIF-1A in a human. In other cases, the nucleic acid sequence for the antigenic epitope may be an exogenous nucleic acid sequence to the subject. For example, the nucleic acid sequence for HIF-1A from a non-human may be used to express HIF-1A in a human.

[0222] In some cases, the nucleic acid sequences to express the antigenic epitope may be wild-type nucleic acid sequences. For example, the naturally occurring nucleic acid sequence for HIF-1A in the genome of a species may be used to express HIF-1A in a subject. In other cases, the nucleic acid sequences encoding the epitope may be synthetic nucleic acid sequences. For example, the naturally occurring nucleic acid sequence for HIF-1A in the genome of a species may be modified using molecular techniques known to one of ordinary skill in the art and may be used to express HIF-1A in a subject.

[0223] In some cases, the nucleic acid sequence encoding the epitope may be an endogenous nucleic acid sequence to the subject. For example, the nucleic acid sequence for IGFBP2 from a human may be used to express IGFBP2 in a human. In other cases, the nucleic acid sequence for the antigenic epitope may be an exogenous nucleic acid sequence to the subject. For example, the nucleic acid sequence for IGFBP2 from a non-human may be used to express IGFBP2 in a human.

[0224] In some cases, the nucleic acid sequences to express the antigenic epitope may be wild-type nucleic acid sequences. For example, the naturally occurring nucleic acid sequence for IGFBP2 in the genome of a species may be used to express IGFBP2 in a subject. In other cases, the nucleic acid sequences encoding the epitope may be synthetic nucleic acid sequences. For example, the naturally occurring nucleic acid sequence for IGFBP2 in the genome of a species may be modified using molecular techniques known to one of ordinary skill in the art and may be used to express IGFBP2 in a subject.

[0225] In some cases, the nucleic acid sequence encoding the epitope may be an endogenous nucleic acid sequence to the subject. For example, the nucleic acid sequence for IGF-1R from a human may be used to express IGF-1R in a human. In other cases, the nucleic acid sequence for the antigenic epitope may be an exogenous nucleic acid sequence to the subject. For example, the nucleic acid sequence for IGF-1R from a non-human may be used to express IGF-1R in a human.

[0226] In some cases, the nucleic acid sequences to express the antigenic epitope may be wild-type nucleic acid sequences. For example, the naturally occurring nucleic acid sequence for IGF-1R in the genome of a species may be used to express IGF-1R in a subject. In other cases, the nucleic acid sequences encoding the epitope may be synthetic nucleic acid sequences. For example, the naturally occurring nucleic acid sequence for IGF-1R in the genome of a species may be modified using molecular techniques known to one of ordinary skill in the art and may be used to express IGF-1R in a subject.

[0227] In some cases, the composition may include nucleic acids which encode one or more epitopes from the proteins Survivin, HIF-1A, IGFBP2, and IGF-1R. In some instances, the plasmid may comprise a nucleic acid sequence encoding a polypeptide that comprises at least 70% sequence identity to IGFBP-2 (SEQ ID NO: 54). In some instances, the plasmid may include a nucleic acid sequence encoding a polypeptide that comprises at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to IGFBP-2 (SEQ ID NO: 54). In some cases, the plasmid may include a nucleic acid sequence encoding a polypeptide that comprises at least 80% sequence identity to IGFBP-2 (SEQ ID NO: 54). In some cases, the plasmid may include a nucleic acid sequence encoding a polypeptide that comprises at least 90% sequence identity to IGFBP-2 (SEQ ID NO: 54). Sometimes, the plasmid may include a nucleic acid sequence encoding a polypeptide that comprises at least 95% sequence identity to IGFBP-2 (SEQ ID NO: 54). Sometimes, the plasmid may include a nucleic

to an epitope sequence selected from SEQ ID NOs: 54, 73, 85, and 87. The plasmid may comprise four nucleic acid sequences in which each of the four nucleic acid sequences encodes a polypeptide comprising at least 90% sequence identity to an epitope sequence selected from SEQ ID NOs: 54, 73, 85, and 87. The plasmid may comprise four nucleic acid sequences in which each of the four nucleic acid sequences encodes a polypeptide comprising at least 95% sequence identity to an epitope sequence selected from SEQ ID NOs: 54, 73, 85, and 87. The plasmid may comprise four nucleic acid sequences in which each of the four nucleic acid sequences encodes a polypeptide comprising at least 99% sequence identity to an epitope sequence selected from SEQ ID NOs: 54, 73, 85, and 87. The plasmid may comprise four nucleic acid sequences in which each of the four nucleic acid sequences encodes a polypeptide comprising 100% sequence identity to an epitope sequence selected from SEQ ID NOs: 54, 73, 85, and 87. The plasmid may comprise four nucleic acid sequences in which each of the four nucleic acid sequences encodes a polypeptide consisting of 100% sequence identity to an epitope sequence selected from SEQ ID NOs: 54, 73, 85, and 87. In some instances, the four nucleic acid sequences independently encodes a polypeptide to an epitope sequence selected from SEQ ID NOs: 54, 73, 85, and 87. In other instances, the four nucleic acid sequences encodes different polypeptides to the epitope sequences selected from SEQ ID NOs: 54, 73, 85, and 87.

[0263] In some instances, a plasmid may comprise a nucleic acid sequence encoding a polypeptide comprising at least 70% sequence identity to SEQ ID NO: 89. In some cases, a plasmid may comprise a nucleic acid sequence encoding a polypeptide comprising at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 89. A plasmid may comprise a nucleic acid sequence encoding a polypeptide comprising at least 80% sequence identity to SEQ ID NO: 89. A plasmid may comprise a nucleic acid sequence encoding a polypeptide comprising at least 90% sequence identity to SEQ ID NO: 89. A plasmid may comprise a nucleic acid sequence encoding a polypeptide comprising at least 95% sequence identity to SEQ ID NO: 89. A plasmid may comprise a nucleic acid sequence encoding a polypeptide comprising at least 99% sequence identity to SEQ ID NO: 89. A plasmid may comprise a nucleic acid sequence encoding a polypeptide comprising 100% sequence identity to SEQ ID NO: 89. A plasmid may comprise a nucleic acid sequence encoding a polypeptide consisting of 100% sequence identity to SEQ ID NO: 89.

[0264] In some instances, a plasmid may comprise a nucleic acid sequence comprising at least 70% sequence identity to SEQ ID NO: 90. In some cases, a plasmid may comprise a nucleic acid sequence comprising at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 90. A plasmid may comprise a nucleic acid sequence comprising at least 80% sequence identity to SEQ ID NO: 90. A plasmid may comprise a nucleic acid sequence comprising at least 90% sequence identity to SEQ ID NO: 90. A plasmid may comprise a nucleic acid sequence comprising at least 95% sequence identity to SEQ ID NO: 90. A plasmid may comprise a nucleic acid sequence comprising at least 99% sequence identity to SEQ ID NO: 90. A plasmid may comprise a nucleic acid sequence comprising 100% sequence identity to SEQ ID NO: 90. A plasmid may comprise a nucleic acid sequence consisting of 100% sequence identity to SEQ ID NO: 90.

[0265] In some instances, a plasmid may comprise a nucleic acid sequence comprising at least 70% sequence identity to SEQ ID NO: 91. In some cases, a plasmid may comprise a nucleic acid sequence comprising at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 91. A plasmid may comprise a nucleic acid sequence comprising at least 80% sequence identity to SEQ ID NO: 91. A plasmid may comprise a nucleic acid sequence comprising at least 90% sequence identity to SEQ ID NO: 91. A plasmid may comprise a nucleic acid sequence comprising at least 95% sequence identity to SEQ ID NO: 91. A plasmid may comprise a nucleic acid sequence comprising at least 99% sequence identity to SEQ ID NO: 91. A plasmid may comprise a nucleic acid sequence comprising 100% sequence identity to SEQ ID NO: 91. A plasmid may comprise a nucleic acid sequence consisting of 100% sequence identity to SEQ ID NO: 91.

[0266] Sometimes, plasmids comprising more than one epitope sequences may comprise spacers between each epitope sequence. In some cases, sequences of the epitopes may be encoded in tandem without the use of spacers. In some cases, sequences of epitopes may be encoded in tandem with the use of spacers. In some cases, the spacers may comprise sequences encoding from about 1 to about 50, about 3 to about 40, about 5 to about 35, or about 10 to about 30 amino acid residues. In some instances, the spacers may comprise sequences encoding about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, or 30 amino acid residues.

[0267] In some cases, the plasmid may contain a nucleic acid sequence coding for at least one tag. In some cases, the tag may be translated into a peptide. Any nucleic acid sequence for a tag known to one of ordinary skill in the art may be used with the plasmids described herein. For example, the tag may be a histidine tag with three histidine residues, a histidine tag with four histidine residues, a histidine tag with five histidine residues, or a histidine tag with six histidine residues, or the like. Expression of the tag in a subject may be determined using any suitable technique known to one of ordinary skill in the art.

[0268] In some cases, plasmids may be sequenced using any sequencing technique known to one of ordinary skill in the art such that the results of the sequencing technique provides nucleotide level resolution of the entire plasmid.

[0269] In some aspects, the composition may be a multiantigen breast cancer vaccine or a multiantigen ovarian cancer vaccine. For example, the multiantigen breast cancer vaccine or multiantigen ovarian cancer vaccine may contain a plurality of antigens. In some cases, expression of one antigen may impact expression of a different antigen. In some cases, expression of more than one antigen may impact expression of a different antigen. In some cases, expression of one antigen may impact expression of more than one different antigen. In some cases, expression of one antigen may not impact expression of a different antigen. In some cases, expression of more than one antigen may not impact expression of a different antigen. In some cases, expression of one antigen may not impact expression of more than one different antigen. For example, antigenic competition may limit the immunogenicity of multiantigen vaccines. Any techniques known to one of ordinary skill in the art may be used to determine if an immune response elicited following administration of a multiple antigen vaccine is of comparable magnitude to each antigen as a single antigen vaccine. For example, ELISPOT (e.g., for secretion of IPN γ) may determine the magnitude of the immune response. In some cases, the ELISPOT may detect rodent, non-human primate or human peptides. In some instances, the multiantigen breast cancer or ovarian cancer vaccine may comprise a plurality of epitopes derived from a plurality of antigens selected from Survivin, HIF-1 α , IGF-1R, and/or IGFBP-2.

Nucleic Acids

[0270] An isolated nucleic acid molecule is a nucleic acid molecule that has been removed from its natural milieu (i.e., that has been subject to human manipulation), its natural milieu being the genome or chromosome in which the nucleic acid molecule is found in nature. As such, "isolated" does not necessarily reflect the extent to which the nucleic acid molecule has been purified, but indicates that the molecule does not include an entire genome or an entire chromosome in which the nucleic acid molecule is found in nature. An isolated nucleic acid molecule can include a gene. An isolated nucleic acid molecule that includes a gene is not a fragment of a chromosome that includes such gene, but rather includes the coding region and regulatory regions associated with the gene, but no additional genes that are naturally found on the same chromosome. An isolated nucleic acid molecule can also include a specified nucleic acid sequence flanked by (i.e., at the 5' and/or the 3' end of the sequence) additional nucleic acids that do not normally flank the specified nucleic acid sequence in nature (i.e., heterologous sequences).

[0271] Isolated nucleic acid molecule can include DNA, both genomic and cDNA, RNA, or a hybrid, where the nucleic acid may contain combinations of deoxyribo- and ribo-nucleotides, and combinations of bases including uracil, adenine, thymine, cytosine, guanine, inosine, xanthine hypoxanthine, isocytosine and isoguanine. Nucleic acids may be obtained by chemical synthesis methods or by recombinant methods. Although the phrase "nucleic acid molecule" primarily refers to the physical nucleic acid molecule and the phrase "nucleic acid sequence" primarily refers to the sequence of nucleotides on the nucleic acid molecule, the two phrases can be used interchangeably, especially with respect to a nucleic acid molecule, or a nucleic acid sequence, being capable of encoding a protein or domain of a protein.

[0272] Nucleic acid molecules may refer to at least two nucleotides covalently linked together. A nucleic acid described herein can contain phosphodiester bonds, although in some cases, as outlined below (for example in the construction of primers and probes such as label probes), nucleic acid analogs are included that can have alternate backbones, comprising, for example, phosphoramidate (Beaucage et al., Tetrahedron 49(10):1925 (1993) and references therein; Letsinger, J. Org. Chem. 35:3800 (1970); Sprinzl et al., Eur. J. Biochem. 81:579 (1977); Letsinger et al., Nucl. Acids Res. 14:3487 (1986); Sawai et al, Chem. Lett. 805 (1984), Letsinger et al., J. Am. Chem. Soc. 110:4470 (1988); and Pauwels et al., Chemica Scripta 26:141 (1986)), phosphorothioate (Mag et al., Nucleic Acids Res. 19:1437 (1991); and U.S. Pat. No. 5,644,048), phosphorodithioate (Briu et al., J. Am. Chem. Soc. 111:2321 (1989)), O-methylphosphoroamidite linkages (see Eckstein, Oligonucleotides and Analogues: A Practical Approach, Oxford University Press), and peptide nucleic acid (also referred to herein as "PNA") backbones and linkages (see Egholm, J. Am. Chem. Soc. 114:1895 (1992); Meier et al., Chem. Int. Ed. Engl. 31:1008 (1992); Nielsen, Nature, 365:566 (1993); Carlsson et al., Nature 380:207 (1996)). Other analog nucleic acids include those with bicyclic structures including locked nucleic acids (also referred to herein as "LNA"), Koshkin et al., J. Am. Chem. Soc. 120:13252 3 (1998); positive backbones (Denpcy et al., Proc. Natl. Acad. Sci. USA 92:6097 (1995)); non-ionic backbones (U.S. Pat. Nos. 5,386,023, 5,637,684, 5,602,240, 5,216,141 and 4,469,863; Kiedrowski et al., Angew. Chem. Intl. Ed. English 30:423 (1991); Letsinger et al., J. Am. Chem. Soc. 110:4470 (1988); Letsinger et al., Nucleoside & Nucleotide 13:1597 (1994); Chapters 2 and 3, ASC Symposium Series 580, "Carbohydrate Modifications in Antisense Research", Ed. Y. S. Sanghui and P. Dan Cook; Mesmaeker et al., Bioorganic & Medicinal Chem. Lett. 4:395 (1994); Jeffs et al., J. Biomolecular NMR 34:17 (1994); Tetrahedron Lett. 37:743 (1996)) and non-ribose backbones, including those described in U.S. Pat. Nos. 5,235,033 and 5,034,506, and Chapters 6 and 7, ASC Symposium Series 580, "Carbohydrate Modifications in Antisense Research", Ed. Y. S. Sanghui and P. Dan Cook. Nucleic acids containing one or more carbocyclic sugars are also included within the definition of nucleic acids (see Jenkins et al., Chem. Soc. Rev. (1995) pp 169-176). Several "nucleic acid analogs are described in Rawls, C & E News Jun. 2, 1997 page 35. "Locked nucleic acids" are also included within the definition of nucleic acid analogs, LNAs are a class of nucleic acid analogues in which the ribose ring is "locked" by a methylene bridge connecting the 2'-O atom with the 4'-C atom. All of

these references are hereby expressly incorporated by reference. These modifications of the ribose-phosphate backbone can be done to increase the stability and half-life of such molecules in physiological environments. For example, PNA:DNA and LNA-DNA hybrids can exhibit higher stability and thus can be used in some embodiments. The target nucleic acids can be single stranded or double stranded, as specified, or contain portions of both double stranded or single stranded sequence. Depending on the application, the "nucleic acids can be DNA (including, e.g., genomic DNA, mitochondrial DNA, and cDNA), RNA (including, e.g., mRNA and rRNA) or a hybrid, where the nucleic acid contains any combination of deoxyribo- and ribo-nucleotides, and any combination of bases, including uracil, adenine, thymine, cytosine, guanine, inosine, xanthine, hypoxanthine, isocytosine, isoguanine, etc.

[0273] A recombinant nucleic acid molecule is a molecule that can include at least one of any nucleic acid sequence encoding any one or more proteins described herein operatively linked to at least one of any transcription control sequence capable of effectively regulating expression of the nucleic acid molecule(s) in the cell to be transfected. Although the phrase "nucleic acid molecule" primarily refers to the physical nucleic acid molecule and the phrase "nucleic acid sequence" primarily refers to the sequence of nucleotides on the nucleic acid molecule, the two phrases can be used interchangeably, especially with respect to a nucleic acid molecule, or a nucleic acid sequence, being capable of encoding a protein. In addition, the phrase "recombinant molecule" primarily refers to a nucleic acid molecule operatively linked to a transcription control sequence, but can be used interchangeably with the phrase "nucleic acid molecule" which is administered to an animal.

[0274] A recombinant nucleic acid molecule includes a recombinant vector, which is any nucleic acid sequence, typically a heterologous sequence, which is operatively linked to the isolated nucleic acid molecule encoding a fusion protein of the present invention, which is capable of enabling recombinant production of the fusion protein, and which is capable of delivering the nucleic acid molecule into a host cell according to the present invention. Such a vector can contain nucleic acid sequences that are not naturally found adjacent to the isolated nucleic acid molecules to be inserted into the vector. The vector can be either RNA or DNA, either prokaryotic or eukaryotic, and preferably in the present invention, is a virus or a plasmid. Recombinant vectors can be used in the cloning, sequencing, and/or otherwise manipulating of nucleic acid molecules, and can be used in delivery of such molecules (e.g., as in a DNA composition or a viral vector-based composition). Recombinant vectors are preferably used in the expression of nucleic acid molecules, and can also be referred to as expression vectors. Preferred recombinant vectors are capable of being expressed in a transfected host cell.

[0275] In a recombinant molecule of the present invention, nucleic acid molecules are operatively linked to expression vectors containing regulatory sequences such as transcription control sequences, translation control sequences, origins of replication, and other regulatory sequences that are compatible with the host cell and that control the expression of nucleic acid molecules of the present invention. In particular, recombinant molecules of the present invention include nucleic acid molecules that are operatively linked to one or more expression control sequences. The phrase "operatively linked" refers to linking a nucleic acid molecule to an expression control sequence in a manner such that the molecule is expressed when transfected (i.e., transformed, transduced or transfected) into a host cell.

Pharmaceutical Compositions

[0276] The immunogenic compositions of the disclosure are preferably formulated as a vaccine for *in vivo* administration to the subject, such that they confer an antibody titer superior to the criterion for seroprotection for each antigenic component for an acceptable percentage of subjects. Antigens with an associated antibody titer above which a subject is considered to be seroconverted against the antigen are well known, and such titers are published by organizations such as WHO. Preferably more than 80% of a statistically significant sample of subjects is seroconverted, more preferably more than 90%, still more preferably more than 93% and most preferably 96-100%.

Adjuvants

[0277] The immunogenic compositions of the disclosure are preferably adjuvanted. An adjuvant can be used to enhance the immune response (humoral and/or cellular) elicited in a patient receiving the vaccine. Sometimes, adjuvants can elicit a TH1-type response. Other times, adjuvants can elicit a TH2-type response. A TH1-type response can be characterized by the production of cytokines such as IFN- γ as opposed to a TH2-type response which can be characterized by the production of cytokines such as IL-4, IL-5 and IL-10.

[0278] Adjuvant can comprise stimulatory molecules such as cytokines. Non-limiting examples of cytokines include: CCL20, α -interferon (IFN- α), β -interferon (IFN- β), γ -interferon, platelet derived growth factor (PDGF), TNF α , TNF β , granulocyte

macrophage colony-stimulating factor (GM-CSF), epidermal growth factor (EGF), cutaneous T cell-attracting chemokine (CTACK), epithelial thymus-expressed chemokine (TECK), mucosae-associated epithelial chemokine (MEC), IL-12, IL-15, IL-28, MHC, CD80, CD86, IL-1, IL-2, IL-4, IL-5, IL-6, IL-10, IL-18, MCP-1, MIP-1a, MIP-1-, IL-8, L-selectin, P-selectin, E-selectin, CD34, GlyCAM-1, MadCAM-1, LFA-1, VLA-1, Mac-1, p150.95, PECAM, ICAM-1, ICAM-2, ICAM-3, CD2, LFA-3, M-CSF, G-CSF, mutant forms of IL-18, CD40, CD40L, vascular growth factor, fibroblast growth factor, IL-7, nerve growth factor, vascular endothelial growth factor, Fas, TNF receptor, Fit, Apo-1, p55, WSL-1, DR3, TRAMP, Apo-3, AIR, LARD, NGRF, DR4, DRS, KILLER, TRAIL-R2, TRICK2, DR6, Caspase ICE, Fos, c-jun, Sp-1, Ap-1, Ap-2, p38, p65Rel, MyD88, IRAK, TRAF6, Ikb, Inactive NIK, SAP K, SAP-I, JNK, interferon response genes, NFkB, Bax, TRAIL, TRAILrec, TRAILrecDRC5, TRAIL-R3, TRAIL-R4, RANK, RANK LIGAND, Ox40, Ox40 LIGAND, NKG2D, MICA, MICB, NKG2A, NKG2B, NKG2C, NKG2E, NKG2F, TAPI, and TAP2. In some instances, the adjuvant is GM-CSF.

[0279] Additional adjuvants include: MCP-1, MIP-1a, MIP-1p, IL-8, RANTES, L-selectin, P-selectin, E-selectin, CD34, GlyCAM-1, MadCAM-1, LFA-1, VLA-1, Mac-1, p150.95, PECAM, ICAM-1, ICAM-2, ICAM-3, CD2, LFA-3, M-CSF, G-CSF, IL-4, mutant forms of IL-18, CD40, CD40L, vascular growth factor, fibroblast growth factor, IL-7, IL-22, nerve growth factor, vascular endothelial growth factor, Fas, TNF receptor, Fit, Apo-1, p55, WSL-1, DR3, TRAMP, Apo-3, AIR, LARD, NGRF, DR4, DR5, KILLER, TRAIL-R2, TRICK2, DR6, Caspase ICE, Fos, c-jun, Sp-1, Ap-1, Ap-2, p38, p65Rel, MyD88, IRAK, TRAF6, Ikb, Inactive NIK, SAP K, SAP-1, JNK, interferon response genes, NFkB, Bax, TRAIL, TRAILrec, TRAILrecDRC5, TRAIL-R3, TRAIL-R4, RANK, RANK LIGAND, Ox40, Ox40 LIGAND, NKG2D, MICA, MICB, NKG2A, NKG2B, NKG2C, NKG2E, NKG2F, TAP1, TAP2 and functional fragments thereof.

[0280] In some aspects, an adjuvant can be a modulator of a toll like receptor. Examples of modulators of toll-like receptors include TLR-9 agonists and are not limited to small molecule modulators of toll-like receptors such as Imiquimod. Other examples of adjuvants that are used in combination with a vaccine described herein can include and are not limited to saponin, CpG ODN and the like.

[0281] Sometimes, adjuvants may include an aluminum salt such as aluminum hydroxide gel (alum), aluminum phosphate, a salt of calcium, iron or zinc, or may be an insoluble suspension of acylated tyrosine, or acylated sugars, cationically or anionically derivatized polysaccharides, or polyphosphazenes.

[0282] Sometimes, suitable adjuvant systems which promote a predominantly Th1 response include, Monophosphoryl lipid A or a derivative thereof, particularly 3-de-O-acylated monophosphoryl lipid A, and a combination of monophosphoryl lipid A, preferably 3-de-O-acylated monophosphoryl lipid A (3D-MPL) together with an aluminum salt. An enhanced system involves the combination of a monophosphoryl lipid A and a saponin derivative, particularly the combination of QS21 and 3D-MPL as disclosed in WO 94/00153, or a less reactogenic composition where the QS21 is quenched with cholesterol as disclosed in WO 96/33739. A particularly potent adjuvant formulation involving QS21, 3D-MPL and tocopherol in an oil in water emulsion is described in WO 95/17210. The vaccine may additionally comprise a saponin, more preferably QS21. The formulation may also comprises an oil in water emulsion and tocopherol (WO 95/17210). Unmethylated CpG containing oligonucleotides (WO 96/02555) are also preferential inducers of a Th1 response and are suitable for use in the present disclosure.

[0283] In some instances, aluminum salts are used. Sometimes in order to minimize the levels of adjuvant (particularly aluminum salts) in the compositions of the disclosure, the polysaccharide conjugates may be unadjuvanted.

[0284] Sometimes, a suitable adjuvant system may include an adjuvant or immunostimulant such as but not limited to detoxified lipid A from any source and non-toxic derivatives of lipid A, saponins and other reagents capable of stimulating a TH1 type response. It has been known that enterobacterial lipopolysaccharide (LPS) is a potent stimulator of the immune system, although its use in adjuvants has been curtailed by its toxic effects. A non-toxic derivative of LPS, monophosphoryl lipid A (MPL), produced by removal of the core carbohydrate group and the phosphate from the reducing-end glucosamine, has been described by Ribí et al (1986, Immunology and Immunopharmacology of bacterial endotoxins, Plenum Publ. Corp., NY, p407-419).

[0285] A further detoxified version of MPL results from the removal of the acyl chain from the 3-position of the disaccharide backbone, and is called 3-O-Deacylated monophosphoryl Lipid A (3D-MPL). It can be purified and prepared by the methods taught in GB 2122204B, which reference also discloses the preparation of diphosphoryl lipid A, and 3-O-deacylated variants thereof.

[0286] In some instances, 3D-MPL is in the form of an emulsion having a small particle size less than 0.2µm in diameter, and its method of manufacture is disclosed in WO 94/21292. Aqueous formulations comprising monophosphoryl lipid A and a surfactant have been described in WO9843670A2. The bacterial lipopolysaccharide derived adjuvants to be formulated in the compositions of the present disclosure may be purified and processed from bacterial sources, or alternatively they may be

synthetic. For example, purified monophosphoryl lipid A is described in Ribi et al 1986 (supra), and 3-O-Deacylated monophosphoryl or diphosphoryl lipid A derived from *Salmonella* sp. is described in GB 2220211 and US 4912094. Other purified and synthetic lipopolysaccharides have been described (Hilgers et al, 1986, *Int. ArchAllergy. Immunol.*, 79(4):392-6; Hilgers et al, 1987, *Immunology*, 60(1):141-6; and EP 0 549 074 B1). A particularly preferred bacterial lipopolysaccharide adjuvant is 3D-MPL.

[0287] Accordingly, the LPS derivatives that may be used in the present disclosure are those immuno stimulants that are similar in structure to that of LPS or MPL or 3D-MPL. In another aspect of the present disclosure the LPS derivatives may be an acylated monosaccharide, which is a sub-portion to the above structure of MPL.

[0288] Saponins are taught in: Lacaille-Dubois, M and Wagner H. (1996. A review of the biological and pharmacological activities of saponins. *Phytomedicine* vol 2 pp 363- 386). Saponins are steroid or triterpene glycosides widely distributed in the plant and marine animal kingdoms. Saponins are noted for forming colloidal solutions in water which foam on shaking, and for precipitating cholesterol. When saponins are near cell membranes they create pore-like structures in the membrane which cause the membrane to burst. Haemolysis of erythrocytes is an example of this phenomenon, which is a property of certain, but not all, saponins.

[0289] Saponins are known as adjuvants in vaccines for systemic administration. The adjuvant and haemolytic activity of individual saponins has been extensively studied in the art (Lacaille-Dubois and Wagner, supra). For example, Quil A (derived from the bark of the South American tree *Quillaja Saponaria* Molina), and fractions thereof, are described in US 5,057,540 and "Saponins as vaccine adjuvants", Kensil, C. R., *CritRev TherDrug Carrier Syst*, 1996, 12 (1-2):1-55; and EP 0362 279 B1.

[0290] Particulate structures, termed Immune Stimulating Complexes (ISCOMS), comprising fractions of Quil A are haemolytic and have been used in the manufacture of vaccines (Morein, B., EP 0 109 942 B1; WO 96/11711; WO 96/33739). The haemolytic saponins QS21 and QS17 (HPLC purified fractions of Quil A) have been described as potent systemic adjuvants, and the method of their production is disclosed in US Patent No.5,057,540 and EP 0362279 B1. Other saponins which have been used in systemic vaccination studies include those derived from other plant species such as *Gypsophila* and *Saponaria* (Bomford et al., *Vaccine*, 10(9):572-577, 1992).

[0291] An enhanced system involves the combination of a non-toxic lipid A derivative and a saponin derivative particularly the combination of QS21 and 3D-MPL as disclosed in WO 94/00153, or a less reactogenic composition where the QS21 is quenched with cholesterol as disclosed in WO 96/33739.

[0292] Sometimes, an adjuvant is selected from bacteria toxoids, polyoxypropylene-polyoxyethylene block polymers, aluminum salts, liposomes, CpG polymers, oil-in-water emulsions, or a combination thereof.

[0293] Sometimes, an adjuvant is an oil-in-water emulsion. The oil-in-water emulsion can include at least one oil and at least one surfactant, with the oil(s) and surfactant(s) being biodegradable (metabolisable) and biocompatible. The oil droplets in the emulsion are generally less than 5 µm in diameter, and may even have a sub-micron diameter, with these small sizes being achieved with a microfluidiser to provide stable emulsions. Droplets with a size less than 220 nm are preferred as they can be subjected to filter sterilization.

[0294] The oils used can include such as those from an animal (such as fish) or vegetable source. Sources for vegetable oils can include nuts, seeds and grains. Peanut oil, soybean oil, coconut oil, and olive oil, the most commonly available, exemplify the nut oils. Jojoba oil can be used e.g. obtained from the jojoba bean. Seed oils include safflower oil, cottonseed oil, sunflower seed oil, sesame seed oil, etc. The grain group can include: corn oil and oils of other cereal grains such as wheat, oats, rye, rice, teff, triticale, and the like. 6-10 carbon fatty acid esters of glycerol and 1,2-propanediol, while not occurring naturally in seed oils, may be prepared by hydrolysis, separation and esterification of the appropriate materials starting from the nut and seed oils. Fats and oils from mammalian milk can be metabolizable and can therefore be used in with the vaccines described herein. The procedures for separation, purification, saponification and other means necessary for obtaining pure oils from animal sources are well known in the art. Fish can contain metabolizable oils which can be readily recovered. For example, cod liver oil, shark liver oils, and whale oil such as spermaceti can exemplify several of the fish oils which can be used herein. A number of branched chain oils can be synthesized biochemically in 5-carbon isoprene units and can be generally referred to as terpenoids. Shark liver oil contains a branched, unsaturated terpenoid known as squalene, 2,6,10,15,19,23-hexamethyl-2,6,10,14,18,22-tetracosahexaene. Squalane, the saturated analog to squalene, can also be used. Fish oils, including squalene and squalane, can be readily available from commercial sources or can be obtained by methods known in the art.

[0295] Other useful oils include tocopherols, can included in vaccines for use in elderly patients (e.g. aged 60 years or older) due to vitamin E been reported to have a positive effect on the immune response in this patient group. Further, tocopherols

have antioxidant properties that can help to stabilize the emulsions. Various tocopherols exist (α , β , γ , δ , ϵ or ξ) but α is usually used. An example of α -tocopherol is DL- α -tocopherol. α -tocopherol succinate can be compatible with cancer vaccines and can be a useful preservative as an alternative to mercurial compounds.

[0296] Mixtures of oils can be used e.g. squalene and α -tocopherol. An oil content in the range of 2-20% (by volume) can be used.

[0297] Surfactants can be classified by their 'HLB' (hydrophile/lipophile balance). In some cases, surfactants have a HLB of at least 10, at least 15, and/or at least 16. Surfactants can include, but are not limited to: the polyoxyethylene sorbitan esters surfactants (commonly referred to as the Tweens), especially polysorbate 20 and polysorbate 80; copolymers of ethylene oxide (EO), propylene oxide (PO), and/or butylene oxide (BO), sold under the DOWFAX™ tradename, such as linear EO/PO block copolymers; octoxynols, which can vary in the number of repeating ethoxy (oxy-1,2-ethanediyl) groups, with octoxynol-9 (Triton X-100, or t-octylphenoxypolyethoxyethanol) being of particular interest; (octylphenoxy)polyethoxyethanol (IGEPAL CA-630/NP-40); phospholipids such as phosphatidylcholine (lecithin); nonylphenol ethoxylates, such as the Tergitol™ NP series; polyoxyethylene fatty ethers derived from lauryl, cetyl, stearyl and oleyl alcohols (known as Brij surfactants), such as triethyleneglycol monolauryl ether (Brij 30); and sorbitan esters (commonly known as the SPANs), such as sorbitan trioleate (Span 85) and sorbitan monolaurate. Non-ionic surfactants can be used herein.

[0298] Mixtures of surfactants can be used e.g. Tween 80/Span 85 mixtures. A combination of a polyoxyethylene sorbitan ester and an octoxynol can also be suitable. Another combination can comprise laureth 9 plus a polyoxyethylene sorbitan ester and/or an octoxynol.

[0299] The amounts of surfactants (% by weight) can be: polyoxyethylene sorbitan esters (such as Tween 80) 0.01 to 1%, in particular about 0.1%; octyl- or nonylphenoxy polyoxyethanols (such as Triton X-100, or other detergents in the Triton series) 0.001 to 0.1%, in particular 0.005 to 0.02%; polyoxyethylene ethers (such as laureth 9) 0.1 to 20%, preferably 0.1 to 10% and in particular 0.1 to 1% or about 0.5%.

[0300] Specific oil-in-water emulsion adjuvants include, but are not limited to:

[0301] A submicron emulsion of squalene, polysorbate 80, and sorbitan trioleate. The composition of the emulsion by volume can be about 5% squalene, about 0.5% polysorbate 80 and about 0.5% Span 85. In weight terms, these ratios become 4.3% squalene, 0.5% polysorbate 80 and 0.48% Span 85. This adjuvant is known as 'MF59'. The MF59 emulsion advantageously includes citrate ions e.g. 10 mM sodium citrate buffer.

[0302] A submicron emulsion of squalene, a tocopherol, and polysorbate 80. These emulsions can have from 2 to 10% squalene, from 2 to 10% tocopherol and from 0.3 to 3% polysorbate 80, and the weight ratio of squalene:tocopherol is preferably ≤ 1 (e.g. 0.90) as this can provide a more stable emulsion. Squalene and polysorbate 80 may be present at a volume ratio of about 5:2 or at a weight ratio of about 11:5. One such emulsion can be made by dissolving Tween 80 in PBS to give a 2% solution, then mixing 90 ml of this solution with a mixture of (5g of DL- α -tocopherol and 5 ml squalene), then microfluidising the mixture. The resulting emulsion has submicron oil droplets e.g. with an average diameter of between 100 and 250 nm, preferably about 180 nm. The emulsion may also include a 3-de-O-acylated monophosphoryl lipid A (3d-MPL). Another useful emulsion of this type may comprise, per human dose, 0.5-10 mg squalene, 0.5-11 mg tocopherol, and 0.1-4 mg polysorbate 80.

[0303] An emulsion of squalene, a tocopherol, and a Triton detergent (e.g. Triton X-100). The emulsion can also include a 3d-MPL (see below). The emulsion can contain a phosphate buffer.

[0304] An emulsion comprising a polysorbate (e.g. polysorbate 80), a Triton detergent (e.g. Triton X-100) and a tocopherol (e.g. an α -tocopherol succinate). The emulsion can include these three components at a mass ratio of about 75:11:10 (e.g. 750 μ ml polysorbate 80, 110 μ ml Triton X-100 and 100 μ ml α -tocopherol succinate), and these concentrations should include any contribution of these components from antigens. The emulsion can also include squalene. The emulsion may also include a 3d-MPL. The aqueous phase can contain a phosphate buffer.

[0305] An emulsion of squalene, polysorbate 80 and poloxamer 401 ("Pluronic™ L121"). The emulsion can be formulated in phosphate buffered saline, pH 7.4. This emulsion can be a useful delivery vehicle for muramyl dipeptides, and can be used with threonyl-MDP in the "SAF-1" adjuvant (0.05-1% Thr-MDP, 5% squalene, 2.5% Pluronic L121 and 0.2% polysorbate 80). It can also be used without the Thr-MDP, as in the "AF" adjuvant (5% squalene, 1.25% Pluronic L121 and 0.2% polysorbate 80).

[0306] An emulsion comprising squalene, an aqueous solvent, a polyoxyethylene alkyl ether hydrophilic nonionic surfactant

(e.g. polyoxyethylene (12) cetostearyl ether) and a hydrophobic nonionic surfactant (e.g. a sorbitan ester or mannide ester, such as sorbitan monoleate or 'Span 80'). The emulsion can be thermoreversible and/or has at least 90% of the oil droplets (by volume) with a size less than 200 nm. The emulsion can also include one or more of: alditol; a cryoprotective agent (e.g. a sugar, such as dodecylmaltoside and/or sucrose); and/or an alkylpolyglycoside. The emulsion can include a TLR4 agonist. Such emulsions can be lyophilized.

[0307] An emulsion of squalene, poloxamer 105 and Abil-Care. The final concentration (weight) of these components in adjuvanted vaccines can be 5% squalene, 4% poloxamer 105 (pluronic polyol) and 2% Abil-Care 85 (Bis-PEG/PPG-16/16 PEG/PPG-16/16 dimethicone; caprylic/capric triglyceride).

[0308] An emulsion having from 0.5-50% of an oil, 0.1-10% of a phospholipid, and 0.05-5% of a non-ionic surfactant. Phospholipid components can include phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidylglycerol, phosphatidic acid, sphingomyelin and cardiolipin. Submicron droplet sizes are advantageous.

[0309] A submicron oil-in-water emulsion of a non-metabolisable oil (such as light mineral oil) and at least one surfactant (such as lecithin, Tween 80 or Span 80). Additives can include, QuilA saponin, cholesterol, a saponin-lipophile conjugate (such as GPI-0100, produced by addition of aliphatic amine to desacylsaponin via the carboxyl group of glucuronic acid), dimethyldioctadecylammonium bromide and/or N,N-dioctadecyl-N,N-bis (2-hydroxyethyl)propanediamine.

Carriers and Excipients

[0310] In some instances, a composition described herein may further comprise carriers and excipients (including but not limited to buffers, carbohydrates, mannitol, proteins, polypeptides or amino acids such as glycine, antioxidants, bacteriostats, chelating agents, suspending agents, thickening agents and/or preservatives), water, oils including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like, saline solutions, aqueous dextrose and glycerol solutions, flavoring agents, coloring agents, detackifiers and other acceptable additives, adjuvants, or binders, other pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH buffering agents, tonicity adjusting agents, emulsifying agents, wetting agents and the like. Examples of excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. In another instances, the pharmaceutical preparation is substantially free of preservatives. In other instances, the pharmaceutical preparation can contain at least one preservative. General methodology on pharmaceutical dosage forms is found in Ansel et al., *Pharmaceutical Dosage Forms and Drug Delivery Systems* (Lippencott Williams & Wilkins, Baltimore Md. (1999)). It will be recognized that, while any suitable carrier known to those of ordinary skill in the art can be employed to administer the pharmaceutical compositions described herein, the type of carrier will vary depending on the mode of administration.

[0311] In some instances, the composition may include a surfactant. Exemplary surfactants may include octylphenoxy polyoxyethanols and polyoxyethylene sorbitan esters, as described in "Surfactant Systems" Eds: Attwood and Florence (1983, Chapman and Hall). Octylphenoxy polyoxyethanols (the octoxynols), including t- octylphenoxypolyethoxyethanol (Triton X-100 TM) are also described in Merck Index Entry 6858 (Page 1162, 12th Edition, Merck & Co. Inc., Whitehouse Station, N.J., USA; ISBN 0911910-12-3). The polyoxyethylene sorbitan esters, including polyoxyethylene sorbitan monooleate (Tween 80 TM) are described in Merck Index Entry 7742 (Page 1308, 12th Edition, Merck & Co. Inc., Whitehouse Station, N.J., USA; ISBN 0911910-12-3). Both may be manufactured using methods described therein, or purchased from commercial sources such as Sigma Inc.

[0312] Exemplary non-ionic surfactants may include Triton X-45, t-octylphenoxy polyethoxyethanol (Triton X-100), Triton X-102, Triton X-114, Triton X-165, Triton X-205, Triton X-305, Triton X-57, Triton X-101, Triton X-128, Breij 35, polyoxyethylene-9-lauryl ether (laureth 9) and polyoxyethylene-9-stearyl ether (steareth 9). Polyoxyethylene ethers may include polyoxyethylene-8-stearyl ether, polyoxyethylene-4-lauryl ether, polyoxyethylene-35-lauryl ether, and polyoxyethylene-23-lauryl ether.

[0313] Alternative terms or names for polyoxyethylene lauryl ether are disclosed in the CAS registry. The CAS registry number of polyoxyethylene-9 lauryl ether is: 9002-92-0. Polyoxyethylene ethers such as polyoxyethylene lauryl ether are described in the Merck index (12th ed: entry 7717, Merck & Co. Inc., Whitehouse Station, N.J., USA; ISBN 0911910-12-3). Laureth 9 is formed by reacting ethylene oxide with dodecyl alcohol, and has an average of nine ethylene oxide units.

[0314] The ratio of the length of the polyoxyethylene section to the length of the alkyl chain in the surfactant (i.e., the ratio of n: alkyl chain length), affects the solubility of this class of surfactant in an aqueous medium. Thus, the surfactants of the present

disclosure may be in solution or may form particulate structures such as micelles or vesicles. As a solution, the surfactants of the present disclosure are safe, easily sterilisable, simple to administer, and maybe manufactured in a simple fashion without the GMP and QC issues associated with the formation of uniform particulate structures. Some polyoxyethylene ethers, such as laureth 9, are capable of forming non-vesicular solutions. However, polyoxyethylene-8 palmitoyl ether (C18E8) is capable of forming vesicles. Accordingly, vesicles of polyoxyethylene-8 palmitoyl ether in combination with at least one additional non-ionic surfactant, can be employed in the formulations of the present disclosure.

[0315] Within the inherent experimental variability of such a biological assay, the polyoxyethylene ethers, or surfactants of general formula (I), of the present disclosure preferably have a haemolytic activity, of approximately between 0.5-0.0001%, more preferably between 0.05-0.0001%, even more preferably between 0.005-0.0001%, and most preferably between 0.003-0.0004%. Ideally, said polyoxyethylene ethers or esters should have a haemolytic activity similar (i.e., within a ten-fold difference) to that of either polyoxyethylene-9 lauryl ether or polyoxyethylene-8 stearyl ether.

[0316] Two or more non-ionic surfactants from the different groups of surfactants described may be present in the vaccine formulation described herein. In particular, a combination of a polyoxyethylene sorbitan ester such as polyoxyethylene sorbitan monooleate (Tween 80™) and an octoxynol such as t-octylphenoxypolyethoxyethanol (Triton) X-100™ is preferred. Another particularly preferred combination of non- ionic surfactants comprises laureth 9 plus a polyoxyethylene sorbitan ester or an octoxynol or both.

[0317] Preferably each non-ionic surfactant is present in the final vaccine formulation at a concentration of between 0.001 to 20%, more preferably 0.01 to 10%, and most preferably up to about 2% (w/v). Where one or two surfactants are present, these are generally present in the final formulation at a concentration of up to about 2% each, typically at a concentration of up to about 0.6% each. One or more additional surfactants may be present, generally up to a concentration of about 1% each and typically in traces up to about 0.2% or 0.1% each. Any mixture of surfactants may be present in the vaccine formulations according to the disclosure. Non-ionic surfactants such as those discussed above have preferred concentrations in the final vaccine composition as follows: polyoxyethylene sorbitan esters such as Tween 80™: 0.01 to 1%, most preferably about 0.1% (w/v); octyl- or nonylphenoxy polyoxyethanols such as Triton X-100™ or other detergents in the Triton series: 0.001 to 0.1%, most preferably 0.005 to 0.02% (w/v); polyoxyethylene ethers of general formula (I) such as laureth 9: 0.1 to 20%, preferably 0.1 to 10% and most preferably 0.1 to 1% or about 0.5% (w/v).

[0318] A composition may be encapsulated within liposomes using well-known technology. Biodegradable microspheres can also be employed as carriers for the pharmaceutical compositions of this invention. Suitable biodegradable microspheres are disclosed, for example, in U.S. Pat. Nos. 4,897,268; 5,075,109; 5,928,647; 5,811,128; 5,820,883; 5,853,763; 5,814,344 and 5,942,252.

[0319] The composition may be administered in liposomes or microspheres (or microparticles). Methods for preparing liposomes and microspheres for administration to a patient are well known to those of skill in the art. U.S. Pat. No. 4,789,734, describes methods for encapsulating biological materials in liposomes. Essentially, the material is dissolved in an aqueous solution, the appropriate phospholipids and lipids added, along with surfactants if required, and the material dialyzed or sonicated, as necessary. A review of known methods is provided by G. Gregoriadis, Chapter 14, "Liposomes," Drug Carriers in Biology and Medicine, pp. 2.sup.87-341 (Academic Press, 1979).

[0320] Microspheres formed of polymers or proteins are well known to those skilled in the art, and can be tailored for passage through the gastrointestinal tract directly into the blood stream. Alternatively, the compound can be incorporated and the microspheres, or composite of microspheres, implanted for slow release over a period of time ranging from days to months. See, for example, U.S. Pat. Nos. 4,906,474, 4,925,673 and 3,625,214, and Jain, TIPS 19:155-157 (1998).

[0321] A composition may include preservatives such as thiomersal or 2-phenoxyethanol. In some instances, the vaccine is substantially free from (e.g. <10 µg/ml) mercurial material e.g. thiomersal-free. α-Tocopherol succinate may be used as an alternative to mercurial compounds.

[0322] For controlling the tonicity, a physiological salt such as sodium salt can be included in the vaccine. Other salts can include potassium chloride, potassium dihydrogen phosphate, disodium phosphate, and/or magnesium chloride, or the like.

[0323] A composition may have an osmolality of between 200 mOsm/kg and 400 mOsm/kg, between 240-360 mOsm/kg, or within the range of 290-310 mOsm/kg.

[0324] A composition may comprise one or more buffers, such as a Tris buffer; a borate buffer; a succinate buffer; a histidine buffer (particularly with an aluminum hydroxide adjuvant); or a citrate buffer. Buffers, in some cases, are included in the 5-20

mM range.

[0325] The pH of the composition may be between about 5.0 and about 8.5, between about 6.0 and about 8.0, between about 6.5 and about 7.5, or between about 7.0 and about 7.8.

[0326] A composition may be sterile. The vaccine can be non-pyrogenic e.g. containing <1 EU (endotoxin unit, a standard measure) per dose, and can be <0.1 EU per dose. The composition can be gluten free.

[0327] A composition may include detergent e.g. a polyoxyethylene sorbitan ester surfactant (known as 'Tweens'), an octoxynol (such as octoxynol-9 (Triton X-100) or t-octylphenoxypolyethoxyethanol), a cetyl trimethyl ammonium bromide ('CTAB'), or sodium deoxycholate, particularly for a split or surface antigen vaccine. The detergent can be present only at trace amounts. Thus the vaccine can include less than 1 mg/ml of each of octoxynol-10 and polysorbate 80. Other residual components in trace amounts can be antibiotics (e.g. neomycin, kanamycin, polymyxin B).

[0328] A composition may be formulated as a sterile solution or suspension, in suitable vehicles, well known in the art. The pharmaceutical compositions may be sterilized by conventional, well-known sterilization techniques, or may be sterile filtered. The resulting aqueous solutions may be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile solution prior to administration. Suitable formulations and additional carriers are described in Remington "The Science and Practice of Pharmacy" (20th Ed., Lippincott Williams & Wilkins, Baltimore Md.).

[0329] A composition may be formulated with one or more pharmaceutically acceptable salts. Pharmaceutically acceptable salts can include those of the inorganic ions, such as, for example, sodium, potassium, calcium, magnesium ions, and the like. Such salts can include salts with inorganic or organic acids, such as hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid, methanesulfonic acid, p-toluenesulfonic acid, acetic acid, fumaric acid, succinic acid, lactic acid, mandelic acid, malic acid, citric acid, tartaric acid or maleic acid. In addition, if the agent(s) contain a carboxy group or other acidic group, it can be converted into a pharmaceutically acceptable addition salt with inorganic or organic bases. Examples of suitable bases include sodium hydroxide, potassium hydroxide, ammonia, cyclohexylamine, dicyclohexyl-amine, ethanolamine, diethanolamine, triethanolamine, and the like.

[0330] Additional salts may comprise a bile acid or a derivative thereof. These include derivatives of cholic acid and salts thereof, in particular sodium salts of cholic acid or cholic acid derivatives. Examples of bile acids and derivatives thereof include cholic acid, deoxycholic acid, chenodeoxycholic acid, lithocholic acid, ursodeoxycholic acid, hyodeoxycholic acid and derivatives such as glyco-, tauro-, amidopropyl- 1-propanesulfonic-, amidopropyl- 2-hydroxy-1-propanesulfonic derivatives of the aforementioned bile acids, or N,N-bis (3Dgluconoamidopropyl) deoxycholamide. A particularly preferred example is sodium deoxycholate (NaDOC) which may be present in the final vaccine dose.

[0331] A composition comprising an active agent such as a peptide or a nucleic acid described herein, in combination with one or more adjuvants may be formulated in conventional manner using one or more physiologically acceptable carriers, comprising excipients, diluents, and/or auxiliaries, e.g., which facilitate processing of the active agents into preparations that can be administered. Proper formulation may depend at least in part upon the route of administration chosen. The agent(s) described herein may be delivered to a patient using a number of routes or modes of administration, including oral, buccal, topical, rectal, transdermal, transmucosal, subcutaneous, intravenous, and intramuscular applications, as well as by inhalation.

[0332] The active agents may be formulated for parenteral administration (e.g., by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, for example solutions in aqueous polyethylene glycol.

[0333] For injectable formulations, the vehicle may be chosen from those known in art to be suitable, including aqueous solutions or oil suspensions, or emulsions, with sesame oil, corn oil, cottonseed oil, or peanut oil, as well as elixirs, mannitol, dextrose, or a sterile aqueous solution, and similar pharmaceutical vehicles. The formulation may also comprise polymer compositions which are biocompatible, biodegradable, such as poly(lactic-co-glycolic)acid. These materials may be made into micro or nanospheres, loaded with drug and further coated or derivatized to provide superior sustained release performance. Vehicles suitable for periocular or intraocular injection include, for example, suspensions of therapeutic agent in injection grade water, liposomes and vehicles suitable for lipophilic substances. Other vehicles for periocular or intraocular injection are well known in the art.

[0334] In some instances, a composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous administration are solutions in

sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic such as lidocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion, it may be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

[0335] When administration is by injection, the active agent may be formulated in aqueous solutions, specifically in physiologically compatible buffers such as Hanks solution, Ringer's solution, or physiological saline buffer. The solution may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active compound may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use. In another embodiment, the pharmaceutical composition does not comprise an adjuvant or any other substance added to enhance the immune response stimulated by the peptide. In another embodiment, the pharmaceutical composition comprises a substance that inhibits an immune response to the peptide. Methods of formulation are known in the art, for example, as disclosed in Remington's Pharmaceutical Sciences, latest edition, Mack Publishing Co., Easton P.

[0336] In addition to the formulations described above, the active agents may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation or transcutaneous delivery (for example subcutaneously or intramuscularly), intramuscular injection or use of a transdermal patch. Thus, for example, the agents may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

[0337] In some cases, compositions comprising one or more agents exert local and regional effects when administered topically or injected at or near particular sites of infection. Direct topical application, e.g., of a viscous liquid, solution, suspension, dimethylsulfoxide (DMSO)-based solutions, liposomal formulations, gel, jelly, cream, lotion, ointment, suppository, foam, or aerosol spray, can be used for local administration, to produce for example local and/or regional effects. Pharmaceutically appropriate vehicles for such formulation include, for example, lower aliphatic alcohols, polyglycols (e.g., glycerol or polyethylene glycol), esters of fatty acids, oils, fats, silicones, and the like. Such preparations can also include preservatives (e.g., p-hydroxybenzoic acid esters) and/or antioxidants (e.g., ascorbic acid and tocopherol). See also Dermatological Formulations: Percutaneous absorption, Barry (Ed.), Marcel Dekker Inc., 1983. In another embodiment, local/topical formulations comprising a transporter, carrier, or ion channel inhibitor are used to treat epidermal or mucosal viral infections.

[0338] Compositions may contain a cosmetically or dermatologically acceptable carrier. Such carriers are compatible with skin, nails, mucous membranes, tissues and/or hair, and can include any conventionally used cosmetic or dermatological carrier meeting these requirements. Such carriers can be readily selected by one of ordinary skill in the art. In formulating skin ointments, an agent or combination of agents can be formulated in an oleaginous hydrocarbon base, an anhydrous absorption base, a water-in-oil absorption base, an oil-in-water water-removable base and/or a water-soluble base. Examples of such carriers and excipients include, but are not limited to, humectants (e.g., urea), glycols (e.g., propylene glycol), alcohols (e.g., ethanol), fatty acids (e.g., oleic acid), surfactants (e.g., isopropyl myristate and sodium lauryl sulfate), pyrrolidones, glycerol monolaurate, sulfoxides, terpenes (e.g., menthol), amines, amides, alkanes, alkanols, water, calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.

[0339] Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents, or coloring agents. The construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art. See, e.g., U.S. Pat. Nos. 5,023,252, 4,992,445 and 5,001,139. Such patches can be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.

[0340] Lubricants which may be used to form pharmaceutical compositions and dosage forms can include, but are not limited to, calcium stearate, magnesium stearate, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, talc, hydrogenated vegetable oil (e.g., peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, and soybean oil), zinc stearate, ethyl oleate, ethyl laurate, agar, or mixtures thereof. Additional lubricants include, for example, a syloid silica gel, a coagulated aerosol of synthetic silica, or mixtures thereof. A lubricant can optionally be added, in an amount of less than about 1 weight percent of the pharmaceutical composition.

[0341] The compositions may be in any form suitable for topical application, including aqueous, aqueous-alcoholic or oily

solutions, lotion or serum dispersions, aqueous, anhydrous or oily gels, emulsions obtained by dispersion of a fatty phase in an aqueous phase (O/W or oil in water) or, conversely, (W/O or water in oil), microemulsions or alternatively microcapsules, microparticles or lipid vesicle dispersions of ionic and/or nonionic type. These compositions may be prepared according to conventional methods. Other than the agents of the invention, the amounts of the various constituents of the compositions according to the invention are those conventionally used in the art. These compositions in particular constitute protection, treatment or care creams, milks, lotions, gels or foams for the face, for the hands, for the body and/or for the mucous membranes, or for cleansing the skin. The compositions can also consist of solid preparations constituting soaps or cleansing bars.

[0342] Compositions may contain adjuvants such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, preserving agents, antioxidants, solvents, fragrances, fillers, sunscreens, odor-absorbers and dyestuffs. The amounts of these various adjuvants are those conventionally used in the fields considered and, for example, are from about 0.01% to about 20% of the total weight of the composition. Depending on their nature, these adjuvants can be introduced into the fatty phase, into the aqueous phase and/or into the lipid vesicles.

[0343] For oral administration, the active agent(s) may be formulated readily by combining the active agent(s) with pharmaceutically acceptable carriers well known in the art. Such carriers enable the agents of the invention to be formulated as tablets, including chewable tablets, pills, dragees, capsules, lozenges, hard candy, liquids, gels, syrups, slurries, powders, suspensions, elixirs, wafers, and the like, for oral ingestion by a patient to be treated. Such formulations can comprise pharmaceutically acceptable carriers including solid diluents or fillers, sterile aqueous media and various non-toxic organic solvents. A solid carrier may be one or more substances which can also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material. In powders, the carrier generally is a finely divided solid which is a mixture with the finely divided active component. In tablets, the active component generally is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired. The powders and tablets contain from about one (1) to about seventy (70) percent of the active compound. Suitable carriers include but are not limited to magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. Generally, the active agents may be included at concentration levels ranging from about 0.5%, about 5%, about 10%, about 20%, or about 30% to about 50%, about 60%, about 70%, about 80% or about 90% by weight of the total composition of oral dosage forms, in an amount sufficient to provide a desired unit of dosage.

[0344] Aqueous suspensions for oral use may contain active agent(s) with pharmaceutically acceptable excipients, such as a suspending agent (e.g., methyl cellulose), a wetting agent (e.g., lecithin, lysolecithin and/or a long-chain fatty alcohol), as well as coloring agents, preservatives, flavoring agents, and the like.

[0345] Oils or non-aqueous solvents can be required to bring the active agents into solution, due to, for example, the presence of large lipophilic moieties. Alternatively, emulsions, suspensions, or other preparations, for example, liposomal preparations, can be used. With respect to liposomal preparations, any known methods for preparing liposomes for treatment of a condition can be used. See, for example, Bangham et al., J. Mol. Biol. 23: 238-252 (1965) and Szoka et al., Proc. Natl. Acad. Sci. USA 75: 4194-4198 (1978). Ligands can also be attached to the liposomes to direct these compositions to particular sites of action.

[0346] Pharmaceutical preparations for oral use can be obtained as a solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; flavoring elements, cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinyl pyrrolidone (PVP). If desired, disintegrating agents can be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate. The agents can also be formulated as a sustained release preparation.

[0347] Dragee cores may be provided with suitable coatings. For this purpose, concentrated sugar solutions can be used, which can optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments can be added to the tablets or dragee coatings for identification or to characterize different combinations of active agents.

[0348] Pharmaceutical preparations that may be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules may contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active agents may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers can be added. All formulations for oral

administration may be in dosages suitable for administration.

[0349] Other forms suitable for oral administration include liquid form preparations including emulsions, syrups, elixirs, aqueous solutions, aqueous suspensions, or solid form preparations which are intended to be converted shortly before use to liquid form preparations. Emulsions may be prepared in solutions, for example, in aqueous propylene glycol solutions or can contain emulsifying agents, for example, such as lecithin, sorbitan monooleate, or acacia. Aqueous solutions may be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizers, and thickening agents. Aqueous suspensions may be prepared by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well known suspending agents. Suitable fillers or carriers with which the compositions may be administered include agar, alcohol, fats, lactose, starch, cellulose derivatives, polysaccharides, polyvinylpyrrolidone, silica, sterile saline and the like, or mixtures thereof used in suitable amounts. Solid form preparations include solutions, suspensions, and emulsions, and can contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.

[0350] A syrup or suspension may be made by adding the active compound to a concentrated, aqueous solution of a sugar, e.g., sucrose, to which can also be added any accessory ingredients. Such accessory ingredients may include flavoring, an agent to retard crystallization of the sugar or an agent to increase the solubility of any other ingredient, e.g., as a polyhydric alcohol, for example, glycerol or sorbitol.

[0351] When formulating compounds for oral administration, it may be desirable to utilize gastroretentive formulations to enhance absorption from the gastrointestinal (GI) tract. A formulation which is retained in the stomach for several hours may release compounds of the invention slowly and provide a sustained release that can be used herein. Disclosure of such gastroretentive formulations are found in Klausner, E. A.; Lavy, E.; Barta, M.; Cserepes, E.; Friedman, M.; Hoffman, A. 2003 "Novel gastroretentive dosage forms: evaluation of gastroretentivity and its effect on levodopa in humans." *Pharm. Res.* 20, 1466-73, Hoffman, A.; Stepensky, D.; Lavy, E.; Eyal, S. Klausner, E.; Friedman, M. 2004 "Pharmacokinetic and pharmacodynamic aspects of gastroretentive dosage forms" *Int. J. Pharm.* 11, 141-53, Streubel, A.; Siepmann, J.; Bodmeier, R.; 2006 "Gastroretentive drug delivery systems" *Expert Opin. Drug Deliver.* 3, 217-3, and Chavanpatil, M. D.; Jain, P.; Chaudhari, S.; Shear, R.; Vavia, P. R. "Novel sustained release, swellable and bioadhesive gastroretentive drug delivery system for ofloxacin" *Int. J. Pharm.* 2006 epub March 24. Expandable, floating and bioadhesive techniques can be utilized to maximize absorption of the compounds of the invention.

[0352] The solubility of the components of the compositions may be enhanced by a surfactant or other appropriate co-solvent in the composition. Such cosolvents include polysorbate 20, 60, and 80, Pluronic F68, F-84 and P-103, cyclodextrin, or other agents known to those skilled in the art. Such co-solvents can be employed at a level of from about 0.01% to 2% by weight.

[0353] The compositions may be packaged in multidose form. Preservatives may be preferred to prevent microbial contamination during use. Suitable preservatives include: benzalkonium chloride, thimerosal, chlorobutanol, methyl paraben, propyl paraben, phenylethyl alcohol, edetate disodium, sorbic acid, Onamer M, or other agents known to those skilled in the art. In the prior art ophthalmic products, such preservatives can be employed at a level of from 0.004% to 0.02%. In the compositions of the present application the preservative, preferably benzalkonium chloride, can be employed at a level of from 0.001% to less than 0.01%, e.g. from 0.001 % to 0.008%, preferably about 0.005% by weight. It has been found that a concentration of benzalkonium chloride of 0.005% can be sufficient to preserve the compositions of the present invention from microbial attack.

[0354] In instances relating to topical/local application, the compositions may include one or more penetration enhancers. For example, the formulations may comprise suitable solid or gel phase carriers or excipients that increase penetration or help delivery of agents or combinations of agents of the invention across a permeability barrier, e.g., the skin. Many of these penetration-enhancing compounds are known in the art of topical formulation, and include, e.g., water, alcohols (e.g., terpenes like methanol, ethanol, 2-propanol), sulfoxides (e.g., dimethyl sulfoxide, decylmethyl sulfoxide, tetradecylmethyl sulfoxide), pyrrolidones (e.g., 2-pyrrolidone, N-methyl-2-pyrrolidone, N-(2-hydroxyethyl)pyrrolidone), laurocapram, acetone, dimethylacetamide, dimethylformamide, tetrahydrofurfuryl alcohol, L- α -amino acids, anionic, cationic, amphoteric or nonionic surfactants (e.g., isopropyl myristate and sodium lauryl sulfate), fatty acids, fatty alcohols (e.g., oleic acid), amines, amides, clofibric acid amides, hexamethylene lauramide, proteolytic enzymes, α -bisabolol, d-limonene, urea and N,N-diethyl-m-toluamide, and the like. Additional examples include humectants (e.g., urea), glycols (e.g., propylene glycol and polyethylene glycol), glycerol monolaurate, alkanes, alkanols, ORGELASE, calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and/or other polymers. In another embodiment, the compositions may include one or more such penetration enhancers.

[0355] The compositions for local/topical application may include one or more antimicrobial preservatives such as quaternary ammonium compounds, organic mercurials, p-hydroxy benzoates, aromatic alcohols, chlorobutanol, and the like.

[0356] The compositions may be formulated into aerosol solutions, suspensions or dry powders. The aerosol can be administered through the respiratory system or nasal passages. For example, one skilled in the art will recognize that a composition of the present invention can be suspended or dissolved in an appropriate carrier, e.g., a pharmaceutically acceptable propellant, and administered directly into the lungs using a nasal spray or inhalant. For example, an aerosol formulation comprising a transporter, carrier, or ion channel inhibitor can be dissolved, suspended or emulsified in a propellant or a mixture of solvent and propellant, e.g., for administration as a nasal spray or inhalant. Aerosol formulations can contain any acceptable propellant under pressure, such as a cosmetically or dermatologically or pharmaceutically acceptable propellant, as conventionally used in the art.

[0357] An aerosol formulation for nasal administration is generally an aqueous solution designed to be administered to the nasal passages in drops or sprays. Nasal solutions can be similar to nasal secretions in that they are generally isotonic and slightly buffered to maintain a pH of about 5.5 to about 6.5, although pH values outside of this range may additionally be used. Antimicrobial agents or preservatives may also be included in the formulation.

[0358] An aerosol formulation for inhalations and inhalants may be designed so that the agent or combination of agents is carried into the respiratory tree of the subject when administered by the nasal or oral respiratory route. Inhalation solutions may be administered, for example, by a nebulizer. Inhalations or insufflations, comprising finely powdered or liquid drugs, may be delivered to the respiratory system as a pharmaceutical aerosol of a solution or suspension of the agent or combination of agents in a propellant, e.g., to aid in disbursement. Propellants may be liquefied gases, including halocarbons, for example, fluorocarbons such as fluorinated chlorinated hydrocarbons, hydrochlorofluorocarbons, and hydrochlorocarbons, as well as hydrocarbons and hydrocarbon ethers.

[0359] Halocarbon propellants may include fluorocarbon propellants in which all hydrogens are replaced with fluorine, chlorofluorocarbon propellants in which all hydrogens are replaced with chlorine and at least one fluorine, hydrogen-containing fluorocarbon propellants, and hydrogen-containing chlorofluorocarbon propellants. Halocarbon propellants are described in Johnson, U.S. Pat. No. 5,376,359, issued Dec. 27, 1994; Byron et al., U.S. Pat. No. 5,190,029, issued Mar. 2, 1993; and Purewal et al., U.S. Pat. No. 5,776,434, issued Jul. 7, 1998. Hydrocarbon propellants useful in the invention include, for example, propane, isobutane, n-butane, pentane, isopentane and neopentane. A blend of hydrocarbons may also be used as a propellant. Ether propellants include, for example, dimethyl ether as well as the ethers. An aerosol formulation of the invention may also comprise more than one propellant. For example, the aerosol formulation may comprise more than one propellant from the same class, such as two or more fluorocarbons; or more than one, more than two, more than three propellants from different classes, such as a fluorohydrocarbon and a hydrocarbon. Pharmaceutical compositions of the present invention may also be dispensed with a compressed gas, e.g., an inert gas such as carbon dioxide, nitrous oxide or nitrogen.

[0360] Aerosol formulations may also include other components, for example, ethanol, isopropanol, propylene glycol, as well as surfactants or other components such as oils and detergents. These components may serve to stabilize the formulation and/or lubricate valve components.

[0361] The aerosol formulation may be packaged under pressure and can be formulated as an aerosol using solutions, suspensions, emulsions, powders and semisolid preparations. For example, a solution aerosol formulation may comprise a solution of an agent of the invention such as a transporter, carrier, or ion channel inhibitor in (substantially) pure propellant or as a mixture of propellant and solvent. The solvent may be used to dissolve the agent and/or retard the evaporation of the propellant. Solvents may include, for example, water, ethanol and glycols. Any combination of suitable solvents may be used, optionally combined with preservatives, antioxidants, and/or other aerosol components.

[0362] An aerosol formulation may be a dispersion or suspension. A suspension aerosol formulation may comprise a suspension of an agent or combination of agents of the instant invention, e.g., a transporter, carrier, or ion channel inhibitor, and a dispersing agent. Dispersing agents may include, for example, sorbitan trioleate, oleyl alcohol, oleic acid, lecithin and corn oil. A suspension aerosol formulation may also include lubricants, preservatives, antioxidant, and/or other aerosol components,

[0363] An aerosol formulation may similarly be formulated as an emulsion. An emulsion aerosol formulation may include, for example, an alcohol such as ethanol, a surfactant, water and a propellant, as well as an agent or combination of agents of the invention, e.g., a transporter, carrier, or ion channel. The surfactant used may be nonionic, anionic or cationic. One example of an emulsion aerosol formulation comprises, for example, ethanol, surfactant, water and propellant. Another example of an

emulsion aerosol formulation comprises, for example, vegetable oil, glyceryl monostearate and propane.

[0364] The compounds may be formulated for administration as suppositories. A low melting wax, such as a mixture of triglycerides, fatty acid glycerides, Witepsol S55 (trademark of Dynamite Nobel Chemical, Germany), or cocoa butter is first melted and the active component is dispersed homogeneously, for example, by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and to solidify.

[0365] The compounds may be formulated for vaginal administration. Pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.

[0366] The compounds may be attached releasably to biocompatible polymers for use in sustained release formulations on, in or attached to inserts for topical, intraocular, periocular, or systemic administration. The controlled release from a biocompatible polymer can be utilized with a water soluble polymer to form an installable formulation, as well. The controlled release from a biocompatible polymer, such as for example, PLGA microspheres or nanospheres, may be utilized in a formulation suitable for intra ocular implantation or injection for sustained release administration, as well. Any suitable biodegradable and biocompatible polymer may be used.

Dosages, Routes of Administration, and Therapeutic Regimens

[0367] The compositions and methods described herein may elicit an immune response to an epitope of an antigenic peptide in a subject. In some cases, the compositions may be breast cancer vaccines or ovarian cancer vaccines. In some cases, the breast cancer vaccine may be a multiantigen breast cancer vaccine. In some cases, the ovarian cancer vaccine may be a multiantigen ovarian cancer vaccine.

[0368] In some cases, the subject may be tumor bearing prior to administration of the vaccine. In other cases, the subject may not be tumor bearing prior to administration of the vaccine. In other cases, the subject may not be tumor bearing prior to administration of the vaccine but become tumor bearing after administration of the vaccine. In other cases, the subject may not be tumor bearing prior to administration of the vaccine and may not become tumor bearing after administration of the vaccine. In some instances, the tumors may be breast cancer tumors. In some cases, the breast cancer tumors in rodents are DMBA-induced tumors. For example, the breast cancer tumors in rodents may be derived from M6 or MMC cells. Often, the breast cancer tumors in humans are triple negative tumors in humans.

[0369] The compositions described herein may be administered to a subject in need thereof as a vaccine. In some cases, the subject may be immunized with the multiantigen breast cancer vaccine or multiantigen ovarian cancer vaccine. For example, the vaccine may be a breast cancer vaccine (e.g., multiantigen vaccine), or ovarian cancer vaccine (e.g., multiantigen vaccine).

[0370] The vaccine described herein may be delivered via a variety of routes. Delivery routes may include oral (including buccal and sub-lingual), rectal, nasal, topical, transdermal patch, pulmonary, vaginal, suppository, or parenteral (including intramuscular, intraarterial, intrathecal, intradermal, intraperitoneal, subcutaneous and intravenous) administration or in a form suitable for administration by aerosolization, inhalation or insufflation. General information on drug delivery systems can be found in Ansel et al., *Pharmaceutical Dosage Forms and Drug Delivery Systems* (Lippencott Williams & Wilkins, Baltimore Md. (1999)). The vaccine described herein can be administered to muscle, or can be administered via intradermal or subcutaneous injections, or transdermally, such as by iontophoresis. Epidermal administration of the vaccine can be employed.

[0371] In some instances, the vaccine may also be formulated for administration via the nasal passages. Formulations suitable for nasal administration, wherein the carrier is a solid, can include a coarse powder having a particle size, for example, in the range of about 10 to about 500 microns which is administered in the manner in which snuff is taken, i.e., by rapid inhalation through the nasal passage from a container of the powder held close up to the nose. The formulation can be a nasal spray, nasal drops, or by aerosol administration by nebulizer. The formulation can include aqueous or oily solutions of the vaccine.

[0372] The vaccine may be a liquid preparation such as a suspension, syrup or elixir. The vaccine can also be a preparation for parenteral, subcutaneous, intradermal, intramuscular or intravenous administration (e.g., injectable administration), such as a sterile suspension or emulsion.

[0373] The vaccine may include material for a single immunization, or may include material for multiple immunizations (i.e. a 'multidose' kit). The inclusion of a preservative is preferred in multidose arrangements. As an alternative (or in addition) to including a preservative in multidose compositions, the compositions can be contained in a container having an aseptic

adaptor for removal of material.

[0374] The vaccine may be administered in a dosage volume of about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, or 1.0 mL. Sometimes the vaccine can be administered in a higher dose e.g. of more than 1 ml.

[0375] In some cases, the subject may be immunized with one dose of the vaccine. In other cases, the subject may be immunized with more than one dose of the vaccine. For example, the subject may be immunized with more than one, more than two, more than three, more than four, more than five, more than six, more than seven, more than eight, more than nine, more than ten, more than 11, more than 12, more than 13, more than 14, more than 15, more than 16, more than 17, more than 18, more than 19 or more than 20 doses of the vaccine. In an exemplary case, the subject is immunized with three doses of the vaccine.

[0376] In the cases that a subject receives more than one dose of the vaccine, time may elapse between the first dose and each subsequent dose of the vaccine. In some cases, the time that elapses between the first dose and each subsequent dose of the vaccine may be seconds, minutes, hours, days, weeks, months or years. For example, more than one dose may be administered to the subject by intervals. In some cases, the intervals may occur over seconds, minutes, hours, days, weeks, months or years. In some cases, subjects may receive a booster dose. For example, the booster may be administered to the subject more than one, more than two, more than three, more than four, more than five, more than six, more than seven, more than eight, more than nine, more than ten, more than 11, more than 12, more than 13, more than 14, more than 15, more than 16, more than 17, more than 18, more than 19 or more than 20 booster doses of the vaccine. In an exemplary case, the subject may receive up to three boosters of the vaccine.

[0377] In some cases, intervals may be the same between each dose of the vaccine. In some cases, intervals may be the same between each booster of the vaccine. In some cases, intervals may be different between each dose of the vaccine. In some cases, intervals may be different between each booster of the vaccine.

[0378] In an exemplary case, more than one dose is administered to the subject over an interval of at least one day. In some cases, the interval may be a one day, two day, three day, four day, five day, six day, seven day, eight day, nine day, ten day, 11 day, 12 day, 13 day, 14 day, 15 day, 16 day, 17 day, 18 day, 19 day, 20 day, 21 day, 22 day, 23 day, 24 day, 25 day, 26 day, 27 day, 28 day, 29 day or 30 day interval. In other cases, the interval may be a range of days, for example, the range of days may be 1-5 days, 1-7 days, 1-10 days, 3-15 days, 5-10 days, 5-15 days, 5-20 days, 7-10 days, 7-15 days, 7-20 days, 7-25 days, 10-15 days, 10-20 days, 10-25 days, 15-20 days, 15-25 days, 15-30 days, 20-30 days, 20-35 days, 20-40 days, 20-50 days, 25-50 days, 30-50 days, 35-50 days, or 40-50 days.

[0379] Subjects may be evaluated after administration of the vaccine. In some cases, the subject may be evaluated within one month (e.g., short term) of the final administration of the vaccine. For example, short term may be one day, two days, three days, four days, five days, six days, seven days, eight days, nine days, ten days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days or 31 days after the final administration of the vaccine. In some cases, the subject may be evaluated within four months (e.g., long term) of the final administration of the vaccine. For example, short term may be one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, ten weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 25 weeks, 26 weeks, 27 weeks, 28 weeks, 29 weeks, 30 weeks or 31 weeks after the final administration of the vaccine.

[0380] In some cases, the subject may receive at least one booster dose of the vaccine after the final administration of the vaccine doses. For example, at least one booster dose may be administered to the subject one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, ten weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 25 weeks, 26 weeks, 27 weeks, 28 weeks, 29 weeks, 30 weeks or 31 weeks after the final administration of the vaccine doses. In some cases, the subject may receive one booster, two boosters, three boosters, four boosters, five boosters, six boosters, seven boosters, eight boosters, nine boosters, ten boosters, 11 boosters, 12 boosters, 13 boosters, 14 boosters, 15 boosters, 16 boosters, 17 boosters, 18 boosters, 19 boosters, 20 boosters, 21 boosters, 22 boosters, 23 boosters, 24 boosters, 25 boosters, 26 boosters, 27 boosters, 28 boosters, 29 boosters or 30 booster doses.

[0381] The disclosure provides in a further aspect a pharmaceutical kit comprising an intradermal administration device and a vaccine formulation as described herein. The device is preferably supplied already filled with the vaccine. Preferably the vaccine is in a liquid volume smaller than for conventional intramuscular vaccines as described herein, particularly a volume of between about 0.05 ml and 0.2 ml. Preferably the device is a short needle delivery device for administering the vaccine to the dermis.

[0382] Suitable devices for use with the intradermal vaccines described herein include short needle devices such as those described in US 4,886,499, US 5,190,521, US 5,328,483, US 5,527,288, US 4,270,537, US 5,015,235, US 5,141,496, US 5,417,662. Intradermal vaccines may also be administered by devices which limit the effective penetration length of a needle into the skin, such as those described in WO99/34850, and functional equivalents thereof. Also suitable are jet injection devices which deliver liquid vaccines to the dermis via a liquid jet injector or via a needle which pierces the stratum corneum and produces a jet which reaches the dermis. Jet injection devices are described for example in US 5,480,381, US 5,599,302, US 5,334,144, US 5,993,412, US 5,649,912, US 5,569,189, US 5,704,911, US 5,383,851, US 5,893,397, US 5,466,220, US 5,339,163, US 5,312,335, US 5,503,627, US 5,064,413, US 5,520, 639, US 4,596,556, US 4,790,824, US 4,941,880, US 4,940,460, WO 97/37705 and WO 97/13537. Also suitable are ballistic powder/particle delivery devices which use compressed gas to accelerate vaccine in powder form through the outer layers of the skin to the dermis. Additionally, conventional syringes may be used in the classical mantoux method of intradermal administration. However, the use of conventional syringes requires highly skilled operators and thus devices which are capable of accurate delivery without a highly skilled user are preferred.

[0383] Another case of the disclosure relates to a method to immunize a subject or population of subjects against a disease in order to prevent a disease, and/or reduce the severity of disease in the subject or population of subjects. The method includes the step of administering to a subject or population of subjects that is not infected with the disease (or believed not to be infected with the disease), a composition of the disclosure.

[0384] The composition of one case of the disclosure may be administered using techniques well known to those in the art. Preferably, compounds are formulated and administered by genetic immunization. Techniques for formulation and administration may be found in "Remington's Pharmaceutical Sciences", 18th ed., 1990, Mack Publishing Co., Easton, Pa. Suitable routes may include parenteral delivery, such as intramuscular, intradermal, subcutaneous, intramedullary injections, as well as, intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, or intraocular injections, just to name a few. Other routes include oral or transdermal delivery. For injection, the composition of one case of the disclosure may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiological saline buffer.

[0385] For parenteral application, which includes intramuscular, intradermal, subcutaneous, intranasal, intracapsular, intraspinal, intrasternal, and intravenous injection, particularly suitable are injectable, sterile solutions, preferably oily or aqueous solutions, as well as suspensions, emulsions, or implants, including suppositories. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulator agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

[0386] For enteral application, particularly suitable are tablets, dragees, liquids, drops, suppositories, or capsules. The pharmaceutical compositions may be prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g., methyl or propyl-p-hydroxybenzoates or sorbic acid). The preparations may also contain buffer salts, flavoring, coloring and sweetening agents as appropriate. A syrup, elixir, or the like can be used wherein a sweetened vehicle is employed.

[0387] Sustained or directed release compositions can be formulated, e.g., liposomes or those wherein the active compound is protected with differentially degradable coatings, e.g., by microencapsulation, multiple coatings, etc. It is also possible to freeze dry the new compounds and use the lyophilizates obtained, for example, for the preparation of products for injection.

[0388] For administration by inhalation, the compounds for use according to one case of the present disclosure are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of e.g., gelatin for use in an inhaler or insufflator may be formulated containing a powder mix

of the compound and a suitable powder base such as lactose or starch. For topical, or transdermal, application, there are employed as non-sprayable forms, viscous to semi-solid or solid forms comprising a carrier compatible with topical application and having a dynamic viscosity preferably greater than water. Suitable formulations include but are not limited to solutions, suspensions, emulsions, creams, ointments, powders, liniments, salves, aerosols, etc., which are, if desired, sterilized or mixed with auxiliary agents, e.g., preservatives, stabilizers, wetting agents, buffers or salts for influencing osmotic pressure, etc. For topical application, also suitable are sprayable aerosol preparations wherein the active ingredient; preferably in combination with a solid or liquid inert carrier material, is packaged in a squeeze bottle or in admixture with a pressurized volatile, normally gaseous propellant, e.g., a freon. The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack may for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration.

[0389] In accordance with one case of the present disclosure the compositions may comprise a pharmaceutically acceptable excipient, carrier, buffer, stabilizer or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient. The precise nature of the carrier or other material may depend on the route of administration, e.g., intravenous, cutaneous or subcutaneous, intramucosal (e.g., gut), intranasal, intramuscular, or intraperitoneal routes.

[0390] In general, the term "biologically active" indicates that a compound (including a protein or peptide) has at least one detectable activity that has an effect on the metabolic or other processes of a cell or organism, as measured or observed *in vivo* (i.e., in a natural physiological environment) or *in vitro* (i.e., under laboratory conditions).

Immunogenicity of Compositions

[0391] The immunogenicity of the compositions described herein may be evaluated in a subject. In some cases, the epitope encoded by the composition (e.g., plasmid-based vaccines) may be evaluated in a recipient subject. For example, the recipient subject may be a rodent, a non-human primate or a human. In some cases, the rodent is a mouse. For example, the mouse may be a neu-TG mouse, a C3 mouse or an FVB mouse.

[0392] The compositions and methods described herein may elicit an immune response to an epitope of an antigenic peptide in a subject. In some instances, the compositions may be a breast cancer vaccine or ovarian cancer vaccine. In some cases, the breast cancer vaccine may be a multiantigen breast cancer vaccine. In some cases, the ovarian cancer vaccine may be a multiantigen ovarian cancer vaccine.

[0393] The immune response may be a Type I immune response, a Type II immune response or both Type I and Type II immune responses. In some cases, a Type I immune response may result in the secretion of inflammatory cytokines (e.g., IPN γ , TNP α) by antigen specific T-cells. The inflammatory cytokines (e.g., Type I cytokines) may activate cytotoxic T-cells which, for example, may kill cells which express at least one epitope encoded for (e.g., nucleic acids, plasmids) or delivered (e.g., peptide, protein) by the vaccine. In some cases, the Th1 cytokines may activate additional immune cells. In some cases, a Type II immune response may result in the secretion of immunosuppressive cytokines (e.g., IL-10, IL-4 and IL-5) by regulatory T-cells. The immunosuppressive cytokines (e.g., Type II cytokines) may activate regulatory T-cells which, for example, may not kill cells which express at least one antigenic epitope encoded for (e.g., nucleic acids, plasmids) or delivered (e.g., peptide, protein) by the vaccine but rather suppress the Th1 immune response.

[0394] Whether a Th1 or a Th2 immune response, or both, may occur in a subject may be the result of the affinity between the epitope and the MHC-T cell receptor interaction. In some cases, the affinity of the binding peptides for MHC molecules may be high. In other cases, the affinity of the binding peptides for MHC molecules may be low. In some cases, low affinity binding peptides may induce a Th2 response. In other cases, high affinity binding peptides may induce a Th1 response. The affinity of candidate binding peptides for MHC molecules may be screened. For example, IFN γ and IL-10 secretion induced by a candidate binding peptide may be determined as described herein or using techniques known to one of ordinary skill in the art.

[0395] The immunogenicity of the vaccine may be analyzed in the subject using any of the plurality of methods known to one of ordinary skill in the art. In some cases, immunogenicity may be analyzed by detecting expression of peptides in the subject encoded by the vaccine administered to the subject. For example, detection methods may include ELISPOT, ELISA, Western blotting, flow cytometry, histology, chromatography, mass spectrometry and the like. Often, immunogenicity to isolated peptides produced in the subject in response to the vaccine may be analyzed. In some cases, a sample of tumor cells, cancer cells, spleen cells or normal cells taken from the subject may be analyzed.

[0396] In some cases, lymphocytes may be isolated from the subject for analysis of immunogenicity. For example, lymphocytes may be isolated from the spleen, from the lymph nodes and/or from the draining lymph nodes. In some cases, the lymphocytes may be isolated after administration of the single dose of the vaccine. In other cases, the lymphocytes may be isolated after administration of the last dose of a plurality of doses of the vaccine. For example, lymphocytes may be isolated one day, two days, three days, four days, five days, six days, seven days, eight days, nine days, ten days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days or 30 days after administration of either the single dose of the vaccine.

[0397] In some cases, the lymphocytes may be isolated after administration of the last dose of a plurality of doses of the vaccine. In other cases, the lymphocytes may be isolated after administration of the last dose of a plurality of doses of the vaccine. For example, lymphocytes may be isolated one day, two days, three days, four days, five days, six days, seven days, eight days, nine days, ten days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days or 30 days after administration of the last dose of a plurality of doses of the vaccine.

[0398] In some cases, a protein detection method may be used to determine the amount of each peptide encoded for by the nucleic acids of the composition (e.g., the plasmid-based vaccine) produced by the subject. For example, an ELISPOT may be performed and the ELISPOT may detect IFN γ . For another example, a different ELISPOT may be performed and the ELISPOT may detect Granzyme B. In some cases, a protein detection method may be used to determine the presence of protein specific T-cells in response to the composition (e.g., plasmid-based vaccine) produced by the subject. For example, an ELISPOT may be performed and the ELISPOT may detect IFN γ . For another example, a different ELISPOT may be performed and the ELISPOT may detect Granzyme B.

[0399] Immunogenicity of the peptides encoded by the vaccine may be determined by comparing the results from subjects after administration of the composition (e.g., vaccine) to the results of the methods described herein from subjects after administration of a control composition (e.g., nothing encoded by the plasmids or no peptides). In some cases, the control may be the adjuvant alone. In other cases, the control may be a negative control (e.g., blank plasmids lacking antigenic peptide epitopes). Immunogenicity may be determined by an increase in the amount of IFN γ produced (e.g., IFN γ positive spots on an ELISPOT) or increase in the amount of tumor specific Granzyme B produced (Granzyme B positive spots on an ELISPOT).

[0400] The increase may be observed in subjects after administration of the composition (e.g., vaccine) compared to subjects administered a control composition. In some cases, the increase may be statistically different than the control as indicated by a P value (e.g., $p < 0.05$). Often, statistically different at $p < 0.05$ is statistically significant.

[0401] For example, the statistical significance of immunogenicity may be determined by comparing two groups ($n=10$ subjects per group) for a 98% power where at least the two-sided level may be 0.05 and the true effect size may be 2.0. In some cases, the effect size may be defined as the difference in mean specific T-cell response level divided by the common standard deviation. A true effect size of about 1.5 or less would not be significant.

[0402] Additional parameters may be analyzed after administration of at least one dose of the vaccine. In some cases, blood may be isolated from a subject and a plurality of tests performed on the blood known to one of ordinary skill in the art. For example, a basic metabolic panel and/or a complete blood count performed. In some cases, additional tissues may be examined. For example, the spleen, skin, skeletal muscle, lymph node, bone, bone marrow, ovary, oviduct, uterus, peripheral nerve, brain, heart, thymus, lung, kidney, liver and/or pancreas may be examined after administration of at least one dose of the vaccine.

Efficacy of the Compositions Using Model Systems

[0403] The compositions described herein may be utilized with a plurality of mouse model systems. In some cases, the mouse models may include genetically diverse mouse models. In some cases, the mouse model may be a tumor implant model. For example, the mice may include, TgMMTV-neu (neu-TG) and TgC3(l)-Tag (C3). In some cases, a genetically similar mouse model may be used. For example, the neu-TG mouse model system may have a genotype similar to two different types of human cancers, (1) human luminal cancer and is estrogen receptor negative (ER-), and (2) HER2+ human breast cancer and overexpresses the neu oncogene. In other cases, the C3 mouse may have a genotype that may be similar to basal breast cancer and/or triple negative breast cancer. The mouse model of DMBA induced breast cancers in FVB mice may be heterogeneous and may have tumors comparable to multiple subtypes of human breast cancers. For example, a mouse model of genetically similar may be Medroxyprogesterone-DMBA-induced tumors in FVB mice (DMBA).

[0404] In some cases, the mouse model may be a tumor implant model. For example, a tumor implant model, as shown in Figure 35, may be used to analyze the therapeutic efficacy of the compositions described herein. For example, the composition may be a breast cancer vaccine. In some cases, tumor cells may be implanted subcutaneously in the mouse. For example, at least 1,000, 2,500, 5,000, 7,500, 10,000, 12,500, 15,000, 17,500, 20,000, 22,500, 25,000, 27,500, 30,000, 35,000, 40,000, 45,000, 50,000, 75,000, 100,000, 125,000, 150,000, 175,000, 200,000, 225,000, 250,000, 275,000, 300,000, 350,000, 400,000, 450,000, 500,000, 750,000, 1,000,000, 1,250,000, 1,500,000, 1,750,000, 2,000,000, 2,500,000, 3,000,000, 3,500,000, 4,000,000, 4,500,000, 5,000,000, 5,500,000, 6,000,000, 6,500,000, 7,000,000, 7,500,000, 8,000,000, 8,500,000, 9,000,000, 9,500,000 or at least 1,000,000,000 tumor cells may be implanted subcutaneously in the mouse. In some cases, the tumor cells may be MMA cells.

[0405] Tumor growth may be measured using methods known to one of ordinary skill in the art. For example, methods of measurement may include tumor diameter, tumor volume, tumor mass and the like. In some cases, imaging, extraction or histologic techniques may be used. For example, any of the techniques may include use of a contrast agent.

[0406] In some cases, the efficacy of the vaccine may be determined by the size of tumor growth relative to a control (e.g., unvaccinated mouse or a mouse treated with a control vaccine). For example, in the absence of vaccination, greater than 90% of the mice may develop tumors and in the presence of vaccination, a 60% inhibition of tumor growth may be observed. In some cases, vaccination may inhibit at least 2%, 5%, 7%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or at least 99% of tumor growth.

[0407] After administration of the vaccine, the subject may be 100% tumor free. In other cases, the subject may be less than 100% tumor free after administration of the vaccine. For example, the subject may be less than 99%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15% or less than 10% tumor free after administration of the vaccine. In some cases, the subject may become tumor free hours after administration of the vaccine. For example, the subject may become tumor free one hour, two hours, three hours, four hours, five hours, six hours, seven hours, eight hours, nine hours, ten hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, 24 hours, 25 hours, 26 hours, 27 hours, 28 hours, 29 hours, 30 hours, 31 hours, 32 hours, 33 hours, 34 hours, 35 hours, 36 hours, 37 hours, 38 hours, 39 hours, 40 hours, 41 hours, 42 hours, 43 hours, 44 hours, 45 hours, 46 hours, 47 hours, 48 hours, 49 hours, 50 hours or more after administration of the vaccine. In other cases, the subject may become tumor free days after administration of the vaccine. For example, the subject may become tumor free one day, two days, three days, four days, five days, six days, seven days, eight days, nine days, ten days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days, 31 days, 32 days, 33 days, 34 days, 35 days, 36 days, 37 days, 38 days, 39 days, 40 days, 41 days, 42 days, 43 days, 44 days, 45 days, 46 days, 47 days, 48 days, 49 days, 50 days or more after administration of the vaccine. In other cases, the subject may become tumor free weeks after administration of the vaccine. For example, the subject may become tumor free one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, ten weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 25 weeks, 26 weeks, 27 weeks, 28 weeks, 29 weeks, 30 weeks, 31 weeks, 32 weeks, 33 weeks, 34 weeks, 35 weeks, 36 weeks, 37 weeks, 38 weeks, 39 weeks, 40 weeks, 41 weeks, 42 weeks, 43 weeks, 44 weeks, 45 weeks, 46 weeks, 47 weeks, 48 weeks, 49 weeks, 50 weeks or more after administration of the vaccine. In other cases, the subject may become tumor free months after administration of the vaccine. For example, the subject may become tumor free one month, two months, three months, four months, five months, six months, seven months, eight months, nine months, ten months, 11 months, 12 months, 13 months, 14 months, 15 months, 16 months, 17 months, 18 months, 19 months, 20 months, 21 months, 22 months, 23 months, 24 months, 25 months, 26 months, 27 months, 28 months, 29 months, 30 months, 31 months, 32 months, 33 months, 34 months, 35 months, 36 months, 37 months, 38 months, 39 months, 40 months, 41 months, 42 months, 43 months, 44 months, 45 months, 46 months, 47 months, 48 months, 49 months, 50 months or more after administration of the vaccine. In other cases, the subject may become tumor free years after administration of the vaccine. For example, the subject may become tumor free one year, two years, three years, four years, five years, six years, seven years, eight years, nine years, ten years, 11 years, 12 years, 13 years, 14 years, 15 years, 16 years, 17 years, 18 years, 19 years, 20 years, 21 years, 22 years, 23 years, 24 years, 25 years, 26 years, 27 years, 28 years, 29 years, 30 years, 31 years, 32 years, 33 years, 34 years, 35 years, 36 years, 37 years, 38 years, 39 years, 40 years, 41 years, 42 years, 43 years, 44 years, 45 years, 46 years, 47 years, 48 years, 49 years, 50 years or more after administration of the vaccine.

[0408] In some cases, the efficacy of the vaccine may be determined by the amount of IFN γ produced in a vaccinated subject (e.g., mouse) relative to a control (e.g., unvaccinated mouse). In some cases, the efficacy of the vaccine may be determined by the amount of IL-10 produced in a vaccinated subject (e.g., mouse) relative to a control (e.g., unvaccinated mouse).

[0409] In some aspects, polyclonality of the epitope-specific immune response may be evaluated. In some cases, an

evaluation of polyclonality may be performed by assessing the production of IgG antibodies in response to epitopes of the administered vaccine. In some cases, IgGs may be elicited to one antigen. In other cases, IgGs may be elicited to multiple antigens. In some cases, a lysate may be prepared from a sample taken from a subject and evaluated from the pre-immunization and post-immunization serum of the subject. For example, a subject may be a mouse of the neu-TG mouse model and IgGs detected using a method of peptide detection, such as ELISA or ELISPOT.

[0410] In some cases, the response to each antigen between pre-vaccination subjects (e.g., mice) and post-vaccination subjects (e.g., mice) may be analyzed using statistical methods. For example, statistical methods may include analysis using single factor ANOVA. In some cases, an analysis of the number of antigens to which subjects (e.g., mice) developed immunity during the course of vaccination may be performed.

Toxicity and Safety Profile of Compositions

[0411] The compositions described herein may be assessed for toxicity and safety. Methods to assess toxicity and safety known to one of ordinary skill in the art may be used with the compositions described herein. In some cases, a dose escalation study may be performed. In some cases, toxicity and safety studies may screen for the development of diseases in the subject, damage to organs in the subject, damage to tissues in the subject, damage to cells in the subject, blood disorders and the like. For example, diseases may include autoimmune diseases.

Manufacture and Quality Control of Compositions

[0412] Manufacture and testing of the compositions described herein (e.g., plasmid-based vaccines) may be performed in compliance with current standards of cGMP Biologics Production Facilities (BPF). Process development may include the transfer of the candidate cells (e.g., cell line(s)) each containing the appropriate plasmid constructs with the kanamycin selection marker to the cGMP BPF. In some cases, a research bank may be generated from the bacterial stock. For example, a scaled pilot production that may match a later cGMP manufacture may be utilized to assess plasmid yield and purity. In some cases, the preliminary manufacturing batch records and quality control testing schedules may be established. For example, the master cell bank(s) may be generated from each bacterial stock. In some cases, quality control testing may be performed inclusive of; plasmid and host cell identity, plasmid copy number, purity, viability, and retention of antibiotic resistance (plasmid retention).

[0413] In some cases, finalized and approved manufacturing batch records and standard operating procedures may be followed for cGMP production and purification of the vaccine plasmid(s) and lot release criteria may be developed. In some cases, the final bulk/pooled purified product may be quality control tested in accordance with current regulatory guidelines and then may be vialled as single dose units following validated fill and finish standard operating procedures. In compliance with cGMP regulations, the vialled product may undergo quality control testing prior to final product release.

Clinical Trials for Ovarian Cancer

[0414] The compositions and methods described herein may be administered to human subjects in need thereof. While standard practices are followed in accordance with rules and regulations set forth by the Federal Department of Agriculture (FDA) and any other relevant governing bodies, administration of the compositions and methods described herein to human subjects may follow established guidelines. In some cases, a pre-investigational new drug (IND) packet may be prepared. In some cases, a standard operating procedure (SOP) for production of the plasmids described herein may be used for manufacturing purposes. For example, manufacturing may occur in a good manufacturing practice (GMP) facility. In some cases, the GMP facility may include a master cell bank.

[0415] A clinical trial may be performed to evaluate the safety and determine the most immunogenic dose of the multi-antigen DNA plasmid-based vaccine. In some instances, the clinical trial may be performed to determine the safety of administration (e.g., intradermal) of a multi-antigen vaccine (e.g., three doses) in subjects (e.g., patients) that may have an ovarian cancer and to determine the immunogenic dose of the compositions (e.g., a multi-antigen vaccine) in subjects. In some cases, the clinical trial may be performed to determine the safety of administration (e.g., intradermal) of a multi-antigen vaccine (e.g., three doses) in subjects (e.g., patients) that may have ovarian cancer and to determine the immunogenic dose of the compositions (e.g., a multi-antigen vaccine) in subjects.

[0416] The clinical trial may be a Phase I trial of the safety and immunogenicity of the compositions described herein (e.g., vaccines). In some cases, subjects with non-metastatic ovarian cancer may be enrolled. In some cases, the patient may have been treated to complete remission. In some cases, patients may have been treated with primary or salvage therapy. In some cases, patients may have completed chemotherapy, radiotherapy and/or use of systemic steroids prior to enrolling in the clinical trial. For example, patients may be at least one day, two days, three days, four days, five days, six days, seven days, eight days, nine days, ten days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days, 31 days, 32 days, 33 days, 34 days, 35 days, 36 days, 37 days, 38 days, 39 days, 40 days, 41 days, 42 days, 43 days, 44 days, 45 days, 46 days, 47 days, 48 days, 49 days, 50 days or more from last cytotoxic chemotherapy and/or radiotherapy and any use of systemic steroids. In an exemplary case, patients may be 28 days from last cytotoxic chemotherapy and/or radiotherapy and any use of systemic steroids.

[0417] In some cases, Phase I may evaluate 3 dose levels of the compositions (e.g., vaccines). For example, subjects may be assigned to one of three doses: Arm 1 (150 mcg), Arm 2 (300 mcg), and Arm 3 (600 mcg). In some cases, no more than ten subjects may be enrolled in each arm. For example, three doses of the vaccine may be administered to each subject such that one month elapses between each dose. In some cases, booster doses may be administered to the subject following the third dose of the vaccine. For example, the booster may be administered such that one booster is administered two months following the third dose of the vaccine and one booster administered four months after the booster.

[0418] In some cases, the Arm 2 cohort of 10 subjects may be enrolled in Phase I of the trial if the doses in Arm 1 are safe. In some cases, if the Arm 2 dose is safe then the immunologic efficacy of both Arm 1 and Arm 2 may be examined. For example, if the Arm 1 dose is more efficacious, the trial may terminate. In some cases, if the efficacy is greater in the Arm 2 dose compared to the Arm 1 does, then subjects may be enrolled into the Arm 3 dose schema. In some cases, if the Arm 3 dose appears safe, the immunologic efficacy between Arm 2 and 3 will be examined. For example, safety may be assessed per CTEP CTCAE v. 4.0. In some cases, benchmarks for safety to move to the next arm may be a grade 3 toxicity rate of $\leq 15\%$ and a grade 4 toxicity rate of $\leq 15\%$.

[0419] Immunologic efficacy of the three doses may be evaluated via an assessment of the generation of T cells. In some cases, immunologic efficacy may be defined as achievement of augmented IFN-g T-cell immunity to the antigens in the vaccine.

[0420] Design and Recruitment Plan. The two endpoints of the Phase I clinical trial may be to, (1) determine the safety of intradermal administration of the vaccine given with GM-CSF as an adjuvant and, (2) determine the immunogenicity of the vaccine. In some cases, subjects may be immunized with the plasmid based vaccine (e.g., 100ug of total plasmid per subject). In some cases, subjects may receive three vaccines administered across intervals (30-days). For example, the vaccines may be administered to the subject at the deltoid region in a draining lymph node site (Fig. 5).

[0421] Subjects with Stage IIb, III, and IV ovarian cancer who have been treated to complete remission may be enrolled in the trial. In some cases, the trial may accrue a target number of subjects (e.g., 22 subjects). Subjects may undergo leukapheresis (e.g., for baseline immunologic assessment) and blood draw (e.g., for baseline toxicity assessment) at beginning of the study and an 180cc blood draw at one, six, and 12 months after the final vaccination. In some cases, blood may be analyzed for changes in serum chemistries as an assessment of potential toxicity. Peripheral blood mononuclear cells and sera collected at these time points may be evaluated for the development of tumor specific immunity as described herein. A leukapheresis product may be obtained after the final vaccination (e.g., 3 months) for additional studies.

[0422] Safety. In some cases, the vaccine may elicit an immediate allergic reaction. In some cases, the vaccine may cause side effects due to immunologic consequences of the vaccination targeting other, unrelated tissues. In some cases, after evaluation of these toxicities, criteria for stopping treatment or removing subjects from the study may be established.

[0423] During Phase I, more than 200 subjects may receive the ovarian cancer vaccine. In some cases, the composition may include GM-CSF (100-150ug) admixed with the ovarian cancer vaccine. In some cases, the composition may be administered using the method of intradermal injection monthly for 3-6 months. For example, intradermal administration may result in allergic reaction to the skin. In some cases, subjects may be monitored following immunizations (e.g., for one hour).

[0424] Subjects may be examined at a routine visit following administration of the vaccine. In some cases, subjects may be evaluated at each visit based on the modified National Cancer Institute toxicity criteria. In some cases, subjects may undergo a complete physical examination. In addition, serum chemistries, including renal function tests, uric acid, blood counts, serum glucose, and liver function tests for each subject may be evaluated. In some cases, the development of connective tissue disorders and laboratory autoantibody responses may be assessed as a potential immunologic toxicity associated with the use

of DNA vaccination. In some cases, the development of anti-DNA antibodies may be assessed, for example, anti-ANA, anti-C3, anti-thyroid and and ds-DNA antibodies. In some cases, assessments may be performed at the end of the vaccination regimen, and at 12 months of follow-up.

[0425] A sample size of 22 subjects may be enrolled into each arm of the trial. In some cases, if no toxicities occur, the probability of a toxicity occurring may be at least 90% if the true toxicity rate, i.e., any Grade 3 or 4 toxicity, is 10% or less. For example, a toxicity occurrence may indicate that the toxicity rate is less than 10%. In some cases, the trial may continue and may be deemed sufficiently safe as long as the observed toxicity rate is consistent with a true grade 3 rate of 15% or less and a true grade 4 rate of 5% or less. In some cases, stopping rules may be utilized such that if sufficient evidence suggests the true toxicity rates exceed these thresholds, the study may be stopped. For example, sufficient evidence may be taken to be a lower one-sided confidence limit in excess of the appropriate threshold. For grade 3, such a limit may be reached if this level of toxicity occurred in 2 of the first 3 or fewer, 3 of the first 7 or fewer, 4 of the first 12 or fewer, 5 of the first 17 or fewer, or 6 of the first 22 or fewer enrolled subjects. For grade 4, one of the following may result in stopping the trial: 2 of the first 10 or fewer, 3 of the first 22 or fewer enrolled subjects experience grade 4 toxicity. For example, if the true probability of grade 3 toxicity is 10% or 30%, then the probability of stopping the study may be approximately .06 and .76, respectively. If the true probability of grade 4 toxicity is 3% or 23%, then the probability of stopping may be roughly .05 and .93, respectively (probabilities estimated from 5,000 simulations).

[0426] Immune genicity. The vaccine may elicit an immunogenic response in the subject. In some cases, the type of immune response elicited after immunization may be determined. For example, the compositions described herein may elicit a Th1 immune response when administered to a subject. In some cases, the Th1 immune response may include formation of and persistence of antigen specific T cells that recognize at least one peptide of the vaccine. For example, a peptide may be a stem cell and/or an EMT antigen.

[0427] The type of immune response may be determined through an assessment of the types of cytokine secreted by antigen specific T cells. In some cases, the types of cytokines may be identified using an ELISPOT assay. For example, an ELISPOT method may include analysis of sample supernatants after antigen stimulation (e.g., 72 hours). In some cases, the sample supernatants may be evaluated for a panel of cytokines. In some cases, the evaluation may be a multiplex analysis. For example, the multiplex analysis of cytokines may include the cytokines for Th1 (e.g., IFN-g, IL-2, TNF-a, IL-1b, GM-CSF), Th17 (IL-17), and Th2 (e.g., IL-6, IL-4, IL-10, IL-13). An exemplary data set is depicted in Figure 37. In some cases, the presence of TGF- β in sample supernatants may also be analyzed. For example, TGF- β may be analyzed using an ELISA method. In some cases, the magnitude of or pattern of secretion may serve as a biomarker of clinical outcome after vaccination.

[0428] Heat maps may be generated from multiplexed cytokine data. In some cases, the heat maps are color coded as to the magnitude of antigen specific cytokine increase or decrease with vaccination. In some cases, the heat maps may depict specific patterns of the type of and magnitude of the immune response to the at least one immunizing antigen.

[0429] In some cases, a subject may be classified as immunized by development of protein specific precursor frequencies that are more robust than 1:20,000 PBMC to the majority of the immunizing antigens. In some cases, if subjects have pre-existent immunity to any of the antigens, then the responses may augment more than twice the baseline response.

[0430] In some cases, the analysis of immunogenicity may determine the magnitude of the Th1 antigen specific immune response. For example, the Th1 response may be determined by performing an IFN-g ELISPOT, which is linear and precise between 2.0 and 3.5×10^5 PBMC/well, has a detection limit of 1:60,000, and has a detection efficiency of 93%. In some cases, pre-vaccine and post-vaccine samples may be analyzed simultaneously to correct for variability. For example, a cryopreservation method that preserves antigen specific T cell responses in frozen cells when compared to freshly isolated PBMC may be used. In some cases, the samples may include $\mu\text{g/ml}$ protein antigens (e.g., recombinant proteins are available on all of the proposed candidate antigens, human myoglobin (negative control)) or $\mu\text{g/ml}$ CMV lysate and 0.5U/ml tt (positive controls) and peptide antigens encompassed within the vaccine at 10 $\mu\text{g/ml}$).

[0431] The ovarian cancer vaccine may exhibit immunologic success that may be analyzed using statistical methods. Often immunologic success of the vaccine may be the occurrence of an immune response (e.g., Th1) to greater than 50% of the antigens expressed by the plasmids within the vaccine. In some cases, the vaccine may be administered to a group of subjects (e.g. 22 subjects) such that the probability of an observed success rate in excess of 50% may be less than 0.1 if the true success rate is 40%. For example, the observed success rate may be .06. In some cases, the vaccine may be administered to a group of subjects (e.g. 22 subjects) such that the probability of an observed success rate in excess of 50% may be greater than 0.7 if the true success rate is 70%.

[0432] For example, use of a group of 22 patients may demonstrate, with at least 80% confidence, that an estimated immunologic response rate may be within at least .14 of the true response rate. In some cases, if half of the subjects elicit an immunogenic response, then the power may be at least 91% for statistical significance (at the two-sided level of .05) and the difference in continuous measures if the true effect size is 1.5. For example, Spearman's correlation coefficient may be used to estimate the correlation between two continuous measures. In some cases, the data may estimate an expected response rate in a larger population.

[0433] For another example, 25% of subjects may elicit a good response to the vaccine. In some cases, 25% of subjects with a good response may be the baseline to evaluate the effectiveness of a vaccine. In some cases, the true response rate may be 60% where use of a group of 22 subjects may provide a power of 97% for a statistically significant response rate compared to the fixed rate of 25% (one-sided level of significance of .05).

Clinical Trials for Breast Cancer

[0434] In some instances, the clinical trial may be a Phase I trial of the safety and immunogenicity of the compositions described herein (e.g., vaccines) for subjects with non-metastatic breast cancer. In some cases, the breast cancer may be node positive triple negative (ER(-) PR(-) HER2/neu(-)) breast cancer (TNBC). In some cases, the patient may have been treated to complete remission. In some cases, patients may have been treated with primary or salvage therapy. In some cases, patients may have completed chemotherapy, radiotherapy and/or use of systemic steroids prior to enrolling in the clinical trial. For example, patients may be at least one day, two days, three days, four days, five days, six days, seven days, eight days, nine days, ten days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days, 31 days, 32 days, 33 days, 34 days, 35 days, 36 days, 37 days, 38 days, 39 days, 40 days, 41 days, 42 days, 43 days, 44 days, 45 days, 46 days, 47 days, 48 days, 49 days, 50 days or more from last cytotoxic chemotherapy and/or radiotherapy and any use of systemic steroids. In an exemplary case, patients may be 28 days from last cytotoxic chemotherapy and/or radiotherapy and any use of systemic steroids.

[0435] In some cases, as described above Phase I may evaluate 3 dose levels of the compositions (e.g., vaccines), such as for example Arm 1 (150 mcg), Arm 2 (300 mcg), and Arm 3 (600 mcg). In some cases, no more than ten subjects may be enrolled in each arm. For example, three doses of the vaccine may be administered to each subject such that one month elapses between each dose. In some cases, booster doses may be administered to the subject following the third dose of the vaccine. For example, the booster may be administered such that one booster is administered two months following the third dose of the vaccine and one booster administered four months after the booster.

[0436] In some cases, the Arm 2 cohort of 10 subjects may be enrolled in Phase I of the trial if the doses in Arm 1 are safe. In some cases, if the Arm 2 dose is safe then the immunologic efficacy of both Arm 1 and Arm 2 may be examined. For example, if the Arm 1 dose is more efficacious, the trial may terminate. In some cases, if the efficacy is greater in the Arm 2 dose compared to the Arm 1 dose, then subjects may be enrolled into the Arm 3 dose schema. In some cases, if the Arm 3 dose appears safe, the immunologic efficacy between Arm 2 and 3 will be examined. For example, safety may be assessed per CTCAE v. 4.0. In some cases, benchmarks for safety to move to the next arm may be a grade 3 toxicity rate of $\leq 15\%$ and a grade 4 toxicity rate of $\leq 15\%$.

[0437] Immunologic efficacy of the three doses may be evaluated via an assessment of the generation of T-cells. In some cases, immunologic efficacy may be defined as achievement of augmented IFN γ T-cell immunity to the antigens in the vaccine.

[0438] Design and recruitment plan. The two endpoints of the Phase I clinical trial may be to, (1) determine the safety of intradermal administration of the vaccine given with GM-CSF as an adjuvant and, (2) determine the immunogenicity of the vaccine. In some cases, subjects may be immunized with the plasmid based vaccine (e.g., 100 μ g of total plasmid per subject). In some cases, subjects may receive three vaccines administered across intervals (30-days). For example, the vaccines may be administered to the subject at the deltoid region in a draining lymph node site (Fig. 5).

[0439] Subjects with Stage IIb, III, and IV breast cancer (e.g., triple negative) who have been treated to complete remission may be enrolled in the trial. In some cases, the trial may accrue a target number of subjects (e.g., 22 subjects). Subjects may undergo leukapheresis (e.g., for baseline immunologic assessment) and blood draw (e.g., for baseline toxicity assessment) at beginning of the study and an 180cc blood draw at one, six, and 12 months after the final vaccination. In some cases, blood may be analyzed for changes in serum chemistries as an assessment of potential toxicity. Peripheral blood mononuclear cells and sera collected at these time points may be evaluated for the development of tumor specific immunity as described herein.

A leukapheresis product may be obtained after the final vaccination (e.g., 3 months) for additional studies.

[0440] Safety. In some cases, the vaccine may elicit an immediate allergic reaction. In some cases, the vaccine may cause side effects due to immunologic consequences of the vaccination targeting other, unrelated tissues. In some cases, after evaluation of these toxicities, criteria for stopping treatment or removing subjects from the study may be established.

[0441] During Phase I, more than 200 subjects may receive the breast cancer vaccine. In some cases, the composition may include GM-CSF (100-150ug) admixed with HER2 peptide/protein/or DNA-based vaccines. In some cases, the composition may be administered using the method of intradermal injection monthly for 3-6 months. For example, intradermal administration may result in allergic reaction to the skin. In some cases, subjects may be monitored following immunizations (e.g., for one hour).

[0442] Subjects may be examined at a routine visit following administration of the vaccine. In some cases, subjects may be evaluated at each visit based on the modified National Cancer Institute toxicity criteria. In some cases, subjects may undergo a complete physical examination. In addition, serum chemistries, including renal function tests, uric acid, blood counts, serum glucose, and liver function tests for each subject may be evaluated. In some cases, the development of connective tissue disorders and laboratory autoantibody responses may be assessed as a potential immunologic toxicity associated with the use of DNA vaccination. In some cases, the development of anti-DNA antibodies may be assessed, for example, anti-ANA, anti-C3, anti-thyroid and ds-DNA antibodies. In some cases, assessments may be performed at the end of the vaccination regimen, and at 12 months of follow-up.

[0443] A sample size of 22 subjects may be enrolled into each arm of the trial. In some cases, if no toxicities occur, the probability of a toxicity occurring may be at least 90% if the true toxicity rate, i.e., any Grade 3 or 4 toxicity, is 10% or less. For example, a toxicity occurrence may indicate that the toxicity rate is less than 10%. In some cases, the trial may continue and may be deemed sufficiently safe as long as the observed toxicity rate is consistent with a true grade 3 rate of 15% or less and a true grade 4 rate of 5% or less. In some cases, stopping rules may be utilized such that if sufficient evidence suggests the true toxicity rates exceed these thresholds, the study may be stopped. For example, sufficient evidence may be taken to be a lower one-sided confidence limit in excess of the appropriate threshold. For grade 3, such a limit may be reached if this level of toxicity occurred in 2 of the first 3 or fewer, 3 of the first 7 or fewer, 4 of the first 12 or fewer, 5 of the first 17 or fewer, or 6 of the first 22 or fewer enrolled subjects. For grade 4, one of the following may result in stopping the trial: 2 of the first 10 or fewer, 3 of the first 22 or fewer enrolled subjects experience grade 4 toxicity. For example, if the true probability of grade 3 toxicity is 10% or 30%, then the probability of stopping the study may be approximately .06 and .76, respectively. If the true probability of grade 4 toxicity is 3% or 23%, then the probability of stopping may be roughly .05 and .93, respectively (probabilities estimated from 5,000 simulations).

[0444] Immunogenicity. The vaccine may elicit an immunogenic response in the subject. In some cases, the type of immune response elicited after immunization may be determined. For example, the compositions described herein may elicit a Th1 immune response when administered to a subject. In some cases, the Th1 immune response may include formation of and persistence of antigen specific T-cells that recognize at least one peptide of the vaccine. For example, a peptide may be a stem cell and/or an EMT antigen.

[0445] The type of immune response may be determined through an assessment of the types of cytokine secreted by antigen specific T-cells. In some cases, the types of cytokines may be identified using an ELISPOT assay. For example, an ELISPOT method may include analysis of sample supernatants after antigen stimulation (e.g., 72 hours). In some cases, the sample supernatants may be evaluated for a panel of cytokines. In some cases, the evaluation may be a multiplex analysis. For example, the multiplex analysis of cytokines may include the cytokines for Th1 (e.g., IFN γ , IL-2, TNF α , IL-1b, GM-CSF), Th17 (IL-17), and Th2 (e.g., IL-6, IL-4, IL-10, IL-13). An exemplary data set is depicted in Figure 37. In some cases, the presence of TGF- β in sample supernatants may also be analyzed. For example, TGF- β may be analyzed using an ELISA method. In some cases, the magnitude of or pattern of secretion may serve as a biomarker of clinical outcome after vaccination.

[0446] Heat maps may be generated from multiplexed cytokine data. In some cases, the heat maps are color coded as to the magnitude of antigen specific cytokine increase (e.g., red, see Figure 37) or decrease (e.g., blue, see FIG. 37) with vaccination. For example, the intensity of the colors may symbolize the lowest (e.g., pale, see FIG. 37) to highest (e.g., vivid, see Figure 37) quartile of response. In some cases, the heat maps may depict specific patterns of the type of and magnitude of the immune response to the at least one immunizing antigen. For example, the magnitude of cytokine secretion.

[0447] In some cases, a subject may be classified as immunized by development of protein specific precursor frequencies that are more robust than 1:20,000 PBMC to the majority of the immunizing antigens. In some cases, if subjects have pre-existent immunity to any of the antigens, then the responses may augment more than twice the baseline response.

[0448] In some cases, the analysis of immunogenicity may determine the magnitude of the Th1 antigen specific immune response. For example, the Th1 response may be determined by performing an IFN γ ELISPOT, which is linear and precise between 2.0 and 3.5 x 10⁵ PBMC/well, has a detection limit of 1:60,000, and has a detection efficiency of 93%. In some cases, pre-vaccine and post-vaccine samples may be analyzed simultaneously to correct for variability. For example, a cryopreservation method that preserves antigen specific T-cell responses in frozen cells when compared to freshly isolated PBMC may be used. In some cases, the samples may include μ g/ml protein antigens (e.g., recombinant proteins are available on all of the proposed candidate antigens, human myoglobin (negative control)) or μ g/ml CMV lysate and 0.5U/ml tt (positive controls) and peptide antigens encompassed within the vaccine at 10 μ g/ml).

[0449] The breast cancer vaccine may exhibit immunologic success that may be analyzed using statistical methods. Often immunologic success of the vaccine may be the occurrence of an immune response (e.g., Th1) to greater than 50% of the antigens expressed by the plasmids within the vaccine. In some cases, the vaccine may be administered to a group of 22 subjects such that the probability of an observed success rate in excess of 50% may be less than 0.1 if the true success rate is 40%. For example, the observed success rate may be .06. In some cases, the vaccine may be administered to a group of 22 subjects such that the probability of an observed success rate in excess of 50% may be greater than 0.7 if the true success rate is 70%.

[0450] For example, use of a group of 22 patients may demonstrate, with at least 80% confidence, that an estimated immunologic response rate may be within at least .14 of the true response rate. In some cases, if half of the subjects elicit an immunogenic response, then the power may be at least 91% for statistical significance (at the two-sided level of 0.05) and the difference in continuous measures if the true effect size is 1.5. For example, Spearman's correlation coefficient may be used to estimate the correlation between two continuous measures. In some cases, the data may estimate an expected response rate in a larger population.

[0451] For another example, 25% of subjects may elicit a good response to the vaccine. In some cases, 25% of subjects with a good response may be the baseline to evaluate the effectiveness of a vaccine. In some cases, the true response rate may be 60% where use of a group of 22 subjects may provide a power of 97% for a statistically significant response rate compared to the fixed rate of 25% (one-sided level of significance of 0.05).

Applications

[0452] The compositions described herein may be administered to a subject in need of a vaccine for preventing breast cancer or ovarian cancer. In some instances, the cancer is breast cancer. In some cases, the cancer is ovarian cancer. The methods described herein may be combined with the compositions described herein for administration to a subject in need of a vaccine for preventing breast cancer or ovarian cancer. In some cases, administration of the vaccine may initiate the elimination of cells as the cells begin to express increased levels proteins that are components of the vaccine. In some cases, the proteins may be stem cell/EMT associated. For example, increased levels of proteins may be expressed during the malignant transformation of normal cells into cancer cells, such as for example breast cancer cells or ovarian cancer cells. In some instances, elimination of the breast cancer or ovarian cancer cells before the disease becomes clinically evident may prevent the occurrence of cancer in a subject. In some cases, elimination of the breast or ovarian cancer cells before the disease becomes clinically evident may prevent the occurrence of breast or ovarian cancer in a subject.

[0453] The vaccine for preventing breast cancer or ovarian cancer may be administered in a single dose administered to the subject, the dose of at least 10 μ g, 15 μ g, 20 μ g, 25 μ g, 30 μ g, 35 μ g, 40 μ g, 45 μ g, 50 μ g, 55 μ g, 60 μ g, 65 μ g, 70 μ g, 75 μ g, 80 μ g, 85 μ g, 86 μ g, 87 μ g, 88 μ g, 89 μ g, 90 μ g, 91 μ g, 92 μ g, 93 μ g, 4 μ g, 95 μ g, 96 μ g, 97 μ g, 98 μ g, 99 μ g, 100 μ g, 101 μ g, 102 μ g, 103 μ g, 104 μ g, 105 μ g, 106 μ g, 107 μ g, 108 μ g, 109 μ g, 110 μ g, 111 μ g, 112 μ g, 113 μ g, 114 μ g, 115 μ g, 116 μ g, 117 μ g, 118 μ g, 119 μ g, 120 μ g, 125 μ g, 130 μ g, 135 μ g, 140 μ g, 145 μ g, 150 μ g, 155 μ g, 160 μ g, 165 μ g, 170 μ g, 175 μ g, 180 μ g, 185 μ g, 190 μ g, 195 μ g, or at least 200 μ g/plasmid. In an exemplary case, the single dose administered to the subject is 100 μ g/plasmid.

[0454] The vaccine for preventing breast cancer or ovarian cancer may be administered in more than one dose administered to the subject, each dose of at least 10 μ g, 15 μ g, 20 μ g, 25 μ g, 30 μ g, 35 μ g, 40 μ g, 45 μ g, 50 μ g, 55 μ g, 60 μ g, 65 μ g, 70 μ g, 75 μ g, 80 μ g, 85 μ g, 86 μ g, 87 μ g, 88 μ g, 89 μ g, 90 μ g, 91 μ g, 92 μ g, 93 μ g, 4 μ g, 95 μ g, 96 μ g, 97 μ g, 98 μ g, 99 μ g, 100 μ g, 101 μ g, 102 μ g, 103 μ g, 104 μ g, 105 μ g, 106 μ g, 107 μ g, 108 μ g, 109 μ g, 110 μ g, 111 μ g, 112 μ g, 113 μ g, 114 μ g, 115 μ g, 116 μ g, 117 μ g, 118 μ g, 119 μ g, 120 μ g, 125 μ g, 130 μ g, 135 μ g, 140 μ g, 145 μ g, 150 μ g, 155 μ g, 160 μ g, 165 μ g, 170 μ g, 175 μ g, 180 μ g, 185 μ g, 190 μ g, 195 μ g, or at least 200 μ g/plasmid. In some cases, each dose administered to the subject may be greater than or less than the previous dose administered to the subject.

[0455] The compositions described herein may be administered to a subject in need thereof of a vaccine for treating breast cancer or ovarian cancer. The methods described herein may be combined with the compositions described herein for administration to a subject in need thereof of a vaccine for treating breast cancer or ovarian cancer. In some cases, administration of the vaccine may initiate the elimination of cells that express increased levels proteins that are components of the vaccine. In some cases, the proteins may be stem cell/EMT associated. For example, increased levels of proteins may be expressed by cancer cells, such as for example breast cancer cells or ovarian cancer cells. In some cases, elimination of cancer cells after the disease becomes clinically evident may prevent the persistence and propagation of breast cancer or ovarian cancer in a subject. In some cases, elimination of the breast or ovarian cancer cells after the disease becomes clinically evident may prevent the persistence and propagation of breast or ovarian cancer in a subject.

Subjects

[0456] The compositions described herein may be administered to a subject in need of a vaccine for breast cancer or ovarian cancer. The methods described herein may be combined with the compositions described herein for administration to a subject in need of a vaccine for breast cancer or ovarian cancer. In some cases, the vaccine may be administered to a subject who does not have breast cancer or ovarian cancer. In other cases, the vaccine may be administered to a subject who has had breast cancer or ovarian cancer. In yet other cases, the vaccine may be administered to a subject who has breast cancer or ovarian cancer.

[0457] In some cases, the subject may be a healthy individual. In some cases, the subject may be an individual with breast cancer or ovarian cancer. For example, the individual may be a patient. In some cases, the subject is a human individual. In other cases, the subject is a non-human individual. For example, non-human individuals may be a non-human primate, including such as chimpanzees and other apes and monkey species; farm animals such as cattle, sheep, pigs, goats and horses; domestic mammals such as dogs and cats; laboratory animals including rodents such as mice, rats and guinea pigs; birds, including domestic, wild and game birds such as chickens, turkeys and other gallinaceous birds, ducks, geese, and the like. The term "subject" does not denote a particular age. Thus, both adult and newborn individuals are intended to be covered.

Breast Cancer and Ovarian Cancer

[0458] Disclosed herein, in certain embodiments, is a vaccine for treating a breast cancer or an ovarian cancer. In some instances, the breast cancer is a relapsed or refractory breast cancer. In some cases, the ovarian cancer is a relapsed or refractory ovarian cancer. In some instances, the breast cancer is a metastasized breast cancer. In some instances, the ovarian cancer is a metastasized ovarian cancer.

Types of Breast Cancer

[0459] The compositions described herein may be administered to a subject in need of a vaccine for cancer, often the cancer is breast cancer. The methods described herein may be combined with the compositions described herein for administration to a subject in need of a vaccine for cancer. Often, the breast cancer may be any type of breast cancer, for example, the breast cancer may be ductal carcinoma in situ, lobular carcinoma in situ, invasive ductal carcinoma, infiltrating ductal carcinoma, inflammatory breast cancer, triple-negative breast cancer, paget disease of the nipple, phyllodes tumor, angiosarcoma, adenoid cystic carcinoma, adenocystic carcinoma, low-grade adenosquamous carcinoma, medullary carcinoma, mucinous carcinoma, colloid carcinoma, papillary carcinoma, tubular carcinoma, metaplastic carcinoma, spindle cell carcinoma, squamous carcinoma, micropapillary carcinoma and mixed carcinoma.

[0460] In some cases, the subject may be classified with a particular grade of breast cancer. For example, the grades of breast cancer may be Grade X, Grade 1, Grade 2, Grade 3 or Grade 4. For another example, breast cancers may be indicated by a category of tubule formation, nuclear grade and/or the mitotic rate. Each category may also be assigned a specific score between one and three. In some cases, the subject may have a particular stage of breast cancer. In some cases, the stages may be assigned based on the tumor, the regional lymph nodes and/or distant metastasis. For example, the stages assigned to the tumor may be TX, T0, Tis, T1, T2, T3 or T4. For example, the stages assigned to the regional lymph nodes may be NX, N0, N1, N2 or N3. For example, the stages assigned to the distant metastasis may be MX, M0 or M1. In some cases, the stages may be stage 0, stage I, stage II, stage III or stage IV. Often the breast cancer is classified as more

than one grade, or stage of cancer.

Additional Therapeutic Agents

[0461] In some instances, the breast or ovarian cancer vaccine described herein is administered to a patient in combination with an additional therapeutic agent. In some instances, the additional therapeutic agent is a chemotherapeutic agent, a steroid, an immunotherapeutic agent, a targeted therapy, or a combination thereof.

[0462] In some embodiments, the additional therapeutic agent is selected from: Adriamycin, Dactinomycin, Bleomycin, Vinblastine, Cisplatin, acivicin; aclarubicin; acodazole hydrochloride; acronine; adozelesin; aldesleukin; altretamine; ambomycin; ametantrone acetate; aminoglutethimide; amsacrine; anastrozole; anthramycin; asparaginase; asperlin; azacitidine; azetepa; azotomycin; batimastat; benzodepa; bicalutamide; bisantrene hydrochloride; bisnafide dimesylate; bizelesin; bleomycin sulfate; brequinar sodium; broprimine; busulfan; cactinomycin; calusterone; caracemide; carbetimer; carboplatin; carmustine; carubicin hydrochloride; carzelesin; cedefingol; chlorambucil; cirolemycin; cladribine; crisnatol mesylate; cyclophosphamide; cytarabine; dacarbazine; daunorubicin hydrochloride; decitabine; dexormaplatin; dezaguanine; dezaguanine mesylate; diaziquone; doxorubicin; doxorubicin hydrochloride; droloxifene; droloxifene citrate; dromostanolone propionate; duazomycin; edatrexate; eflornithine hydrochloride; elsamitrucin; enloplatin; enpromate; epipropidine; epirubicin hydrochloride; erbulozole; esorubicin hydrochloride; estramustine; estramustine phosphate sodium; etanidazole; etoposide; etoposide phosphate; etoprine; fadrozole hydrochloride; fazarabine; fenretinide; floxuridine; fludarabine phosphate; fluorouracil; flurocitabine; fosquidone; fostriecin sodium; gemcitabine; gemcitabine hydrochloride; hydroxyurea; idarubicin hydrochloride; ifosfamide; iimofosine; interleukin II (including recombinant interleukin II, or rIL2), interferon alfa-2a; interferon alfa-2b; interferon alfa-n1; interferon alfa-n3; interferon beta-1a; interferon gamma-1b; iproplatin; irinotecan hydrochloride; lanreotide acetate; letrozole; leuprolide acetate; liarozole hydrochloride; lometrexol sodium; lomustine; losoxantrone hydrochloride; masoprocol; maytansine; mechlorethamine hydrochloride; megestrol acetate; melengestrol acetate; melphalan; menogaril; mercaptopurine; methotrexate; methotrexate sodium; metoprine; meturedopa; mitindomide; mitocarcin; mitocromin; mitogillin; mitomalcin; mitomycin; mitosper; mitotane; mitoxantrone hydrochloride; mycophenolic acid; nocodazole; nogalamycin; ormaplatin; oxisuran; pegaspargase; peliomycin; pentamustine; peplomycin sulfate; perfosfamide; pipobroman; pipsulfan; piroxantrone hydrochloride; plicamycin; plomestane; porfimer sodium; porfiromycin; prednimustine; procarbazine hydrochloride; puromycin; puromycin hydrochloride; pyrazofurin; riboprine; rogletimide; safingol; safingol hydrochloride; semustine; simtrazene; sparfosate sodium; sparsomycin; spirogermanium hydrochloride; spiromustine; spiroplatin; streptonigrin; streptozocin; sulofenur; talisomycin; tecogalan sodium; tegafur; teloxantrone hydrochloride; temoporfin; teniposide; teroxirone; testolactone; thiamiprine; thioguanine; thiotepa; tiazofurin; tirapazamine; toremifene citrate; trestolone acetate; triciribine phosphate; trimetrexate; trimetrexate glucuronate; triptorelin; tubulozole hydrochloride; uracil mustard; uredepa; vapreotide; verteporfin; vinblastine sulfate; vincristine sulfate; vindesine; vindesine sulfate; vinepidine sulfate; vinglycinate sulfate; vinleurosine sulfate; vinorelbine tartrate; vinrosidine sulfate; vinzolidine sulfate; vorozole; zeniplatin; zinostatin; zorubicin hydrochloride.

[0463] In some embodiments, the additional therapeutic agent is selected from: 20-epi-1, 25 dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; aclarubicin; acylfulvene; adecypenol; adozelesin; aldesleukin; ALL-TK antagonists; altretamine; ambamustine; amidox; amifostine; aminolevulinic acid; amrubicin; amsacrine; anagrelide; anastrozole; andrographolide; angiogenesis inhibitors; antagonist D; antagonist G; antarelix; anti-dorsalizing morphogenetic protein-1; antiandrogen, prostatic carcinoma; antiestrogen; antineoplaston; antisense oligonucleotides; aphidicolin glycinate; apoptosis gene modulators; apoptosis regulators; apurinic acid; ara-CDP-DL-PTBA; arginine deaminase; asulacrine; atamestane; atrimustine; axinastatin 1; axinastatin 2; axinastatin 3; azasetron; azatoxin; azatyrosine; baccatin III derivatives; balanol; batimastat; BCR/ABL antagonists; benzochlorins; benzoylstauroporine; beta lactam derivatives; beta-alethine; betaclamycin B; betulinic acid; bFGF inhibitor; bicalutamide; bisantrene; bisaziridinylspermine; bisnafide; bistratene A; bizelesin; breflate; broprimine; budotitane; buthionine sulfoximine; calcipotriol; calphostin C; camptothecin derivatives; canarypox IL-2; capecitabine; carboxamide-amino-triazole; carboxyamidotriazole; CaRest M3; CARN 700; cartilage derived inhibitor; carzelesin; casein kinase inhibitors (ICOS); castanospermine; cecropin B; cetorelix; chlorins; chloroquinoxaline sulfonamide; cicaprost; cisporphyrin; cladribine; clomifene analogues; clotrimazole; collismycin A; collismycin B; combretastatin A4; combretastatin analogue; conagenin; crambescidin 816; crisnatol; cryptophycin 8; cryptophycin A derivatives; curacin A; cyclopentantraquinones; cycloplatin; cypemycin; cytarabine ocfosfate; cytolytic factor; cytostatin; dacliximab; decitabine; dehydrididemnin B; deslorelin; dexamethasone; dexifosfamide; dexrazoxane; dexverapamil; diaziquone; didemnin B; didox; diethylnorspermine; dihydro-5-azacytidine; 9-dioxamycin; diphenyl spiromustine; docosanol; dolasetron; doxifluridine; droloxifene; dronabinol; duocarmycin SA; ebselen; ecomustine; edelfosine; edrecolomab; eflornithine; elemene; emitefur; epirubicin; epristeride; estramustine analogue; estrogen agonists; estrogen antagonists; etanidazole; etoposide phosphate; exemestane; fadrozole; fazarabine; fenretinide; filgrastim; finasteride; flavopiridol; flezelastine; fluasterone; fludarabine; fluorodaunorubicin hydrochloride; forfenimex; formestane; fostriecin; fotemustine; gadolinium texaphyrin; gallium nitrate; galocitabine; ganirelix; gelatinase inhibitors; gemcitabine;

glutathione inhibitors; hepsulfam; heregulin; hexamethylene bisacetamide; hypericin; ibandronic acid; idarubicin; idoxifene; idramantone; ilmofofine; ilomastat; imidazoacridones; imiquimod; immunostimulant peptides; insulin-such as for example growth factor-1 receptor inhibitor; interferon agonists; interferons; interleukins; iobenguane; iododoxorubicin; ipomeanol, 4-; iroplact; irsogladine; isobengazole; isohomohalicondrin B; itasetron; jasplakinolide; kahalalide F; lamellarin-N triacetate; lanreotide; leinamycin; lenograstim; lentinan sulfate; leptolstatin; letrozole; leukemia inhibiting factor; leukocyte alpha interferon; leuprolide+estrogen+progesterone; leuprorelin; levamisole; liarozole; linear polyamine analogue; lipophilic disaccharide peptide; lipophilic platinum compounds; lissoclinamide 7; lobaplatin; lombricine; lometrexol; lonidamine; losoxantrone; lovastatin; loxoribine; lurtotecan; lutetium texaphyrin; lysofylline; lytic peptides; maitansine; mannostatin A; marimastat; masoprocol; maspin; matrilysin inhibitors; matrix metalloproteinase inhibitors; menogaril; merbarone; meterelin; methioninase; metoclopramide; MIF inhibitor; mifepristone; miltefosine; mirimostim; mismatched double stranded RNA; mitoguazone; mitolactol; mitomycin analogues; mitonafide; mitotoxin fibroblast growth factor-saporin; mitoxantrone; mofarotene; molgramostim; monoclonal antibody, human chorionic gonadotrophin; monophosphoryl lipid A+myobacterium cell wall sk; mopidamol; multiple drug resistance gene inhibitor; multiple tumor suppressor 1 -based therapy; mustard anticancer agent; mycaperoxide B; mycobacterial cell wall extract; myriaporone; N-acetyldinaline; N-substituted benzamides; nafarelin; nagrestip; naloxone+pentazocine; napavin; naphterpin; nartograstim; nedaplatin; nemorubicin; neridronic acid; neutral endopeptidase; nilutamide; nisamycin; nitric oxide modulators; nitroxide antioxidant; nitrullyn; O6-benzylguanine; octreotide; okicenone; oligonucleotides; onapristone; ondansetron; ondansetron; oracin; oral cytokine inducer; ormaplatin; osaterone; oxaliplatin; oxaunomycin; palauamine; palmitoylrhizoxin; pamidronic acid; panaxytriol; panomifene; parabactin; pazelliptine; pegaspargase; peldesine; pentosan polysulfate sodium; pentostatin; pentozole; perflubron; perfosfamide; perillyl alcohol; phenazinomycin; phenylacetate; phosphatase inhibitors; picibanil; pilocarpine hydrochloride; pirarubicin; piritrexim; placetin A; placetin B; plasminogen activator inhibitor; platinum complex; platinum compounds; platinum-triamine complex; porfimer sodium; porfiromycin; prednisone; propyl bis-acridone; prostaglandin J2; proteasome inhibitors; protein A-based immune modulator; protein kinase C inhibitor; protein kinase C inhibitors, microalgal; protein tyrosine phosphatase inhibitors; purine nucleoside phosphorylase inhibitors; purpurins; pyrazoloacridine; pyridoxylated hemoglobin polyoxyethylene conjugate; raf antagonists; raltitrexed; ramosetron; ras farnesyl protein transferase inhibitors; ras inhibitors; ras-GAP inhibitor; retelliptine demethylated; rhenium Re 186 etidronate; rhizoxin; ribozymes; RII retinamide; rogletimide; rohitukine; romurtide; roquinimex; rubiginone B1; ruboxyl; safingol; saintopin; SarCNU; sarcophytol A; sargramostim; Sdi 1 mimetics; semustine; senescence derived inhibitor 1; sense oligonucleotides; signal transduction inhibitors; signal transduction modulators; single chain antigen-binding protein; sizofiran; sobuzoxane; sodium borocaptate; sodium phenylacetate; solverol; somatomedin binding protein; sonermin; sparfosic acid; spicamycin D; spiromustine; splenopentin; spongistatin 1; squalamine; stem cell inhibitor; stem-cell division inhibitors; stipiamide; stromelysin inhibitors; sulfinosine; superactive vasoactive intestinal peptide antagonist; suradista; suramin; swainsonine; synthetic glycosaminoglycans; tallimustine; tamoxifen methiodide; tauromustine; tazarotene; tecogalan sodium; tegafur; tellurapyrylium; telomerase inhibitors; temoporfin; temozolomide; teniposide; tetrachlorodecaoxide; tetrazomine; thaliblastine; thiocoraline; thrombopoietin; thrombopoietin mimetic; thymalfasin; thymopoietin receptor agonist; thymotrinan; thyroid stimulating hormone; tin ethyl etiopurpurin; tirapazamine; titanocene bichloride; topsentin; toremifene; totipotent stem cell factor; translation inhibitors; tretinoin; triacetyluridine; tricirbine; trimetrexate; triptorelin; tropisetron; turosteride; tyrosine kinase inhibitors; tyrphostins; UBC inhibitors; ubenimex; urogenital sinus-derived growth inhibitory factor; urokinase receptor antagonists; vaporeotide; variolin B; vector system, erythrocyte gene therapy; velaresol; veramine; verdins; verteporfin; vinorelbine; vinxaltine; vitaxin; vorozole; zanoterone; zeniplatin; zilascorb; and zinostatin stimalamer.

[0464] In some embodiments, the additional therapeutic agent is selected from: agents which act by arresting cells in the G2-M phases due to stabilized microtubules, e.g., Erbulozole (also known as R-55104), Dolastatin 10 (also known as DLS-10 and NSC-376128), Mivobulin isethionate (also known as CI-980), Vincristine, NSC-639829, Discodermolide (also known as NVP-XX-A-296), ABT-751 (Abbott, also known as E-7010), Altorhyrtins (such as Altorhyrtin A and Altorhyrtin C), Spongistatins (such as Spongistatin 1, Spongistatin 2, Spongistatin 3, Spongistatin 4, Spongistatin 5, Spongistatin 6, Spongistatin 7, Spongistatin 8, and Spongistatin 9), Cemadotin hydrochloride (also known as LU-103793 and NSC-D-669356), Epothilones (such as Epothilone A, Epothilone B, Epothilone C (also known as desoxyepothilone A or dEpoA), Epothilone D (also referred to as KOS-862, dEpoB, and desoxyepothilone B), Epothilone E, Epothilone F, Epothilone B N-oxide, Epothilone A N-oxide, 16-aza-epothilone B, 21-aminoepothilone B (also known as BMS-310705), 21-hydroxyepothilone D (also known as Desoxyepothilone F and dEpoF), 26-fluoroepothilone), Auristatin PE (also known as NSC-654663), Soblidotin (also known as TZT-1027), LS-4559-P (Pharmacia, also known as LS-4577), LS-4578 (Pharmacia, also known as LS-477-P), LS-4477 (Pharmacia), LS-4559 (Pharmacia), RPR-112378 (Aventis), Vincristine sulfate, DZ-3358 (Daiichi), FR-182877 (Fujisawa, also known as WS-9885B), GS-164 (Takeda), GS-198 (Takeda), KAR-2 (Hungarian Academy of Sciences), BSF-223651 (BASF, also known as ILX-651 and LU-223651), SAH-49960 (Lilly/Novartis), SDZ-268970 (Lilly/Novartis), AM-97 (Armad/Kyowa Hakko), AM-132 (Armad), AM-138 (Armad/Kyowa Hakko), IDN-5005 (Indena), Cryptophycin 52 (also known as LY-355703), AC-7739 (Ajinomoto, also known as AVE-8063A and CS-39.HCl), AC-7700 (Ajinomoto, also known as AVE-8062, AVE-8062A, CS-39-L-Ser.HCl, and RPR-258062A), Vitilevuamide, Tubulysin A, Canadensol, Centaureidin (also known as NSC-106969), T-138067 (Tularik, also known as T-67, TL-138067 and TI-138067), COBRA-1 (Parker Hughes Institute, also known as DDE-261 and WHI-261), H10 (Kansas State University), H16 (Kansas State University), Oncocidin A1 (also known as BTO-956 and DIME), DDE-313 (Parker

Hughes Institute), Fijianolide B, Laulimalide, SPA-2 (Parker Hughes Institute), SPA-1 (Parker Hughes Institute, also known as SPIKET-P), 3-IAABU (Cytoskeleton/Mt. Sinai School of Medicine, also known as MF-569), Narcosine (also known as NSC-5366), Nascapine, D-24851 (Asta Medica), A-105972 (Abbott), Hemiasterlin, 3-BAABU (Cytoskeleton/Mt. Sinai School of Medicine, also known as MF-191), TMPN (Arizona State University), Vanadocene acetylacetonate, T-138026 (Tularik), Monsatrol, Inanocine (also known as NSC-698666), 3-1AABE (Cytoskeleton/Mt. Sinai School of Medicine), A-204197 (Abbott), T-607 (Tularik, also known as T-900607), RPR- 115781 (Aventis), Eleutherobins (such as Desmethyleleutherobin, Desaetyeleutherobin, Isoeleutherobin A, and Z-Eleutherobin), Caribaeoside, Caribaeolin, Halichondrin B, D-64131 (Asta Medica), D-68144 (Asta Medica), Diazonamide A, A-293620 (Abbott), NPI-2350 (Nereus), Taccalonolide A, TUB-245 (Aventis), A-259754 (Abbott), Diozostatin, (-)-Phenylahistin (also known as NSCL-96F037), D-68838 (Asta Medica), D-68836 (Asta Medica), Myoseverin B, D-43411 (Zentaris, also known as D-81862), A-289099 (Abbott), A-318315 (Abbott), HTI-286 (also known as SPA-110, trifluoroacetate salt) (Wyeth), D-82317 (Zentaris), D-82318 (Zentaris), SC-12983 (NCI), Resverastatin phosphate sodium, BPR-OY-007 (National Health Research Institutes), and SSR-250411 (Sanofi).

[0465] In some embodiments, the additional therapeutic agent is selected from: agents that affect the tumor micro-environment such as cellular signaling network (e.g. phosphatidylinositol 3-kinase (PI3K) signaling pathway, signaling from the B-cell receptor and the IgE receptor). Examples of agents that affect the tumor micro-environment include PI3K signaling inhibitor, syc kinase inhibitor, Protein Kinase Inhibitors such as for example dasatinib, erlotinib, everolimus, gefitinib, imatinib, lapatinib, nilotinib, pazopanib, sorafenib, sunitinib, temsirolimus; Other Angiogenesis Inhibitors such as for example GT-111, JI-101, R1530; Other Kinase Inhibitors such as for example AC220, AC480, ACE-041, AMG 900, AP24534, Arry-614, AT7519, AT9283, AV-951, axitinib, AZD1152, AZD7762, AZD8055, AZD8931, bafetinib, BAY 73-4506, BGJ398, BGT226, BI 811283, BI6727, BIBF 1120, BIBW 2992, BMS-690154, BMS-777607, BMS-863233, BSK-461364, CAL-101, CEP-11981, CYC116, DCC-2036, dinaciclib, dovitinib lactate, E7050, EMD 1214063, ENMD-2076, fostamatinib disodium, GSK2256098, GSK690693, INCB18424, INNO-406, JNJ-26483327, JX-594, KX2-391, linifanib, LY2603618, MGCD265, MK-0457, MK1496, MLN8054, MLN8237, MP470, NMS-1116354, NMS-1286937, ON 01919.Na, OSI-027, OSI-930, Btk inhibitor, PF-00562271, PF-02341066, PF-03814735, PF-04217903, PF-04554878, PF-04691502, PF-3758309, PHA-739358, PLC3397, progenipoiectin, R547, R763, ramucirumab, regorafenib, RO5185426, SAR103168, SCH 727965, SGI-1176, SGX523, SNS-314, TAK-593, TAK-901, TKI258, TLN-232, TTP607, XL147, XL228, XL281RO5126766, XL418, XL765.

[0466] In some embodiments, the additional therapeutic agent is selected from: inhibitors of mitogen-activated protein kinase signaling, e.g., U0126, PD98059, PD184352, PD0325901, ARRY-142886, SB239063, SP600125, BAY 43-9006, wortmannin, or LY294002; Syk inhibitors; mTOR inhibitors; and antibodies (e.g., rituxan).

[0467] In some embodiments, the additional therapeutic agent is selected from: interferons, interleukins, Tumor Necrosis Factors, Growth Factors, or the like.

[0468] In some embodiments, the additional therapeutic agent is selected from: anacetim, filgrastim, lenograstim, molgramostim, pegfilgrastim, sargramostim; Interferons such as for example interferon alfa natural, interferon alfa-2a, interferon alfa-2b, interferon alfacon-1, interferon alfa-nl, interferon beta natural, interferon beta-la, interferon beta-lb, interferon gamma, peginterferon alfa-2a, peginterferon alfa-2b; Interleukins such as for example aldesleukin, oprelvekin; Other Immunostimulants such as for example BCG vaccine, glatiramer acetate, histamine dihydrochloride, immunocyanin, lentinan, melanoma vaccine, mifamurtide, pegademase, pidotimod, plerixafor, poly I:C, poly ICLC, roquinimex, tasonermin, thymopentin; Immunosuppressants such as for example abatacept, abetimus, alefacept, antilymphocyte immunoglobulin (horse), antithymocyte immunoglobulin (rabbit), eculizumab, efalizumab, everolimus, gusperimus, leflunomide, muromab-CD3, mycophenolic acid, natalizumab, sirolimus; TNF alpha Inhibitors such as for example adalimumab, afelimomab, certolizumab pegol, etanercept, golimumab, infliximab; Interleukin Inhibitors such as for example anakinra, basiliximab, canakinumab, daclizumab, mepolizumab, rilonacept, tocilizumab, ustekinumab; Calcineurin Inhibitors such as for example ciclosporin, tacrolimus; Other Immunosuppressants such as for example azathioprine, lenalidomide, methotrexate, thalidomide.

[0469] In some embodiments, the additional therapeutic agent is selected from: Adalimumab, Alemtuzumab, Basiliximab, Bevacizumab, Cetuximab, Certolizumab pegol, Daclizumab, Eculizumab, Efalizumab, Gemtuzumab, Ibritumomab tiuxetan, Infliximab, Muromonab-CD3, Natalizumab, Panitumumab, Ranibizumab, Rituximab, Tositumomab, Trastuzumab, or the like, or a combination thereof.

[0470] In some embodiments, the additional therapeutic agent is selected from: Monoclonal Antibodies such as for example alemtuzumab, bevacizumab, catumaxomab, cetuximab, edrecolomab, gemtuzumab, panitumumab, rituximab, trastuzumab; Immunosuppressants, eculizumab, efalizumab, muromab-CD3, natalizumab; TNF alpha Inhibitors such as for example adalimumab, afelimomab, certolizumab pegol, golimumab, infliximab; Interleukin Inhibitors, basiliximab, canakinumab, daclizumab, mepolizumab, tocilizumab, ustekinumab; Radiopharmaceuticals, ibritumomab tiuxetan, tositumomab; Others Monoclonal Antibodies such as for example abagovomab, adecatumumab, alemtuzumab, anti-CD30 monoclonal antibody

Xmab2513, anti-MET monoclonal antibody MetMab, apolizumab, apomab, arcitumomab, basiliximab, bispecific antibody 2B1, blinatumomab, brentuximab vedotin, capromab pendetide, cixutumumab, claudiximab, conatumumab, dacetuzumab, denosumab, eculizumab, epratuzumab, epratuzumab, ertumaxomab, etaracizumab, figitumumab, fresolimumab, galiximab, ganitumab, gemtuzumab ozogamicin, glembatumumab, ibritumomab, inotuzumab ozogamicin, ipilimumab, lexatumumab, lintuzumab, lintuzumab, lucatumumab, mapatumumab, matuzumab, milatuzumab, monoclonal antibody CC49, necitumumab, nimotuzumab, oregovomab, pertuzumab, ramacurimab, ranibizumab, siplizumab, sonepcizumab, tanezumab, tositumomab, trastuzumab, tremelimumab, tucotuzumab celmoleukin, veltuzumab, visilizumab, volociximab, zalutumumab.

[0471] In some embodiments, the additional therapeutic agent is selected from: Nitrogen Mustards such as for example, bendamustine, chlorambucil, chlormethine, cyclophosphamide, ifosfamide, melphalan, prednimustine, trofosfamide; Alkyl Sulfonates like busulfan, mannosulfan, treosulfan; Ethylene Imines like carboquone, thiotepa, triaziquone; Nitrosoureas like carmustine, fotemustine, lomustine, nimustine, ranimustine, semustine, streptozocin; Epoxides such as for example, etoglucid; Other Alkylating Agents such as for example dacarbazine, mitobronitol, pipobroman, temozolomide; Folic Acid Analogues such as for example methotrexate, perimetrexed, pralatrexate, raltitrexed; Purine Analogs such as for example cladribine, clofarabine, fludarabine, mercaptopurine, nelarabine, tioguanine; Pyrimidine Analogs such as for example azacitidine, capecitabine, carmofur, cytarabine, decitabine, fluorouracil, gemcitabine, tegafur; Vinca Alkaloids such as for example vinblastine, vincristine, vindesine, vinflunine, vinorelbine; Podophyllotoxin Derivatives such as for example etoposide, teniposide; Colchicine derivatives such as for example demecolcine; Taxanes such as for example docetaxel, paclitaxel, paclitaxel poliglumex; Other Plant Alkaloids and Natural Products such as for example trabectedin; Actinomycines such as for example dactinomycin; Anthracyclines such as for example aclarubicin, daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, pirarubicin, valrubicin, zorubincin; Other Cytotoxic Antibiotics such as for example bleomycin, ixabepilone, mitomycin, plicamycin; Platinum Compounds such as for example carboplatin, cisplatin, oxaliplatin, satraplatin; Methylhydrazines such as for example procarbazine; Sensitizers such as for example aminolevulinic acid, efaproxiral, methyl aminolevulinate, porfimer sodium, temoporfin; Protein Kinase Inhibitors such as for example dasatinib, erlotinib, everolimus, gefitinib, imatinib, lapatinib, nilotinib, pazopanib, sorafenib, sunitinib, temsirolimus; Other Antineoplastic Agents such as for example alitretinoin, altretamine, amzacrine, anagrelide, arsenic trioxide, asparaginase, bexarotene, bortezomib, celecoxib, denileukin diftitox, estramustine, hydroxycarbamide, irinotecan, lonidamine, masoprocol, miltefosine, mitoguazone, mitotane, oblimersen, pegaspargase, pentostatin, romidepsin, sitimagene ceradenovec, tiazofurine, topotecan, tretinoin, vorinostat; Estrogens such as for example diethylstilbenol, ethinylestradiol, fosfestrol, polyestradiol phosphate; Progestogens such as for example gestonorone, medroxyprogesterone, megestrol; Gonadotropin Releasing Hormone Analogs such as for example buserelin, goserelin, leuprorelin, triptorelin; Anti-Estrogens such as for example fulvestrant, tamoxifen, toremifene; Anti-Androgens such as for example bicalutamide, flutamide, nilutamide, , Enzyme Inhibitors, aminoglutethimide, anastrozole, exemestane, formestane, letrozole, vorozole; Other Hormone Antagonists such as for example abarelix, degarelix; Immunostimulants such as for example histamine dihydrochloride, mifamurtide, pidotimod, plerixafor, roquinimex, thymopentin; Immunosuppressants such as for example everolimus, gusperimus, leflunomide, mycophenolic acid, sirolimus; Calcineurin Inhibitors such as for example ciclosporin, tacrolimus; Other Immunosuppressants such as for example azathioprine, lenalidomide, methotrexate, thalidomide; and Radiopharmaceuticals such as for example, iobenguane.

[0472] In some embodiments, the additional therapeutic agent is selected from a checkpoint inhibitor. Exemplary checkpoint inhibitors include:

PD-L1 inhibitors such as Genentech's MPDL3280A (RG7446), Anti-mouse PD-L1 antibody Clone 10F.9G2 (Cat # BE0101) from BioXcell, anti-PD-L1 monoclonal antibody MDX-1105 (BMS-936559) and BMS-936559 from Bristol-Meyer's Squibb, MSB0010718C, mouse anti-PD-L1 Clone 29E.2A3, and AstraZeneca's MEDI4736;

PD-L2 inhibitors such as GlaxoSmithKline's AMP-224 (Amplimmune), and rHlgM12B7;

PD-1 inhibitors such as anti-mouse PD-1 antibody Clone J43 (Cat # BE0033-2) from BioXcell, anti-mouse PD-1 antibody Clone RMP1-14 (Cat # BE0146) from BioXcell, mouse anti-PD-1 antibody Clone EH12, Merck's MK-3475 anti-mouse PD-1 antibody (Keytruda, pembrolizumab, lambrolizumab), AnaptysBio's anti-PD-1 antibody known as ANB011, antibody MDX-1 106 (ONO-4538), Bristol-Myers Squibb's human IgG4 monoclonal antibody nivolumab (Opdivo®, BMS-936558, MDX1106), AstraZeneca's AMP-514 and AMP-224, and Pidilizumab (CT-011) from CureTech Ltd;

CTLA-4 inhibitors such as Bristol Meyers Squibb's anti-CTLA-4 antibody ipilimumab (also known as Yervoy®, MDX-010, BMS-734016 and MDX-101), anti-CTLA4 Antibody, clone 9H10 from Millipore, Pfizer's tremelimumab (CP-675,206, ticilimumab), and anti-CTLA4 antibody clone BNI3 from Abcam;

LAG3 inhibitors such as anti-Lag-3 antibody clone eBioC9B7W (C9B7W) from eBioscience, anti-Lag3 antibody LS-B2237 from LifeSpan Biosciences, IMP321 (ImmuFact) from Immutep, anti-Lag3 antibody BMS-986016, and the LAG-3 chimeric antibody A9H12;

B7-H3 inhibitors such as MGA271;

KIR inhibitors such as Lirilumab (IPH2101);

CD137 inhibitors such as urelumab (BMS-663513, Bristol-Myers Squibb), PF-05082566 (anti-4-1BB, PF-2566, Pfizer), or XmAb-5592 (Xencor);

PS inhibitors such as Baviximab;

and inhibitors such as an antibody or fragments (e.g., a monoclonal antibody, a human, humanized, or chimeric antibody) thereof, RNAi molecules, or small molecules to TIM3, CD52, CD30, CD20, CD33, CD27, OX40, GITR, ICOS, BTLA (CD272), CD160, 2B4, LAIR1, TIGHT, LIGHT, DR3, CD226, CD2, or SLAM.

Samples

[0473] A sample for analysis of the immunogenicity, safety and/or toxicity may be isolated from an individual. In some cases, the sample may be selected from the group consisting of: whole blood, fractionated blood, serum, plasma, sweat, tears, ear flow, sputum, lymph, bone marrow suspension, lymph, urine, saliva, semen, vaginal flow, feces, transcervical lavage, cerebrospinal fluid, brain fluid, ascites, breast milk, vitreous humor, aqueous humor, sebum, endolymph, peritoneal fluid, pleural fluid, cerumen, epicardial fluid, and secretions of the respiratory, intestinal and genitourinary tracts. In some cases, the sample may be tissue, often a biopsy sample. For example, the biopsy may contain skin tissue, breast tissue, glandular tissue, skeletal muscle tissue and/or adipose tissue.

Kits

[0474] Disclosed herein are kits and articles of manufacture for use with one or more methods described herein. The kits can contain one or more of the polypeptides and/or one or more of the nucleic acid molecules described herein, such as the polypeptides and nucleic acid molecules identified as SEQ ID NOs: 1-91, or polypeptides and/or nucleic acid molecules having a sequence at least 40%, 50%, 60%, 70%, 80%, 90%, 95%, or more sequence homology with a polypeptide or nucleic acid molecule selected from the group consisting of SEQ ID NOs: 1-91. The kits can also contain nucleic acids that encode one or more of the polypeptides described herein. The kits can further contain adjuvants, reagents, and buffers necessary for the makeup and delivery of the vaccines.

[0475] The kits can also include a carrier, package, or container that is compartmentalized to receive one or more containers such as vials, tubes, and the like, each of the container(s) comprising one of the separate elements, such as the polypeptides and adjuvants, to be used in a method described herein. Suitable containers include, for example, bottles, vials, syringes, and test tubes. The containers can be formed from a variety of materials such as glass or plastic. The articles of manufacture disclosed herein contain packaging materials. Examples of pharmaceutical packaging materials include, but are not limited to, blister packs, bottles, tubes, bags, containers, bottles, and any packaging material suitable for a selected formulation and intended mode of administration and treatment.

[0476] A kit typically includes labels listing contents and/or instructions for use, and package inserts with instructions for use. A set of instructions will also typically be included.

EXAMPLES

[0477] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention.

EXAMPLE 1

Identification of Breast Cancer Antigens and Determination of Epitopes that Elicit a Th1 CD4+ T-Cell Response

[0478] An antibody analysis has been performed using 224 individuals' sera. One hundred and twenty four Stage I/II breast cancer (BrCA) patients; 78 ER+ (63%), 31 HER2+ (25%), and 15 TNBC (12%), were evaluated for antibody responses against each candidate protein. The control population consisted of 100 age-matched women. The candidate proteins analyzed for immunogenicity as exemplified in the FIG.s described below using mouse models. Additionally, candidate proteins analyzed for immunogenicity are listed in Figures 19 and 23.

[0479] Indirect ELISA assays using recombinant proteins. Recombinant proteins were available for all proposed candidate antigens. Subject sera were analyzed at titrations of 1:100 and 1:200 in duplicates or triplicates. Western blot analysis demonstrated that sensitivity and specificity of the ELISA assays were 70% or greater with the exception of CD105 which could not be validated by Western Blot.

[0480] Screen breast cancer cases and controls. All proteins tested were immunogenic, i.e., there was at least one individual analyzed who demonstrated detectable IgG antibody immunity directed against the specific antigen that could be documented by western blot with appropriate specificity controls (example for CDH3 in Fig. 3). Antibody responses could be identified in both volunteer controls as well as cancer patients. To describe the incidence of immunity to a particular antigen, the mean ug/ml and two standard deviations of the control population was used to determine a cutoff value above which a response was considered positive with 95% confidence. The incidence of antibody immunity for the tested antigens ranged from 2% (BrCA patients to Yb-1) to 13% (BrCA patients to CDC25b) positive. Six antigens demonstrated a greater than 2-fold difference in incidence of response between BrCA patients and donors; CDC25b, CDH3, Survivin, MDM2, SATB1, and ID1. Of note, SATB1 and ID1 responses were found in a greater number of volunteer donors as compared to cancer patients. Figure 4, Panel B shows results from the 9 antigens where there was 2-fold or less difference in incidence between BrCA patients and donors.

[0481] Statistical analysis for cancer-specificity of immune responses. Four of the antigens demonstrated statistically significant differences in immunity between cancer patients and controls using unpaired T-tests with Welch's correction. BrCA patients had a higher level of antibody immunity to CDC25B ($p=0.02$), CDH3 ($p=0.0002$), Survivin ($p=0.09$) than volunteer controls.

[0482] Identification of candidate antigens for epitope mapping. 15 immunogenic proteins associated with stem cell/EMT were identified to move forward to epitope mapping.

[0483] For example, see FIG. 28 which depicts IFN γ and IL-10 secretion by T-cells in response to epitopes from the C terminus of IGFBP-2. In particular, FIG. 28 at part (A) shows an ELISPOT for IFN γ (white) and IL-10 (black) in breast cancer patient PBMC for IGFBP-2 peptides presented as interquartile box plots with Tukey whiskers ($n=20$). Median corrected spots per well (CSPW) are indicated by the horizontal bar. At part (B), the percent of PBMC stimulated with IGFBP-2 peptides induced an IFN γ (white bars) response, an IL-10 (black bars) response, or both (gray bars) in ELISPOT.

[0484] In another example, see FIG. 29, which depicts Th1 immune response and inhibition of tumor growth to the N-terminus, but not C-terminus of IGFBP-2. (A) IFN γ ELISPOT in splenocytes from mice immunized with the indicated vaccine. The data are presented as corrected spots per well (CSPW). The horizontal bar indicates the mean CSPW $\pm$ SEM. $n=10$ mice/group; $*p<0.01$. (B) Mean tumor volume ($\text{mm}^3\pm$ SEM) from mice injected with pUMVC3 alone ($\bullet$), pUMVC3-hIGFBP2 (1-328) ($\blacksquare$), pUMVC3-hIGFBP2 (164-328) ($\blacktriangle$) or pUMVC3-hIGFBP2 (1-163) ($\circ$). $n=5$ mice/group; $**p<0.001$.

[0485] In yet another example, see FIG. 30, which depicts IGFBP-2 vaccine-induced Th2 abrogated the anti-tumor effect of IGFBP-2-specific Th1. Type II cytokines IL-4 and IL-10 (A) and Type I cytokines TNF α and IFN γ (B) secretion from T-cell lines expanded with peptides in IGFBP2 (1-163) or IGFBP2 (164-328) (mean ng/ml $\pm$ SD); $**p<0.001$, $*p<0.01$ and $\#p<0.05$. (C) Mean tumor volume ($\text{mm}^3\pm$ SEM) from mice infused with CD3+ T-cells expanded from mice vaccinated with pUMVC3-hIGFBP2 (1-163) ($\circ$), pUMVC3-hIGFBP2 (164-328) ($\blacktriangle$) or naïve T-cells ($\bullet$). $n=4$ mice/group; $*p<0.01$. (D) Mean tumor volume ($\text{mm}^3\pm$ SEM) from mice injected with pUMVC3 alone ($\bullet$), pUMVC3-hIGFBP2 (164-328) ($\blacktriangle$), pUMVC3-hIGFBP2 (1-163) ($\circ$) or pUMVC3-hIGFBP2 (1-163) + pUMVC3-hIGFBP2 (164-328) ($\blacktriangledown$). $n=5$ mice/group; $*p<0.01$. FIG. 1 Th1 and Th2 epitopes vary in functional avidity.

[0486] For another example, see FIG. 16, which depicts Western blot analysis of HIF1 α expression in a single plasmid, pHIF1 α and a plasmid encoding 5 antigens, BCMA5. 10-fold dilutions of anti-HIF α 0.1-10 $\mu\text{g}/\mu\text{L}$ were used to probe the blot after cuts

were made along the dashed lines indicated. Only one lysate-loaded lane was used per antibody titration.

EXAMPLE 2

Identification of Promiscuous High Affinity Binding Class II Epitopes Derived From Stem Cell/EMT Antigens

[0487] Archived leukapheresis from 20 BrCA patients and 20 control donors was used. The mean age of the BRCA patients was 63 (range 49-87) and the mean age of the controls was 38 (range 29-65). Of the BrCA patients 81% were Stage I or II at the time of diagnosis, 10% were of unknown stage and the remainder were Stage III.

[0488] Constructed peptides per *in silico* mapping. Class II epitopes for the first 6 immunogenic BCS/EMT proteins were predicted using an algorithm method. Briefly, protein sequences of the candidate antigens were screened for potential MHC II epitopes using 3 publically available web based algorithms. Each protein was screened across the most common 14 HLA-DR alleles. A maximum of 20 epitopes were chosen/allele based on an estimated binding affinity. Each amino acid (aa) in each predicted epitope was given a score (sum score) dependent on the number of times the aa appeared in a predicted high binding epitope. The Sum Score was multiplied by the number of alleles with epitopes that included that specific amino acid, thus, each amino acid was thus assigned a multi-score which is the product of the frequency of increased binding affinity and the promiscuity of predicted responses across a broad population range. Forty-nine peptides derived from all 6 candidate proteins, chosen based on the multi-score of each epitope, were constructed for screening. Peptides that allowed at least 25% coverage of the full length protein were selected. The median peptide coverage for the candidate proteins was 28% of the total sequence (range 26-45%).

[0489] Samples screened by IFN γ ELISPOT. FIG. 6 shows cumulative data on all donors for IFN γ responses to all peptides/antigen for representative antigens. In general, IFN γ responses were higher in volunteer donors as compared to BrCA patients and were statistically higher for survivin (BIRC5); $p < 0.001$, MDM2; $p < 0.001$, SOX-2; $p = 0.01$, and Yb-1; $p < 0.001$.

[0490] A positive response was defined as a mean value of experimental replicates statistically greater ($p < 0.05$) than the mean replicates of the no antigen wells. The percent incidence was similar across donor type with 24-38% of subjects responding to a particular antigen above the median of responses. A two-way ANOVA to detect differences between experimental groups or peptides attributes 2.82% of the variation in response to donor type ($p = 0.0265$) and 71.33% of the variation to the specific peptide tested ($p = 0.003$) for IFN γ responses. Although donor type was weakly significant, the attributable variation is small.

[0491] Identification and screening of peptides from each of the candidate antigens. Four epitopes were identified from each of the candidate antigens for IFN γ responses.

EXAMPLE 3

Evaluation of Stem Cell/EMT Antigen-Derived Epitopes Preferentially Elicit T-Cells that Secrete IFN γ or IL-10 and Selection of Peptides as Candidate Vaccine Epitopes with Low Immune Suppressive Potential

[0492] FIG. 7 shows cumulative data on all donors for IL-10 responses to all peptides/antigen for representative antigens. In general, IL-10 responses were of lower magnitude than IFN γ responses and volunteer donors demonstrated statistically significant higher median responses for most antigens- survivin (birc5); $p < 0.0001$, CDC25b; $p = 0.044$, CDH3; $p = 0.037$, FOXQ1; $p = 0.0014$, HIF1 α ; $p = 0.017$, MDM2; $p = 0.0039$, SOX-2; $p = 0.044$, and Yb-1; $p = 0.0007$.

[0493] Similar to IFN γ data, for IL-10, the donor type accounts for less than 0.01% of the variation between antigens ($p = 0.911$) while the individual peptide accounts for 90.51% ($p < 0.0001$).

[0494] Identification of peptides that induced antigen specific IFN γ secreting T-cells compared to IL-10 secreting T-cells. A matrix scoring system that prioritized antigens for *in vivo* evaluation of extended epitopes that demonstrated IFN γ specific activity in the absence of IL-10 activity across the populations was used. Extended epitopes were superior to shorter class II epitopes in that the longer epitopes elicited a diverse immune response consisting of both T and B-cells and anti-tumor responses were dependent on both CD4 and CD8 T-cells. Regions in a candidate antigen that contained multiple epitopes that

preferentially induced a greater magnitude and incidence of IFN γ responses and little or no IL-10 inducing activity were identified. A ratio (IFN γ /IL-10 activity ratio) of the incidence X magnitude of antigen specific IFN γ induction/ the incidence X magnitude of antigen specific IL-10 induction was evaluated (see FIG. 10 and 11).

[0495] For example, FIG. 10 depicts a higher magnitude and incidence of IFN γ predominance. IFN γ /IL-10 activity ratios for selected antigens. IFN γ /IL-10 ratio, defined as the mean cSPW x incidence per peptide, shown by donor type. IFN γ cSPW x incidence shown on the positive y-axis for volunteer donors, shown in white bars, and cancer donors, shown in white bars with black pattern. IL-10 cSPW x incidence shown on the negative y-axis for volunteer donors, shown in black bars, and cancer donors, shown in black bars with white pattern. (A) CDH3, (B) HIF1 α , (C) survivin, and (D) FOXQ1.

[0496] For example, FIG. 11, shows the lower magnitude and incidence IFN γ predominance. IFN γ /IL-10 activity ratios for selected antigens. IFN γ /IL-10 ratio, defined as the mean cSPW x incidence per peptide, shown by donor type. IFN γ cSPW x incidence shown on the positive y-axis for volunteer donors, shown in white bars, and cancer donors, shown in white bars with black pattern. IL-10 cSPW x incidence shown on the negative y-axis for volunteer donors, shown in black bars, and cancer donors, shown in black bars with white pattern. (A) CDH3, (B) HIF1 α , (C) survivin, and (D) FOXQ1.

[0497] The evaluated antigens were categorized into 4 major groups based on the IFN γ /IL-10 activity ratio. The first group, exemplified by CDH3 (FIG. 10) displayed a high incidence/magnitude IFN γ response with very little IL-10 activity. This pattern indicated a top tier antigen and included CDH3, SOX2, MDM2, and Yb-1. The second tier antigens demonstrated a similar predominant IFN γ response with minimal to no IL-10 induction in regions of selected extended epitopes, however the magnitude of the immune response was greater than a log lower than the top tier candidates. FIG. 11, HIF1 α , exemplifies This category which also includes CD105, CDC25B, and SATB1. Vaccine candidates were derived from these categories (see FIG. 10 and 11).

[0498] The other two groups had characteristics which were much less desirable for a vaccine immunogen. Although there are epitopes that stimulate a high magnitude and incidence IFN γ response, these sequences equally induce high magnitude IL-10 immunity at an equal incidence in tested individuals. Antigens such as c-met, IGF-1R, PRL3, and SIX1 are grouped into this category. Finally, some candidate antigens were not immunogenic as demonstrated by both a low incidence as well as low magnitude of any immune response, as shown in Figure 19 for FOXQ1. ID1 and SNAIL also were associated with very low incidence and magnitude of immune response. Immunogenic and inducing high magnitude and incidence IL-10 responses or weakly immunogenic, these latter two categories of antigens will be excluded from further consideration for the final vaccine formulation. In FIG. 9, a list of extended epitopes based on IFN γ /IL-10 activity ratio is shown. See also FIGS. 17-20.

EXAMPLE 4

Identification of the Response of Peptide Specific Th1 Cells to Protein Presented on Endogenous APC

[0499] T-cell lines generated against candidate epitopes. PBMC derived from 3 donors who have demonstrated positive responses in the ELISPOT assay were stimulated with 10ug/ml of the antigenic peptide. IL-12 (10ng/ml) and IL-2 (10u/ml) were added into the culture on Day 5. The peptide stimulation and cytokine addition was repeated twice at 7-10 day intervals. The cultures were subsequently expanded with CD3/CD28 beads. IL-2 (30u/ml) was added into the culture every 2-3 days for 10-11 days. The established peptide specific T-cell lines were then evaluated using a 3-day IFN γ ELISPOT assay. The cultured T-cells were stimulated with different concentrations of the peptide and commercially available recombinant protein loaded on autologous APC. Irrelevant peptides and proteins were used as negative controls. The response to peptide and protein antigens which was significantly ($p < 0.05$) increased compared with no antigen control, in at least one donor, was defined as positive response. MHC II and MHC I blocking antibodies (10 μ g/ml) were added into some of the antigen stimulated wells to validate whether the epitope was MHC restricted. In addition, a portion of the T-cells were stained with CD3 FITC, CD4 PE-Cy7, CD45RO APC, and CD62L PE or CCR7 PE to evaluate the central memory cell population in the T-cell lines as compared with the cells before antigen stimulation (PBMC).

[0500] T-cell lines screened against positive and negative controls for specificity to both peptide and recombinant protein. FIG. 29 shows validation data for HIF1 α peptide p60-82 as a representative example. A HIF1 α p60-82 specific T-cell line responded to the peptide and recombinant HIF1 α protein presented on endogenous APC. Both the peptide (10ug/ml and 50 ug/ml) and protein (1ug/ml) significantly stimulated IFN γ response from the peptide specific T-cell line. Irrelevant peptide (HIV p52-68) and protein (CD105) did not (FIG. 15A). MHC II antibody significantly inhibited both peptide and protein induced IFN γ responses, but MHC I antibody did not (FIG. 15A). The CD45RO+CD62L+CD4+ central memory cells proliferated in the

cultured T-cell line (73%) as compared to the basal level in PBMC before culture (9%).

[0501] For example, see FIG. 8, which shows peptides in extended sequences validate as native epitopes. CD105 extended epitope (52aa) QNGTWPREVLLVLSVNS SVFLHL QALGI PLHLAYNSSLVTFQEPPGVNTTEL (SEQ ID NO: 1) (one of 2 epitopes in the sequence).

[0502] Similarly, validated peptides were identified and derived from CD105, SATB1, CDH3, SOX2, YB1, and MDM2. Of the peptides validated, all peptide specific T-cell lines demonstrated statistically positive peptide responses. MHC II antibody inhibited more than 70% of the peptide specific responses in 75% of peptide specific lines evaluated, and MHC I antibody inhibited more than 70% of the peptide responses in 20% of the lines. MHC II antibody inhibited >70% of the protein specific responses among all the positive protein responders (90%). Central memory T-cell populations were significantly increased after culture.

[0503] For the 6 antigens in the top and second tier groups, CDH3, SOX2, MDM2, YB1, HIF1 α , and CD105, areas of extended epitopes suitable for vaccination with high to moderately high IFN γ ratio and low to minimal IL-10 ratio were identified. Each sequence encompassed 2 or more shorter (15-22-aa) validated Class II epitopes. The extended sequences range from 32-aa to 90-aa in length (see Table 6).

[0504] Linked together, the sequences derived from CDH3, Yb-1, MDM2, SOX2, and CD105, encode a unique fusion protein termed "STEMVAC" (see Supplemental Table 5).

[0505] Identification of candidate epitopes for inclusion in a multi-antigen vaccine from each of the candidate antigens. Five extended epitopes were derived from 5 of the 15 candidate antigens suitable for a vaccine that preferentially induced IFN γ secretion with little Th2 (IL-10) were identified. These sequences were combined into a unique fusion protein, STEMVAC, which is the basis of a breast cancer vaccine.

EXAMPLE 5

Construction of a Multiantigen Th1 Polyepitope Plasmid Based Vaccine Targeting Stem Cell/EMT Antigens and Determination of Safety and Immunogenicity

[0506] Determination of immunogenicity and effectiveness of plasmid based vaccine constructs containing either or both short Th epitopes or extended Th epitopes using the TgMMTVneu mouse model with the IGF-1R antigen. In order to directly compare the ability of the short and extended epitope plasmid vaccines to control tumor growth, a syngeneic tumor implant model was employed. Mice (TgMMTVneu) were separated into 4 vaccination groups (pIGF-IRexep, pIGF-IRshep, vector, and IGF-IR peptides) and implanted with syngeneic breast cancer cells (MMC) 7 days after the 3rd vaccination. Dosages were as stated above. The ability of MMC cells to form a tumor, and the tumor growth rate was measured. The IGF-IR peptide vaccine, the short epitope plasmid vaccine, and the extended epitope plasmid vaccine all significantly controlled tumor growth compared to the group that was vaccinated with vector alone ($p < 0.0001$, from 14-31 days). The mice vaccinated with pIGF-IRexep had the slowest growing tumors, but they were not significantly different from tumor growth in animals vaccinated with pIGF-IRshep, $p > 0.05$.

[0507] For example, FIG. 2 Th2 immune responses abrogate the anti-tumor efficacy of Th1 immune responses.

[0508] For example, FIG. 21 HIF1 α peptide and plasmid vaccine immunogenicity and efficacy were determined in mice. (A) DTH responses were measured by change in ear thickness (mm) 24 hours after application of HIF1 α peptide mix in 50% DMSO. Plotted are responses of individual FVB/NJ mice from the different vaccination cohorts: Controls (both adjuvant only and vector groups, see Methods), HIF1 α Peps (peptide vaccine), and pHif1 α (plasmid vaccine). Dotted line represents 0.0mm change in ear thickness from baseline. *** $p < 0.001$ vs. controls. (B) DTH responses measured 24 hours after application of HIF1 α peptide mix in 50% DMSO. Plotted are responses of individual MMTV-C3(1)-Tag transgenic mice from the different vaccination cohorts as listed above. *** $p < 0.001$ vs. controls. (C) Efficacy of vaccines to control M6 tumor growth was assessed by measuring tumor volume (mm³) over time post-implant (days) in MMTV-C3(1)-Tag transgenic mice. Vaccination groups were adjuvant only (o), Vector ($\square$), HIF1 α Peptides ($\blacktriangle$), or pHIF1 α ($\blacksquare$). Error bars show SEM for each group. HIF1 α peptide vaccinated mice and HIF1 α DNA vaccinated mice had significantly smaller tumor burden vs. control mice as early as 24 days after implant. **** $p < 0.0001$ vs. adjuvant only group. (D) IFN γ ELISPOT assessed T-cell responses to peptide or control stimulations. Each plotted point represents the spots per well of individual FVB/NJ mice in vaccination groups treated with

adjuvant only (o), Vector (□), HIF1α Peptides (▲), or pHifla (■). Lines show Mean & SEM of responses. *** $p < 0.001$ HIF1α peptides vs. No Ag response. Although HIF1α plasmid generated DTH responses, IFNγ ELISPOT are low level.

[0509] For another example, FIG. 22 CD105 peptide and plasmid vaccine immunogenicity and efficacy were determined in mice. (A) DTH responses were measured by change in ear thickness (mm) 24 hours after application of CD105 peptide mix in 50% DMSO. Plotted are responses of individual FVB/NJ mice from the different vaccination cohorts: Controls (both adjuvant only and vector groups, see Methods), CD105 Peps (peptide vaccine), and pCD105 (plasmid vaccine). Dotted line represents 0.0mm change in ear thickness from baseline. * $p < 0.05$, *** $p < 0.001$ vs. controls. (B) DTH responses measured 24 hours after application of CD105 peptide mix in 50% DMSO. Plotted are responses of individual MMTV-C3(1)-Tag transgenic mice from the different vaccination cohorts as listed above. *** $p < 0.001$ vs. controls. (C) Efficacy of vaccines to control M6 tumor growth was assessed by measuring tumor volume (mm³) over time post-implant (days) in MMTV-C3(1)-Tag transgenic mice. Vaccination groups were adjuvant only (o), Vector (□), CD105 Peptides (▲), or pCD105 (■). Error bars show SEM for each group. CD105 peptide vaccinated mice and CD105 DNA vaccinated mice had significantly smaller tumor burden vs. control mice as early as 24 days after implant. **** $p < 0.0001$ vs. adjuvant only group. (D) IFNγ ELISPOT assessed T-cell responses to peptide or control stimulations. Each plotted point represents the spots per well of individual FVB/NJ mice in vaccination groups treated with adjuvant only (o), Vector (□), CD105 Peptides (▲), or pCD105 (■). Lines show Mean & SEM of responses. No significance found for CD105 peptide responses in any group.

[0510] For another example, FIG. 23 CDH3 peptide and plasmid vaccine immunogenicity and efficacy were determined in mice. (A) DTH responses were measured by change in ear thickness (mm) 24 hours after application of CDH3 peptide mix in 50% DMSO. Plotted are responses of individual FVB/NJ mice from the different vaccination cohorts: Controls (see Methods), CDH3 Peps (peptide vaccine), pCDH3 (plasmid vaccine) and pUbVV-CDH3. Dotted line represents 0.0mm change in ear thickness from baseline. * $p < 0.05$, ** $p < 0.01$ vs. controls. (B) DTH responses measured 24 hours after application of CDH3 peptide mix in 50% DMSO. Plotted are responses of individual FVB/N/Tg-neu transgenic mice from the different vaccination cohorts as listed above. * $p < 0.05$, ** $p < 0.01$ vs. controls. (C) Efficacy of vaccines to control MMC tumor growth was assessed by measuring tumor volume (mm³) over time post-implant (days) in FVB/N/Tg-neu transgenic mice. Vaccination groups were adjuvant only (o), Vector (□), CDH3 Peptides (▲), pCDH3 (■), or pUBVV-CDH3 (◆). Error bars show SEM for each group. Neither CDH3 peptide or DNA vaccinated mice had significantly smaller tumor burden vs. control mice. (D) IFNγ ELISPOT assessed T-cell responses to peptide or control stimulations. Each plotted point represents the spots per well of individual FVB/NJ mice in vaccination groups treated with adjuvant only (o), CDH3 Peptides (▲), pCDH3 (■), or pUBVV-CDH3 (◆). Lines show Mean & SEM of responses. **** $p < 0.0001$ CDH3 peptides vs. No Ag response.

[0511] For another example, FIG. 24, SOX2 peptide and plasmid vaccine immunogenicity and efficacy were determined in mice. (A) DTH responses were measured by change in ear Thickness (mm) 24 hours after application of SOX2 peptide mix in 50% DMSO. Plotted are responses of individual FVB/NJ mice from the different vaccination cohorts: Controls (see Methods), SOX2 Peps (peptide vaccine), pSOX2 (plasmid vaccine) and pUbVV-SOX2. Dotted line represents 0.0mm change in ear Thickness from baseline. No significance found versus controls. (B) DTH responses measured 24 hours after application of SOX2 peptide mix in 50% DMSO. Plotted are responses of individual FVB/N/Tg-neu transgenic mice from the different vaccination cohorts as listed above. * $p < 0.05$ vs. controls. (C) Efficacy of vaccines to control MMC tumor growth was assessed by measuring tumor volume (mm³) over time post-implant (days) in FVB/N/Tg-neu transgenic mice. Vaccination groups were adjuvant only (o), Vector (□), SOX2 Peptides (A), pSOX2 (■), or pUBVV-SOX2 (◆). Error bars show SEM for each group. *** $p < 0.001$, **** $p < 0.0001$ vs. adjuvant only group. (D) IFNγ ELISPOT assessed T-cell responses to peptide or control stimulations. Each plotted point represents the spots per well of individual FVB/NJ mice in vaccination groups treated with adjuvant only (o), SOX2 Peptides (▲), pSOX2 (■), or pUBVV-SOX2 (◆). Lines show Mean & SEM of responses. *** $p < 0.001$ SOX2 peptides, **** $p < 0.0001$ pSOX2, **** $p < 0.0001$ pUbVV-SOX2 vs. No Ag response. Although SOX2 peptide and plasmid generated IFNγ ELISPOT responses, DTH responses are low level or not significant in plasmid and peptide.

[0512] For another example, FIG. 25 MDM2 peptide and plasmid vaccine immunogenicity and efficacy were determined in mice. (A) DTH responses were measured by change in ear Thickness (mm) 24 hours after application of MDM2 peptide mix in 50% DMSO. Plotted are responses of individual FVB/NJ mice from the different vaccination cohorts: Controls (see Methods), MDM2 Peps (peptide vaccine), pMDM2 (plasmid vaccine) and pUbVV-MDM2. Dotted line represents 0.0mm change in ear Thickness from baseline. *** $p < 0.001$ vs. controls. (B) DTH responses measured 24 hours after application of MDM2 peptide mix in 50% DMSO. Plotted are responses of individual FVB/N/Tg-neu transgenic mice from the different vaccination cohorts as listed above. *** $p < 0.001$ vs. controls. (C) IFNγ ELISPOT assessed T-cell responses to peptide or control stimulations. Each plotted point represents the spots per well of individual FVB/NJ mice in vaccination groups treated with adjuvant only (o), Vector (□), MDM2 Peptides (▲), pMDM2 (■), or pUBVV-MDM2 (◆). Lines show Mean & SEM of responses. *** $p < 0.001$ pMDM2 vs. No Ag response.

[0513] Following vaccination, the masses of mice were determined. For example, at FIG. 26 the mass of mice three months

after the last vaccine. Mice (n=5) were left untreated, immunized with pUMVC3 alone, pUMVC3-hHifla (30-119), or pUMVC3-hCD105 (87-138), x axis, with CFA/IFA as an adjuvant. The mass of each mouse, y axis, (mean $\pm$ SEM) was recorded three months after the last vaccine. The mass of mice was also determined ten days after the last vaccine. See FIG. 27 Mice (n=5) were left untreated, immunized with pUMVC3 alone, pUMVC3-hHifla (30-119), or pUMVC3-hCD105 (87-138), x axis, with CFA/IFA as an adjuvant. The mass of each mouse, y axis, (mean $\pm$ SEM) was recorded ten days after the last vaccine.

[0514] Determination and construction of sequences for short and extended epitopes from IGF-1R. Two plasmids were constructed, the DNA sequences verified, and used for vaccination experiments. The short epitope plasmid, pIGF-IRshep, expressed a protein with tandemly linked MHC II epitopes corresponding to human IGF-1R. Additionally, there are four amino acids at the N-terminus (MAVP) and three amino acids at the C-terminus (AAA) that are not related to the IGF-1R sequence. The extended epitope plasmid, pIGF-IRexep, expresses a protein with two 1360. Additionally, there are four amino acids at the N-terminus (MAVP) and three amino acids at the C-terminus (AAA) that are not related to the IGF-1R sequence. The vector backbone of each plasmid is pUMVC3, which contains the CMV promoter, directing constitutive expression of the genes in mammalian cells. This vector is qualified for clinical use. The chosen epitopes in the C-terminal region of IGF-1R were assayed with synthetic peptides and demonstrated a propensity to induce greater stimulation of Th1 (IFN γ) compared to Th2 (IL-10) cells in ELISPOT assays of human PBMC samples (described in original proposal).

[0515] Evaluation of the immunogenicity of short and extended IGF-1R epitopes via IFN γ ELISPOT in TgMMTVneu mice. Vaccination experiments were designed to test the immunogenicity of the short and extended IGF-1R epitope plasmids in an adoptive cell transfer assay in TgMMTVneu mice. Eight mice per group were vaccinated five times at 2 week intervals with either pIGF-IRexep, pIGF-IRshep, IGF-1R peptides (p1 196-1210, p1242-1256, p1332-1351, and p1341-1355) or pUMVC3 (vector only). Plasmids and peptides were dosed at 50ug/ injection with CFA/IFA adjuvant. Two weeks after the last vaccination, splenocytes of each vaccination group were isolated and separated into CD3+ T-cell and CD3-negative fractions using magnetic beads that negatively select for mouse T-cells (MACS). Each cell fraction was monitored by flow cytometry to ascertain the percent of T and B cells in each fraction. The CD3+ fractions contained >96% T-cells and <3.3% B cells for all groups. The CD3-negative fractions contained 71-75% B cells and 2.4-6% T-cells for all groups. The splenocyte fractions were then injected into the tail vein (10^6 cells/mouse) of unvaccinated TgMMTVneu mice that had MMC tumor cells implanted 5 days previous (2×10^5 MMC/mouse). Tumor volumes were measured. CD3+ T-cells from peptide vaccinated mice significantly inhibited tumor growth ($p < 0.001$) compared to vector control, but CD3+ T-cells from either of the IGF-1R plasmid vaccine groups did not promote significant tumor protection. CD3-negative splenocytes (majority B cells) from pIGF-IRexep vaccinated animals did inhibit tumor growth significantly ($p < 0.001$) compared to vector control. Neither CD3-negative cells from pIGF-IRshep nor peptide vaccinated mice controlled tumor growth.

[0516] As T-cell immunity is required for the generation of anti-tumor antibodies, a delayed type hypersensitivity (DTH) assay to show that antigen-specific reactive T-cells were generated by pIGF-IRexep vaccination was performed. FVB mice were received three injections, at two week intervals, with either pIGF-IRexep, pUMVC3 vector, IGF-1R peptides, or adjuvant alone (plasmids and peptides were dosed at 50ug/ injection with CFA/IFA adjuvant). Two weeks after the 3rd vaccination the DTH assay was performed by vigorously rubbing either PBS or the IGF-1R peptide mix on to the mouse ears, and ear swelling was monitored for three days. The results demonstrate that significant DTH responses to IGF-1R peptides occurred in peptide-vaccinated and pIGF-IRexep-vaccinated mice compared to vector and adjuvant controls compared to ears treated with PBS ($p < 0.05$, 4-48 hrs by one way ANOVA). Neither vector nor adjuvant controls had significant DTH reactions compared to PBS treatments.

[0517] Evaluation of the clinical efficacy of short vs. extended IGF-1R epitopes in TgMMTVneu mice. In order to directly compare the ability of the short and extended epitope plasmid vaccines to control tumor growth, a syngeneic tumor implant model was employed. Mice (TgMMTVneu) were separated into 4 vaccination groups (pIGF-IRexep, pIGF-IRshep, vector, and IGF-1R peptides) and implanted with syngeneic breast cancer cells (MMC) 7 days after the 3rd vaccination. Dosages were as stated above. The ability of MMC cells to form a tumor, and the tumor growth rate was measured. The IGF-1R peptide vaccine, the short epitope plasmid vaccine, and the extended epitope plasmid vaccine all significantly controlled tumor growth compared to the group that was vaccinated with vector alone ($p < 0.0001$, from 14-31 days). The mice vaccinated with pIGF-IRexep had the slowest growing tumors, but they were not significantly different from tumor growth in animals vaccinated with pIGF-IRshep, $p > 0.05$.

[0518] Determination of the mechanism of action of the therapeutic efficacy via blocking studies. In order to further delineate the role of B and T-cells in the tumor protection mediated by the pIGF-IRexep and IGF-1R peptide vaccines, critical effectors were blocked using depleting antibodies specific for T and B cells. Mice were depleted of lymphocyte classes with specific antibodies following vaccination. MMC tumor growth was measured after vaccination in animals depleted for T or B cells. The pIGF-IRexep vaccine was tumor protective compared to vector-vaccinated animals ($p < 0.01$), except in the groups

where B or T-cells had been depleted. this result indicates a role for both lymphocyte classes in the protective immune response. The IGF-IR peptide vaccine was tumor protective compared to vectorvaccinated animals ($p < 0.01$), except in the group where T-cells had been depleted. Depletion of B cells had no significant effect on tumor protection by the peptide vaccine. The extended epitope plasmid vaccine can induce tumor protective immunity through both B and T-cells, but the short epitope peptides induce only tumor protective T-cell immunity.

EXAMPLE 6

Determination of the Safety and Immunogenicity of Individual Antigen Vaccines

[0519] Stem cell/EMT associated proteins elicit 1gG antibody immunity. FIG. 4 shows the incidence of antibody immunity stem cell/EMT antigens in BrCA patients and volunteer donors. % of volunteer donors positive is shown as white bars and BrCA patient positive as black bars. (A) Antigens with greater than 2-fold difference in incidence between the two populations, (B) 2fold or less incidence in positivity between the two populations. Y-axis, % positive, X-axis, antigens.

[0520] At FIG. 5, the results of a population based epitope screening experiment are shown. In greater detail, at FIG. 6, antigen specific IFN γ responses for stem cell/EMT proteins. IFN γ ELISPOT responses to stem cell/EMT antigens. Y-axis shows corrected spots/well (corrected for background) and X-axis shows the antigen tested for both volunteer donors (white bars) and BrCA patients (gray bars). Data is presented as interquartile box plots with Tukey whiskers. Median CSPW are indicated by the horizontal bar.

[0521] Further at FIG. 7, antigen specific IL-10 responses for stem cell/EMT proteins. IL-10 ELISPOT responses to stem cell/EMT antigens. Y-axis shows corrected spots/well (corrected for background) and X-axis shows the antigen tested for both volunteer donors (white bars) and BrCA patients (gray bars). Data is presented as interquartile box plots with Tukey whiskers. Median CSPW are indicated by the horizontal bar.

[0522] All rodent experiments were performed from the same standard operating procedures (SOP) consistent with what is required for the submission of an Investigational New Drug (IND) application with the FDA. For immunology studies, FVB/NJ mice (n=7/group) were vaccinated four times, intradermally in the ear, every 7-10 days with either CFA/IFA+PBS (control), CFA/IFA+50 μ g pUMVC3 (vector control), CFA/IFA+50 μ g each of validated peptides derived from the individual antigens in a mix, or CFA/IFA+50 μ g pUMVC3 encoding the extended epitope from an individual antigen. Three days after the fourth vaccination, a delayed type hypersensitivity test (DTH) was performed. Peptide and DNA vaccinated mice were given 50 μ g of each antigenic peptide in an equal volume DMSO rubbed onto their unvaccinated ear. The CFA/IFA and CFA/IFA+50 μ g pUMVC3 control mice were either treated with vaccinating peptides (n=4), control peptides (n=4), or DMSO+PBS (n=6) rubbed onto the unvaccinated ear. Experimental groups were tested with a mix of antigen specific peptides in DSMO. Ears were measured prior to treatment (0 hours) and at 24 hours, and the overall change in ear Thickness between the two time points compared. Significance was measured at the $p=0.05$ level by a one-way ANOVA with Tukey's post-hoc test to determine differences between each pair of treatment group. Ten days after DTH, mice were sacrificed and spleens processed for use in an IFN γ ELISPOT assay with 300,000 cells/well in a 2-day culture with antigenic stimulants or controls. Significant differences in IFN γ responses were measured at the $p=0.05$ level by two-Way ANOVA with Bonferroni's post-hoc test to determine differences within each treatment group comparing no antigen stimulation (NoAg) with each of the other stimulations.

[0523] For clinical efficacy studies, MMTV-neuTG (neuTG) or MMTV-C3(1)Tg (C3T) transgenic mice (n=6/group) were vaccinated four times, intradermally in the ear, every 7 to 10 days with either CFA/IFA+PBS, CFA/IFA+50 μ g pUMVC3, CFA/IFA+50 μ g each of identified short peptide epitopes as a mix, or CFA/IFA+50 μ gPUMVC3 encoding the chosen extended epitope sequence. 7 to 10 days after the fourth vaccination, 5×10^5 syngeneic tumor cells for the particular model were implanted subcutaneously. After tumors developed, they were measured 2-3x/week. A significant difference in tumor volume was considered at the $p=0.05$ level by two-way ANOVA with Bonferroni's post-hoc test to determine differences between each pair of treatment groups at measurement time points. 28 days after tumor implant a DTH was performed. Peptide and DNA vaccinated mice were given 50 μ g of each immunizing peptide + equal volume DMSO rubbed onto their unvaccinated ear. The CFA/IFA and CFA/IFA + 50 μ g pUMVC3 control mice were either treated with immunizing peptides (n=3), control peptides (n=3), or DMSO + PBS (n=5) rubbed onto the unvaccinated ear. Ears were measured prior to treatment (0 hours) and at 24 hours, and the overall change in ear Thickness between the two time points compared. Significance was measured at the $p=0.05$ level by one-way ANOVA with Tukey's post-hoc test to determine differences between each pair of treatment groups.

[0524] An IFN γ ELISPOT was performed on murine cryopreserved cells and a validated DTH response correlated with IFN γ

ELISPOT. In matched analysis of DTH and IFN γ ELISPOT, 97 matched assays and analysis of 7 different antigens, there was a statistically significant correlation between the two tests, $p < 0.0001$.

[0525] Safety studies were performed in mice. FIG. 35 shows that a multi-epitope IGF-1R vaccine inhibits the growth of implanted breast cancer. Mice were vaccinated with the IGF-1R peptides twice one week apart and then 1×10^6 MMC cells were injected sq. Data shows the mean implanted tumor measurement from 8 mice $\pm$ SEM (PBS alone (●); IGF-1R vaccine (○)).

[0526] Additionally, FIG. 13 shows immunogenicity and efficacy of a Yb-1 plasmid based vaccine. Yb-1 peptide and plasmid vaccine immunogenicity and efficacy in mice. (A) DTH responses were measured by change in ear Thickness (mm) 24 hours after application of Yb1 peptide mix in 50% DMSO. Plotted are responses of individual FVB/NJ mice from the different vaccination cohorts: Controls (see Methods), YB1 Peps (peptide vaccine), pYB1 (plasmid vaccine) and pUbVV-YB1. Dotted line represents 0.0mm change in ear Thickness from baseline. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ vs. controls. (B) DTH responses measured 24 hours after application of YB1 peptide mix in 50% DMSO. Plotted are responses of individual FVB/N/Tg-neu transgenic mice from the different vaccination cohorts as listed above. * $p < 0.05$, ** $p < 0.01$ vs. controls. (C) IFN γ ELISPOT assessed T-cell responses to peptide or control stimulations. Each plotted point represents the spots per well of individual FVB/NJ mice in vaccination groups treated with adjuvant only (○), Vector (□), YB1 Peptides (▲), pYB1 (■), or pUBVV-YB1 (◆). Lines show Mean & SEM of responses. No significance found for YB1 peptide responses in any group.

[0527] A simultaneous *in vivo* evaluation was also performed in TgMMTNneu mice (see FIG. 12).

[0528] Construction of vaccines. The plasmid constructs created to date are shown in Supplemental Table 25. Each extended epitope was encoded in pUMVC3. Several constructs with multiple antigens were generated in preparation for testing once single antigen toxicity studies were complete.

[0529] All constructs were tested for expression by transfection into HEK293 cells and evaluating resultant cell lysates for antigen expression in the presence or absence of the proteasome inhibitor MG132. Expressed protein of transfected extended epitopes in all constructs generated has been detected. Primary antibodies directed against extended epitopes were either affinity-purified from rabbit antisera obtained from rabbits inoculated with the extended epitope as a long peptide or as commercially available antibodies. Expressed protein of the individual antigens in HEK293 cells was significantly increased when multiple epitopes were encoded in a single plasmid compared to single antigen constructs (see FIG. 16). Western blot analysis of HIF1 α extended epitope expression demonstrated in plasmid-transfected HEK293 cell lysates. Each plasmid directed the expression of the expected size proteins, which were absent in the vector transfection control. Expression of HIF1 α peptide (10.4 kDa) and HIF1 α fragment of BCMA5 fusion protein (43.2 kDa) were verified in pHIF1 α (single antigen vaccine) and pBCMA5 (a five antigen vaccine)-transfected HEK293 lysates, respectively.

[0530] To address the issue of the therapeutic efficacy of several antigens encoded in one vector or 3 individual antigen encoding plasmids, neuTG mice were immunized at 18 weeks with vaccines against neu, IGF-1R and IGFBP-2. An adjuvant control only group, a group with peptides derived from the antigens, a group with 3 plasmids encoding epitopes from each single antigen (50 ug/each), and a group with a single plasmid encoding epitopes linked together from the 3 antigens were treated. All the vaccines significantly delayed the development of breast tumors in the transgenic animals as compared to controls, peptides; $p = 0.0004$, 3 plasmids; $p = 0.0001$, and the single plasmid with 3 antigens; $p = 0.0003$. There was no statistical difference in efficacy between each of the 3 vaccine approaches.

[0531] All antigens tested to date have shown immunogenicity in rodent models either by DTH and ELIPOT and antitumor effect, with the exception of CDH3. For example, FIG. 3 demonstrates antigen specific 1gG immunity. Western blot validation of 1gG antibody response to CDH3. Western blot probing recombinant human CDH3 with (I) polyclonal anti CDH3 Ab, a representative ELISA positive BrCA patients sample (II) and an ELISA negative subject sample (III). Molecular weight marker (far left). Size of CDH3 is marked at 175 kDa.

[0532] Determination of the toxicity of the vaccination via blood chemistry and histology studies. There were no untoward effects to vaccination observed in any of the mice immunized with any of the antigens. The mice experienced no mass loss or decrease in grooming prior to final analysis. Acute and chronic toxicity studies on the individual antigen vaccines have seen no toxicity; hematologic, chemical or histological. An acute and chronic toxicity report (for SATB1 and CDC25B). Acute toxicity studies 1 week after 4th vaccination and chronic toxicity studies 3 months after 4th vaccination.

[0533] As shown in FIG. 36, multiantigen ployepitope vaccines prevent the development of breast cancer in neu-TG mice. (A) Disease free survival (B) Overall survival (n=15/group).

SATB1 and CDC25B Toxicity Results

[0534] Chronic Toxicity Study. Mice were injected with 100 mcg pUMVC3 alone, pUMVC3-hSATB1 (387-450) or pUMVC3-hCDC25B (124-164) four times, 7-10 days apart, using CFA/IFA. Control mice were not treated (see Tables 1 and 3).

Table 1: Timeline for Vaccinations and Tissue/Blood Collections

		day -30	day -20	day -10	day 0	3 months
Chronic Toxicity Study Design		CFA Vac#1	IFA Vac#2	IFA Vac#3	IFA Vac#4	
Control	n=5	N/A	N/A	N/A	N/A	Collect organs and sera, weigh mice
pUMVC3	n=5	100µg	100µg	100µg	100µg	
pUMVC3-hSATB1 (387-450)	n=5	100µg	100µg	100µg	100µg	
pUMVC3-hCDC25B (124-164)	n=5	100µg	100µg	100µg	100µg	

[0535] Serum chemistries and CBC. All serum chemistry and complete blood count values for all groups were not significantly different from control (untreated) mice except HCT in the CDC25B group, MCH in the SATB1 group, and Polys in both pUMVC3 and SATB1 groups (see Tables 5 and 6). Of note, the HCT values of all groups is within the limits of the established ranges. Additionally, although the MCH values of the SATB1 group is significantly different, although it is closer to the established range of values available from Jackson Laboratory (15.2-15.6 pg) than that of the control group. The pUMVC3 vehicle also achieved significance in % Polys which indicates that the difference may be a vehicle effect and not a direct result of the SATB1 insert (see Tables 5-16).

[0536] Pathology. There were no treatment related lesions, which could be considered consistent with a toxic response that distinguished one group from another (see Tables 13-16).

[0537] Mass. Three months following the vaccination, the mass of animals receiving pUMVC3-hSATB1 (387-450) was 23.4 ± 2.3 grams (g), those receiving pUMVC3-hCDC25B(124-164) was 23.4 ± 1.3 g, those receiving pUMVC3 was 23.6 ± 1.4 g and healthy untreated controls was 21.5 ± 1.1. There were no statistically significant differences between any of the groups (see Tables 17-24).

[0538] Acute Toxicity Study. Mice were injected with 100 mcg pUMVC3 alone, pUMVC3-hSATB1 (387-450) or pUMVC3-hCDC25B (124-164) four times, 7-10 days apart, using CFA/IFA. Control mice were not treated (see Table 2).

Table 2: Timeline for Vaccinations and Tissue/Blood Collections

		day -30	day -20	day -10	day 0	10 days
Acute Toxicity Study Design		CFA Vac#1	IFA Vac#2	IFA Vac#3	IFA Vac#4	
Control	n=5	N/A	N/A	N/A	N/A	Collect organs and sera, weigh mice
pUMVC3	n=5	100µg	100µg	100µg	100µg	
pUMVC3-hSATB1 (387-450)	n=5	100µg	100µg	100µg	100µg	
pUMVC3-hCDC25B (124-164)	n=5	100µg	100µg	100µg	100µg	

[0539] Serum chemistries and CBC. All serum chemistry and complete blood count values for all groups were not significantly different from control (untreated) mice except Chloride in the SATB1 and CDC25B group, Calcium, Osm, ALT, Polys in the CDC25B group, and Lymph in the pUMVC3 groups (Table 7 and 8). Of note, Chloride in the SATB1 and CDC25B group is closer to the established ranges (110-204 meq/l) than that of the control group. Similarly, Osm in the CDC25B group is closer to the established range (321-330 arbitrary units) than that of the control group. ALT for all groups is within the limits of the established ranges (see Tables 5-16).

[0540] Pathology. There were no treatment related lesions, which could be considered consistent with a toxic response that distinguished one group from another (Tables 17-24).

[0541] Mass. Ten days following the vaccination, the mass of animals receiving pUMVC3-hSATB1 (387-450) was 20.9 ± 0.7

grams (g), those receiving pUMVC3-hCDC25B (124-164) was 21 ± 1.2 g, those receiving pUMVC3 was 21.3 ± 1.0 g and healthy untreated controls was 21.4 ± 1.5 g. There were no statistically significant differences between any of the groups.

Hifla and CD105 Toxicity Results

[0542] **Chronic toxicity study.** Mice were injected with 100 mcg pUMVC3 alone, pUMVC3-hHif1a (30-119) or pUMVC3-hCD105 (87-138) four times, 7-10 days apart, using CFA/IFA. Control mice were not treated (see Table 3).

Table 3: Timeline for Vaccinations and Tissue/Blood Collections

		day -30	day -20	day -10	day 0	3 months
Chronic Toxicity Study Design		CFA Vac#1	IFA Vac#2	IFA Vac#3	IFA Vac#4	Collect organs and sera, weigh mice
Control	n=5	N/A	N/A	N/A	N/A	
pUMVC3	n=5	100µg	100µg	100µg	100µg	
pUMVC3-hHifla (30-119)	n=5	100µg	100µg	100µg	100µg	
pUMVC3-hCD105 (87-138)	n=5	100µg	100µg	100µg	100µg	

[0543] **Serum chemistries and CBC.** All serum chemistry and complete blood count values for all groups were not significantly different from control (untreated) mice except BUN in the pUMVC3 and Hifla groups, Anion Gap in all groups, Osmolality in the pUMVC3 group, and Cholesterol in the Hifla and CD105 groups (Table 9 and 10). Of note, BUN and Anion Gap in the significantly different groups is closer to the established ranges (18-28 mg/dl and 23.3-27 arbitrary units, respectively) than that of the control group. The established ranges of Osmolality is 321-330, but none of the groups was in this range, and the treatment groups were not significantly different than the untreated mice. Although Cholesterol is significantly different in treatment groups as compared to control groups, the values of all groups is within the limits of the established range of 50-138 (see Tables 5-16).

[0544] **Pathology.** Organs were collected for this study but have not yet been analyzed by the pathologist (see Tables 17-24).

[0545] **Mass.** Three months following the vaccination, the mass of animals receiving pUMVC3-hHifla (30-119) was 23.4 ± 2.4 grams (g), those receiving pUMVC3-hCD105 (87-138) was 22.3 ± 1.6 g, those receiving pUMVC3 was 21.5 ± 1.4 g and healthy untreated controls was 23.1 ± 1.7 g. There were no statistically significant differences between any of the groups.

[0546] **Acute toxicity study.** Mice were injected with 100 mcg pUMVC3 alone, pUMVC3-hHif1a (30-119) or pUMVC3-hCD105 (87-138) four times, 7-10 days apart, using CFA/IFA. Control mice were not treated (see Table 4).

Table 4: Timeline for Vaccinations and Tissue/Blood Collections

		day -30	day -20	day -10	day 0	10 days
Acute Toxicity Study Design		CFA Vac#1	IFA Vac#2	IFA Vac#3	IFA Vac#4	Collect organs and sera, weigh mice
Control	n=5	N/A	N/A	N/A	N/A	
pUMVC3	n=5	100µg	100µg	100µg	100µg	
pUMVC3-hHifla (30-119)	n=5	100µg	100µg	100µg	100µg	
pUMVC3-hCD105 (87-138)	n=5	100µg	100µg	100µg	100µg	

[0547] **Serum chemistries and CBC.** All serum chemistry and complete blood count values for all groups were not significantly different from control (untreated) mice except Cholesterol & Globulin in the Hifla group, Phosphorous for all groups, Calcium in the pUMVC3 group, Chloride in the CD105 group, and Lymph & White Blood Cells in the pUMVC3 and Hifla groups (see Tables 5-16). Although Cholesterol, White Blood Cells, and Calcium is significantly different in the Hifla group as compared to control groups, the values of all groups is within the limits of the established range of 50-138 mg/dl, 2-15 K/µL & 8-14 meq/l, respectively. Of note, the Globulin, Chloride, and Phosphorous in the treatment groups are closer to the established ranges (1.9-2.4 g/dL, 110-204meq/l, & 4.6-10.8 mg/dl, respectively) than that of the control group (see Tables 5-

16).

[0548] Pathology. There were no treatment related lesions, which could be considered consistent with a toxic response that distinguished one group from another (Tables 17-24).

[0549] Mass. Ten days following the vaccination, the mass of animals receiving pUMVC3-hHif1a (30-119) was 20.8 ± 1.6 grams (g), those receiving pUMVC3-hCD105 (87-138) was 20.5 ± 1.4 g, those receiving pUMVC3 was 21.5 ± 2.2 g and healthy untreated controls was 21.1 ± 1.1 g. There were no statistically significant differences between any of the groups (see Tables 5-16).

Table 5: Summary of (Chronic) Serum Chemistries for All Groups (Median and Range)

Parameter (units)	Control / Untreated		pUMVC3		pUMVC3-hSATB1 (387-450)		pUMVC3- hCDC25B(124-164)	
	Median	Range	Median	Range	Median	Range	Median	Range
Glucose Serum (mg/dl)	123.5	52-159	128	52-162	135	46-208	67	47-102
BUN (mg/dl)	27	22-33	25	21-33	31	27-36	26.5	25-30
Creatinine (mg/dl)	0.25	0.2-0.3	0.2	0.2-0.3	0.2	0.2-0.3	0.2	0.2-0.2
Sodium (meq/l)	151.5	150-155	151	149-153	150	147-152	152.5	152-153
Potassium (meq/l)	9.55	9-10.2	8.1	7.8-9.3	8.7	6.5-9.7	8.7	8.1-8.8
Na/K Ratio	15.5	15-17	19	16-19	17	16-23	17.5	17-19
Chloride (meq/l)	107	105-110	108	107-108	106	105-108	110	105-113
Carbon Dioxide (meq/l)	18.5	15-23	19	16-25	19	16-29	23	17-31
Anion Gap	35.5	32-39	32	26-37	30	24-37	28	25-32
Calcium (meq/l)	10.05	9.6-10.6	9.7	9.3-10.4	9.7	9.1-10	9.8	9.3-9.8
Phosphorus (meq/l)	18.9	17-22.3	18	14.9-19.7	18	15.7-21	15.45	13.9-18.9
Osm	314.5	312-326	313	310-316	313	307-316	313	311-316
Total Protein (g/dl)	5.25	4.6-5.4	5.2	4.8-5.6	5.2	4.7-5.9	5.45	4.9-5.5
Albumin (g/dl)	3.1	2.8-3.2	3	2.8-3.1	2.9	2.6-3.3	3.1	2.7-3.2
Globulin (g/dl)	2.15	1.8-2.2	2.1	2-2.5	2.3	2.1-2.6	2.3	2.2-2.4
Alb/Glob Ratio	1.5	1.4-1.6	1.4	1.2-1.5	1.3	1.2-1.3	1.3	1.2-1.4
Bilirubin Total (mg/dl)	0.1	0.1-0.2	0.1	0.1-0.2	0.1	0.1-0.1	0.1	0.1-0.1
ALP (U/L)	99.5	90-108	107	75-148	100	82-149	101	88-114
GGT (U/L)	1	0-2	1	0-1	1	0-1	1	1-1
ALT (U/L)	56	32-61	48	41-59	43	39-57	58	51-65
AST (U/L)	140	73-207	172	104-210	98	78-181	139	126-145
Cholesterol (mg/dl)	125	98-133	138	131-150	129	118-150	129	119-133
* p<0.05 compared to control (untreated)								

Table 6: Summary of (Chronic) CBC for All Groups (Median and Range)

Parameter (units)	Control / Untreated		pUMVC3		pUMVC3-hSATB1 (387-450)		pUMVC3-hCDC25B(124-164)	
	Median	Range	Median	Range	Median	Range	Median	Range
WBC (K/ μ L)	2.65	2.4-3.7	1.7	0.6-3.9	1.7	1.4-2.5	1.2	1.1-2.7
RBC (M/ μ L)	9.66	8.56-11.2	9.28	8.78-9.54	9.52	9.06-10.84	8.95	7.32-9.2
HGB (g/dl)	13.2	11-13.6	12.8	12-14.6	14	13.6-15.6	12.3	10-13.2
HCT (%)	50	46-56.4	46.8	44.6-48.8	48.4	46.2-55.6	44.6 *	37.6-44.8
MCV (fL)	51.65	50.5-53.9	51.1	49.7-51.2	50.9	49.6-51.7	50	48.9-51.3
MCH (pg)	13.3	12.2-13.9	14	13.3-15.4	14.5 *	14.2-15.1	13.95	13.5-14.4
MCHC (%)	25.35	24-26.9	28.1	25.9-30	28.1	19-29.7	27.75	26.8-29.3
Platelet Count (K/ μ L)	860	540-1072	734	672-952	768	568-1104	478	320-1006
Polys(/ μ L)	475	180-540	130*	0-340	90 *	10-280	115	50-380
Lymph(/ μ L)	2140	1750-2960	1260	0-3550	1460	1260-2330	1050	990-2240
Monos(/ μ L)	125	80-260	70	0-200	30	30-120	50	20-80
Eos(/ μ L)	35	0-80	0	0-40	30	0-60	0	0-10
Baso(/ μ L)	0	0-0	0	0-0	0	0-0	0	0-0

* p<0.05 compared to control (untreated)

Table 7: Summary of (Acute) Serum Chemistries for All Groups (Median and Range)

Parameter (units)	Control / Untreated		pUMVC3		pUMVC3-hSATB1 (387-450)		pUMVC3-hCDC25B(124-164)	
	Median	Range	Median	Range	Median	Range	Median	Range
Glucose Serum (mg/dl)	226	111-267	198	93-266	259	67-356	258	57-343
BUN (mg/dl)	26	25-28	30	24-33	26	23-28	25	24-32
Creatinine (mg/dl)	0.2	0.2-0.2	0.2	0.2-0.2	0.3	0.2-0.3	0.2	0.2-0.3
Sodium (meq/l)	147	145-150	148	146-149	148	147-150	149	146-151
Potassium (meq/l)	7.2	6.9-8.4	8	6.6-9	8.2	7.4-9	8.2	7.6-9
Na/K Ratio	21	18-21	19	17-22	18	17-20	18	17-20
Chloride (meq/l)	105	102-108	109	105-110	109 *	107-113	109 *	108-111
Carbon Dioxide (meq/l)	19	16-22	17	14-22	20	14-24	22	17-23
Anion Gap	29	28-35	30	27-34	25	23-32	26	25-29
Calcium (meq/l)	9.2	9-9.7	9.1	8.6-9.7	9.5	9.3-10.3	10.2 *	9.6-10.9
Phosphorus (meq/l)	18.6	12.9-21	13.9	12-19.3	19.6	17.9-21.6	18	15.8-19.7
Osm	308	306-312	310	307-312	314	308-317	316 *	310-317
Total Protein (g/dl)	4.9	4.3-5.4	4.8	4.5-5.4	4.6	4.3-5.6	4.6	4.4-5.4
Albumin (g/dl)	3	2.7-3.3	3	2.7-3.1	2.7	2.5-3.2	2.7	2.6-3.2
Globulin (g/dl)	1.8	1.6-2.1	2	1.8-2.3	1.9	1.7-2.4	1.9	1.8-2.2
Alb/Glob Ratio	1.6	1.6-1.7	1.4	1.3-1.7	1.4	1.2-1.5	1.4	1.4-1.5
Bilirubin Total (mg/dl)	0.1	0.1-0.2	0.1	0.1-0.2	0.1	0.1-0.2	0.1	0.1-0.2

Parameter (units)	Control / Untreated		pUMVC3		pUMVC3-hSATB1 (387-450)		pUMVC3- hCDC25B(124-164)	
	Median	Range	Median	Range	Median	Range	Median	Range
ALP (U/L)	95	92-107	103	83-118	97	81-109	97	89-107
GGT (U/L)	0	0-1	0	0-1	0	0-1	0	0-1
ALT (U/L)	36	28-38	70	45-77	69	46-71	62 *	56-143
AST (U/L)	100	65-235	133	104-196	108	90-174	124	117-130
Cholesterol (mg/dl)	136	113-155	121	108-134	104	89-121	97	86-124
* p<0.05 compared to control (untreated)								

Table 8: Summary of (Acute) CBC for All Groups (Median and Range)

Parameter (units)	Control / Untreated		pUMVC3		pUMVC3-hSATB1 (387-450)		pUMVC3- hCDC25B(124-164)	
	Median	Range	Median	Range	Median	Range	Median	Range
WBC (K/ μ L)	4	3.2-4.6	2.8	1.6-3.8	2.5	1.9-4.2	3.6	3.1-4.4
RBC (M/ μ L)	9.2	8.12-9.58	9.2	8.16-9.34	8.64	7.92-9.6	8.36	7.96-9.16
HGB (g/dl)	13.6	12.4-14	13.2	12-14	12.4	11.6-14	12	11.2-14
HCT (%)	44.8	41-46.8	44	38.8-45.8	41.6	39.2-47	40.4	38.8-45.4
MCV (fL)	48.7	48.3-50.5	48.2	47.3-49.1	49.4	48.1-50	49	48.1-49.7
MCH (pg)	14.5	13.6-15.3	14.7	14.3-14.9	14.6	13.8-14.9	14.5	14.3-15.3
MCHC (%)	29.9	27.8-30.9	30.4	29.7-31.5	29.9	28.7-30	29.8	29.3-30.9
Platelet Count (K/ μ L)	816	598-968	844	528-896	978	728-1130	1080	508-1100
Polys(/ μ L)	310	70-340	230	120-340	270	190-460	510 *	310-640
Lymph(/ μ L)	3800	3070-4190	2600 *	1310-3380	2230	1500-3600	2810	2530-3960
Monos (/ μ L)	60	0-140	80	0-190	100	80-150	160	120-180
Eos(/ μ L)	0	0-50	30	0-30	0	0-40	0	0-40
Baso(/ μ L)	0	0-0	0	0-0	0	0-0	0	0-0
* p<0.05 compared to control (untreated)								

Table 9: Summary of (Chronic) Serum Chemistries for All Groups (Median and Range)

Parameter (units)	Control / Untreated		pUMVC3		pUMVC3-hHifla(30-119)		pUMVC3-hCD105(87-138)	
	Median	Range	Median	Range	Median	Range	Median	Range
Glucose (mg/dl)	211	58-242	177	89-341	227	75-333	239	86-301
BUN (mg/dl)	32	25-34	26	25-29	26 **	21-27	24 **	20-28
Creatinine (mg/dl)	0.3	0.3-0.3	0.3	0.2-0.3	0.3	0.3-0.4	0.3	0.2-0.3
Sodium (meq/l)	152	151-153	150	149-151	152	149-153	150	148-154
Potassium (meq/l)	9	7.8-9.4	7.4	7.3-9	8.5	7.7-9.4	7.3	7-9.7
Na/K Ratio	17	16-20	20	17-20	18	16-19	21	16-21
Chloride (meq/l)	110	106-112	109	106-111	111	110-114	111	110-112
Carbon Dioxide (meq/l)	17	15-24	22	20-22	21	19-22	19	19-22
Anion Gap	34	29-36	27 *	27-29	27 *	26-30	25 **	24-33
Calcium (meq/l)	9.8	9.4-10	9.2	9.1-10.1	9.7	9.5-9.8	9.4	8.9-9.8

Parameter (units)	Control / Untreated		pUMVC3		pUMVC3-hHifla(30-119)		pUMVC3-hCD105(87-138)	
	Median	Range	Median	Range	Median	Range	Median	Range
Phosphorus (meq/l)	19.3	14.8-21	17.2	11.6-17.3	18.5	16.2-19.5	15.5	13.4-16.8
Osm	321	315-321	314 *	308-320	318	314-322	315	312-316
Total Protein (g/dl)	4.7	4.7-5.1	4.7	4.5-6.6	4.5	4.3-5.5	4.5	4.3-5.4
Albumin (g/dl)	2.8	2.8-3	2.6	2.5-3.5	2.5	2.4-3.2	2.5	2.5-3.1
Globulin (g/dl)	1.9	1.9-2.1	2.1	2-3.1	2	1.9-2.3	1.9	1.8-2.3
Alb/Glob Ratio	1.5	1.4-1.5	1.3	1.1-1.3	1.3	1.2-1.4	1.3	1.3-1.4
Bilirubin Total (mg/dl)	0.1	0.1-0.2	0.1	0.1-0.2	0.1	0.1-0.2	0.1	0.1-0.2
ALP (U/L)	90	79-103	88	50-96	92	80-97	87	81-96
GGT (U/L)	0	0-1	0	0-0	0	0-1	0	0-1
ALT (U/L)	44	43-60	55	41-59	50	45-56	51	39-60
AST (U/L)	100	75-102	111	110-228	98	83-142	107	79-184
Cholesterol (mg/dl)	135	106-144	106	88-124	99 *	88-117	94 **	83-118
** p<0.01 compared to control (untreated)								
* p<0.05 compared to control (untreated)								

Table 10: Summary of (Chronic) Serum Chemistries for All Groups (Median and Range)

Parameter (units)	Control / Untreated		pUMVC3		pUMVC3-hHifla(30-119)		pUMVC3-hCD105(87-138)	
	Median	Range	Median	Range	Median	Range	Median	Range
WBC (K/ μ L)	3.8	2.3-5.6	3.8	2.2-5	3.4	3-5.2	4.4	2.8-6.4
RBC (M/ μ L)	9.96	7.2-10.32	9.24	8.62-9.68	8.8	8.2-10.02	8.9	8.14-9.72
HGB (g/dl)	14.8	10.4-15.4	13.4	12.6-14	13.2	11.6-15	13	12.2-14.2
HCT (%)	47.2	34.4-50.8	43.2	41.2-49.2	42.4	39.2-47.4	41.4	38-45.8
MCV (fL)	48.9	47.3-49.3	47.4	46.3-50.9	48	47.2-48.6	46.7	45.8-47.4
MCH (pg)	15	14.4-15.1	14.5	14.3-14.7	15	14.2-15	14.7	14.6-15.1
MCHC (%)	30.7	30.2-31.3	30.7	28.1-31	30.9	29.5-31.7	31.8	31.1-32.5
Platelet Count (K/ μ L)	908	598-1080	950	630-1112	908	842-1210	910	722-972
Polys (/ μ L)	230	50-340	390	180-2600	410	170-680	490	260-560
Lymph (/ μ L)	3570	2160-5260	2390	1740-3910	2960	2400-4470	4000	2210-5890
Monos (/ μ L)	0	0-0	0	0-150	0	0-40	30	0-40
Eos (/ μ L)	0	0-40	0	0-30	30	0-80	0	0-90
Baso (/ μ L)	0	0-0	0	0-0	0	0-0	0	0-0

Table 11: Summary of (Acute) Serum Chemistries for All Groups (Median and Range)

Parameter (units)	Control / Untreated		pUMVC3		pUMVC3-hHifla(30-119)		pUMVC3-hCD105(87-138)	
	Median	Range	Median	Range	Median	Range	Median	Range
WBC (K/ μ L)	4.3	3.6-5.1	2.6	2-2.8	2.9	1.5-3.9	3.4	2.3-4.6
RBC (M/ μ L)	9.2	8.5-9.9	9.2	8.2-9.5	9.1	7.4-9.78	9.66	9.18-10.77
HGB (g/dl)	12.9	12.3-14.4	13.2	11.4-13.8	12.9	9.6-14.1	13.8	13.5-15.6
HCT (%)	44.4	42-50.4	43.8	38.4-45.9	43.8	36.3-46.5	46.8	44.4-51.9
MCV (fL)	48.5	19.6-51	48.3	46.9-48.8	47.7	47.4-48.9	48.3	48-49.1
MCH (pg)	14.6	13.4-15	14.4	13.9-14.5	14.3	12.8-14.5	14.5	14.2-14.8
MCHC (%)	29.8	27.7-30.3	29.7	29-30.1	29.8	26.1-30.5	30.1	29.4-30.2

Parameter (units)	Control / Untreated		pUMVC3		pUMVC3-hHifla(30-119)		pUMVC3-hCD105(87-138)	
	Median	Range	Median	Range	Median	Range	Median	Range
Platelet Count (K/ μ L)	687	414-894	843	450-1227	825	474-1032	825	597-1011
Polys (μ L)	140	40-330	200	20-350	480	100-630	360	90-480
Lymph (μ L)	4130	3460-4540	2160	1580-2460	2470	1200-3240	2750	2120-4050
Monos (μ L)	130	40-150	140	80-140	70	0-120	140	90-210
Eos (μ L)	40	0-150	30	0-80	0	0-30	40	0-60
Baso (μ L)	0	0-0	0	0-0	0	0-0	0	0-0
* p<0.05 compared to control (untreated)								

Table 12: Summary of (Acute) Serum Chemistries for All Groups (Median and Range)

Parameter (units)	Control / Untreated		pUMVC3		pUMVC3-hHifla(30-119)		pUMVC3-hCD105(87-138)	
	Median	Range	Median	Range	Median	Range	Median	Range
Glucose Serum (mg/dl)	122	60-192	66	54-162	83	70-84	85	75-113
BUN (mg/dl)	27	24-30	26	20-28	25	23-28	25	19-25
Creatinine (mg/dl)	0.3	0.2-0.3	0.2	0.2-0.3	0.3	0.2-0.3	0.2	0.2-0.3
Sodium (meq/l)	150	148-153	151	149-152	150	149-153	152	151-153
Potassium (meq/l)	8.9	8.1-9.5	9.3	8.4-9.8	8.9	8.1-9.5	9.2	8.9-9.4
Na/K Ratio	17	16-19	16	15-18	17	16-19	17	16-17
Chloride (meq/l)	105	102-108	108	107-108	109	104-109	108	107-111
Carbon Dioxide (meq/l)	17	12-22	19	16-23	20	19-22	20	19-22
Anion Gap	36	33-43	34	26-37	31	30-34	32	30-34
Calcium (meq/l)	9.7	9.4-10.4	9.4	9-9.6	9.5	9.4-9.8	9.6	9.5-9.7
Phosphorus (meq/l)	18.8	17.6-21.1	14.9	14.1-15.7	15	11.2-15.8	13.3	12.3-14.7
Osm	312	310-315	311	309-314	309	307-317	311	311-317
Total Protein (g/dl)	4.8	4.4-5	4.9	4.4-5.1	5	4.7-5.2	5	4.9-5.1
Albumin (g/dl)	3	2.8-3.2	3.1	2.7-3.3	3	2.9-3.2	3	3-3.2
Globulin (g/dl)	1.8	1.6-1.8	1.8	1.7-2	1.9	1.8-2.2	1.9	1.9-2
Alb/Glob Ratio	1.8	1.7-1.8	1.7	1.6-1.8	1.6	1.4-1.8	1.6	1.5-1.7
Bilirubin Total (mg/dl)	0.2	0.2-0.3	0.2	0.2-0.3	0.2	0.2-0.2	0.2	0.2-0.2
ALP (U/L)	124	106-140	108	88-120	114	97-119	115	106-117
GGT (U/L)	0	0-0	0	0-1	0	0-0	0	0-0
ALT (U/L)	44	41-46	42	34-51	54	47-105	41	38-52
AST (U/L)	122	88-135	95	76-149	109	89-161	113	87-147
Cholesterol (mg/dl)	129	111-143	114	94-126	105	101-107	113	106-128
* p<0.05 compared to control (untreated)								

Table 13: Histology of Control (Untreated) Mice (Chronic)

Organ	Mouse 1	Mouse 2	Mouse 3	Mouse 4	Mouse 5
Bone Marrow	NSL	NSL	NSL	N/A	NSL
Brain	NSL	NSL	NSL	N/A	NSL
Heart	NSL	NSL	NSL	N/A	NSL
Kidney	NSL	NSL	Mild tubular ectasia	N/A	NSL
Lung	NSL	NSL	NSL	N/A	NSL
Adrenal	NSL	NSL	NSL	N/A	NSL
Liver	Mild MF random MG, focal mild acute hepatic necrosis	Mild MF random MG, focal mild acute hepatic necrosis	mild MF MG	N/A	mild MF MG
Thymus	NSL	NSL	NSL	N/A	N/A
Spleen	NSL	NSL	mild hemosiderosis	N/A	NSL
Pancreas	NSL	NSL	NSL	N/A	NSL
Ear	NSL	Focal mild neutrophilic dermatitis & folliculitis (incidental)	NSL	N/A	N/A
Ovary	NSL	NSL	NSL	N/A	NSL
Uterus	NSL	NSL	NSL	N/A	NSL
Salivary Gland	NSL	NSL	NSL	N/A	NSL
Lymphnodes	small fragments	NSL	NSL	N/A	NSL
Brown Fat	NSL	N/A	NSL	N/A	N/A
Comment	There is no evidence of	There is no evidence of	There is no evidence of any	N/A	There is no evidence of
	any test-article related lesions in any of the tissues examined	any test-article related lesions in any of the tissues examined	test-article related lesions in any of the tissues examined		any test-article related lesions in any of the tissues examined

NSL: no significant lesions
MF: multifocal
MG: microgranuloma
NA: tissue not available

Table 14: Histology of pUMVC3 Immunized Mice (Chronic)

Organ	Mouse 1	Mouse 2	Mouse 3	Mouse 4	Mouse 5
Bone Marrow	NSL	NSL	NSL	NSL	NSL
Brain	NSL	NSL	NSL	NSL	NSL
Heart	NSL	NSL	NSL	NSL	NSL
Kidney	NSL	NSL	NSL	NSL	NSL
Lung	NSL	mild PV PB LA	mild PV LA	NSL	NSL
Adrenal	mild x zone lipidosi	NSL	mild x zone lipidosi	NSL	mild x zone lipidosi
Liver	MF random MG	mild MF random MG	mild MF random MG	mild MF random MG	Moderate random MG & EMH
Thymus	NSL	NSL	NSL	NSL	N/A
Spleen	NSL	NSL	Mild hemosiderosis & MZ expansion	Mild hemosiderosis & MZ expansion	Mild hemosiderosis & MZ expansion
Pancreas	mild islet enlargement	mild islet enlargement	mild islet enlargement	NSL	mild islet enlargement
Ear	FE moderate granulomatous &	FE moderate granulomatous &	FE severe granulomatous &	FE moderate granulomatous &	FE moderate & focal

Organ	Mouse 1	Mouse 2	Mouse 3	Mouse 4	Mouse 5
	focal pyogranulomatous auricular chondritis & dermatitis/cellulitis with lipid laden macrophages & free lipid, multifocal to coalescing, with epidermal hyperplasia chronic active	focal pyogranulomatous auricular chondritis & dermatitis/cellulitis with lipid laden macrophages & free lipid, multifocal to coalescing , with epidermal hyperplasia chronic active	focal pyogranulomatous auricular chondritis & dermatitis/cellulitis with lipid laden macrophages & free lipid, multifocal to coalescing , with epidermal hyperplasia chronic active	focal pyogranulomatous auricular chondritis & dermatitis/cellulitis with lipid laden macrophages & free lipid, multifocal to coalescing , with epidermal hyperplasia chronic active	pyogranulomatous auricular chondritis & dermatitis/cellulitis with lipid laden macrophages & free lipid, multifocal to coalescing , with epidermal hyperplasia chronic active
Ovary	N/A	NSL	NSL	NSL	NSL
Uterus	N/A	NSL	NSL	NSL	NSL
Salivary Gland	N/A	NSL	NSL	NSL	NSL
Lymphnodes	Extracellular lipid & foamy macs in sinuses, marked germinal centers, focal acute necrosis in subcapsular sinus	Mild extracellular lipid	Extracellular lipid & foamy macs in sinuses, marked germinal centers, focal acute necrosis in subcapsular sinus; tiny	Extracellular lipid & foamy macs in sinuses, marked germinal centers, focal acute necrosis in subcapsular sinus	Extracellular lipid & foamy macs in sinuses, marked germinal centers, focal acute necrosis in subcapsular sinus
Brown Fat	N/A	N/A	N/A	N/A	N/A
Comment	There is no evidence of any test-article related lesions in any	There is no evidence of any test-article related lesions in any	There is no evidence of any test-article related lesions in any	There is no evidence of any test-article related lesions in any	There is no evidence of any test-article related lesions in any
	of the tissues examined	of the tissues examined	of the tissues examined	of the tissues examined	of the tissues examined

FE: Focally extensive
LH: lymphoid hyperplasia
MZ: Marginal zone
EMH: extramedullary hematopoiesis
PV: Paravascular
PB: Parabronchial
LA: Lymphoid aggregates

Table 15: Histology of pUMVC3-hSATB1 (387-450) Immunized Mice (Chronic)

Organ	Mouse 1	Mouse 2	Mouse 3	Mouse 4	Mouse 5
Bone Marrow	granulocytic hyperplasia	granulocytic hyperplasia	granulocytic hyperplasia	granulocytic hyperplasia	granluocytic hyperplasia
Brain	NSL	NSL	NSL	NSL	NSL
Kidney	NSL	NSL	NSL	NSL	NSL
Lung	NSL	NSL	Mild PV PB LA	minimal PV PB LA	moderate PV PB LA
Adrenal	mild x zone lipidosis	Mild x zone lipidosis	NSL	mild x zone lipofuscinosis	NSL
Liver	mild random MG & EMH	mild random MG & EMH	mild random MG	mild mf random MG	mild random MG
Thymus	NSL	NSL	Tiny	N/A	NSL
Spleen	NSL	NSL	NSL	NSL	NSL
Pancreas	NSL	NSL	NSL	NSL	NSL
Ear	FE moderate & focal pyogranulomatous auricular	FE moderate & focal pyogranulomatous auricular	FE moderate & focal pyogranulomatous auricular	FE severe & focal pyogranulomatous auricular chondritis &	FE moderate & focal pyogranulomatous auricular

Organ	Mouse 1	Mouse 2	Mouse 3	Mouse 4	Mouse 5
	chondritis & dermatitis/cellulitis with lipid laden macrophages & free lipid, multifocal to coalescing , with epidermal hyperplasia chronic active	chondritis & dermatitis/cellulitis with lipid laden macrophages & free lipid, multifocal to coalescing , with epidermal hyperplasia chronic active	chondritis & dermatitis/cellulitis with lipid laden macrophages & free lipid, multifocal to coalescing , with epidermal hyperplasia chronic active	dermatitis/cellulitis with lipid laden macrophages & free lipid, multifocal to coalescing , with epidermal hyperplasia chronic active	chondritis & dermatitis/cellulitis with lipid laden macrophages & free lipid, multifocal to coalescing , with epidermal hyperplasia chronic active
Ovary	NSL	NSL	NSL	NSL	NSL
Uterus	NSL	NSL	NSL	NSL	NSL
Salivary Gland	NSL	NSL	NSL	NSL	NSL
Skeletal Muscle	NSL	NSL	NSL	NSL	NSL
Lymphnodes	Extracellular lipid & foamy macs in sinuses, marked germinal centers, focal acute necrosis in subcapsular sinus	Extracellular lipid & foamy macs in sinuses, marked germinal centers, focal acute necrosis in subcapsular sinus; Moderate sinuoid hemoderosis & acute hemorrhage	Extracellular lipid & foamy macs in sinuses, marked germinal centers, focal acute necrosis in subcapsular sinus	Extracellular lipid & foamy macs in sinuses, marked germinal centers, focal acute necrosis in subcapsular sinus	Extracellular lipid & foamy macs in sinuses, marked germinal centers, focal acute necrosis in subcapsular sinus
Brown Fat	N/A	N/A	N/A	N/A	N/A
Comment	There is no evidence of any test-article related lesions in any of the tissues	There is no evidence of any test-article related lesions in any of the tissues	There is no evidence of any test-article related lesions in any of the tissues	There is no evidence of any test-article related lesions in any of the tissues	There is no evidence of any test-article related lesions in any of the tissues
examined	examined	examined	examined	examined	examined

Table 16: Histology of pUMVC3-hCDC25B (124-164) Immunized Mice (Chronic)

Organ	Mouse 1	Mouse 2	Mouse 3	Mouse 4	Mouse 5
Bone Marrow	granulocytic hyperplasia	NSL	NSL	NSL	NSL
Brain	NSL	NSL	NSL	NSL	NSL
Kidney	NSL	NSL	NSL	NSL	NSL
Lung	moderate PV PB LA	NSL	mild PV PB LA	moderate PV PB LA	mild PV PB LA
Adrenal	mild x zone lipofuscinosis	NSL	mild x zone lipofuscinosis	NSL	NSL
Liver	mild random MG	mild random MG	mild random MG	moderate PV PB LA & mild MF acute necrosis	Mild random MG
Thymus	NSL	NSL	NSL	NSL	NSL
Spleen	NSL	NSL	NSL	NSL	NSL
Pancreas	NSL	NSL	NSL	NSL	NSL
Ear	FE moderate & focal pyogranulomatous auricular chondritis & dermatitis/cellulitis with lipid laden macrophages &	FE moderate & focal pyogranulomatous auricular chondritis & dermatitis/cellulitis with lipid laden macrophages &	FE moderate & focal pyogranulomatous auricular chondritis & dermatitis/cellulitis with lipid laden macrophages &	FE moderate & focal pyogranulomatous auricular chondritis & dermatitis/cellulitis with lipid laden macrophages &	FE moderate & focal pyogranulomatous auricular chondritis & dermatitis/cellulitis with lipid laden macrophages &

Organ	Mouse 1	Mouse 2	Mouse 3	Mouse 4	Mouse 5
	free lipid, multifocal to coalescing , with epidermal hyperplasia chronic active	free lipid, multifocal to coalescing , with epidermal hyperplasia chronic active	free lipid, multifocal to coalescing , with epidermal hyperplasia chronic active	free lipid, multifocal to coalescing , with epidermal hyperplasia chronic active	free lipid, multifocal to coalescing , with epidermal hyperplasia chronic active
Ovary	NSL	NSL	NSL	NSL	NSL
Uterus	NSL	NSL	NSL	NSL	NSL
Salivary Gland	NSL	NSL	NSL	NSL	NSL
Skeletal Muscle	NSL	NSL	NSL	NSL	NSL
Lymphnodes	Extracellular lipid & foamy macs in sinuses, marked germinal centers, focal acute necrosis in subcapsular sinus	Extracellular lipid & foamy macs in sinuses, marked germinal centers, focal acute necrosis in subcapsular sinus	Extracellular lipid & foamy macs in sinuses, marked germinal centers, focal acute necrosis in subcapsular sinus	Extracellular lipid & foamy macs in sinuses, marked germinal centers, focal acute necrosis in subcapsular sinus	Extracellular lipid & foamy macs in sinuses, marked germinal centers, focal acute necrosis in subcapsular sinus
Brown Fat	N/A	NSL	N/A	N/A	N/A
Comment	There is no evidence of any test-article related lesions in any of the tissues examined	There is no evidence of any test-article related lesions in any of the tissues examined	There is no evidence of any test-article related lesions in any of the tissues examined	There is no evidence of any test-article related lesions in any of the tissues examined	There is no evidence of any test-article related lesions in any of the tissues examined

Table 17: Histology of control (untreated) mice

Organ	Mouse 1	Mouse 2	Mouse 3	Mouse 4	Mouse 5
Bone Marrow	NSL	NSL	NSL	NSL	NSL
Brain	NSL	NSL	NSL	NSL	NSL
Kidney	NSL	NSL	NSL	NSL	NSL
Adrenal	NSL	NSL	NSL	NSL	NSL
Liver	NSL	NSL	NSL	NSL	mild random EMH
Thymus	NSL	NSL	NSL	NSL	NSL
Spleen	Moderate marginal zone hypercellularity & germinal centers	Moderate marginal zone hypercellularity & germinal centers	Moderate marginal zone hypercellularity & germinal centers	Moderate marginal zone hypercellularity & germinal centers	Moderate marginal zone hypercellularity & germinal centers
Pancreas	Mild islet enlargement	N/A	Mild islet enlargement	NSL	NSL
Ear	NSL	NSL	NSL	NSL	NSL
Ovary	NSL	NSL	NSL	small sample-CL only	small sample-CL only
Uterus	NSL	NSL	NSL	NSL	NSL
Salivary Gland	NSL	NSL	NSL	NSL	NSL
Draining and/or Distal LN	NSL	NSL	moderate sinusoidal increased mast cells.	Few germinal centers	N/A
Brown Fat	NSL	NSL	NSL	NSL	NSL
Comment	There is no evidence of any test-article related lesions in any of the tissues	There is no evidence of any test-article related lesions in any of the tissues	There is no evidence of any test- article related lesions in any of the tissues	There is no evidence of any test-article related lesions in any of the tissues	There is no evidence of any test-article related lesions in any of the tissues

Organ	Mouse 1	Mouse 2	Mouse 3	Mouse 4	Mouse 5
	examined	examined	examined	examined	examined

Table 18: Histology of pUMVC3 Immunized Mice

Organ	Mouse 1	Mouse 2	Mouse 3	Mouse 4	Mouse 5
Bone Marrow	NSL	NSL	NSL	NSL	NSL
Brain	NSL	NSL	NSL	NSL	NSL
Kidney	NSL	NSL	Mild MF lymphocytes in inters titium	NSL	NSL
Adrenal	NSL	NSL	NSL	NSL	mild multifocal spindle cell hyperplasia
Liver	mild random EMH & microgranulomas	Focal mild fibrosis & neutrophils	mild MF EMH	mild MF EMH & random MG	mild MF EMH & random MG
Thymus	NSL	NSL	NSL	NSL	NSL
Spleen	Moderate marginal zone hypercellularity & germinal centers	Mild marginal zone hypercellularity	Mild marginal zone hypercellularity & germinal centers	Mild marginal zone hypercellularity & germinal centers	Moderate marginal zone hypercellularity & germinal centers
Pancreas	NSL	NSL	NSL	NSL	NSL
Ear	FE moderate to severe granulomatous & focal pyogranulomatous auricular chondritis & dermatitis/cellulitis with lipid laden macrophages & free lipid,	FE mild granulomatous & focal pyogranulomatous auricular chondritis & dermatitis/cellulitis with lipid laden macrophages & free lipid, multifocal to	FE moderate to severe granulomatous & focal pyogranulomatous auricular chondritis & dermatitis/cellulitis with lipid laden macrophages & free lipid,	FE moderate granulomatous & focal pyogranulomatous auricular chondritis & dermatitis/cellulitis with lipid laden macrophages & free lipid, multifocal to	severe histiocytic to granulomatous & pyogranulomatous auricular chondritis & dermatitis/cellulitis/ myo sitis with lipid laden macrophages & free lipid, multifocal to
	multifocal to coalescing , with epidermal hyperplasia chronic active (injection site)	coalescing , with epidermal hyperplasia chronic active (injection site)	multifocal to coalescing , with epidermal hyperplasia chronic active (injection site)	coalescing , with epidermal hyperplasia chronic active (injection site)	coalescing, with epidermal & cartilagenous hyperplasia & hemorrhage & cytic degeneraion, chronic active (injection site)
Ovary	NSL	NSL	NSL	NSL	NSL
Uterus	NSL	NSL	NSL	NSL	NSL
Salivary Gland	NSL	NSL	NSL	NSL	NSL
Skeletal Muscle	NSL	Multifocal mild to moderate granulomatous to fibrosis myositis & cellulitis	Multifocal mild to moderate granulomatous to fibrosis myositis & cellulitis	Multifocal mild to moderate granulomatous to fibrosis myositis & cellulitis	NSL
Draining and/or Distal LN	Extracellular lipid & foamy macs in sinuses	Extracellular lipid & foamy macs in sinuses	Extracellular lipid & foamy macs in sinuses	Extracellular lipid & foamy macs in sinuses	Extracellular lipid & foamy macs in sinuses; mild red blood cells within sinuses
Brown Fat	N/A	NSL	NSL	NSL	NSL
Comment	There is no evidence of any test-article related	There is no evidence of any test-article related	There is no evidence of any test-article related	There is no evidence of any test-article related	There is no evidence of any test-article related

Organ	Mouse 1	Mouse 2	Mouse 3	Mouse 4	Mouse 5
	lesions in any of the tissues examined	lesions in any of the tissues examined	lesions in any of the tissues examined	lesions in any of the tissues examined	lesions in any of the tissues examined

Table 19: Histology of pUMVC3-hSATB1(387-450) Immunized Mice

Organ	Mouse 1	Mouse 2	Mouse 3	Mouse 4	Mouse 5
Bone Marrow	NSL	NSL	NSL	NSL	NSL
Brain	NSL	NSL	NSL	NSL	NSL
Kidney	Mild MF tubular ectasia	Mild MF tubular ectasia	Mild MF tubular ectasia	Mild MF tubular ectasia	Mild MF tubular ectasia
Adrenal	NSL	NSL	NSL	NSL	NSL
Liver	mild MF EMH & random MG	moderate MF EMH & random MG; focal fibrosis & neutrophils	Mild EMH	Moderate EMH & random MG	Moderate EMH & random MG;focal mild acute coagulative necrosis
Thymus	NSL	NSL	NSL	NSL	NSL
Spleen	Moderate marginal zone hypercellularity & germinal centers	Moderate marginal zone hypercellularity & germinal centers	Moderate marginal zone hypercellularity & germinal centers	Moderate marginal zone hypercellularity & germinal centers	Moderate marginal zone hypercellularity & germinal centers
Pancreas	NSL	NSL	NSL	NSL	NSL
Ear	severe histiocytic to granulomatous & pyogranulomatous auricular chondritis & dermatitis/cellulitis /m yositis with lipid laden macrophages & free lipid, MF to coalescing , w/ epidermal & cartilagenous hyperplasia, chronic active (injection site)	severe histiocytic to granulomatous & pyogranulomatous auricular chondritis & dermatitis/cellulitis /my ositis with lipid laden macrophages & free lipid, MF to coalescing , with epidermal & cartilagenous hyperplasia, chronic active (injection site)	moderate granulomatous & pyogranulomatous auricular chondritis & dermatitis/cellulitis /my ositis with lipid laden macrophages & free lipid, MF to coalescing , with epidermal & cartilagenous hyperplasia, chronic active (injection site)	moderate to severe histiocytic to granulomatous & pyogranulomatous auricular chondritis & dermatitis/cellulitis /my ositis with lipid laden macrophages & free lipid, MF to coalescing , with epidermal & cartilagenous hyperplasia, chronic active (injection site)	severe histiocytic to granulomatous & pyogranulomatous auricular chondritis & dermatitis/cellulitis /my ositis with lipid laden macrophages & free lipid, MF to coalescing , with epidermal & cartilagenous & enlarged & prominent nerves, chronic active (injection site)
Ovary	NSL	NSL	NSL	NSL	NSL
Uterus	NSL	NSL	NSL	NSL	NSL
Salivary Gland	NSL	NSL	N/A	NSL	NSL
Skeletal Muscle	NSL	NSL	NSL	NSL	NSL
Draining and/or Distal LN	Extracellular lipid & foamy macs in sinuses marked with pyogranulomatous lymphadenitis	Extracellular lipid & foamy macs in sinuses	Extracellular lipid & foamy macs in sinuses; Red blood cells, histiocytes & hemosiderin in sinusoids	Lipid & lipid laden macs in sinusoids with mild pernodal granulomatous cellultis; minimal lipid & lipid-laden macs in sinusoids	Lipid & lipid laden macs in sinusoids; Histiocytes in sinusoids
Brown Fat	NSL	NSL	NSL	NSL	NSL
Comment	There is no evidence of any test-article related lesions in any of	There is no evidence of any test-article related lesions in any of	There is no evidence of any test-article related lesions in any of	There is no evidence of any test-article related lesions in any of	Mammary Fat Pad - ducts mild hyperplasia. There is no evidence of

Organ	Mouse 1	Mouse 2	Mouse 3	Mouse 4	Mouse 5
	the tissues examined	the tissues examined	the tissues examined	the tissues examined	any test-article related lesions in any tissues examined

Table 20: Histology of pUMVC3-hCDC25B (124-164) Immunized Mice

Organ	Mouse 1	Mouse 2	Mouse 3	Mouse 4	Mouse 5
Bone Marrow	NSL	NSL	NSL	NSL	NSL
Brain	NSL	NSL	NSL	NSL	NSL
Kidney	NSL	NSL	Mild MF tubular ectasia	Mild MF tubular ectasia	Mild MF tubular ectasia, multifocal mild tubular hyperplasia & cysts
Adrenal	NSL	NSL	NSL	NSL	NSL
Liver	mild EMH	mild focal fibrosis & neutrophils, mild EMH	Mild EMH	Mild EMH	Mild EMH & MG with ISCH
Thymus	NSL	NSL	NSL	NSL	NSL
Spleen	Moderate marginal zone hypercellularity & germinal centers	Moderate marginal zone hypercellularity & germinal centers	Moderate marginal zone hypercellularity & germinal centers	Moderate marginal zone hypercellularity & germinal centers	Moderate marginal zone hypercellularity & germinal centers
Pancreas	NSL	NSL	NSL	NSL	NSL
Ear	severe histiocytic to granulomatous & pyogranulomatous auricular chondritis & dermatitis/cellulitis/ myositis with lipid laden macrophages & free lipid, MF to coalescing, with epidermal & cartilagenous & chronic active	severe histiocytic to granulomatous & pyogranulomatous auricular chondritis & dermatitis/cellulitis/ myositis with lipid laden macrophages & free lipid, MF to coalescing, with epidermal & cartilagenous & squamous retention cyst, chronic active	severe histiocytic to granulomatous & pyogranulomatous auricular chondritis & dermatitis/cellulitis/ myositis with lipid laden macrophages & free lipid, MF to coalescing, with epidermal & cartilagenous hyperplasia, chronic active	moderate granulomatous & pyogranulomatous auricular chondritis & dermatitis/cellulitis/ myositis with lipid laden macrophages & free lipid, MF to coalescing, with epidermal hyperplasia, chronic active	severe granulomatous & pyogranulomatous auricular chondritis & dermatitis/cellulitis/ myositis with lipid laden macrophages & free lipid, MF to coalescing, with epidermal hyperplasia, chronic active
Ovary	NSL	NSL	NSL	NSL	NSL
Uterus	NSL	NSL	NSL	NSL	NSL
Salivary Gland	NSL	NSL	NSL	NSL	NSL
Skeletal Muscle	NSL	NSL	NSL	NSL	NSL
Draining and/or Distal LN	Marked lipid & lipid laden macs in sinusoids; multifocal mild granulomatous lymphadenitis; Histiocytes in sinusoids	Marked lipid & lipid laden macs in sinusoids; multifocal mild granulomatous lymphadenitis; Histiocytes in sinusoids	Marked lipid & lipid laden macs in sinusoids; multifocal mild granulomatous lymphadenitis; Histiocytes in sinusoids	Marked lipid & lipid laden macs in sinusoids; multifocal mild granulomatous lymphadenitis; Histiocytes in sinusoids	Marked lipid & lipid laden macs in sinusoids; multifocal mild granulomatous lymphadenitis; Histiocytes in sinusoids
Brown Fat	NSL	NSL	NSL	NSL	NSL
Comment	There is no evidence of any test-article related	There is no evidence of any test-article related	There is no evidence of any test-article related	There is no evidence of any test-article related	There is no evidence of any test-article related

Organ	Mouse 1	Mouse 2	Mouse 3	Mouse 4	Mouse 5
	lesions in any of the tissues examined	lesions in any of the tissues examined	lesions in any of the tissues examined	lesions in any of the tissues examined	lesions in any of the tissues examined
ISCH: intrasinusoidal cell hypercellularity					

Table 21: Histology of Untreated (control) Mice

Organ	Mouse 1	Mouse 2	Mouse 3	Mouse 4	Mouse 5
Bone Marrow	NSL	NSL	NSL	N/A	NSL
Brain	NSL	NSL	NSL	N/A	NSL
Kidney	NSL	Mild multifocal tubular ectasia	Mild multifocal tubular ectasia	N/A	NSL
Adrenal	NSL	NSL	NSL	N/A	NSL
Liver	Mild MF EMH	Mild MF EMH	Mild MF EMH	N/A	Minimal EMH
Thymus	NSL	NSL	Mild medullary hypercellularity	N/A	NSL
Spleen	NSL	NSL	NSL	N/A	Mild marginal zone hypercellularity
Pancreas	NSL	NSL	NSL	N/A	NSL
Ear	Minimal lymphocytic focal dermatitis	NSL	NSL	N/A	NSL
Ovary	NSL	NSL	N/A	N/A	NSL
Oviduct	NSL	NSL	NSL	N/A	NSL
DLN	Minimal germinal center	N/A	NSL	N/A	NSL
Distal LN	NSL	N/A	NSL	N/A	NSL
Comment	There is no histologic evidence of any test-article related lesions in any of the tissues examined.	There is no histologic evidence of any test-article related lesions in any of the tissues examined.	There is no histologic evidence of any test-article related lesions in any of the tissues examined.	N/A	There is no histologic evidence of any test-article related lesions in any of the tissues examined.

Table 22: Histology of pUMVC3 Immunized Mice

Organ	Mouse 1	Mouse 2	Mouse 3	Mouse 4	Mouse 5
Bone Marrow	NSL	NSL	NSL	NSL	NSL
Brain	NSL	NSL	NSL	NSL	NSL
Kidney	Mild tubular ectasia & multifocal mild tubular hyperplasia	Mild tubular ectasia & multifocal mild tubular hyperplasia	Mild tubular ectasia & multifocal mild tubular hyperplasia	NSL	NSL
Adrenal	NSL	NSL	NSL	NSL	NSL
Liver	Mild MF EMH	Mild MF EMH	Mild MF EMH	Mild MF EMH	Mild MF EMH
Thymus	NSL	NSL	NSL	NSL	NSL
Spleen	Mild marginal zone hyperplasia	Mild marginal zone hyperplasia, mild free lipid	Mild marginal zone hypercellularity	Moderate marginal zone hyperplasia	Moderate marginal zone hyperplasia
Pancreas	NSL	NSL	NSL	NSL	NSL
Ear	FE moderate granulomatous & lymphocytic auricular chondritis & dermatitis/cellulitis	FE moderate granulomatous & lymphocytic auricular chondritis & dermatitis/cellulitis	FE moderate granulomatous & lymphocytic auricular chondritis & dermatitis/cellulitis	FE moderate granulomatous & lymphocytic auricular chondritis & dermatitis/cellulitis	FE moderate granulomatous & lymphocytic auricular chondritis & dermatitis/cellulitis

Organ	Mouse 1	Mouse 2	Mouse 3	Mouse 4	Mouse 5
	with lipid laden macrophages & free lipid, multifocal to coalescing, chronic active	with lipid laden macrophages & free lipid, multifocal to coalescing, chronic active	with lipid laden macrophages & free lipid, multifocal to coalescing, chronic active	with lipid laden macrophages & free lipid, multifocal to coalescing, chronic active	with lipid laden macrophages & free lipid, multifocal to coalescing, chronic active
Ovary	N/A	N/A	N/A	N/A	N/A
Oviduct	NSL	NSL	NSL	NSL	NSL
DLN	LH moderate with MF lipidosis	Multifocal mild granulomatous & lymphocytic adenitis with lipid laden macrophages & free lipid. Moderate LH.	Multifocal mild granulomatous & lymphocytic adenitis with lipid laden macrophages & free lipid. Moderate LH.	Multifocal mild granulomatous & lymphocytic adenitis with lipid laden macrophages & free lipid. Moderate LH.	Multifocal mild granulomatous & lymphocytic adenitis with lipid laden macrophages & free lipid. Moderate LH.
Distal LN	NSL	NSL	NSL	NSL	NSL
Comment	There is no evidence of any test-article related lesions in any of the tissues examined other than the injection site & This is likely related to adjuvant.	There is no evidence of any test-article related lesions in any of the tissues examined other than the injection site & DLN which are likely due to adjuvant.	There is no evidence of any test-article related lesions in any of the tissues examined other than the injection site & This is likely related to adjuvant.	There is no evidence of any test-article related lesions in any of the tissues examined other than the injection site & This is likely related to adjuvant.	There is no evidence of any test-article related lesions in any of the tissues examined other than the injection site & This is likely related to adjuvant.

Table 23: Histology of pUMVC3-hHif1a (30-119) Immunized Mice

Organ	Mouse 1	Mouse 2	Mouse 3	Mouse 4	Mouse 5
Bone Marrow	NSL	NSL	NSL	NSL	
Brain	NSL	NSL	NSL	NSL	
Kidney	Focal mild tubular hyperplasia	NSL	Moderate unilateral hydronephrosis	NSL	Minimal tubular ectasia
Adrenal	NSL	NSL	NSL	NSL	NSL
Liver	Mild MF EMH	Mild MF EMH	Moderate MF EMH	Moderate EMH	Mild MF EMH
Thymus	NSL	NSL	NSL	NSL	NSL
Spleen	Moderate marginal zone hyperplasia	Moderate marginal zone hyperplasia	Moderate marginal zone hyperplasia	Moderate marginal zone hyperplasia	Mild marginal zone hyperplasia
Pancreas	NSL	NSL	NSL	NSL	
Ear	FE moderate granulomatous & lymphocytic auricular chondritis & dermatitis/cellulitis with lipid laden macrophages & free lipid, multifocal to coalescing, chronic active	FE moderate granulomatous & lymphocytic auricular chondritis & dermatitis/cellulitis with lipid laden macrophages & free lipid, multifocal to coalescing, chronic active	FE moderate granulomatous & lymphocytic auricular chondritis & dermatitis/cellulitis with lipid laden macrophages & free lipid, multifocal to coalescing, chronic active	FE moderate granulomatous & lymphocytic auricular chondritis & dermatitis/cellulitis with lipid laden macrophages & free lipid, multifocal to coalescing, chronic active	FE moderate granulomatous & lymphocytic auricular chondritis & dermatitis/cellulitis with lipid laden macrophages & free lipid, multifocal to coalescing, chronic active
Ovary	N/A	N/A	NSL	NSL	NSL
Oviduct	NSL	NSL	NSL	NSL	NSL
DLN	Multifocal moderate	Multifocal moderate	Multifocal moderate	Multifocal moderate	Multifocal moderate

Organ	Mouse 1	Mouse 2	Mouse 3	Mouse 4	Mouse 5
	granulomatous & lymphocytic	granulomatous & lymphocytic	granulomatous & lymphocytic adenitis with lipid	granulomatous & lymphocytic	granulomatous & lymphocytic
	adenitis with lipid laden macrophages & free lipid. Moderate LH.	adenitis with lipid laden macrophages & free lipid. Moderate LH.	laden macrophages & free lipid. Moderate LH.	adenitis with lipid laden macrophages & free lipid. Moderate LH.	adenitis with lipid laden macrophages & free lipid. Moderate LH.
Distal LN	NSL	NSL	NSL	NSL	NSL
Comment	There is no evidence of any test-article related lesions in any of the tissues examined other than the injection site & DLN which are likely due to adjuvant.	There is no evidence of any test-article related lesions in any of the tissues examined other than the injection site & DLN which are likely due to adjuvant.	There is no evidence of any test-article related lesions in any of the tissues examined other than the injection site & DLN which are likely due to adjuvant.	There is no evidence of any test-article related lesions in any of the tissues examined other than the injection site & DLN which are likely due to adjuvant.	There is no evidence of any test-article related lesions in any of the tissues examined other than the injection site & DLN which are likely due to adjuvant.

Table 24: Histology of pUMVC3-hHif1a (87-138) Immunized Mice

Organ	Mouse 1	Mouse 2	Mouse 3	Mouse 4	Mouse 5
Bone Marrow	Granulocytic hyperplasia	NSL	NSL	NSL	NSL
Brain	NSL	NSL	NSL	NSL	NSL
Kidney	NSL	NSL	NSL	NSL	NSL
Adrenal	NSL	NSL	NSL	NSL	NSL
Liver	Mild MF EMH	Mild focal acute coagulative necrosis	Mild focal acute coagulative necrosis with neutrophils; mild EMH	Mild MF EMH	Mild MF EMH
Thymus	NSL	NSL	NSL	NSL	NSL
Spleen	NSL	Moderate marginal zone hypercellularity	Moderate marginal zone hypercellularity	NSL	Moderate marginal zone hypercellularity
Pancreas	NSL	NSL	NSL	NSL	NSL
Ear	FE moderate granulomatous & lymphocytic auricular chondritis & dermatitis/cellulitis with lipid laden macrophages & free lipid, multifocal to coalescing, chronic active	FE moderate granulomatous & lymphocytic auricular chondritis & dermatitis/cellulitis with lipid laden macrophages & free lipid, multifocal to coalescing, chronic active	FE moderate granulomatous & lymphocytic auricular chondritis & dermatitis/cellulitis with lipid laden macrophages & free lipid, multifocal to coalescing, chronic active	FE moderate granulomatous & lymphocytic auricular chondritis & dermatitis/cellulitis with lipid laden macrophages & free lipid, multifocal to coalescing, chronic active	FE moderate granulomatous & lymphocytic auricular chondritis & dermatitis/cellulitis with lipid laden macrophages & free lipid, multifocal to coalescing, chronic active
Ovary	N/A	NSL	NSL	NSL	NSL
Oviduct	NSL	NSL	NSL	NSL	NSL
DLN	Multifocal mild granulomatous & lymphocytic adenitis with lipid laden macrophages & free lipid. Moderate LH.	Multifocal minimal granulomatous & lymphocytic adenitis with lipid laden macrophages & free lipid. Moderate LH.	Multifocal moderate granulomatous & lymphocytic adenitis with lipid laden macrophages & free lipid. Moderate LH.	Multifocal moderate granulomatous & lymphocytic adenitis with lipid laden macrophages & free lipid. Moderate LH.	Multifocal mild granulomatous & lymphocytic adenitis with lipid laden macrophages & free lipid. Moderate LH.

Organ	Mouse 1	Mouse 2	Mouse 3	Mouse 4	Mouse 5
Distal LN	NSL	NSL	NSL	NSL	NSL
Comment	There is no evidence of any test-article related lesions in any of	There is no evidence of any test-article related lesions in any of	There is no evidence of any test-article related lesions in any of	There is no evidence of any test-article related lesions in any of	There is no evidence of any test-article related lesions in any of
	the tissues examined other than the injection site & DLN which are likely due to adjuvant.	the tissues examined other than the injection site & DLN which are likely due to adjuvant.	the tissues examined other than the injection site & DLN which are likely due to adjuvant.	the tissues examined other than the injection site & DLN which are likely due to adjuvant.	the tissues examined other than the injection site & DLN which are likely due to adjuvant.
DLN: Draining Lymph Nodes					

[0550] An exemplary list of plasmid based vaccines, some of which were administered to subjects as described herein is provided in Table 25.

Table 25: Plasmid Based Vaccines Constructed to Date

Plasmid Name	Size (bp)	Antigen(s) Expressed	Epitope Region (a.a. numbers)	Plasmid Type
pCD105 (87-138)	4210	CD105/Endoglin	87-138	Single Ag
pCDC25B (124-164)	4177	CDC25B	124-164	Single Ag
pCDH3 (85-164)	4294	CDH3/P-cadherin	85-164	Single Ag
pHIF1α (30-119)	4324	HIF1α	30-119	Single Ag
pMDM2 (53-129)	4288	MDM2/HDM2	53-129	Single Ag
pSATB1 (387-450)	4246	SATB1	387-450	Single Ag
pSOX2 (185-243)	4231	SOX2	185-243	Single Ag
pYB1 (130-161)	4153	Yb-1	130-161	Single Ag
pUbGM-CD105	4424	CD105/Endoglin	87-138	Ubiquitin-fusion 1
pUbGM-CDC25B	4391	CDC25B	124-164	Ubiquitin-fusion 1
pUbGM-CDH3	4508	CDH3/P-cadherin	85-164	Ubiquitin-fusion 1
pUbGM-HIF1α	4538	HIF1α	30-119	Ubiquitin-fusion 1
pUbGM-MDM2	4502	MDM2/HDM2	53-129	Ubiquitin-fusion 1
pUbGM-SATB1	4460	SATB1	387-450	Ubiquitin-fusion 1
pUbGM-SOX2	4445	SOX2	185-243	Ubiquitin-fusion 1
pUbGM-YB1	4367	Yb-1	130-161	Ubiquitin-fusion 1
pUbVV-CD105	4421	CD105/Endoglin	87-138	Ubiquitin-fusion 2
pUbVV-CDC25B	4388	CDC25B	124-164	Ubiquitin-fusion 2
pUbVV-CDH3	4505	CDH3/P-cadherin	85-164	Ubiquitin-fusion 2
pUbVV-HIF1α	4535	HIF1α	30-119	Ubiquitin-fusion 2
pUbVV-MDM2	4499	MDM2/HDM2	53-129	Ubiquitin-fusion 2
pUbVV-SATB1	4457	SATB1	387-450	Ubiquitin-fusion 2
pUbVV-SOX2	4442	SOX2	185-243	Ubiquitin-fusion 2

Plasmid Name	Size (bp)	Antigen(s) Expressed	Egitope Region (a.a: numbers)	Plasmid Type
pUbVV-YB1	4364	Yb-1	130-161	Ubiquitin-fusion 2
pBCMA2-IC	4507	IGF-IR, CDC25B	As listed for single Ags	Two Ag
pBCMA3-ICH	4789	IGF-IR, CDC25B, HIP1 α	As listed for single Ags	Three Ag
pBCMA4-ICHC	4957	IGF-IR, CDC25B, HIF1 α , CD105	As listed for single Ags	Four Ag
pBCMA5-ICHCS	5161	IGF-IR, CDC25B, HIF1 α , CD105, SATB1	As listed for single Ags	Five Ag
pBCMA6-ICHCSS	5350	IGF-IR, CDC25B, HIF1 α , CD105, SATB1, SOX2	As listed for single Ags	Six Ag
pBCMA7-ICHCSSC	5602	IGF-IR, CDC25B, HIF1 α , CD105, SATB1, SOX2, CDH3	As listed for single Ags	Seven Ag
pBCMA8-ICHCSSCM	5848	IGF-IR, CDC25B, HIF1 α , CD105, SATB1, SOX2, CDH3, MDM2	As listed for single Ags	Eight Ag
pSTEMVAC-6(HCYSCM)	5290	HIF1 α , CD105, Yb-1, SOX2, CDH3, MDM2	As listed for single Ags	Six Ag
pSTEMVAC-5(CYSCM)	5008	CD105, Yb-1, SOX2, CDH3, MDM2	As listed for single Ags	Five Ag
pSTEMVAC-4(CSCM)	4927	CD105, SOX2, CDH3, MDM2	As listed for single Ags	Four Ag
pUbGM-BCMA5	5375	IGF-IR, CDC25B, HIF1 α , CD105, SATB1	As listed for single Ags	Ubiquitin-fusion 1, Five Ag
pUbVV-BCMA5	5372	IGF-IR, CDC25B, HIF1 α , CD105, SATB1	As listed for single Ags	Ubiquitin-fusion 2, Five Ag
pIGF1Rexp-ss	4372	IGF-IR	1196-1261, 1323-1360	Single Ag

EXAMPLE 7

Determine the Safety and Immunogenicity of Multiepitope Antigen Vaccines in Humans

[0551] An exemplary composition is show in FIG. 14, the composition is a vaccine and termed STEMVAC.

[0552] FIG. 15A shows a validation of peptide specific T-cells as native epitopes for HIF1 α . The peptide (A) and HIF1 α protein (B) induced IPN γ responses. *indicates $p < 0.05$ vs. no-Ag (white columns). C-D, The peptide (10ug/ml;C) and protein (1ug/ml;D) (black columns) induced responses inhibited by MHC II Ab, not by MHC IAb (dark grey). ** indicates $p < 0.05$ vs. peptide or protein. Light grey, MHC II and MHC I Ab only.

[0553] Another exemplary composition is a vaccine comprising a HER2 epitope. FIG. 31 shows that HER2 Th1 epitope based vaccines may increase survival which is associated with epitope spreading in advanced stage HER2+breast cancer patients. (A) Overall survival of 37 stage IV breast cancer patients after HER2 Th1 vaccination is 38% at a median follow-up of 8.5 years. Time 0 indicates the start of vaccination. (B) Kaplan-Meier curves in vaccinated patients; overall survival between epitope spreading-positive (ES+, solid line) (median 84 mo) and negative (ES-, dotted line) patients (median 24 mo).

[0554] At FIG. 32, the results comparing plasmid and peptide based vaccines are shown. Extended Th plasmid based vaccines are more effective than peptide based vaccine in generating tumor antigen specific Th1 immunity. Post-vaccination ELISPOT responses are shown for ARM 1 (○) and ARM 2 (●). ELISPOT responses to HER2 ICD Th peptide 776 and for HER2 ICD or ECD protein domains are reported as antigen specific T-cells/ 10^6 PBMC with each circle representing an individual patient response; and bold bars indicate the median in all panels.

[0555] Persistent HER2 ICD specific immunity >1 year after plasmid DNA based vaccination has ended. HER2 ICD specific IENy ELISPOT response to HER2 ICD is shown for 10 patients. See FIG. 33. Values plotted for each subject are pre-immunization (pre), maximal response during vaccination (max) and response after 1 year (LTFU).

[0556] Using supernatants from ELISPOT assays during the conduct of a Phase II study of a HER2 peptide vaccine from eight advanced stage HER2+ breast cancer patients receiving vaccinations. At FIG. 37, the values collected via cytokine multiplexing are color coded as to the magnitude of antigen specific cytokine increase (red) or decrease (blue) with vaccination (displayed as a cytokine "heat map"). The intensity of the colors symbolizes lowest (pale) to highest (vivid) quartile of response. The data suggest specific patterns of Th response to the HER2 ICD protein (immunizing antigen); Th1/17, Th2, and "mixed". Patient 12 and 17 increased HER2 specific Type 1 cytokine and IL-17 secretion with vaccination. Th1s type of response is similar to what would be expected after immunization with a vaccine designed to elicit Th1 immunity. Patient 16 decreased both HER2 specific Th1 and Th17 cytokine production. This phenotype may limit the development or retention of tumor antigen specific immunity. Data is expressed as post-vaccine minus pre-vaccine cytokine level (1 month after last vaccine). Dark red: 4th (highest) quartile increase in cytokine level with descending red colors reflecting the 3rd, 2nd, and 1st quartile increase respectively. Dark blue: 4th (highest) quartile decrease in cytokine level with descending blue colors reflecting the 3rd, 2nd, and 1st quartile decrease respectively.

EXAMPLE 8

[0557]
Table 26. Epitopes and Construct Sequences

Name	Sequence	SEQ ID NO
IGFBP-2	MLPRVGCPALPLPPPILPLPLPLJLLJLGASGGGGGARAEVLFRCPPCTPER LAACGPPPVAPPAAVAAVAGGARMPCAELVREPGCGCCSVCARLEGEACG VYTPRCGQLRCYPHPGSELPLQALVMGEGTCEKRRDAEYGASPEQVADN GDDHSEGGI.VF	54
	ATGCTGCCGAGAGTGGGCTGCCCCGCGCTGCCGCTGCCGCCGCCGCCGC TGCTGCCGCTGCTGCCGCTGCTGCTGCTGCTACTGGGCGCGAGTGGCGG CGGCGGCGGGGCGCGCGGAGGTGCTGTTCCGCTGCCCGCCCTGCAC ACCCGAGCGCCTGGCCGCCTGCGGGCCCCCGCGGTTGCGCCGCCCGCC GCGGTGGCCGCAGTGGCCGGAGGCGCCCGCATGCCATGCCCGGAGCTC GTCCGGGAGCCGGGCTGCGGCTGCTGCTCGGTGTGCGCCCGGCTGGAG GGCGAGGCGTGC GGCGTCTACACCCCGCGCTGCGGCCAGGGGCTGCGC TGCTATCCCCACCCGGGCTCCGAGCTGCCCCTGCAAGGCGCTGGTTCATGG GCGAGGGCACTTGTGAGAAGCGCCGGGACGCCGAGTATGGCGCCAGCC CGGAGCAGGTTCAGACAAATGGCGATGACCACTCAGAAGGAGGCCTGG TGGAG	43
Survivin	GCAFLSVKKQFEELTLGEFLKLDREKAKNIAKETNNK	85
	GGCTGCGCCTTCCTGTCCGTGAAGAAGCAGTTCGAGGAGCTGACCCTGG GCGAGTTCCTGAAGCTGGACCGCGAGCGGCCAAGAACAAGATCGCCA AGGAGACCAACAACAAG	86
HIF-1A	RSKESEVIYELAHQLPLPHNVSSHLDKASVMRLTISYLRVRKLLDAGDLDI EDDMKAQMNCFYI.KALDGFVMVI.TDDGDMIYISDNVNK	87
	CGCTCCAAGGAGTCCGAGGTGTCTACGAGCTGGCCCACCAGCTGCCCC TGCCCCACAACGTGTCTCCACCTGGACAAGGCTCCGTGATGCGCCT GACCATCTCCTACCTGCGCGTGCGCAAGCTGCTGGACGCGGGCGACCTG GACATCGAGGACGACATGAAGGCCAGATGAACCTGCTTCTACCTGAAG GCCCTGGACGGCTTCGTGATGGTGTGACCGACGACGGCGACATGATCT ACATCTCCGACAACGTGAACAAG	88
	WSFGVVLWEIATLAEQPYQGLSNEQVLRFVMEGGLLDKPDNCPDMLFEL MRMCWQYNPKMRPSFLEHKAENGPGPGVLVLRASFDERQPYAHMNGGR KNERALP	73

Name	Sequence	SEQ ID NO
IGF-1R	TGGTCCTTCGGCGTGGTGCTGTGGGAGATCGCCACCCTGGCCGAGCAGC CCTACCAGGGCCTGTCCAACGAGCAGGTGCTGCGCTTCGTGATGGAGGG CGGCCTGCTGGACAAGCCCGACAACCTGCCCCGACATGCTGTTTCGAGCTG ATGCGCATGTGCTGGCAGTACAACCCCAAGATGCGCCCCCTCCTTCCTGG AGCACAAAGGCCGAGAACGGCCCCGGCCCCGGCGTGCTGGTGCTGCGCG CCTCCTTCGACGAGCGCCAGCCCTACGCCACATGAACGGaGGCCGCAA GAACGAGCGCGCCCTGCCC	63
IGFBP2-Survivin-HIF1A-IGF1R	MAVPMLPRVGC PALPLPPPLPLPLPLLLLLLGASGGGGGARAEVLFRCPPC TPERLAACGPPPVAPPAVA AVAGGARMPCaELVREPGCGCSVCARLEG	89
	EACGVYTPRCGQGLRCYPIIPGSELPLQALVMGEGTCEKRRDAEYGASPEQ VADNGDDHSEGG LVEQLGCAI'LSYKKQIEELTLGEI'FLKLDRLERAKNKIAK ETNNKGSEFRSKESEVFYELAIQ LPLPINVSSIILDKASVMRLTISYLRVRK LLDAGDLDIEDDMKAQMNCI'FYLKALDGI'VMVLTDDGDMIIYISDNVNKYR SGRPVPWSFGVVI.WEIA TI.AEQPYQGLSNEQVI.RFVMEGGIJD.KPDNCPD MLI'ELMRMC'WQYNPKMRPSI'LEHKAENGP GPV LVLRA SI'DERQPYAHM NGGRKNERAI.PAAA	90
	ATGGCGGTACCaATGC1GCCGAGAGTGGGCTGCCCGCGCTGCCGCTGC CGCCGCCCGCGCTGC1GCCGCTGC1GCCGCTGC1GC1GCTGC1AC1GGG CGCGAGTGGCGGCGGCGGCGGGGCGCGCGCGGAGGTGCTGTTCCGCTG CCCGCCCTGCACACCCGAGCGCCTGGCCGCCTGCGGGCCCCCGCCGTT GCGCCGCCCGCCGCGGTGGCCGCAGTGGCCGAGGCGCCCGCATGCCA TGCGCGGAGCTCGTCCGGGAGCCGGGCTGCGGCTGCTGCTCGGTGTGCG CCCGGC1GGAGGGCGAGGCG1GCGGGGIC1ACACCCCGCGCTGCGGCC AGGGGCTGCGCTGCTATCCCCACCCGGGCTCCGAGCTGCCCTGCAGGC GCTGGTCATGGGCGAGGGCACTTGTGAGAAGCGCCGGGACGCCGAGTA TGGCGCCAGCCCGGAGCAGGTTGCAGACAATGGCGATGACCACTCAGA AGGAGGCCTGGTGAGCaattgGGCTGCGCCTTCCTGTCCGTGAAGAAGCA GTTTCGAGGAGCTGACCCTGGGCGAGTTCTCTGAAGCTGGACCGCGAGCG CGCCAAAGAACAAGATCGCCAAGGAGACCAACAACAAGgGATCCGAATT CCGCTCCAAGGAGTCCGAGGTGTCTACGAGCTGGCCCACCAGCTGCCC CTGCCCCACAACGTGTCTCTCCACCTGGACAAGGCCCTCCGTGATGCGCC TGACCATCTCCTACCTGCGCGTGCGCAAGCTGCTGGACGCI GGCGACCT GGACATCGAGGACGACATGAAGGCCCAGATGAAGTCTTCTACCTGAA GGCCCTGGACGGCTTCGTGATGGTGGCTGACCGACGACGGCGACA1GATC TACATCTCCGACAACGTGAACAAGTACagatccggcgccgCCGGTACCTTGGTC CTTCGGCGTGGTGCTGTGGGAGATCGCCACCCTGGCCGAGCAGCCCTAC CAGGGCCTGTCCAACGAGCAGGTGCTGCGCTTCGTGATGGAGGGCGGC CTGCTGGACAAGCCCCGACAACCTGCCCCGACATGCTGTTTCGAGCTGATGC GCATGTGTCTGGCAGTACAACCCCAAGATGCGCCCCCTCCTTCC1GGAGCA CAAGGCCGAGAACGGCCCCGGCCCCGGCGTGCTGGTGCTGCGCGCCCTC CTTCGACGAGCGCCAGCCCTACGCCACATGAACGGaGGCCGCAAGAAC GAGCGCGCCCTGCCCGCGGCGGCATAG	
pUMCV3 - IGFBP2-Survivin-HIF1A-IGF1R	TGGCCATTGCATACGTTGTATCCATATCATAATATGTACATTTATATTGG CTCATGTCCAACAT1ACCGCCATGT1GACAT1GAT1AT1GACTAGT1AT1 AATAG1AA1CAAT1ACGGGG1CAT1AG1TCATAGCCCA1A1AT1GGAG1T CCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAAC GACCCCCGCCCAT1GACGTCAATAATGACGTATGTTCCCATAGTAACGC CAATAGGGAC1TTCCAT1GACGTCAATGGGTGGAG1AT1TACGGTAAAC TGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCT ATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACA TGACCTTATGGGACTTTCCCTACTTGGCAGTACATCTACGTATTAGTCATC GCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGAT AGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCAT1GACGTCAA TGGGAGTTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCTGT AACAACTCCGCCCCATTGACGCAAAATGGGCGGTAGGCGTGTACGGTGG GAGG1CTATATAAGCAGAGCTCGT1TAGTGAACCG1CAGATCGCCTGGA GACGCCATCCACGCTGT1TTTGACCTCCA1AGAAGACACCGGGACCGATC CAGCC1CCGCGGCCGGGAACGGTGCATTGGAACGCGGATTCCCCG1GCC AAGAGTGACGTAAGTACCGCCTATAGACTCTATAGGCACACCCCTTTGG CTCTTATGCATGCTATACTGTTTTTGGCTTGGGGCCTATACACCCCCGCT TCCTTATGCTATAGGTGATGGTATAGCTTAGCCTATAGGTGTGGGTTATT GACCATTATTGACCACTCCAACGGTGGAGGGCAGTGTAGTCTGAGCAGT	91
	ACTCGTTGCTGCCGCGCGCGCCACCAGACATAATAGCTGACAGACTAAC	

Name	Sequence	SEQ ID NO
	AGACTGTTCTTTCCATGGGTCTTTTCTGCAGTCACCGTCGTCGACGGTA TCGATAAGCTTGATATCGAATTGCCGCCACCATGGCGGTACCaATGCTG CCGAGAGTGGGCTGCCCCGCGCTGCCGCCTGCCGCCGCCGCCGCTGCTGC CGCTGCTGCCGCTGCTGCTGCTGCTACTGGGCGCGAGTGGCGGCCGCCG CGGGGGCGCGCGGAGGTGCTGTTCCGCTGCCCCGCCCTGCACACCCGAG CGCCTGGCCGCTGCGGGCCCCGCCGTTGCGCCGCCGCCGCCGCGGTGG CCGCAGTGGCCCGAGGCGCCCGCATGCCATGCCCGGAGCTCGTCCGGG AGCCGGGCTGCGGCTGCTGCTCGGTGTGCGCCCGGCTGGAGGGCGAGG CGTGCGGGCTCTACACCCCGCGCTGCGGCCAGGGGCTGCGCTGCTATCC CCACCCGGGCTCCGAGCTGCCCTGCAGGCGCTGGTCAATGGGCGAGGG CACTTGTGAGAAGCGCCGGGACGCCGAGTATGGCGCCAGCCCGGAGCA GGTTGCAGACAATGGCGATGACCACTCAGAAGGAGGCCTGGTGGAGCaa tggGGCTGCGCCCTCCCTGJCCGTGAAGAAGCAGTTCGAGGAGCTGACCC GGGCGAGTTCCCTGAAGCTGGACCGCGAGCGCGCCAAGAACAAGATCGC CAAGGAGACCAACAACAAGgGATCCGAATTCCGCTCCAAGGAGTCCGA GGTGTCTACGAGCTGGCCCACCAGCTGCCCTGCCCCACAACGTGTCC TCCCACCTGGACAAGGCCCTCCGTGATGCGCTGACCATCTCCTACCTGC GCGTGCGCAAGCTGCTGGACGCTGGCGACCTGGACATCGAGGACGACAT GAAGGCCCAGATGAAGTGTCTACCTGAAGGCCCTGGACGGCTTCGTG ATGGTGCCTGACCGACGCGCGACATGATCTACATCTCCGACAACGTGA ACAAGTACagatccggccggCCGCTACCTGGTCCCTTCGGCGTGCTGCTGTGGG AGATCGCCACCCTGCGCGAGCAGCCCTACCAGGGCTGTCCAACGAGC AGGTGCTGCGCTTCGTGATGGAGGGCGGCCCTGCTGGACAAGCCCGACA ACTGCCCGGACATGCTGTTCGAGCTGATGCGCACTGTGCTGGCAGTACAA CCCCAAGATGCGCCCCCTCCTTCCTGGAGCACAAGGCCGAGAACGGCCCC GGCCCCGGCGTGCTGGTGCTGCGCGCCTCCTTCGACGAGCGCCAGCCCT ACGCCACATGAACGGAAGCGCAAGAACGAGCGCGCCCTGCCCGCGG CCGCATAGTGATAGATCTTTTCCCTCTGCCAAAAATTATGGGGACATC ATGAAGCCCCCTGAGCATCTGACTTCTGGCTAATAAAGGAAATTTATTT TCATTGCAATAGTGTGTGGGAATTTTTGTGTCTCTACCTCGGAAGGACA TATGGGAGGGCAAATCATTTAAACATCAGAATGAGTATTTGGTTTAGA GTTTGGCAACATATGCCCATCTTCCGCTTCCTCGCTCACTGACTCGCTG CGCTCGGCTCGTTCGGCTGCGCGGAGCGGTATCAGCTCACCTCAAAAGCGG TAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGT GAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTG CTGGCGTTTTCATAGGCTCCGCCCCCTGACGAGCATCAAAAAATC GACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACC AGGGCTTTCCCCCTGGAAGCTCCCTCGTGGCTCTCCTGTTCGACCCCTG CCGCTTACCGGATACCTGTCCGCTTTCTCCCTTCGCGGAAGCGTGGCGCT TTCTCATAGCTCACGCTGTAGGTATCTCAGTTCCGTGTAGGTGCTTCGCT CCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGC CTTATCCGGTAACATCTGTCTTGAGTCCAACCCGGTAAGACACGACTTA TCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTAT GTAGGCGGTGCTACAGAGTTCTTGAAGTGCTGGCCTAACTACGGCTACA CTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTT CGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAAACAAACCACCGTGG TAGCGGTGGTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAA GGATCTCAAGAAGATCCTTTGATCTTTCTACGGGGTCTGACGCTCAGT GGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAA GGATCTTACCTAGATCCTTTTAAATTAAAAATGAAGTTTAAATCAAT CTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATC AGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTTCATCCATAGTTGC	
	CTGACTCGGGGGGGGGGGGGCGCTGAGGTCTGCTCTGTAAGAAGGTGT TGCTGACTCATACCAAGGCCTGAATCGCCCCATCATCCAGCCAGAAAAGTG AGGGAGCCACGGTTGATGAGAGCTTTGTTGTAGGTGGACCAGTTGGTGA TTTTGAACTTTTGCTTTGCCACGGAACGGTCTGCGTTGTGCGGGAAGATG CGTGATCTGATCCTTCAACTCAGCAAAAAGTTCGATTTATTCAACAAAGC CGCCGTCCCGTCAAGTCAGCGTAATGCTCTGCCAGTGTTACAACCAATT AACCAATTCTGATTAGAAAAACTCATCGAGCATCAAATGAAACTGCAAT TTATTCATATCAGGATTATCAATACCATATTTTTGAAAAAGCCGTTTCTG TAATGAAGGAGAAAACTCACCGAGGCAGTTCCATAGGATGGCAAGATC CTGGTATCGGTCTGCGATTCCGACTCGTCCAACATCAATACAACCTATT AATTTCCCCTCGTCAAAAAATAAGGTTATCAAGTGAGAAATCACCATGAG TGACGACTGAATCCGGTGAGAATGGCAAAAAGCTTATGCATTTCTTTCCA GACTTGTTC AACAGGCCAGCCATTACGCTCGTCAATAAAATCACCTCGCA TCAACCAAACCGTTATTCATTCTGTGATTGCGCCTGAGCGAGACGAAATA CGCGATCGCTGTAAAAGGACAATTACAAACAGGAATCGAATGCAACC GGCGCAGGAACACTGCCAGCGCATCAACAATATTTTCACCTGAATCAGG ATATTCTTCTAATACCTGGAATGCTGTTTTCCCGGGGATCGCAGTGGTG AGTAACCATGCATCATCAGGAGTACGGATAAAATGCTTGATGGTCCGA AGAGGCATAAAATCCGTCAGCCAGTTTAGTCTGACCATCTCATCTGTAA CATCATTTGGCAACGCTACCTTTGCCATGTTTCAGAAACAACCTCTGGCGC ATCGGGCTTCCCATACAATCGATAGATTGTTCGACCTGATTGCCCGACA TTATCGCGAGCCCATTTATACCCATATAAATCAGCATCCATGTTGGAAT TTAAATCGCGGCCCTCGAGCAAGACGTTTCCCGTTGAATATGGCTCATAAC ACCCCTTGTATTACTGTTTATGTAAGCAGACAGTTTATTGTTCATGATG ATATATTTTATCTTGTGCAATGTAACATCAGAGATTTTGAGACACAAC GTGGCTTTCCCCCCCCCCCCATTATTGAAGCATTTATCAGGGTTATTGTC TCATGAGCGGATACATATTTGAAIGTATTTAGAAAAATAAACAAATAGG GGTTCGCGGCACATTTCCCCGAAAAGTGGCACCTGACGCTCAAGAAACC ATTATTATCATGACATTAACCTATAAAAAATAGGCGTATCACGAGGCCCT TTCGTCTCGCGCTTTCGGTGATGACGGTGAAAACCTCTGACACATGCA GCCTCCCGGAGACGGTCAACAGCTTGTCTGTAAAGCGGATGCGCGGAGCAG	

Name	Sequence	SEQ ID NO
	ACAAGCCCGTCAGGGCGCGTCAGCGGGTGTGCGGGGTGTCGGGGCTG GCTTAACTATGCGGCATCAGAGCAGATTGTACTGAGAGTGCACCATATG CGGTGTGAAATACCGCACAGATGCGTAAGGAGAAAATACCGCATCAGA TTGGCTAT	

EXAMPLE 9

Multi-antigen Construct Design and Expression

[0558] The pUMVC3-IGFBP2-Survivin-HIF1a-IGF1R fusion construct is according to Fig. 40 and Table 27. The fusion protein was expressed in HEK-293 cells and protein expression was checked by western blot analysis. The protein expression bands were further quantified using the NIH Image J software. Fig. 41 illustrates the protein expression of IGFBP-2, Survivin, HIF-1A, and IGF-1R.

Table 27.

Tumor Antigen	RefSeq Number	Amino Acids	Mouse Homology
IGFBP-2	NP_000588	1-163	72%
Survivin	NP_001159	83-120	87%
HIF1a	NP_001521	30-119	94%
IGF-IR	NP_000866	1196-1261	100%
		1323-1360	97%

EXAMPLE 10

Lentiviral infection of ID8 with luciferase vector and cell line selection.

[0559] ID8 cells, ovarian surface epithelial cells derived from the C57B6 mice were infected with 2 mL/well pLentilli-Luc2 viral vector supernatant (Applied Biological Materials Inc.) in the presence of 8 µg/ml polybrene (EMD Millipore Corporation). After overnight incubation at 37°C/5% CO₂, the viral supernatant and media with polybrene were removed and the plate was washed with PBS prior to the addition of warmed media. Cells were cultured in growth media for 72 hours and then placed under drug selection with 1 µg/mL puromycin, added daily (Invitrogen). One hundred µl of cells were added per well in a white 96-well plate (EMD Millipore Corporation) and equal volume of 3000µg/ml d-luciferin was added immediately before reading. Lines were selected based maximal relative light units after addition of substrate as a measure of functional luciferase expression.

In vivo propagation of ID8-luc2 tumors.

[0560] Albino C57/BL/6/BrdCsHsd-Tyr^c (Harlan Laboratories) were given a 200 µL intraperitoneal injection of 5X10⁶ ID8 cells. With the mouse in the supine position, half the dose was injected using a 25 gauge needle in the lower left quadrant and the other half in the lower right quadrant. At designated intervals after tumor implant, the mice were weighed, bled, and imaged to monitor tumor progression.

Bioluminescence/Imaging.

[0561] Bioluminescent images were taken with Xenogen IVIS using D-luciferin, (In Vivo Imaging Solutions) (Fig. 42A-Fig. 42B).

Images were normalized using Living Image software (PerkinElmer). Maximum luminescent intensity and total flux in photons per second were calculated and reported for each mouse's upper abdominal (metastasis) or lower abdominal (primary) region.

[0562] Fig. 42A shows the total flux (photons/second) in Primary implant and Fig. 3B shows the total flux at the metastatic sites. In addition, representative animals are shown as adjuvant alone (Fig. 42C), and Tri-antigen vaccinated (Fig. 42D).

EXAMPLE 11

Method of identifying promiscuous MHC class II epitopes for development of human vaccines.

[0563] Predicted MHCII epitopes to 14 of the frequent HLA-DR proteins were identified using compiled results from three different publicly available algorithms. The algorithm-generated epitope binding scores were used to map epitopes within protein sequences predicted to contain epitopes that interact with multiple HLA-DR proteins, referred to as "promiscuous epitopes". The 14 HLA-DR proteins screened by the algorithms were: HLA-DRB1*0101, HLA-DRB 1*0301, HLA-DRB 1*0401, HLA-DRB 1*0404, HLA-DRB 1*0405, HLA-DRB1*0701, HLA-DRB1*0802, HLA-DRB1*0901, HLA-DRB1*1101, HLA-DRB1*1201, HLA-DRB1*1302, HLA-DRB1*1501, HLA-DRB4*0101, and HLA-DRB5*0101. The web-based algorithms employed were SYFPEITHI (<http://www.syfpeithi.de/Scripts/MHCServer.dll/EpitopePrediction.htm>), PROPPRED (<http://www.imtech.res.in/raghava/propred/>), and RANKPEP (<http://imed.med.ucm.es/Tools/rankpep.html>). The number of HLA-DR proteins available for screening varied for each website (6, 11, or 13 of the 14 listed above). Query protein sequences were obtained from the NCBI database and copied in the FASTA format for entry into the algorithm search engines and the top twenty scoring epitopes for each HLA-DR protein were used to create the "MHCII heatmap" of the query protein. For compiling and analyzing the epitope prediction data a MS Excel-based workbook was developed, referred to as the "MHCII Heatmap Template". Because each of the three algorithms has a different numerical scoring system for identified epitopes, the epitope scores were first normalized before compiling results from the different search methods. To normalize epitope scores, all scores were divided by the top score obtained by each algorithm, such that the epitope with the highest predicted affinity would have a normalized score of 1.0. The normalized scores were then pasted in to the MHCII Heatmap Template, which, with several embedded equations and functions, performed the following tasks: (i) each amino acid of a particular epitope was assigned the normalized score of the epitope, (ii) the number of different HLA-DR proteins/alleles that had epitopes at each amino acid position was calculated and graphed, (iii) the sum of the normalized scores from every epitope was calculated and graphed at every amino acid position, and (iv) a "Multiple Score" was calculated and graphed, which was the product of the normalized score sum and the number of HLA-DR alleles. The Multiple Score represents both the epitope binding strength and the epitope promiscuity, and this value was used to create the MHCII heatmap of the query protein. The graph of amino acid position (x axis) versus Multiple Score (y axis) allows easy visualization of protein regions predicted to contain promiscuous epitopes. Additionally, an MS Access application was created to simplify the input of FASTA protein sequences into vertical columns of the MHCII Heatmap Template. Once protein sequence has been entered, MHCII heatmap figures can be created by color-coding the amino acids based on Multiple Score values to aid in peptide selection for immunological assays. Generally, color-coding indicates Multiple Scores of 75-100%, 50-75%, 25-50%, and 10-25%.

[0564] Peptides were constructed based on composite scores. Peripheral blood mononuclear cells (PBMC) from 40 human donors were evaluated by ELISPOT for antigen-specific IFN-gamma (g) and IL-10 production induced by the predicted epitopes covering a minimum of 25 % of the protein. For the IFN-g ELISPOT, cells were plated at 2×10^5 per well (96-well plate) in medium with 10 ug/mL of the various peptides or HIVp17, PHA (1 ug/ml), CEF (2.5 ug/mL) or medium alone for 7 days at 37°C in 5% CO₂. On day 5, recombinant human IL-2 (10 U/ml) was added. A second in vitro stimulation (IVS) was performed on day 8 by adding 2×10^5 peptide-loaded (same concentrations as listed above) autologous irradiated (3000 rads) human PBMC to the original culture, and incubated for 24h. 96-well nitrocellulose plates were coated with 10 ug/ml anti-human IFN-g. The washed nitrocellulose plates were blocked with 2% bovine serum albumin in DPBS followed by a 24h incubation with the PBMC culture. After extensive washing, biotinylated anti-human IFN-g was added for 2h. For the IL-10 ELISPOT, an anti-human IL-10-coated (2 ug/ml) nitrocellulose 96-well plate was blocked as described above. PBMC concentration and peptide stimulations were as described above, except that PHA was used at 20 ug/ml. After extensive washing, biotinylated anti-human IL-10 was added for 2h. After extensive washing, 1 ug/mL Streptavidin-AP was added for 45 minutes. Spots were visualized by incubating the plate with BCIP and NBT solutions spots were counted on the C.T.L. ELISPOT plate reader. The raw data was imported into the TVG database ELISPOT tool and positive responses were defined by a statistically significant difference ($p < 0.05$) between the mean number of spots from five replicates in the experimental wells and the mean number from no antigen control wells. A TH1/TH2 ratio was created that analyzed both the magnitude and frequency of ELISPOT responses for each of the predicted class II-specific peptides using the following algorithm: (corrected mean spots per well) x (percent of responding donors). TH1/TH2 activity ratios are also derived from ELISA assays for the Type I and II cytokines using antigen

specific T-cell stimulated media as well as by multi-plex assay for complex TH1/TH2 phenotypes. Incidence and magnitude are incorporated into those analyses in a similar fashion.

[0565] Fig. 43A and Fig. 43B illustrate TH1 response as a function of protein sequences. Selective TH1 inducing sequences were identified in the N-terminus of HIF1a and the C-terminus of Survivin. The mean cSPW x incidence per peptide is shown by donor type. IFN-g cSPW x incidence is shown on the positive y-axis for volunteer donors (n=20) (white) and cancer donors (n=20) (gray). IL-10 cSPW x incidence is shown on the negative y-axis for volunteer donors (solid black) and cancer donors (dotted black). Fig. 43A shows the TH1 response with respect to HIF-1A peptides. Fig. 43B shows the TH1 response with respect to Survivin peptides. Vertical lines show the selected sequences.

EXAMPLE 12

[0566] Studies of antibody immunity show that IGF-IR, HIF1a and Survivin are also ovarian cancer antigens (Fig. 44). It was previously demonstrated that IGFBP-2 is immunogenic in ovarian cancer patients. Serum samples were taken at the time of primary surgery from 120 patients with ovarian cancer and analyzed by indirect ELISA using commercially available recombinant proteins. 100 age-matched volunteer control sera were analyzed in a similar fashion. IgG antibodies were assessed as an indicator of cellular immunity as cognate CD4+T-cells are needed for immunoglobulin class switching from IgM to IgG. Results were confirmed by Western blot. Ovarian cancer patients had significantly higher levels of antibodies to the antigenic proteins than controls (Fig. 44). Patients also demonstrated a significantly higher incidence of antibodies ranging from 8-25% positivity (median 15%) compared to controls (range 1-6%).

SEQUENCE LISTING

[0567]

<110> Disis, Mary L.
Cecil, Denise
Slota, Meredith

<120> BREAST AND OVARIAN CANCER VACCINES

<130> 41299-768.602

<150> US 61/972,176
<151> 2014-03-28

<160> 91

<170> PatentIn version 3.5

<210> 1
<211> 52
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 1
Gln Asn Gly Thr Trp Pro Arg Glu Val Leu Leu Val Leu Ser Val Asn
1 5 10 15

Ser Ser Val Phe Leu His Leu Gln Ala Leu Gly Ile Pro Leu His Leu
 20 25 30

Ala Tyr Asn Ser Ser Leu Val Thr Phe Gln Glu Pro Pro Gly Val Asn
 35 40 45

Thr Thr Glu Leu
 50

<210> 2

<211> 156
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 2
cagaacggca cctggcccccg cgaggtgctg ctggtgctgt ccgtgaactc ctccgtgttc 60
ctgcacctac aggccctggg catccccctg cacctggcct acaactcctc cctggtgacc 120
ttccaggagc cccccggcgt gaacaccacc gagctg 156

<210> 3
<211> 276
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 3
accgtgttca tgcgcctgaa catcatctcc cccgacctgt ccggctgcac ctccaagggc 60
ctggtgctgc ccgccgtgct gggcatcacc ttcgggcct tctgatcgg cgccctgctg 120
accgccgcc tgtggtacat ctactccac acccgctccc cctccaagcg cgagcccgctg 180
gtggccgtgg ccgccccgc ctctccgag tctctctcca ccaaccactc catcggctcc 240
accagtcca cccctgctc cactcctcc atggcc 276

<210> 4
<211> 267
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 4
accgtgtcca tgcgcctgaa catcgtgtcc cccgacctgt ccggcaaggg cctggtgctg 60
ccctccgtgc tgggcatcac cttcggcgcc ttctgatcg gcgccctgct gaccgccgcc 120
ctgtggtaca tctactccca caccgcggcc ccctccaagc gcgagcccg tgtggccgtg 180
gccgcccccg cctctccga gtctctctcc accaaccact ccacggctc caccagtcc 240
acccctgct ccactctc catggcc 267

<210> 5
<211> 267
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 5
accgtgtcca tgcgcctgaa catcgtgtcc cccgacctgt ccggcaaggg cctggtgctg 60
ccctccgtgc tgggcatcac cttcggcgcc ttctgatcg gcgccctgct gaccgccgcc 120
ctgtggtaca tctactccca caccgcggcc ccctccaagc gcgagcccg tgtggccgtg 180
gccgcccccg cctctccga gtctctctcc accaaccact ccacggctc caccagtcc 240
acccctgct ccactctc catggcc 267

<210> 6
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 6
Glu Ala Arg Met Leu Asn Ala Ser Ile Val Ala Ser Phe Val Glu Leu
1 5 10 15

Pro Leu

<210> 7
<211> 52
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 7
Gln Asn Gly Thr Trp Pro Arg Glu Val Leu Leu Val Leu Ser Val Asn
1 5 10 15

Ser Ser Val Phe Leu His Leu Gln Ala Leu Gly Ile Pro Leu His Leu
 20 25 30

Ala Tyr Asn Ser Ser Leu Val Thr Phe Gln Glu Pro Pro Gly Val Asn
 35 40 45

Thr Thr Glu Leu
 50

<210> 8
<211> 92
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 8
Thr Val Phe Met Arg Leu Asn Ile Ile Ser Pro Asp Leu Ser Gly Cys
1 5 10 15

Thr Ser Lys Gly Leu Val Leu Pro Ala Val Leu Gly Ile Thr Phe Gly
 20 25 30

Ala Phe Leu Ile Gly Ala Leu Leu Thr Ala Ala Leu Trp Tyr Ile Tyr
 35 40 45

Ser His Thr Arg Ser Pro Ser Lys Arg Glu Pro Val Val Ala Val Ala
 50 55 60

Ala Pro Ala Ser Ser Glu Ser Ser Ser Thr Asn His Ser Ile Gly Ser
65 70 75 80

Thr Gln Ser Thr Pro Cys Ser Thr Ser Ser Met Ala
 85 90

<210> 9
<211> 89
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 9
Thr Val Ser Met Arg Leu Asn Ile Val Ser Pro Asp Leu Ser Gly Lys
1 5 10 15

Gly Leu Val Leu Pro Ser Val Leu Gly Ile Thr Phe Gly Ala Phe Leu
 20 25 30

Ile Gly Ala Leu Leu Thr Ala Ala Leu Trp Tyr Ile Tyr Ser His Thr
35 40 45

Arg Gly Pro Ser Lys Arg Glu Pro Val Val Ala Val Ala Ala Pro Ala
50 55 60

Ser Ser Glu Ser Ser Ser Thr Asn His Ser Ile Gly Ser Thr Gln Ser
65 70 75 80

Thr Pro Cys Ser Thr Ser Ser Met Ala
85

<210> 10
<211> 89
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 10
Thr Val Ser Met Arg Leu Asn Ile Val Ser Pro Asp Leu Ser Gly Lys
1 5 10 15

Gly Leu Val Leu Pro Ser Val Leu Gly Ile Thr Phe Gly Ala Phe Leu
20 25 30

Ile Gly Ala Leu Leu Thr Ala Ala Leu Trp Tyr Ile Tyr Ser His Thr
35 40 45

Arg Ala Pro Ser Lys Arg Glu Pro Val Val Ala Val Ala Ala Pro Ala
50 55 60

Ser Ser Glu Ser Ser Ser Thr Asn His Ser Ile Gly Ser Thr Gln Ser
65 70 75 80

Thr Pro Cys Ser Thr Ser Ser Met Ala
85

<210> 11
<211> 96
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 11
ggagtgccag tgcagggctc caagtacgct gccgaccgca accactaccg ccgctaccca 60
cgccgtcgcg gccaccccgc caactaccag cagaac 96

<210> 12
<211> 96
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 12
ggcgtgcccg tgcagggctc caagtacgcc gccgaccgca accactaccg ccgctacccc 60
cgccgcgcgc gccccccccg caactaccag cagaac 96

<210> 13
<211> 96
<212> DNA
<213> Artificial Sequence

<220>

<223> Synthetic polynucleotide or polypeptide

<400> 13
ggcgtgcccg tgcagggctc caagtacgcc gccgaccgca accactaccg ccgctacccc 60
cgccgccgcg gcccccccg caactaccag cagaac 96

<210> 14
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 14
Glu Asp Val Phe Val His Gln Thr Ala Ile Lys Lys Asn Asn Pro Arg
1 5 10 15

Lys

<210> 15
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 15
Tyr Arg Arg Asn Phe Asn Tyr Arg Arg Arg Arg Pro Glu Asn
1 5 10

<210> 16
<211> 32
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 16
Gly Val Pro Val Gln Gly Ser Lys Tyr Ala Ala Asp Arg Asn His Tyr
1 5 10 15

Arg Arg Tyr Pro Arg Arg Arg Gly Pro Pro Arg Asn Tyr Gln Gln Asn
20 25 30

<210> 17
<211> 177
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 17
ggcctcaatg cgcacggcgc agcgcagatg cagcccatgc accgctacga cgtgagcgcc 60
ctgcagtaca actccatgac cagctcgcag acctacatga acggctcgcc cacctacagc 120
atgtcctact cgcagcaggg cacccttggc atggctcttg gctccatggg ttcggtg 177

<210> 18
<211> 177
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 18
ggcctgaacg cccacggcgc cgcccagatg cagcccatgc accgctacga cgtgtccgcc 60
ctgcagtaca actccatgac ctccctcccag acctacatga acggctcccc cacctactcc 120
atgtcctact cccagcaggg cccccccggc atggccctgg gctccatggg ctccgtg 177

<210> 19
<211> 177
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 19
ggcctgaacg cccacggcgc cgcccagatg cagcccatgc accgctacga cgtgtccgcc 60
ctgcagtaca actccatgac ctccctcccag acctacatga acggctcccc cacctactcc 120
atgtcctact cccagcaggg cccccccggc atggccctgg gctccatggg ctccgtg 177

<210> 20
<211> 59
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 20
Gly Leu Asn Ala His Gly Ala Ala Gln Met Gln Pro Met His Arg Tyr
1 5 10 15
Asp Val Ser Ala Leu Gln Tyr Asn Ser Met Thr Ser Ser Gln Thr Tyr
20 25 30
Met Asn Gly Ser Pro Thr Tyr Ser Met Ser Tyr Ser Gln Gln Gly Thr
35 40 45
Pro Gly Met Ala Leu Gly Ser Met Gly Ser Val
50 55

<210> 21
<211> 240
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 21
aggtcactga aggaaaggaa tccattgaaa atcttcccat ccaaactgat cttacgaaga 60
cacaagagag attgggtggt tgctccaata tctgtccctg aaaatggcaa gggtccttc 120
ccacagagac tgaatcagct caagtctaataaagatagag acaccaagat tttctacagc 180
atcacggggc cgggtgcaga cagcccacct gaggggtgtct tcgctgtaga gaaggagaca 240

<210> 22
<211> 216
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 22
ttgaaaatct tcccatccaa acgtatctta cgaagacaca agagagattg ggtggttgct 60
ccaatatctg tccctgaaaa tggcaagggt cccttcccac agagactgaa tcagctcaag 120

tctaataaag atagagacac caagattttc tacagcatca cggggccggg tgcagacagc 180
ccacctgagg gtgtcttcgc tgtagagaag gagaca 216

<210> 23
<211> 216
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 23
ttgaaaaatct tcccatccaa acgtatctta cgaagacaca agagagattg ggtggttgct 60
ccaatatctg tccctgaaaa tggcaagggt cccttcccac agagactgaa tcagotcaag 120
tctaataaag atagagacac caagattttc tacagcatca cggggccggg tgcagacagc 180
ccacctgagg gtgtcttcgc tgtagagaag gagaca 216

<210> 24
<211> 216
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 24
gtgatgaact cccccccctc ccgcatcctg cgcgcgcgca agcgcgagtg ggtgatgcc 60
cccatctccg tgcccgagaa cggcaagggc cccttcccc agcgctgaa ccagotgaag 120
tccaacaagg accgcggcac caagctgttc tactccatca ccggccccgg cgcgactcc 180
ccccccgagg gcgtgttcac catcgagaag gagacc 216

<210> 25
<211> 80
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 25
Arg Ser Leu Lys Glu Arg Asn Pro Leu Lys Ile Phe Pro Ser Lys Arg
1 5 10 15

Ile Leu Arg Arg His Lys Arg Asp Trp Val Val Ala Pro Ile Ser Val
20 25 30

Pro Glu Asn Gly Lys Gly Pro Phe Pro Gln Arg Leu Asn Gln Leu Lys
35 40 45

Ser Asn Lys Asp Arg Asp Thr Lys Ile Phe Tyr Ser Ile Thr Gly Pro
50 55 60

Gly Ala Asp Ser Pro Pro Glu Gly Val Phe Ala Val Glu Lys Glu Thr
65 70 75 80

<210> 26
<211> 72
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 26
Leu Lys Ile Phe Pro Ser Lys Arg Ile Leu Arg Arg His Lys Arg Asp
1 5 10 15

Trp Val Val Ala Pro Ile Ser Val Pro Glu Asn Gly Lys Gly Pro Phe
20 25 30

Pro Gln Arg Leu Asn Gln Leu Lys Ser Asn Lys Asp Arg Asp Thr Lys
35 40 45

Ile Phe Tyr Ser Ile Thr Gly Pro Gly Ala Asp Ser Pro Pro Glu Gly
50 55 60

Val Phe Ala Val Glu Lys Glu Thr
65 70

<210> 27
<211> 72
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 27
Ala Met His Ser Pro Pro Thr Arg Ile Leu Arg Arg Arg Lys Arg Glu
1 5 10 15

Trp Val Met Pro Pro Ile Phe Val Pro Glu Asn Gly Lys Gly Pro Phe
20 25 30

Pro Gln Arg Leu Asn Gln Leu Lys Ser Asn Lys Asp Arg Gly Thr Lys
35 40 45

Ile Phe Tyr Ser Ile Thr Gly Pro Gly Ala Asp Ser Pro Pro Glu Gly
50 55 60

Val Phe Thr Ile Glu Lys Glu Ser
65 70

<210> 28
<211> 72
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 28
Val Met Asn Ser Pro Pro Ser Arg Ile Leu Arg Arg Arg Lys Arg Glu
1 5 10 15

Trp Val Met Pro Pro Ile Ser Val Pro Glu Asn Gly Lys Gly Pro Phe
20 25 30

Pro Gln Arg Leu Asn Gln Leu Lys Ser Asn Lys Asp Arg Gly Thr Lys
35 40 45

Leu Phe Tyr Ser Ile Thr Gly Pro Gly Ala Asp Ser Pro Pro Glu Gly
50 55 60

Val Phe Thr Ile Glu Lys Glu Thr
65 70

<210> 29
<211> 231
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 29
acctacacca tgaaggaggt gctgttctac ctgggccagt acatcatgac caagcgctg 60

tacgacgaga agcagcagca catcgtgtac tgctccaacg acctgctggg cgacctgttc 120
ggcgtgccct ccttctccgt gaaggagcac cgcaaatct acaccatgat ctaccgcaac 180
ctggtggtgg tgaaccagca ggagtcctcc gactccggca cctccgtgtc c 231

<210> 30
<211> 222
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 30
acctacacca tgaaggagat catcttctac atcggccagt acatcatgac caagcgcctg 60
tacgacgaga agcagcagca catcgtgtac tgctccaacg acctgctggg cgacctgttc 120
ggcgtgccct ccttctccgt gaaggagcac cgcaaatct acgcatgat ctaccgcaac 180
ctggtggcgg tgtcccagca ggactccggc acctccctgt cc 222

<210> 31
<211> 222
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 31
atctacacca tgaaggagat catcttctac atcggccagt acatcatgac caagcgcctg 60
tacgacgaga agcagcagca catcgtgtac tgctccaacg acctgctggg cgacctgttc 120
ggcgtgccct ccttctccgt gaaggagcac cgcaaatct acgcatgat ctaccgcaac 180
ctggtggtgg tgtcccagca ggactccggc acctccctct cc 222

<210> 32
<211> 76
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 32
Thr Tyr Thr Met Lys Glu Val Leu Phe Tyr Leu Gly Gln Tyr Ile Met
1 5 10 15

Thr Lys Arg Leu Tyr Asp Glu Lys Gln Gln His Ile Val Tyr Cys Ser
20 25 30

Asn Asp Leu Leu Gly Asp Leu Phe Gly Val Pro Ser Phe Ser Val Lys
35 40 45

Glu His Arg Lys Ile Tyr Thr Met Ile Tyr Arg Asn Leu Val Val Val
50 55 60

Asn Gln Gln Glu Ser Ser Asp Ser Gly Thr Ser Val
65 70 75

<210> 33
<211> 74
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 33
Thr Tyr Thr Met Lys Glu Ile Ile Phe Tyr Ile Gly Gln Tyr Ile Met

1 5 10 15

Thr Lys Arg Leu Tyr Asp Glu Lys Gln Gln His Ile Val Tyr Cys Ser
20 25 30

Asn Asp Leu Leu Gly Asp Val Phe Gly Val Pro Ser Phe Ser Val Lys
35 40 45

Glu His Arg Lys Ile Tyr Ala Met Ile Tyr Arg Asn Leu Val Ala Val
50 55 60

Ser Gln Gln Asp Ser Gly Thr Ser Leu Ser
65 70

<210> 34
<211> 74
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 34

Ile Tyr Thr Met Lys Glu Ile Ile Phe Tyr Ile Gly Gln Tyr Ile Met
1 5 10 15

Thr Lys Arg Leu Tyr Asp Glu Lys Gln Gln His Ile Val Tyr Cys Ser
20 25 30

Asn Asp Leu Leu Gly Asp Val Phe Gly Val Pro Ser Phe Ser Val Lys
35 40 45

Glu His Arg Lys Ile Tyr Ala Met Ile Tyr Arg Asn Leu Val Val Val
50 55 60

Ser Gln Gln Asp Ser Gly Thr Ser Pro Ser
65 70

<210> 35
<211> 987
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 35

atggcggtac ccatgcaact gtctgtctct agacagaacg gcacctggcc ccgcgaggtg 60

ctgctggtgc tgtccgtgaa ctctccgtg ttctgcacc tacaggccct gggcatcccc 120

ctgcacctgg cctacaactc ctccctggtg accttcagg agccccccgg cgtgaacacc 180

accgagctga gatccaccgg tggagtgcc gtgcagggct ccaagtacgc tgccgaccgc 240

aaccactacc gccgtaccc acgccgtgc gccccacccc gcaactacca gcagaacacg 300

cgtggcctca atgcgcacgg cgcagcgcag atgcagccca tgcaccgcta cgacgtgagc 360

gccctgcagt acaactccat gaccagctcg cagacctaca tgaacggctc gcccacctac 420

agcatgtcct actcgcagca gggcaccocct gccatggctc ttggctccat gggttcgggtg 480

agatcccaat tgaggtcact gaaggaaagg aatccattga aaatcttccc atccaaacgt 540

atcttacgaa gacacaagag agattgggtg gttgctccaa tatctgtccc tgaaaatggc 600

aagggtccct tcccacagag actgaatcag ctcaagtcta ataaagatag agacaccaag 660

attttctaca gcatcacggg gccgggtgca gacagcccac ctgagggtgt cttecgctgta 720

gagaaggaga caagatccgc cggcgaaacc tacaccatga aggaggtgct gttctacctg 780

ggccagtaca tcatgaccaa gcgcctgtac gacgagaagc agcagcacat cgtgtactgc 840

tccaacgacc tgctgggcga cctgttcggc gtgccctcct tctccgtgaa ggagcaccgc 900

aaaatctaca ccatgatcta ccgcaacctg gtggtggtga accagcagga gtccctccgac 960

tccggcacct ccggtgtccag atcttag	987
<210> 36	
<211> 1059	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic polynucleotide or polypeptide	
<400> 36	
atggcgggtac ccatgaccgt gttcatgccc ctgaacatca tctccccga cctgtccggc	60
tgcacctcca agggcctggg gctgcccgcc gtgctgggca tcaccttcgg cgccttcctg	120
atcggcgccc tgcctgaccg cgcctgtggg tacatctact cccacacccg ctccccctcc	180
aagcgcgagc cctgggtggc cgtggccgcc cccgcctcct ccgagtcctc ctccaccaac	240
cactccatcg gctccaccca gtccaccccc tgctccacct cctccatggc caccgggtga	300
gtgccagtgc agggctccaa gtacgtgcc gaccgcaacc actaccgccg ctaccacgc	360
cgtcgcggcc caccocgcaa ctaccagcag aacacgcgtg gcctcaatgc gcacggcgca	420
gcgcagatgc agcccatgca ccgctacgac gtgagcgccc tgcagtacaa ctccatgacc	480
agctcgcaga cctacatgaa cggctcgccc acctacagca tgcctactc gcagcagggc	540
acccctggca tggctcttgg ctccatgggt tcggtgagat cccaattgtt gaaaatcttc	600
ccatccaaac gtatcttacg aagacacaag agagattggg tggttgctcc aatatctgtc	660
cctgaaaatg gcaagggtcc ctccccacag agactgaatc agctcaagtc taataaagat	720
agagacacca agatcttcta cagcatcacg gggccgggtg cagacagccc acctgagggt	780
gtcttcgctg tagagaagga gacaagatcc gccggcgaaa cctacaccat gaaggagggtg	840
ctgttctacc tgggccagta catcatgacc aagcgcctgt acgacgagaa gcagcagcac	900
atcgtgtact gctccaacga cctgctgggc gacctgttcg gcgtgccctc cttctccgtg	960
aaggagcacc gaaaatcta caccatgacg taccgcaacc tgggtggtgtg gaaccagcag	1020
gagtcctccg actccggcac ctccgtgtcc agatcttag	1059
<210> 37	
<211> 1041	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic polynucleotide or polypeptide	
<400> 37	
atggcgggtac ccatgaccgt gtccatgccc ctgaacatcg tgtccccga cctgtccggc	60
aagggcctgg tgcctgcctc cgtgctgggc atcaccttcg gcgccttcct gatcggcgcc	120
ctgctgaccg ccgcctgtgt gtacatctac tcccacaccc ggggcccctc caagcgcgag	180
cccgtggtgg cctggccgcc cccgcctcc tccgagtcct cctccaccaa ccactccatc	240
ggctccaccc agtccacccc ctgctccacc tcctccatgg ccaccggtgg cgtgcccggtg	300
cagggctcca agtacgcgcg cgaccgcaac cactaccgcc gctacccccg ccgcgcgggc	360
cccccccgca actaccagca gaacacgcgt ggctgaacg cccacggcgc cggccagatg	420
cagcccatgc accgctacga cgtgtccgcc ctgcagtaca actccatgac ctccctccag	480
acctacatga acggctcccc cacctactcc atgtctact cccagcaggg caccoccggc	540
atggccctgg gctccatggg ctccgtgaga tcccaattgg ccatgcactc ccccccacc	600
cgcatacctgc gccgcgcaa gcgcgagtg gtgatgccc ccatcttcgt gcccgagaac	660
ggcaaggggc ccttccccc gccgcctgaac cagctgaagt ccaacaagga ccgcggcacc	720
aagatcttct actccatcac cggccccggc gccgactccc ccccgaggg cgtgttcacc	780
atcgagaagg agtccagatc cggcggcgaa acctacacca tgaaggagat catcttctac	840
atcggccagt acatcatgac caagcgcctg tacgacgaga agcagcagca catcgtgtac	900
tgctccaacg acctgctggg cgacgtgttc ggcgcgccct ccttctccgt gaaggagcac	960

cgcaagatct acgccatgat ctaccgcaac ctggtggccg tgtcccagca ggactccggc 1020
acctccctgt ccagatctta g 1041

<210> 38
<211> 1041
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 38
atggcgtac ccatgaccgt gtccatgcgc ctgaacatcg tgtccccga cctgtccggc 60
aagggcctgg tgctgccctc cgtgctgggc atcaccttcg ggccttcct gatcggcgcc 120
ctgctgaccg ccgccctgtg gtacatctac tcccacacc ggcgccctc caagcgcgag 180
cccgtggtgg ccgtggccgc ccccgctcc tccgagtcct cctccaccaa ccactccatc 240
ggctccaccc agtccacccc ctgctccacc tcctccatgg ccaccggtgg cgtgcccggtg 300
caggggtcca agtacgccgc cgaccgcaac cactaccgcc gctacccccg ccgccgcggc 360
cccccccgca actaccagca gaacacgcgt ggctgaacg ccacgcgcgc cgcacagatg 420
cagcccatgc accgctacga cgtgtccgcc ctgcagtaca actccatgac ctccctccag 480
acctacatga acggctcccc cacctactcc atgtcctact ccagcaggg cacccccggc 540
atggccctgg gctccatggg ctccgtgaga tcccaattgg tgatgaactc cccccctcc 600
cgcatcctgc gccgcgcgca ggcgcgagtg gtgatgcccc ccctctccgt gcccgagaac 660
ggcaagggcc ccttccccca ggcctgaac cagctgaagt ccaacaagga ccgcggcacc 720
aagctgttct actccatcac ogggcccggc gccgactccc ccccgaggg cgtgttcacc 780
atcgagaagg agaccagatc ogccggcgaa atctacacca tgaaggagat catcttctac 840
atcggccagt acatcatgac caagcgctg tacgacgaga agcagcagca catcgtgtac 900
tgctccaacg acctgctggg cgacgtgttc ggcgtgccct cttctccgt gaaggagcac 960
cgcaagatct acgccatgat ctaccgcaac ctggtggtgg tgtcccagca ggactccggc 1020
acctccccct ccagatctta g 1041

<210> 39
<211> 328
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 39
Met Ala Val Pro Met Gln Leu Ser Cys Ser Arg Gln Asn Gly Thr Trp
1 5 10 15

Pro Arg Glu Val Leu Leu Val Leu Ser Val Asn Ser Ser Val Phe Leu
20 25 30

His Leu Gln Ala Leu Gly Ile Pro Leu His Leu Ala Tyr Asn Ser Ser
35 40 45

Leu Val Thr Phe Gln Glu Pro Pro Gly Val Asn Thr Thr Glu Leu Arg
50 55 60

Ser Thr Gly Gly Val Pro Val Gln Gly Ser Lys Tyr Ala Ala Asp Arg
65 70 75 80

Asn His Tyr Arg Arg Tyr Pro Arg Arg Arg Gly Pro Pro Arg Asn Tyr
85 90 95

Gln Gln Asn Thr Arg Gly Leu Asn Ala His Gly Ala Ala Gln Met Gln
100 105 110

- - - - -

Pro Met His Arg Tyr Asp Val Ser Ala Leu Gln Tyr Asn Ser Met Thr
115 120 125

Ser Ser Gln Thr Tyr Met Asn Gly Ser Pro Thr Tyr Ser Met Ser Tyr
130 135 140

Ser Gln Gln Gly Thr Pro Gly Met Ala Leu Gly Ser Met Gly Ser Val
145 150 155 160

Arg Ser Gln Leu Arg Ser Leu Lys Glu Arg Asn Pro Leu Lys Ile Phe
165 170 175

Pro Ser Lys Arg Ile Leu Arg Arg His Lys Arg Asp Trp Val Val Ala
180 185 190

Pro Ile Ser Val Pro Glu Asn Gly Lys Gly Pro Phe Pro Gln Arg Leu
195 200 205

Asn Gln Leu Lys Ser Asn Lys Asp Arg Asp Thr Lys Ile Phe Tyr Ser
210 215 220

Ile Thr Gly Pro Gly Ala Asp Ser Pro Pro Glu Gly Val Phe Ala Val
225 230 235 240

Glu Lys Glu Thr Arg Ser Ala Gly Glu Thr Tyr Thr Met Lys Glu Val
245 250 255

Leu Phe Tyr Leu Gly Gln Tyr Ile Met Thr Lys Arg Leu Tyr Asp Glu
260 265 270

Lys Gln Gln His Ile Val Tyr Cys Ser Asn Asp Leu Leu Gly Asp Leu
275 280 285

Phe Gly Val Pro Ser Phe Ser Val Lys Glu His Arg Lys Ile Tyr Thr
290 295 300

Met Ile Tyr Arg Asn Leu Val Val Val Asn Gln Gln Glu Ser Ser Asp
305 310 315 320

Ser Gly Thr Ser Val Ser Arg Ser
325

<210> 40
<211> 352
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 40
Met Ala Val Pro Met Thr Val Phe Met Arg Leu Asn Ile Ile Ser Pro
1 5 10 15

Asp Leu Ser Gly Cys Thr Ser Lys Gly Leu Val Leu Pro Ala Val Leu
20 25 30

Gly Ile Thr Phe Gly Ala Phe Leu Ile Gly Ala Leu Leu Thr Ala Ala
35 40 45

Leu Trp Tyr Ile Tyr Ser His Thr Arg Ser Pro Ser Lys Arg Glu Pro
50 55 60

Val Val Ala Val Ala Ala Pro Ala Ser Ser Glu Ser Ser Ser Thr Asn
65 70 75 80

His Ser Ile Gly Ser Thr Gln Ser Thr Pro Cys Ser Thr Ser Ser Met
85 90 95

Ala Thr Gly Gly Val Pro Val Gln Gly Ser Lys Tyr Ala Ala Asp Arg
100 105 110

Asn His Tyr Arg Arg Tyr Pro Arg Arg Arg Gly Pro Pro Arg Asn Tyr
115 120 125

Gln Gln Asn Thr Arg Gly Leu Asn Ala His Gly Ala Ala Gln Met Gln
130 135 140

Pro Met His Arg Tyr Asp Val Ser Ala Leu Gln Tyr Asn Ser Met Thr
145 150 155 160

Ser Ser Gln Thr Tyr Met Asn Gly Ser Pro Thr Tyr Ser Met Ser Tyr
165 170 175

Ser Gln Gln Gly Thr Pro Gly Met Ala Leu Gly Ser Met Gly Ser Val
180 185 190

Arg Ser Gln Leu Leu Lys Ile Phe Pro Ser Lys Arg Ile Leu Arg Arg
195 200 205

His Lys Arg Asp Trp Val Val Ala Pro Ile Ser Val Pro Glu Asn Gly
210 215 220

Lys Gly Pro Phe Pro Gln Arg Leu Asn Gln Leu Lys Ser Asn Lys Asp
225 230 235 240

Arg Asp Thr Lys Ile Phe Tyr Ser Ile Thr Gly Pro Gly Ala Asp Ser
245 250 255

Pro Pro Glu Gly Val Phe Ala Val Glu Lys Glu Thr Arg Ser Ala Gly
260 265 270

Glu Thr Tyr Thr Met Lys Glu Val Leu Phe Tyr Leu Gly Gln Tyr Ile
275 280 285

Met Thr Lys Arg Leu Tyr Asp Glu Lys Gln Gln His Ile Val Tyr Cys
290 295 300

Ser Asn Asp Leu Leu Gly Asp Leu Phe Gly Val Pro Ser Phe Ser Val
305 310 315 320

Lys Glu His Arg Lys Ile Tyr Thr Met Ile Tyr Arg Asn Leu Val Val
325 330 335

Val Asn Gln Gln Glu Ser Ser Asp Ser Gly Thr Ser Val Ser Arg Ser
340 345 350

<210> 41
<211> 346
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 41
Met Ala Val Pro Met Thr Val Ser Met Arg Leu Asn Ile Val Ser Pro
1 5 10 15

Asp Leu Ser Gly Lys Gly Leu Val Leu Pro Ser Val Leu Gly Ile Thr
20 25 30

Phe Gly Ala Phe Leu Ile Gly Ala Leu Leu Thr Ala Ala Leu Trp Tyr
35 40 45

Ile Tyr Ser His Thr Arg Gly Pro Ser Lys Arg Glu Pro Val Val Ala
50 55 60

Val Ala Ala Pro Ala Ser Ser Glu Ser Ser Ser Thr Asn His Ser Ile
65 70 75 80

Gly Ser Thr Gln Ser Thr Pro Cys Ser Thr Ser Ser Met Ala Thr Gly
85 90 95

Glv Val Pro Val Gln Glv Ser Lvs Tvr Ala Ala Asp Arg Asn His Tvr

100 105 110

Arg Arg Tyr Pro Arg Arg Arg Gly Pro Pro Arg Asn Tyr Gln Gln Asn
115 120 125

Thr Arg Gly Leu Asn Ala His Gly Ala Ala Gln Met Gln Pro Met His
130 135 140

Arg Tyr Asp Val Ser Ala Leu Gln Tyr Asn Ser Met Thr Ser Ser Gln
145 150 155 160

Thr Tyr Met Asn Gly Ser Pro Thr Tyr Ser Met Ser Tyr Ser Gln Gln
165 170 175

Gly Thr Pro Gly Met Ala Leu Gly Ser Met Gly Ser Val Arg Ser Gln
180 185 190

Leu Ala Met His Ser Pro Pro Thr Arg Ile Leu Arg Arg Arg Lys Arg
195 200 205

Glu Trp Val Met Pro Pro Ile Phe Val Pro Glu Asn Gly Lys Gly Pro
210 215 220

Phe Pro Gln Arg Leu Asn Gln Leu Lys Ser Asn Lys Asp Arg Gly Thr
225 230 235 240

Lys Ile Phe Tyr Ser Ile Thr Gly Pro Gly Ala Asp Ser Pro Pro Glu
245 250 255

Gly Val Phe Thr Ile Glu Lys Glu Ser Arg Ser Ala Gly Glu Thr Tyr
260 265 270

Thr Met Lys Glu Ile Ile Phe Tyr Ile Gly Gln Tyr Ile Met Thr Lys
275 280 285

Arg Leu Tyr Asp Glu Lys Gln Gln His Ile Val Tyr Cys Ser Asn Asp
290 295 300

Leu Leu Gly Asp Val Phe Gly Val Pro Ser Phe Ser Val Lys Glu His
305 310 315 320

Arg Lys Ile Tyr Ala Met Ile Tyr Arg Asn Leu Val Ala Val Ser Gln
325 330 335

Gln Asp Ser Gly Thr Ser Leu Ser Arg Ser
340 345

<210> 42
<211> 346
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 42
Met Ala Val Pro Met Thr Val Ser Met Arg Leu Asn Ile Val Ser Pro
1 5 10 15

Asp Leu Ser Gly Lys Gly Leu Val Leu Pro Ser Val Leu Gly Ile Thr
20 25 30

Phe Gly Ala Phe Leu Ile Gly Ala Leu Leu Thr Ala Ala Leu Trp Tyr
35 40 45

Ile Tyr Ser His Thr Arg Ala Pro Ser Lys Arg Glu Pro Val Val Ala
50 55 60

Val Ala Ala Pro Ala Ser Ser Glu Ser Ser Ser Thr Asn His Ser Ile
65 70 75 80

Gly Ser Thr Gln Ser Thr Pro Cys Ser Thr Ser Ser Met Ala Thr Gly
85 90 95

Gly Val Pro Val Gln Gly Ser Lys Tyr Ala Ala Asp Arg Asn His Tyr
100 105 110

Arg Arg Tyr Pro Arg Arg Arg Gly Pro Pro Arg Asn Tyr Gln Gln Asn
115 120 125

Thr Arg Gly Leu Asn Ala His Gly Ala Ala Gln Met Gln Pro Met His
130 135 140

Arg Tyr Asp Val Ser Ala Leu Gln Tyr Asn Ser Met Thr Ser Ser Gln
145 150 155 160

Thr Tyr Met Asn Gly Ser Pro Thr Tyr Ser Met Ser Tyr Ser Gln Gln
165 170 175

Gly Thr Pro Gly Met Ala Leu Gly Ser Met Gly Ser Val Arg Ser Gln
180 185 190

Leu Val Met Asn Ser Pro Pro Ser Arg Ile Leu Arg Arg Arg Lys Arg
195 200 205

Glu Trp Val Met Pro Pro Ile Ser Val Pro Glu Asn Gly Lys Gly Pro
210 215 220

Phe Pro Gln Arg Leu Asn Gln Leu Lys Ser Asn Lys Asp Arg Gly Thr
225 230 235 240

Lys Leu Phe Tyr Ser Ile Thr Gly Pro Gly Ala Asp Ser Pro Pro Glu
245 250 255

Gly Val Phe Thr Ile Glu Lys Glu Thr Arg Ser Ala Gly Glu Ile Tyr
260 265 270

Thr Met Lys Glu Ile Ile Phe Tyr Ile Gly Gln Tyr Ile Met Thr Lys
275 280 285

Arg Leu Tyr Asp Glu Lys Gln Gln His Ile Val Tyr Cys Ser Asn Asp
290 295 300

Leu Leu Gly Asp Val Phe Gly Val Pro Ser Phe Ser Val Lys Glu His
305 310 315 320

Arg Lys Ile Tyr Ala Met Ile Tyr Arg Asn Leu Val Val Val Ser Gln
325 330 335

Gln Asp Ser Gly Thr Ser Pro Ser Arg Ser
340 345

<210> 43

<211> 489

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic polynucleotide or polypeptide

<400> 43

atgctgccga	gagtgggctg	ccccgcgctg	ccgctgccgc	cgccgccgct	gctgccgctg	60
ctgccgctgc	tgctgctgct	actgggcgcg	agtggcggcg	gcggcggggc	gcgcgcggag	120
gtgctgttcc	gctgcccgcc	ctgcacaccc	gagcgcctgg	ccgcctgcgg	gccccgccg	180
gttgccgcgc	ccgccgcggt	ggccgcagtg	gccggaggcg	ccgcgatgcc	atgcgcggag	240
ctcgtccggg	agccgggctg	cggctgctgc	tcggtgtgcg	cccggctgga	gggcgaggcg	300
tgcggcgtct	acaccccgcg	ctgcggccag	gggtgcgct	gctatcccca	cccgggctcc	360
gagctgcccc	tgcaggcgct	ggtcatgggc	gagggcactt	gtgagaagcg	ccgggacgcc	420
gagtatggcg	ccagcccgga	gcaggttgca	gacaatggcg	atgaccactc	agaaggaggc	480
ctggtggag						489

<210> 44

<211> 423

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 44
atgctgcccc gcctgggcgg ccccgccctg cccctgctgc tgcctccct getgctgctg 60
ctgctgctgg gcgcgggcgg ctgcggcccc ggcgtgcgcg ccgaggtgct gttccgctgc 120
ccccctgca ccccgagcg cctggccgcc tgcggccccc ccccgacgc cccctgcgcc 180
gagctggtgc gcgagcccg ctgcggctgc tgcctcgtgt gcgcccgcca ggagggcgag 240
gcctgcggcg tgtacatccc ccgctgcgcc cagaccctgc gctgctaccc caaccccggc 300
tccgagctgc cctgaaggc cctggtgacc ggcgcgggca cctgcgagaa gcgcgcgctg 360
ggcaccaccc cccagcaggt ggccgactcc gacgacgacc actccgaggg cggcctggtg 420
gag 423

<210> 45
<211> 423
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 45
atgctgcccc gcctgggcgg ccccgccctg cccctgctgc tgcctccct getgctgctg 60
ctgctgctgg gcgcgggcgg ctgcggcccc ggcgtgcgcg ccgaggtgct gttccgctgc 120
ccccctgca ccccgagcg cctggccgcc tgcggccccc ccccgacgc cccctgcgcc 180
gagctggtgc gcgagcccg ctgcggctgc tgcctcgtgt gcgcccgcca ggagggcgag 240
gcctgcggcg tgtacatccc ccgctgcgcc cagaccctgc gctgctaccc caaccccggc 300
tccgagctgc cctgaaggc cctggtgacc ggcgcgggca cctgcgagaa gcgcgcgctg 360
ggcaccaccc cccagcaggt ggccgactcc gaggacgacc actccgaggg cggcctggtg 420
gag 423

<210> 46
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 46
Asn His Val Asp Ser Thr Met Asn Met Leu Gly Gly Gly Gly Ser
1 5 10 15

<210> 47
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 47
Glu Leu Ala Val Phe Arg Glu Lys Val Thr Glu Gln His Arg Gln
1 5 10 15

<210> 48
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 48
Leu Gly Leu Glu Glu Pro Lys Lys Leu Arg Pro Pro Pro Ala Arg
1 5 10 15

<210> 49
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 49
Asp Gln Val Leu Glu Arg Ile Ser Thr Met Arg Leu Pro Asp Glu
1 5 10 15

<210> 50
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 50
Gly Pro Leu Glu His Leu Tyr Ser Leu His Ile Pro Asn Cys Asp
1 5 10 15

<210> 51
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 51
Lys His Gly Leu Tyr Asn Leu Lys Gln Cys Lys Met Ser Leu Asn
1 5 10 15

<210> 52
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 52
Pro Asn Thr Gly Lys Leu Ile Gln Gly Ala Pro Thr Ile Arg Gly
1 5 10 15

<210> 53
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 53
Pro Glu Cys His Leu Phe Tyr Asn Glu Gln Gln Glu Ala Arg Gly
1 5 10 15

<210> 54
<211> 163
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 54
Met Leu Pro Arg Val Gly Cys Pro Ala Leu Pro Leu Pro Pro Pro Pro
1 5 10 15

Leu Leu Pro Leu Leu Pro Leu Leu Leu Leu Leu Gly Ala Ser Gly
20 25 30

Gly Gly Gly Gly Ala Arg Ala Glu Val Leu Phe Arg Cys Pro Pro Cys
35 40 45

Thr Pro Glu Arg Leu Ala Ala Cys Gly Pro Pro Pro Val Ala Pro Pro
50 55 60

Ala Ala Val Ala Ala Val Ala Gly Gly Ala Arg Met Pro Cys Ala Glu
65 70 75 80

Leu Val Arg Glu Pro Gly Cys Gly Cys Cys Ser Val Cys Ala Arg Leu
85 90 95

Glu Gly Glu Ala Cys Gly Val Tyr Thr Pro Arg Cys Gly Gln Gly Leu
100 105 110

Arg Cys Tyr Pro His Pro Gly Ser Glu Leu Pro Leu Gln Ala Leu Val
115 120 125

Met Gly Glu Gly Thr Cys Glu Lys Arg Arg Asp Ala Glu Tyr Gly Ala
130 135 140

Ser Pro Glu Gln Val Ala Asp Asn Gly Asp Asp His Ser Glu Gly Gly
145 150 155 160

Leu Val Glu

<210> 55
<211> 141
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 55
Met Leu Pro Arg Leu Gly Gly Pro Ala Leu Pro Leu Leu Leu Pro Ser
1 5 10 15

Leu Leu Leu Leu Leu Leu Leu Gly Ala Gly Gly Cys Gly Pro Gly Val
20 25 30

Arg Ala Glu Val Leu Phe Arg Cys Pro Pro Cys Thr Pro Glu Arg Leu
35 40 45

Ala Ala Cys Gly Pro Pro Pro Asp Ala Pro Cys Ala Glu Leu Val Arg
50 55 60

Glu Pro Gly Cys Gly Cys Cys Ser Val Cys Ala Arg Gln Glu Gly Glu
65 70 75 80

Ala Cys Gly Val Tyr Ile Pro Arg Cys Ala Gln Thr Leu Arg Cys Tyr
85 90 95

Pro Asn Pro Gly Ser Glu Leu Pro Leu Lys Ala Leu Val Thr Gly Ala
100 105 110

Gly Thr Cys Glu Lys Arg Arg Val Gly Thr Thr Pro Gln Gln Val Ala

115

120

125

Asp Ser Asp Asp Asp His Ser Glu Gly Gly Leu Val Glu

130135140

<210> 56

<211> 141

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic polynucleotide or polypeptide

<400> 56

Met Leu Pro Arg Leu Gly Gly Pro Ala Leu Pro Leu Leu Leu Pro Ser

151015

Leu Leu Leu Leu Leu Leu Gly Ala Gly Gly Cys Gly Pro Gly Val

202530

Arg Ala Glu Val Leu Phe Arg Cys Pro Pro Cys Thr Pro Glu Arg Leu

354045

Ala Ala Cys Gly Pro Pro Pro Asp Ala Pro Cys Ala Glu Leu Val Arg

505560

Glu Pro Gly Cys Gly Cys Cys Ser Val Cys Ala Arg Gln Glu Gly Glu

65707580

Ala Cys Gly Val Tyr Ile Pro Arg Cys Ala Gln Thr Leu Arg Cys Tyr

859095

Pro Asn Pro Gly Ser Glu Leu Pro Leu Lys Ala Leu Val Thr Gly Ala

100105110

Gly Thr Cys Glu Lys Arg Arg Val Gly Ala Thr Pro Gln Gln Val Ala

115120125

Asp Ser Glu Asp Asp His Ser Glu Gly Gly Leu Val Glu

130135140

<210> 57

<211> 1101

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic polynucleotide or polypeptide

<400> 57

acgatgcgga gactgctgca ggaaacggag ctggtggagc cgctgacacc tagcggagcg60

atgcccaacc aggcgcagat gcggatcctg aaagagacgg agctgaggaa ggtgaagggtg120

cttggatctg gcgcttttgg cacagtctac aagggcctct ggatccctga tggggagaat180

gtgaaaattc cagtggccat caaagtgttg agggaaaaca catcccccaa agccaacaaa240

gaaatcttag acgaagcata cgtgatggct ggtgtgggct ccccatatgt ctcccgctt300

ctgggcatct gcctgacatc cacggtgcag ctggtgacac agcttatgcc ctatggctgc360

ctcttagacc atgtccggga aaaccgcgga cgcctgggct occaggacct gctgaactgg420

tgtatgcaga ttgccaaagg gatgagctac ctggaggatg tgcggctcgt acacagggac480

ttggccgctc ggaacgtgct ggtcaagagt cccaaccatg tcaaaattac agacttcggg540

ctggctcggc tgctggacat tgacgagaca gagtacatg cagatggggg caaggtgccc600

atcaagtgga tggcgctgga gtccattctc cgccggcggt tcaccaccca gagtgatgtg660

tggagttatg gtgtgactgt gtgggagctg atgacttttg gggccaaacc ttacgatggg720

atcccagccc gggagatccc tgacctgtg gaaaagggg agcggtgcc ccagccccc780

atctgcacca ttgatgtcta catgatcatg gtcaaagtgt ggatgattga ctctgaatgt840

cccccaaat tcccaaat attctctcaa ttctcccca tcccaaaaa ccccaaccc900

tttgtggtca tccagaatga ggacttggct cccggagctg gcggcatggt gcaccacagg 960
caccgcagct catctcctct gcctgctgcc cgacctgctg gtgccactct ggaaaggccc 1020
aagactctct ccccgaggaa gaatggggtc gtcaaagacg tttttgcctt tgggggtgcc 1080
gtggagaacc ccgagtactt g 1101

<210> 58
<211> 1101
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 58
accatgcgcc gcctgctgca ggagaccgag ctggtggagc ccctgacccc ctccggcgcc 60
gtgcccaacc aggccagat gcgcacctg aaggagaccg agctgcgcaa gctgaagggtg 120
ctgggctccg gcgccttcgg caccgtgtac aagggcactct ggatccccga cggcgagAAC 180
gtgaagatcc ccgtggccat caaggtgctg cgcgagaaca cctcccccaa ggccaacaag 240
gagatcctgg acgaggccta cgtgatggcc ggcgtgggct cccctacgt gtccgcctg 300
ctgggcatct gcctgacctc caccgtgcag ctggtgacct agctgatgcc ctacggctgc 360
ctgctggacc acgtgcgcga gcaccgcggc cgcctgggct cccaggacct gctgaactgg 420
tgcggtcaga tcgccaaggc catgtcctac ctggaggagc tgcgcctggt gcaccgcgac 480
ctggccgccc gcaacgtgct ggtgaagtcc cccaaccacg tgaagatcac cgacttcggc 540
ctggcccgcc tgctggacat cgacgagacc gagtaccacg ccgacggcgg caaggtgccc 600
atcaagtgga tggccctgga gtccatcctg cgcgcgcgct tcaccacca gtccgacgtg 660
tggtcctacg gcgtgaccgt gtgggagctg atgaccttcg gcgccaagcc ctacgacggc 720
atccccgccc gcgagatccc cgacctgctg gagaagggcg agcgctgcc ccagcccccc 780
atctgcacca tcgacgtgta catgatcatg gtgaagtgtc ggatgatcga ctccgagtgc 840
cgcccccgct tccgcgagct ggtgtccgag ttctcccgca tggcccgcga ccccagcgc 900
ttcgtggtga tccagaacga ggacctggcc ctgggcaccg gctccaccgc ccaccgcgc 960

caccgtcctc cctccccccc ccccccatc cgccccgcg gcgccacct ggagcgcccc 1020
aagaccctgt ccccggaac gaacggcgtg gtgaaggacg tgttcgcctt cggcggcgcc 1080
gtggagaacc ccgagtacct g 1101

<210> 59
<211> 1101
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 59
accatgcgcc gcctgctgca ggagaccgag ctggtggagc ccctgacccc ctccggcgcc 60
atgcccaacc aggccagat gcgcacctg aaggagaccg agctgcgcaa ggtgaagggtg 120
ctgggctccg gcgccttcgg caccgtgtac aagggcactct ggatccccga cggcgagAAC 180
gtgaagatcc ccgtggccat caaggtgctg cgcgagaaca cctcccccaa ggccaacaag 240
gagatcctgg acgaggccta cgtgatggcc ggcgtgggct cccctacgt gtccgcctg 300
ctgggcatct gcctgacctc caccgtgcag ctggtgacct agctgatgcc ctacggctgc 360
ctgctggacc acgtgcgcga gcaccgcggc cgcctgggct cccaggacct gctgaactgg 420
tgcggtcaga tcgccaaggc catgtcctac ctggaggacg tgcgcctggt gcaccgcgac 480
ctggccgccc gcaacgtgct ggtgaagtcc cccaaccacg tgaagatcac cgacttcggc 540
ctggcccgcc tgctggacat cgacgagacc gagtaccacg ccgacggcgg caaggtgccc 600
atcaagtgga tggccctgga gtccatcctg cgcgcgcgct tcaccacca gtccgacgtg 660

tggtcctacg gcgtgaccgt gtgggagctg atgaccttcg gcgcccaagcc ctacgacggc 720
atccccgccc gcgagatccc cgacctgctg gagaagggcg agcgccctgcc ccagcccccc 780
atctgcacca tcgacgtgta catgatcatg gtgaagtgtc ggatgatcga ctccgagtgc 840
cgcccccgct tccgcgagct ggtgtccgag ttctcccgca tggcccgcgga cccccagcgc 900
ttcgtggtga tccagaacga ggacctgacc cccggcaccg gctccaccgc ccaccgcccgc 960
caccgctcct cctccccccct gccccccgtg cgccccgcgc gcgccaccct ggagcgcccc 1020
aagaccctgt cccccggcaa gaacggcgtg gtgaaggacg tgttcgcctt cggcggcgcc 1080
gtggagaacc ccgagtacct g 1101

<210> 60
<211> 367
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 60
Thr Met Arg Arg Leu Leu Gln Glu Thr Glu Leu Val Glu Pro Leu Thr
1 5 10 15

Pro Ser Gly Ala Met Pro Asn Gln Ala Gln Met Arg Ile Leu Lys Glu
20 25 30

Thr Glu Leu Arg Lys Val Lys Val Leu Gly Ser Gly Ala Phe Gly Thr
35 40 45

Val Tyr Lys Gly Ile Trp Ile Pro Asp Gly Glu Asn Val Lys Ile Pro
50 55 60

Val Ala Ile Lys Val Leu Arg Glu Asn Thr Ser Pro Lys Ala Asn Lys
65 70 75 80

Glu Ile Leu Asp Glu Ala Tyr Val Met Ala Gly Val Gly Ser Pro Tyr
85 90 95

Val Ser Arg Leu Leu Gly Ile Cys Leu Thr Ser Thr Val Gln Leu Val
100 105 110

Thr Gln Leu Met Pro Tyr Gly Cys Leu Leu Asp His Val Arg Glu Asn
115 120 125

Arg Gly Arg Leu Gly Ser Gln Asp Leu Leu Asn Trp Cys Met Gln Ile
130 135 140

Ala Lys Gly Met Ser Tyr Leu Glu Asp Val Arg Leu Val His Arg Asp
145 150 155 160

Leu Ala Ala Arg Asn Val Leu Val Lys Ser Pro Asn His Val Lys Ile
165 170 175

Thr Asp Phe Gly Leu Ala Arg Leu Leu Asp Ile Asp Glu Thr Glu Tyr
180 185 190

His Ala Asp Gly Gly Lys Val Pro Ile Lys Trp Met Ala Leu Glu Ser
195 200 205

Ile Leu Arg Arg Arg Phe Thr His Gln Ser Asp Val Trp Ser Tyr Gly
210 215 220

Val Thr Val Trp Glu Leu Met Thr Phe Gly Ala Lys Pro Tyr Asp Gly
225 230 235 240

Ile Pro Ala Arg Glu Ile Pro Asp Leu Leu Glu Lys Gly Glu Arg Leu
245 250 255

Pro Gln Pro Pro Ile Cys Thr Ile Asp Val Tyr Met Ile Met Val Lys
260 265 270

Cys Trp Met Ile Asp Ser Glu Cys Arg Pro Arg Phe Arg Glu Leu Val
275 280 285

Ser Glu Phe Ser Arg Met Ala Arg Asp Pro Gln Arg Phe Val Val Ile
290 295 300

Gln Asn Glu Asp Leu Ala Pro Gly Ala Gly Gly Met Val His His Arg
305 310 315 320

His Arg Ser Ser Ser Pro Leu Pro Ala Ala Arg Pro Ala Gly Ala Thr
325 330 335

Leu Glu Arg Pro Lys Thr Leu Ser Pro Gly Lys Asn Gly Val Val Lys
340 345 350

Asp Val Phe Ala Phe Gly Gly Ala Val Glu Asn Pro Glu Tyr Leu
355 360 365

<210> 61

<211> 367

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic polynucleotide or polypeptide

<400> 61

Thr Met Arg Arg Leu Leu Gln Glu Thr Glu Leu Val Glu Pro Leu Thr
1 5 10 15

Pro Ser Gly Ala Val Pro Asn Gln Ala Gln Met Arg Ile Leu Lys Glu
20 25 30

Thr Glu Leu Arg Lys Leu Lys Val Leu Gly Ser Gly Ala Phe Gly Thr
35 40 45

Val Tyr Lys Gly Ile Trp Ile Pro Asp Gly Glu Asn Val Lys Ile Pro
50 55 60

Val Ala Ile Lys Val Leu Arg Glu Asn Thr Ser Pro Lys Ala Asn Lys
65 70 75 80

Glu Ile Leu Asp Glu Ala Tyr Val Met Ala Gly Val Gly Ser Pro Tyr
85 90 95

Val Ser Arg Leu Leu Gly Ile Cys Leu Thr Ser Thr Val Gln Leu Val
100 105 110

Thr Gln Leu Met Pro Tyr Gly Cys Leu Leu Asp His Val Arg Glu His
115 120 125

Arg Gly Arg Leu Gly Ser Gln Asp Leu Leu Asn Trp Cys Val Gln Ile
130 135 140

Ala Lys Gly Met Ser Tyr Leu Glu Glu Val Arg Leu Val His Arg Asp
145 150 155 160

Leu Ala Ala Arg Asn Val Leu Val Lys Ser Pro Asn His Val Lys Ile
165 170 175

Thr Asp Phe Gly Leu Ala Arg Leu Leu Asp Ile Asp Glu Thr Glu Tyr
180 185 190

His Ala Asp Gly Gly Lys Val Pro Ile Lys Trp Met Ala Leu Glu Ser
195 200 205

Ile Leu Arg Arg Arg Phe Thr His Gln Ser Asp Val Trp Ser Tyr Gly
210 215 220

Val Thr Val Trp Glu Leu Met Thr Phe Gly Ala Lys Pro Tyr Asp Gly
225 230 235 240

Ile Pro Ala Arg Glu Ile Pro Asp Leu Leu Glu Lys Gly Glu Arg Leu
245 250 255

Pro Gln Pro Pro Ile Cys Thr Ile Asp Val Tyr Met Ile Met Val Lys
260 265 270

Cys Trp Met Ile Asp Ser Glu Cys Arg Pro Arg Phe Arg Glu Leu Val
275 280 285

Ser Glu Phe Ser Arg Met Ala Arg Asp Pro Gln Arg Phe Val Val Ile
290 295 300

Gln Asn Glu Asp Leu Ala Leu Gly Thr Gly Ser Thr Ala His Arg Arg
305 310 315 320

His Arg Ser Ser Ser Pro Pro Pro Pro Ile Arg Pro Ala Gly Ala Thr
325 330 335

Leu Glu Arg Pro Lys Thr Leu Ser Pro Gly Lys Asn Gly Val Val Lys
340 345 350

Asp Val Phe Ala Phe Gly Gly Ala Val Glu Asn Pro Glu Tyr Leu
355 360 365

<210> 62

<211> 367

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic polynucleotide or polypeptide

<400> 62

Thr Met Arg Arg Leu Leu Gln Glu Thr Glu Leu Val Glu Pro Leu Thr
1 5 10 15

Pro Ser Gly Ala Met Pro Asn Gln Ala Gln Met Arg Ile Leu Lys Glu
20 25 30

Thr Glu Leu Arg Lys Val Lys Val Leu Gly Ser Gly Ala Phe Gly Thr
35 40 45

Val Tyr Lys Gly Ile Trp Ile Pro Asp Gly Glu Asn Val Lys Ile Pro
50 55 60

Val Ala Ile Lys Val Leu Arg Glu Asn Thr Ser Pro Lys Ala Asn Lys
65 70 75 80

Glu Ile Leu Asp Glu Ala Tyr Val Met Ala Gly Val Gly Ser Pro Tyr
85 90 95

Val Ser Arg Leu Leu Gly Ile Cys Leu Thr Ser Thr Val Gln Leu Val
100 105 110

Thr Gln Leu Met Pro Tyr Gly Cys Leu Leu Asp His Val Arg Glu His
115 120 125

Arg Gly Arg Leu Gly Ser Gln Asp Leu Leu Asn Trp Cys Val Gln Ile
130 135 140

Ala Lys Gly Met Ser Tyr Leu Glu Asp Val Arg Leu Val His Arg Asp
145 150 155 160

Leu Ala Ala Arg Asn Val Leu Val Lys Ser Pro Asn His Val Lys Ile
165 170 175

Thr Asp Phe Gly Leu Ala Arg Leu Leu Asp Ile Asp Glu Thr Glu Tyr
180 185 190

His Ala Asp Gly Gly Lys Val Pro Ile Lys Trp Met Ala Leu Glu Ser
195 200 205

Ile Leu Arg Arg Arg Phe Thr His Gln Ser Asp Val Trp Ser Tyr Gly
210 215 220

Val Thr Val Trp Glu Leu Met Thr Phe Gly Ala Lys Pro Tyr Asp Gly
225 230 235 240

Ile Pro Ala Arg Glu Ile Pro Asp Leu Leu Glu Lys Gly Glu Arg Leu
245 250 255

Pro Gln Pro Pro Ile Cys Thr Ile Asp Val Tyr Met Ile Met Val Lys
260 265 270

Cys Trp Met Ile Asp Ser Glu Cys Arg Pro Arg Phe Arg Glu Leu Val
275 280 285

Ser Glu Phe Ser Arg Met Ala Arg Asp Pro Gln Arg Phe Val Val Ile
290 295 300

Gln Asn Glu Asp Leu Thr Pro Gly Thr Gly Ser Thr Ala His Arg Arg
305 310 315 320

His Arg Ser Ser Ser Pro Leu Pro Pro Val Arg Pro Ala Gly Ala Thr
325 330 335

Leu Glu Arg Pro Lys Thr Leu Ser Pro Gly Lys Asn Gly Val Val Lys
340 345 350

Asp Val Phe Ala Phe Gly Gly Ala Val Glu Asn Pro Glu Tyr Leu
355 360 365

<210> 63
<211> 312
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 63
tggtccttcg gcgtggtgct gtgggagatc gccaccctgg ccgagcagcc ctaccagggc 60
ctgtccaacg agcaggtgct gcgcttcgtg atggagggcg gcctgctgga caagcccgac 120
aactgccccg acatgctgtt cgagctgatg cgcattgtgt ggcagtacaa cccaagatg 180
cgccccctct tcctggagca caaggccgag aacggccccg gccccggcgt gctggtgctg 240
cgcgccctct tcgacgagcg ccagccctac gccacatga acggaggccg caagaacgag 300
cgcgccctgc cc 312

<210> 64
<211> 312
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 64
tggtccttcg gcgtggtgct gtgggagatc gccaccctgg ccgagcagcc ctaccagggc 60
ctgtccaacg agcaggtgct gcgcttcgtg atggagggcg gcctgctgga caagcccgac 120
aactgccccg acatgctgtt cgagctgatg cgcattgtgt ggcagtacaa cccaagatg 180
cgccccctct tcctggagca caaggccgag aacggccccg gccccggcgt gctggtgctg 240
cgcgccctct tcgacgagcg ccagccctac gccacatga acggcggccg cgccaacgag 300
cgcgccctgc cc 312

<210> 65
<211> 306
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 65
tggtccttcg gcgtggtgct gtgggagatc gccaccctgg ccgagcagcc ctaccagggc 60
ctgtccaacg agcaggtgct gcgcttcgtg atggagggcg gcctgctgga caagcccgac 120
aactgccccg acatgctggt cgagctgatg cgcattgtgt ggcagtacaa cccaagatg 180
cgccctctct tcctggagca caaggccgag aacggccccg gcgtgctggt gctgcgcgcc 240
tccttcgacg agcgcagcc ctacgcccac atgaacggcg gccgcgcaa cgagcgcgcc 300
ctgccc 306

<210> 66
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 66
Asp Tyr Arg Ser Tyr Arg Phe Pro Lys Leu Thr Val Ile Thr Glu
1 5 10 15

<210> 67
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 67
Ile Arg Gly Trp Lys Leu Phe Tyr Asn Tyr Ala Leu Val Ile Phe
1 5 10 15

<210> 68
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 68
Val Val Thr Gly Tyr Val Lys Ile Arg His Ser His Ala Leu Val
1 5 10 15

<210> 69
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 69
Phe Phe Tyr Val Gln Ala Lys Thr Gly Tyr Glu Asn Phe Ile His
1 5 10 15

<210> 70
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 70
Leu Ile Ile Ala Leu Pro Val Ala Val Leu Leu Ile Val Gly Gly
1 5 10 15

<210> 71
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 71
Leu Val Ile Met Leu Tyr Val Phe His Arg Lys Arg Asn Asn Ser
1 5 10 15

<210> 72
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 72
Asn Cys His His Val Val Arg Leu Leu Gly Val Val Ser Gln Gly
1 5 10 15

<210> 73
<211> 104
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 73
Trp Ser Phe Gly Val Val Leu Trp Glu Ile Ala Thr Leu Ala Glu Gln
1 5 10 15

Pro Tyr Gln Gly Leu Ser Asn Glu Gln Val Leu Arg Phe Val Met Glu
20 25 30

Gly Gly Leu Leu Asp Lys Pro Asp Asn Cys Pro Asp Met Leu Phe Glu
35 40 45

Leu Met Arg Met Cys Trp Gln Tyr Asn Pro Lys Met Arg Pro Ser Phe
50 55 60

Leu Glu His Lys Ala Glu Asn Gly Pro Gly Pro Gly Val Leu Val Leu
65 70 75 80

Arg Ala Ser Phe Asp Glu Arg Gln Pro Tyr Ala His Met Asn Gly Gly
85 90 95

Arg Lys Asn Glu Arg Ala Leu Pro
100

<210> 74
<211> 104
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 74
Trp Ser Phe Gly Val Val Leu Trp Glu Ile Ala Thr Leu Ala Glu Gln
1 5 10 15

Pro Tyr Gln Gly Leu Ser Asn Glu Gln Val Leu Arg Phe Val Met Glu
20 25 30

Pro Tyr Gln Gly Leu Ser Asn Glu Gln Val Leu Arg Phe Val Met Glu
20 25 30

Gly Gly Leu Leu Asp Lys Pro Asp Asn Cys Pro Asp Met Leu Phe Glu
35 40 45

Leu Met Arg Met Cys Trp Gln Tyr Asn Pro Lys Met Arg Pro Ser Phe
50 55 60

Leu Glu His Lys Ala Glu Asn Gly Pro Gly Pro Gly Val Leu Val Leu
65 70 75 80

Arg Ala Ser Phe Asp Glu Arg Gln Pro Tyr Ala His Met Asn Gly Gly
85 90 95

Arg Ala Asn Glu Arg Ala Leu Pro
100

<210> 75
<211> 102
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 75
Trp Ser Phe Gly Val Val Leu Trp Glu Ile Ala Thr Leu Ala Glu Gln
1 5 10 15

Pro Tyr Gln Gly Leu Ser Asn Glu Gln Val Leu Arg Phe Val Met Glu
20 25 30

Gly Gly Leu Leu Asp Lys Pro Asp Asn Cys Pro Asp Met Leu Phe Glu
35 40 45

Leu Met Arg Met Cys Trp Gln Tyr Asn Pro Lys Met Arg Pro Ser Phe
50 55 60

Leu Glu His Lys Ala Glu Asn Gly Pro Gly Val Leu Val Leu Arg Ala
65 70 75 80

Ser Phe Asp Glu Arg Gln Pro Tyr Ala His Met Asn Gly Gly Arg Ala
85 90 95

Asn Glu Arg Ala Leu Pro
100

<210> 76
<211> 1947
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 76
atggcgttac caatgctgcc gagagtgggc tgccccgcgc tgccgctgcc gccgccgcgc 60
ctgctgccgc tgctgccgct gctgctgctg ctactgggcg cgagtggcgg cggcggcggg 120
gcgcgcgcgg aggtgctgtt ccgctgcccg ccctgcacac ccgagcgctt gccgcctgc 180
gggccccgc cggttgccgc gcccgccgc gtggccgcag tggccggagg cgcgccgatg 240
ccatgcgcgg agctcgctcc ggagccgggc tcgcgctgct gctcgggtgt cgcgccgctg 300
gagggcgagg cgtgcggcgt ctacaccccg cgctgcggcc aggggctgcg ctgctatccc 360
caccgggct ccgagctgcc cctgcaggcg ctggtcatgg gcgagggcac ttgtgagaag 420
cgccgggacg ccgagtatgg cgcagcccg gaggcgggtg cagacaatgg cgatgaccac 480
tcagaaggag gcttgggtga gcaattgacg atgcggagac tgctgcagga aacggagctg 540
gtggagccgc tgacacctag cggagcgatg cccaaccagg cgcagatgcg gatcctgaaa 600
gagacggagc tgaggaaggt gaaggtgctt ggatctggcg cttttggcac agtctacaag 660

ggcatctgga tccctgatgg ggagaatgtg aaaattccag tggccatcaa agtgttgagg 720
gaaaacacat cccccaagc caacaaagaa atcttagacg aagcatacgt gatggctggt 780
gtgggctccc catatgtctc ccgccttctg ggcatctgcc tgacatccac ggtgcagctg 840
gtgacacagc ttatgcccta tggctgcctc ttagaccatg tccgggaaaa ccgcggacgc 900
ctgggctccc aggacctgct gaactggtgt atgcagattg ccaaggggat gagctacctg 960
gaggatgtgc ggctcgtaca cagggacttg gccgctcgga acgtgctggt caagagtccc 1020
aaccatgtca aaattacaga cttcgggctg gctcggctgc tggacattga cgagacagag 1080
taccatgcag atggggggcaa ggtgcccata aagtggatgg cgctggagtc cattctccgc 1140
cggcggttca cccaccagag tgatgtgtgg agttatggtg tgactgtgtg ggagctgatg 1200
acttttgggg ccaaacctta cgatgggata ccagcccggg agatccctga cctgctggaa 1260
aagggggagc ggctgcccca gccccccata tgcaccattg atgtctacat gatcatggtc 1320
aatgttgga tgattgactc tgaatgtcgg ccaagattcc gggagttggt gtctgaattc 1380

tcccgcgatg ccagggaccc ccagcgcttt gtggtcatcc agaatgagga cttggctccc 1440
ggagctggcg gcatggtgca ccacaggcac cgcagctcat ctctctgcc tgctgccga 1500
cctgctggtg ccactctgga aaggcccaag actctctccc cagggaagaa tggggtcgtc 1560
aaagacgttt ttgcctttgg gggtgccgtg gagaaccccg agtacttggg ccggccggta 1620
ccttggtcct tcggcggtgt gctgtgggag atcgccaccc tggccgagca gccctaccag 1680
ggcctgtcca acgagcaggt gctgcgcttc gtgatggagg gccgcctgct ggacaagccc 1740
gacaactgcc ccgacatgct gttcgagctg atgcgcatgt gctggcagta caacccaag 1800
atgcgcccct ccttcctgga gcacaaggcc gagaacggcc ccggccccgg cgtgctggtg 1860
ctgcgcgect ccttcgacga gcgccagccc tacgccaca tgaacggagg ccgcaagaac 1920
gagcgcgccc tgcccgcggc cgcatag 1947

<210> 77

<211> 1881

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic polynucleotide or polypeptide

<400> 77

atggcggtac caatgctgcc ccgcctgggc ggccccgccc tgccctgct gctgccctcc 60
ctgctgctgc tgctgctgct gggcgccggc ggctgcggcc ccggcgctgc cgcagaggtg 120
ctgttccgct gccccccctg cccccccgag cgcctggccg cctgcggccc ccccccgac 180
gccccctgcg ccgagctggt gcgcgagccc ggctgcggct gctgctccgt gtgcgcccgc 240
caggagggcg aggcctgcgg cgtgtacatc ccccgctgcg ccagacccct gcgctgctac 300
cccaaccccg gctccgagct gccctgaag gccctggtga ccggcgccgg cacctgcgag 360
aagcgcccg tgggcaccac cccccagcag gtggccgact ccgacgacga ccaactccgag 420
ggcggcctgg ttgagcaatt gaccatgcgc cgctgctgc aggagaccga gctggtggag 480
cccctgaccc cctccggcgc cgtgcccaac caggcccaga tgcgcatcct gaaggagacc 540
gagctgcgca agctgaaggt gctgggctcc ggcgccttcg gcaccgtgta caagggcatc 600
tggatccccg acggcgagaa cgtgaagatc cccgtggcca tcaaggctgt gcgcgagaac 660
acctccccca aggccaacaa ggagatcctg gacgaggcct acgtgatggc cggcgtgggc 720
tccccctacg tgtccgcct gctgggcata tgctgacct ccaccgtgca gctggtgacc 780
cagctgatgc cctacggctg cctgctggac cactgcgcg agcaccgcgg ccgcctgggc 840
tcccaggacc tgctgaactg gtgcgtgcag atcgccaagg gcatgtccta cctggaggag 900
gtgcgcctgg tgcaccgcga cctggccgcc cgcaacgtgc tggatgaagt cccaaccac 960

gtgaagatca ccgacttcgg cctggccccg ctgctggaca tcgacgagac cgagtaccac 1020
gccgacggcg gcaagggtgcc catcaagtgg atggccctgg agtccatcct gcgcgcgcgc 1080
ttcaccaccc agtccgacgt gtggtcctac ggcgtgaccg tgtgggagct gatgaccttc 1140

ggcgccaagc cctacgacgg catccccgcc cgcgagatcc ccgacctgct ggagaagggc 1200
gagcgccctgc cccagccccc catctgcacc atcgacgtgt acatgatcat ggtgaagtgc 1260
tggatgatcg actccgagtg ccgccccccg ttccgcgagc tgggtgtccga gttctcccgc 1320
atggcccgcg acccccagcg cttcgtggtg atccagaacg aggacctggc cctgggcacc 1380
ggctccaccg cccaccgccc ccaccgctcc tcctcccccc ccccccccat ccgccccgcc 1440
ggcgccaacc tggagcgccc caagaccctg tcccccgga agaacggcgt ggtgaaggac 1500
gtgttcgcct tcggggggcg cgtggagaac cccgagtacc tgggcccggc ggtaccttgg 1560
tccttcggcg tggtgctgtg ggagatcgcc accctggccg agcagcccta ccagggcctg 1620
tccaacgagc aggtgctgcg cttcgtgatg gagggcgggc tgctggacaa gcccgacaac 1680
tgccccgaca tgctgttcga gctgatgcgc atgtgctggc agtacaaccc caagatgcgc 1740
ccctccttcc tggagcacia ggccgagaac ggccccggcc ccggcgtgct ggtgctgcgc 1800
gcctccttcg acgagcgcca gccctacgcc cacatgaacg gcggccgcgc caacgagcgc 1860
gccctgcccg cggccgcata g 1881

<210> 78

<211> 1875

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic polynucleotide or polypeptide

<400> 78

atggcggtag caatgctgcc ccgcctgggc ggccccgccc tgccctctgt gctgccctcc 60
ctgctgctgc tgctgctgct gggcgccggc ggctgcccgc ccggcgtgcg cgcagaggtg 120
ctgttccgct gccccccctg cccccccgag cgcctggccg cctgcggccc ccccccgac 180
gccccctgcg ccgagctggt gcgcgagccc ggctgcccgt gctgctccgt gtgcgcccgc 240
caggagggcg aggctgcgg cgtgtacatc ccccgctgcg ccagaccct gcgctgctac 300
cccaaccccg gctccgagct gccctgaag gccctggtga ccggcgccgg cacctgcgag 360
aagcgccgcg tgggcgccac ccccagcag gtggccgact ccgaggaaga ccaactccgag 420
ggcggcctgg tggagcaatt gaccatgcgc cgcctgctgc aggagaccga gctggtggag 480
cccctgaacc cctccggcgc catgcccaac caggcccaga tgcgcatcct gaaggagacc 540
gagctgcgca aggtgaaggt gctgggctcc ggcgcccttc gcaccgtgta caagggcata 600
tggatccccg acggcgagaa cgtgaagatc cccgtggcca tcaaggtgct gcgcgagaac 660

acctccccca aggccaacaa ggagatcctg gacgaggcct acgtgatggc cggcgtgggc 720
tccccctaag tgtccgcct gctgggcata tgctgacct ccaccgtgca gctggtgacc 780
cagctgatgc cctacggctg cctgctggac cactgcccgc agcaccgcgg ccgcctgggc 840
tcccaggacc tgctgaactg gtgcgtgcag atcgccaagg gcatgtccta cctggaggac 900
gtgcgcctgg tgcaaccgca cctggccgcc cgcaacgtgc tggtgaaatc ccccaaccac 960
gtgaagatca ccgacttcgg cctggcccgc ctgctggaca tcgacgagac cgagtaccac 1020
gccgacggcg gcaagggtgc catcaagtgg atggccctgg agtccatcct gcgcgcgcgc 1080
ttcaccaccc agtccgacgt gtggtcctac ggcgtagccg tgtgggagct gatgaccttc 1140
ggcgccaagc cctacgacgg catccccgcc cgcgagatcc ccgacctgct ggagaagggc 1200
gagcgccctgc cccagccccc catctgcacc atcgacgtgt acatgatcat ggtgaagtgc 1260
tggatgatcg actccgagtg ccgccccccg ttccgcgagc tgggtgtccga gttctcccgc 1320
atggcccgcg acccccagcg cttcgtggtg atccagaacg aggacctgac ccccggcacc 1380
ggctccaccg cccaccgccc ccaccgctcc tcctcccccc tgccccccgt gcgccccgcc 1440
ggcgccaacc tggagcgccc caagaccctg tcccccgga agaacggcgt ggtgaaggac 1500
gtgttcgcct tcggggggcg cgtggagaac cccgagtacc tgggcccggc ggtaccttgg 1560
tccttcggcg tggtgctgtg ggagatcgcc accctggccg agcagcccta ccagggcctg 1620
tccaacgagc aggtgctgcg cttcgtgatg gagggcgggc tgctggacaa gcccgacaac 1680
tgccccgaca tgctgttcga gctgatgcgc atgtgctggc agtacaaccc caagatgcgc 1740

- - - - -
ccctccttcc tggagcacaa ggccgagaaac ggccccggcg tgctggtgct gcgcgcctcc 1800
ttcgacgagc gccagcccta cgcccacatg aacggcgggc gcgccaacga gcgcgcctg 1860
cccgcgccg catag 1875

<210> 79
<211> 648
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 79
Met Ala Val Pro Met Leu Pro Arg Val Gly Cys Pro Ala Leu Pro Leu
1 5 10 15

Pro Pro Pro Pro Leu Leu Pro Leu Leu Pro Leu Leu Leu Leu Leu
20 25 30

Gly Ala Ser Gly Gly Gly Gly Gly Ala Arg Ala Glu Val Leu Phe Arg
35 40 45

Cys Pro Pro Cys Thr Pro Glu Arg Leu Ala Ala Cys Gly Pro Pro Pro
50 55 60

Val Ala Pro Pro Ala Ala Val Ala Ala Val Ala Gly Gly Ala Arg Met
65 70 75 80

Pro Cys Ala Glu Leu Val Arg Glu Pro Gly Cys Gly Cys Cys Ser Val
85 90 95

Cys Ala Arg Leu Glu Gly Glu Ala Cys Gly Val Tyr Thr Pro Arg Cys
100 105 110

Gly Gln Gly Leu Arg Cys Tyr Pro His Pro Gly Ser Glu Leu Pro Leu
115 120 125

Gln Ala Leu Val Met Gly Glu Gly Thr Cys Glu Lys Arg Arg Asp Ala
130 135 140

Glu Tyr Gly Ala Ser Pro Glu Gln Val Ala Asp Asn Gly Asp Asp His
145 150 155 160

Ser Glu Gly Gly Leu Val Glu Gln Leu Thr Met Arg Arg Leu Leu Gln
165 170 175

Glu Thr Glu Leu Val Glu Pro Leu Thr Pro Ser Gly Ala Met Pro Asn
180 185 190

Gln Ala Gln Met Arg Ile Leu Lys Glu Thr Glu Leu Arg Lys Val Lys
195 200 205

Val Leu Gly Ser Gly Ala Phe Gly Thr Val Tyr Lys Gly Ile Trp Ile
210 215 220

Pro Asp Gly Glu Asn Val Lys Ile Pro Val Ala Ile Lys Val Leu Arg
225 230 235 240

Glu Asn Thr Ser Pro Lys Ala Asn Lys Glu Ile Leu Asp Glu Ala Tyr
245 250 255

Val Met Ala Gly Val Gly Ser Pro Tyr Val Ser Arg Leu Leu Gly Ile
260 265 270

Cys Leu Thr Ser Thr Val Gln Leu Val Thr Gln Leu Met Pro Tyr Gly
275 280 285

Cys Leu Leu Asp His Val Arg Glu Asn Arg Gly Arg Leu Gly Ser Gln
290 295 300

Asp Leu Leu Asn Trp Cys Met Gln Ile Ala Lys Gly Met Ser Tyr Leu

305											310											315											320
Glu	Asp	Val	Arg	Leu	Val	His	Arg	Asp	Leu	Ala	Ala	Arg	Asn	Val	Leu																		
				325					330													335											
Val	Lys	Ser	Pro	Asn	His	Val	Lys	Ile	Thr	Asp	Phe	Gly	Leu	Ala	Arg																		
				340					345													350											
Leu	Leu	Asp	Ile	Asp	Glu	Thr	Glu	Tyr	His	Ala	Asp	Gly	Gly	Lys	Val																		
				355					360													365											
Pro	Ile	Lys	Trp	Met	Ala	Leu	Glu	Ser	Ile	Leu	Arg	Arg	Arg	Phe	Thr																		
				370					375													380											
His	Gln	Ser	Asp	Val	Trp	Ser	Tyr	Gly	Val	Thr	Val	Trp	Glu	Leu	Met																		
				385					390													395											
Thr	Phe	Gly	Ala	Lys	Pro	Tyr	Asp	Gly	Ile	Pro	Ala	Arg	Glu	Ile	Pro																		
				405					410													415											
Asp	Leu	Leu	Glu	Lys	Gly	Glu	Arg	Leu	Pro	Gln	Pro	Pro	Ile	Cys	Thr																		
				420					425													430											
Ile	Asp	Val	Tyr	Met	Ile	Met	Val	Lys	Cys	Trp	Met	Ile	Asp	Ser	Glu																		
				435					440													445											
Cys	Arg	Pro	Arg	Phe	Arg	Glu	Leu	Val	Ser	Glu	Phe	Ser	Arg	Met	Ala																		
				450					455													460											
Arg	Asp	Pro	Gln	Arg	Phe	Val	Val	Ile	Gln	Asn	Glu	Asp	Leu	Ala	Pro																		
				465					470													475											
Gly	Ala	Gly	Gly	Met	Val	His	His	Arg	His	Arg	Ser	Ser	Ser	Pro	Leu																		
				485					490													495											
Pro	Ala	Ala	Arg	Pro	Ala	Gly	Ala	Thr	Leu	Glu	Arg	Pro	Lys	Thr	Leu																		
				500					505													510											
Ser	Pro	Gly	Lys	Asn	Gly	Val	Val	Lys	Asp	Val	Phe	Ala	Phe	Gly	Gly																		
				515					520													525											
Ala	Val	Glu	Asn	Pro	Glu	Tyr	Leu	Gly	Arg	Pro	Val	Pro	Trp	Ser	Phe																		
				530					535													540											
Gly	Val	Val	Leu	Trp	Glu	Ile	Ala	Thr	Leu	Ala	Glu	Gln	Pro	Tyr	Gln																		
				545					550													555											
Gly	Leu	Ser	Asn	Glu	Gln	Val	Leu	Arg	Phe	Val	Met	Glu	Gly	Gly	Leu																		
				565					570													575											
Leu	Asp	Lys	Pro	Asp	Asn	Cys	Pro	Asp	Met	Leu	Phe	Glu	Leu	Met	Arg																		
				580					585													590											
Met	Cys	Trp	Gln	Tyr	Asn	Pro	Lys	Met	Arg	Pro	Ser	Phe	Leu	Glu	His																		
				595					600													605											
Lys	Ala	Glu	Asn	Gly	Pro	Gly	Pro	Gly	Val	Leu	Val	Leu	Arg	Ala	Ser																		
				610					615													620											
Phe	Asp	Glu	Arg	Gln	Pro	Tyr	Ala	His	Met	Asn	Gly	Gly	Arg	Lys	Asn																		
				625					630													635											
Glu	Arg	Ala	Leu	Pro	Ala	Ala	Ala																										
				645																													

<210> 80

<211> 626

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic polynucleotide or polypeptide

<400> 80

Met Ala Val Pro Met Leu Pro Arg Leu Gly Gly Pro Ala Leu Pro Leu

```

1      5      10      15
Leu Leu Pro Ser Leu Leu Leu Leu Leu Leu Gly Ala Gly Gly Cys
20      25      30
Gly Pro Gly Val Arg Ala Glu Val Leu Phe Arg Cys Pro Pro Cys Thr
35      40      45
Pro Glu Arg Leu Ala Ala Cys Gly Pro Pro Pro Asp Ala Pro Cys Ala
50      55      60
Glu Leu Val Arg Glu Pro Gly Cys Gly Cys Cys Ser Val Cys Ala Arg
65      70      75      80
Gln Glu Gly Glu Ala Cys Gly Val Tyr Ile Pro Arg Cys Ala Gln Thr
85      90      95
Leu Arg Cys Tyr Pro Asn Pro Gly Ser Glu Leu Pro Leu Lys Ala Leu
100     105     110
Val Thr Gly Ala Gly Thr Cys Glu Lys Arg Arg Val Gly Thr Thr Pro
115     120     125
Gln Gln Val Ala Asp Ser Asp Asp Asp His Ser Glu Gly Gly Leu Val
130     135     140
Glu Gln Leu Thr Met Arg Arg Leu Leu Gln Glu Thr Glu Leu Val Glu
145     150     155     160
Pro Leu Thr Pro Ser Gly Ala Val Pro Asn Gln Ala Gln Met Arg Ile
165     170     175
Leu Lys Glu Thr Glu Leu Arg Lys Leu Lys Val Leu Gly Ser Gly Ala
180     185     190
Phe Gly Thr Val Tyr Lys Gly Ile Trp Ile Pro Asp Gly Glu Asn Val
195     200     205
Lys Ile Pro Val Ala Ile Lys Val Leu Arg Glu Asn Thr Ser Pro Lys
210     215     220
Ala Asn Lys Glu Ile Leu Asp Glu Ala Tyr Val Met Ala Gly Val Gly
225     230     235     240
Ser Pro Tyr Val Ser Arg Leu Leu Gly Ile Cys Leu Thr Ser Thr Val
245     250     255
Gln Leu Val Thr Gln Leu Met Pro Tyr Gly Cys Leu Leu Asp His Val
260     265     270
Arg Glu His Arg Gly Arg Leu Gly Ser Gln Asp Leu Leu Asn Trp Cys
275     280     285
Val Gln Ile Ala Lys Gly Met Ser Tyr Leu Glu Glu Val Arg Leu Val
290     295     300
His Arg Asp Leu Ala Ala Arg Asn Val Leu Val Lys Ser Pro Asn His
305     310     315     320
Val Lys Ile Thr Asp Phe Gly Leu Ala Arg Leu Leu Asp Ile Asp Glu
325     330     335
Thr Glu Tyr His Ala Asp Gly Gly Lys Val Pro Ile Lys Trp Met Ala
340     345     350
Leu Glu Ser Ile Leu Arg Arg Arg Phe Thr His Gln Ser Asp Val Trp
355     360     365
Ser Tyr Gly Val Thr Val Trp Glu Leu Met Thr Phe Gly Ala Lys Pro
370     375     380
Tyr Asp Gly Ile Pro Ala Arg Glu Ile Pro Asp Leu Leu Glu Lys Gly
385     390     395     400
Glu Arg Leu Pro Gln Pro Pro Ile Cys Thr Ile Asp Val Tyr Met Ile
405     410     415

```

Met Val Lys Cys Trp Met Ile Asp Ser Glu Cys Arg Pro Arg Phe Arg
420 425 430

Glu Leu Val Ser Glu Phe Ser Arg Met Ala Arg Asp Pro Gln Arg Phe
435 440 445

Val Val Ile Gln Asn Glu Asp Leu Ala Leu Gly Thr Gly Ser Thr Ala
450 455 460

His Arg Arg His Arg Ser Ser Ser Pro Pro Pro Pro Ile Arg Pro Ala
465 470 475 480

Gly Ala Thr Leu Glu Arg Pro Lys Thr Leu Ser Pro Gly Lys Asn Gly
485 490 495

Val Val Lys Asp Val Phe Ala Phe Gly Gly Ala Val Glu Asn Pro Glu
500 505 510

Tyr Leu Gly Arg Pro Val Pro Trp Ser Phe Gly Val Val Leu Trp Glu
515 520 525

Ile Ala Thr Leu Ala Glu Gln Pro Tyr Gln Gly Leu Ser Asn Glu Gln
530 535 540

Val Leu Arg Phe Val Met Glu Gly Gly Leu Leu Asp Lys Pro Asp Asn
545 550 555 560

Cys Pro Asp Met Leu Phe Glu Leu Met Arg Met Cys Trp Gln Tyr Asn
565 570 575

Pro Lys Met Arg Pro Ser Phe Leu Glu His Lys Ala Glu Asn Gly Pro
580 585 590

Gly Pro Gly Val Leu Val Leu Arg Ala Ser Phe Asp Glu Arg Gln Pro
595 600 605

Tyr Ala His Met Asn Gly Gly Arg Ala Asn Glu Arg Ala Leu Pro Ala
610 615 620

Ala Ala
625

<210> 81

<211> 624

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic polynucleotide or polypeptide

<400> 81

Met Ala Val Pro Met Leu Pro Arg Leu Gly Gly Pro Ala Leu Pro Leu
1 5 10 15

Leu Leu Pro Ser Leu Leu Leu Leu Leu Leu Gly Ala Gly Gly Cys
20 25 30

Gly Pro Gly Val Arg Ala Glu Val Leu Phe Arg Cys Pro Pro Cys Thr
35 40 45

Pro Glu Arg Leu Ala Ala Cys Gly Pro Pro Pro Asp Ala Pro Cys Ala
50 55 60

Glu Leu Val Arg Glu Pro Gly Cys Gly Cys Cys Ser Val Cys Ala Arg
65 70 75 80

Gln Glu Gly Glu Ala Cys Gly Val Tyr Ile Pro Arg Cys Ala Gln Thr
85 90 95

Leu Arg Cys Tyr Pro Asn Pro Gly Ser Glu Leu Pro Leu Lys Ala Leu
100 105 110

Val Thr Gly Ala Gly Thr Cys Glu Lys Arg Arg Val Gly Ala Thr Pro
115 120 125

115	120	125
Gln Gln Val Ala Asp Ser Glu Asp Asp His Ser Glu Gly Gly Leu Val 130 135 140		
Glu Gln Leu Thr Met Arg Arg Leu Leu Gln Glu Thr Glu Leu Val Glu 145 150 155 160		
Pro Leu Thr Pro Ser Gly Ala Met Pro Asn Gln Ala Gln Met Arg Ile 165 170 175		
Leu Lys Glu Thr Glu Leu Arg Lys Val Lys Val Leu Gly Ser Gly Ala 180 185 190		
Phe Gly Thr Val Tyr Lys Gly Ile Trp Ile Pro Asp Gly Glu Asn Val 195 200 205		
Lys Ile Pro Val Ala Ile Lys Val Leu Arg Glu Asn Thr Ser Pro Lys 210 215 220		
Ala Asn Lys Glu Ile Leu Asp Glu Ala Tyr Val Met Ala Gly Val Gly 225 230 235 240		
Ser Pro Tyr Val Ser Arg Leu Leu Gly Ile Cys Leu Thr Ser Thr Val 245 250 255		
Gln Leu Val Thr Gln Leu Met Pro Tyr Gly Cys Leu Leu Asp His Val 260 265 270		
Arg Glu His Arg Gly Arg Leu Gly Ser Gln Asp Leu Leu Asn Trp Cys 275 280 285		
Val Gln Ile Ala Lys Gly Met Ser Tyr Leu Glu Asp Val Arg Leu Val 290 295 300		
His Arg Asp Leu Ala Ala Arg Asn Val Leu Val Lys Ser Pro Asn His 305 310 315 320		
Val Lys Ile Thr Asp Phe Gly Leu Ala Arg Leu Leu Asp Ile Asp Glu 325 330 335		
Thr Glu Tyr His Ala Asp Gly Gly Lys Val Pro Ile Lys Trp Met Ala 340 345 350		
Leu Glu Ser Ile Leu Arg Arg Arg Phe Thr His Gln Ser Asp Val Trp 355 360 365		
Ser Tyr Gly Val Thr Val Trp Glu Leu Met Thr Phe Gly Ala Lys Pro 370 375 380		
Tyr Asp Gly Ile Pro Ala Arg Glu Ile Pro Asp Leu Leu Glu Lys Gly 385 390 395 400		
Glu Arg Leu Pro Gln Pro Pro Ile Cys Thr Ile Asp Val Tyr Met Ile 405 410 415		
Met Val Lys Cys Trp Met Ile Asp Ser Glu Cys Arg Pro Arg Phe Arg 420 425 430		
Glu Leu Val Ser Glu Phe Ser Arg Met Ala Arg Asp Pro Gln Arg Phe 435 440 445		
Val Val Ile Gln Asn Glu Asp Leu Thr Pro Gly Thr Gly Ser Thr Ala 450 455 460		
His Arg Arg His Arg Ser Ser Ser Pro Leu Pro Pro Val Arg Pro Ala 465 470 475 480		
Gly Ala Thr Leu Glu Arg Pro Lys Thr Leu Ser Pro Gly Lys Asn Gly 485 490 495		
Val Val Lys Asp Val Phe Ala Phe Gly Gly Ala Val Glu Asn Pro Glu 500 505 510		
Tyr Leu Gly Arg Pro Val Pro Trp Ser Phe Gly Val Val Leu Trp Glu 515 520 525		

Ile Ala Thr Leu Ala Glu Gln Pro Tyr Gln Gly Leu Ser Asn Glu Gln
530 535 540

Val Leu Arg Phe Val Met Glu Gly Gly Leu Leu Asp Lys Pro Asp Asn
545 550 555 560

Cys Pro Asp Met Leu Phe Glu Leu Met Arg Met Cys Trp Gln Tyr Asn
565 570 575

Pro Lys Met Arg Pro Ser Phe Leu Glu His Lys Ala Glu Asn Gly Pro
580 585 590

Gly Val Leu Val Leu Arg Ala Ser Phe Asp Glu Arg Gln Pro Tyr Ala
595 600 605

His Met Asn Gly Gly Arg Ala Asn Glu Arg Ala Leu Pro Ala Ala Ala
610 615 620

<210> 82
<211> 89
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 82
Asp Ser Lys Thr Phe Leu Ser Arg His Ser Leu Asp Met Lys Phe Ser
1 5 10 15

Tyr Cys Asp Glu Arg Ile Thr Glu Leu Met Gly Tyr Glu Pro Glu Glu
20 25 30

Leu Leu Gly Arg Ser Ile Tyr Glu Tyr Tyr His Ala Leu Asp Ser Asp
35 40 45

His Leu Thr Lys Thr His His Asp Met Phe Thr Lys Gly Gln Val Thr
50 55 60

Thr Gly Gln Tyr Arg Met Leu Ala Lys Arg Gly Gly Tyr Val Trp Val
65 70 75 80

Glu Thr Gln Ala Thr Val Ile Tyr Asn
85

<210> 83
<211> 26
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 83
Ser Asp Asn Val Asn Lys Tyr Met Gly Leu Thr Gln Phe Glu Leu Thr
1 5 10 15

Gly His Ser Val Phe Asp Phe Thr His Pro
20 25

<210> 84
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 84
Gly Gly Tyr Val Trp Val Glu Thr Gln Ala Thr Val Ile Tyr Asn Thr
1 5 10 15

Lys Asn Ser Gln
20

<210> 85
<211> 38
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 85
Gly Cys Ala Phe Leu Ser Val Lys Lys Gln Phe Glu Glu Leu Thr Leu
1 5 10 15

Gly Glu Phe Leu Lys Leu Asp Arg Glu Arg Ala Lys Asn Lys Ile Ala
20 25 30

Lys Glu Thr Asn Asn Lys
35

<210> 86
<211> 114
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 86
ggctgcgcct tcctgtccgt gaagaagcag ttcgaggagc tgaccctggg cgagttcctg 60
aagctggacc gcgagcgcgc caagaacaag atcgccaagg agaccaacaa caag 114

<210> 87
<211> 88
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 87
Arg Ser Lys Glu Ser Glu Val Phe Tyr Glu Leu Ala His Gln Leu Pro
1 5 10 15

Leu Pro His Asn Val Ser Ser His Leu Asp Lys Ala Ser Val Met Arg
20 25 30

Leu Thr Ile Ser Tyr Leu Arg Val Arg Lys Leu Leu Asp Ala Gly Asp
35 40 45

Leu Asp Ile Glu Asp Met Lys Ala Gln Met Asn Cys Phe Tyr Leu Lys
50 55 60

Ala Leu Asp Gly Phe Val Met Val Leu Thr Asp Asp Gly Asp Met Ile
65 70 75 80

Tyr Ile Ser Asp Asn Val Asn Lys
85

<210> 88
<211> 267
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 88

cgctccaagg agtccgaggt gttctacgag ctggcccacc agctgccctt gccccacaac 60
gtgtcctccc acctggacaa ggcctccgtg atgcgcctga ccatctccta cctgcgcgtg 120
cgcaagctgc tggacgctgg cgacctggac atcgaggacg acatgaaggc ccagatgaac 180
tgcttctacc tgaaggccct ggacggcttc gtgatgggtg tgaccgacga cggcgacatg 240
atctacatct ccgacaacgt gaacaag 267

<210> 89
<211> 415
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polynucleotide or polypeptide

<400> 89
Met Ala Val Pro Met Leu Pro Arg Val Gly Cys Pro Ala Leu Pro Leu
1 5 10 15

Pro Pro Pro Pro Leu Leu Pro Leu Leu Pro Leu Leu Leu Leu Leu Leu
20 25 30

Gly Ala Ser Gly Gly Gly Gly Gly Ala Arg Ala Glu Val Leu Phe Arg
35 40 45

Cys Pro Pro Cys Thr Pro Glu Arg Leu Ala Ala Cys Gly Pro Pro Pro
50 55 60

Val Ala Pro Pro Ala Ala Val Ala Ala Val Ala Gly Gly Ala Arg Met
65 70 75 80

Pro Cys Ala Glu Leu Val Arg Glu Pro Gly Cys Gly Cys Cys Ser Val
85 90 95

Cys Ala Arg Leu Glu Gly Glu Ala Cys Gly Val Tyr Thr Pro Arg Cys
100 105 110

Gly Gln Gly Leu Arg Cys Tyr Pro His Pro Gly Ser Glu Leu Pro Leu
115 120 125

Gln Ala Leu Val Met Gly Glu Gly Thr Cys Glu Lys Arg Arg Asp Ala
130 135 140

Glu Tyr Gly Ala Ser Pro Glu Gln Val Ala Asp Asn Gly Asp Asp His
145 150 155 160

Ser Glu Gly Gly Leu Val Glu Gln Leu Gly Cys Ala Phe Leu Ser Val
165 170 175

Lys Lys Gln Phe Glu Glu Leu Thr Leu Gly Glu Phe Leu Lys Leu Asp
180 185 190

Arg Glu Arg Ala Lys Asn Lys Ile Ala Lys Glu Thr Asn Asn Lys Gly
195 200 205

Ser Glu Phe Arg Ser Lys Glu Ser Glu Val Phe Tyr Glu Leu Ala His
210 215 220

Gln Leu Pro Leu Pro His Asn Val Ser Ser His Leu Asp Lys Ala Ser
225 230 235 240

Val Met Arg Leu Thr Ile Ser Tyr Leu Arg Val Arg Lys Leu Leu Asp
245 250 255

Ala Gly Asp Leu Asp Ile Glu Asp Asp Met Lys Ala Gln Met Asn Cys
260 265 270

Phe Tyr Leu Lys Ala Leu Asp Gly Phe Val Met Val Leu Thr Asp Asp
275 280 285

Gly Asp Met Ile Tyr Ile Ser Asp Asn Val Asn Lys Tyr Arg Ser Gly
290 295 300

Arg Pro Val Pro Trp Ser Phe Gly Val Val Leu Trp Glu Ile Ala Thr
305 310 315 320

Leu Ala Glu Gln Pro Tyr Gln Gly Leu Ser Asn Glu Gln Val Leu Arg
325 330 335

Phe Val Met Glu Gly Gly Leu Leu Asp Lys Pro Asp Asn Cys Pro Asp
340 345 350

Met Leu Phe Glu Leu Met Arg Met Cys Trp Gln Tyr Asn Pro Lys Met
355 360 365

Arg Pro Ser Phe Leu Glu His Lys Ala Glu Asn Gly Pro Gly Pro Gly
370 375 380

Val Leu Val Leu Arg Ala Ser Phe Asp Glu Arg Gln Pro Tyr Ala His
385 390 395 400

Met Asn Gly Gly Arg Lys Asn Glu Arg Ala Leu Pro Ala Ala Ala
405 410 415

<210> 90

<211> 1248

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic polynucleotide or polypeptide

<400> 90

atggcgggtac caatgctgcc gagagtgggc tgccccgcgc tgcgctgcc gccgcgcgcg	60
ctgctgccgc tgctgccgct gctgctgctg ctactgggcg cgagtggcgg cggcggcggg	120
gcgcgcgcgg aggtgctgtt cgcgtgcccg ccctgcacac ccgagcgcct ggccgcctgc	180
gggccccgcg cggttgcgcc gcccgccgcg gtggccgcag tggcgcgagg cgcgcgcgcatg	240
ccatgcgcgg agctcgtccg ggagccgggc tgcggctgct gctcgggtgtg cgcgcggctg	300
gagggcgagg cgtgcggcgt ctacaccccg cgtgcgggcc aggggctgcg ctgctatccc	360
cacccgggct ccgagctgcc cctgcaggcg ctggtcatgg gcgagggcac ttgtgagaag	420
cgcggggacg ccgagtatgg cgcagcccg gagcaggttg cagacaatgg cgatgaccac	480
tcagaaggag gcctggtgga gcaattgggc tgcgccttcc tgtccgtgaa gaagcagttc	540
gaggagctga ccctgggcga gttcctgaag ctggaccgcg agcgcgcaa gaacaagatc	600
gccaaaggaga ccaacaacaa gggatccgaa ttccgctcca aggagtccga ggtgttotac	660
gagctggccc accagctgcc cctgccccac aacgtgtcct cccacctgga caaggcctcc	720
gtgatgcgcc tgaccatctc ctacctgcgc gtgcgcgaagc tgctggacgc tggcgacctg	780
gacatcgagg acgadatgaa ggcccagatg aactgcttct acctgaaggc cctggacggc	840
ttcgtgatgg tgctgaccga cgacggcgac atgatctaca tctccgacaa cgtgaacaag	900
tacagatccg gccggccggt accttggtcc tcgcgcgtgg tgctgtggga gatcgccacc	960
ctggccgagc agccctacca gggcctgtcc aacgagcagg tgctgcgctt cgtgatggag	1020
ggcggcctgc tggacaagcc cgacaactgc cccgacatgc tgttcgagct gatgcgcatg	1080
tgctggcagt acaaccccaa gatgcgcccc tccttcctgg agcacaaggc cgagaacggc	1140
cccgcccccg gcgtgctggt gctgcgcgcc tccttcgacg agcgccagcc ctacgcccac	1200
atgaacggag gccgcaagaa cgagcgcgcc ctgccgcggc ccgcatag	1248

<210> 91

<211> 5248

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic polynucleotide or polypeptide

<400> 91

tggccattgc atacgttgta tccatatcat aatatgtaca tttatatatgg ctcatgtcca	60
--	----

acattaccgc catgttgaca ttgattattg actagttatt aatagtaatc aattacgggg	120
tcattagttc atagcccata tatggagttc cgcgttacat aacttacggt aaatggcccg	180
cctggctgac cgcccaacga ccccgccca ttgacgtcaa taatgacgta tgttcccata	240
gtaacgccaa tagggacttt ccattgacgt caatgggtgg agtatttacg gtaaactgcc	300
caottggcag tacatcaagt gtatcatatg ccaagtacgc cccctattga cgtcaatgac	360
ggtaaatggc ccgcctggca ttatgcccag tacatgacct tatgggactt tcctacttgg	420
cagtacatct acgtattagt catcgctatt accatgggtga tgcggttttg gcagtacatc	480
aatgggcgtg gatagcgggt tgactcacgg ggatttccaa gtctccacco cattgacgtc	540
aatgggagtt tgttttggca ccaaaatcaa cgggactttc caaaatgtcg taacaactcc	600
gccccattga cgcaaatggg cggtaggcgt gtacgggtgg aggtctatat aagcagagct	660
cgtttagtga accgtcagat cgcctggaga cgccatccac gctgttttga cctccataga	720
agacacccgg accgatccag cctccgcggc cgggaacggt gcattggaac gcggattccc	780
cgtgccaaga gtgacgtaag taccgcctat agactctata ggcacacccc tttggctctt	840
atgcatgcta tactgttttt ggcttggggc ctatacacco ccgcttcctt atgctatagg	900
tgatggtata gcttagccta taggtgtggg ttattgacca ttattgacca ctccaacggt	960
ggagggcagt gtagtctgag cagtactcgt tgctgccgcg cgcgccacca gacataatag	1020
ctgacagact aacagactgt tcctttccat gggctctttc tgcagtcacc gtcgtcgacg	1080
gtatcgataa gcttgatata gaattgccgc caccatggcg gtaccaatgc tgcgagagt	1140
gggctgcccc gcgctgccgc tgccgcgcgc gccgctgctg ccgctgctgc cgtgctgct	1200
gctgctactg ggcgcgagtg gcggcggcgg cggggcgcgc gcggaggtgc tgttcgctg	1260
cccgccctgc acaccgagc gcctggccgc ctgcggggcc ccgccggttg cgcgcgccgc	1320
cgcggtggcc gcagtggccg gaggcgcgcc catgccatgc gcggagctcg tccgggagcc	1380
gggctgcggc tgctgctcgg tgtgcgcccg gctggagggc gaggcgtgcg gcgtctacac	1440
cccgcgctgc gcccaggggc tgcgctgcta tccccaccg ggctccgagc tgccccctgca	1500
ggcgctggtc atgggcgagg gcacttgtga gaagcgcccg gacgccgagt atggcgccag	1560
cccggagcag gttgcagaca atggcgatga cactcagaa ggaggcctgg tggagcaatt	1620
gggctgcgcc ttcctgtccg tgaagaagca gttcgaggag ctgaccctgg gcgagttcct	1680
gaagctggac cgcgagcgcg ccaagaacaa gatcgccaag gagaccaaca acaagggatc	1740
cgaattccgc tccaaggagt ccgaggtggt ctacgagctg gccaccagc tgcccctgcc	1800
ccacaacgtg tcctcccacc tggacaaggc ctccgtgatg cgcctgacca tctcctacct	1860
gcgcgtgcgc aagctgctgg acgctggcga cctggacatc gaggacgaca tgaaggccca	1920
gatgaactgc ttctacctga aggccctgga cggcttcgtg atggtgctga ccgacgacgg	1980
cgacatgata tacatctccg acaacgtgaa caagtacaga tccggccggc cggtagcttg	2040
gtccttcggc gtggtgctgt gggagatcgc caccctggcc gagcagccct accaggccct	2100
gtccaaacgag caggtgctgc gcttcgtgat ggaggcggc ctgctggaca agcccgacaa	2160
ctgccccgac atgctgttcg agctgatgcg catgtgctgg cagtacaacc ccaagatgcg	2220
cccctccttc ctggagcaca aggcgcgaaa cggccccggc ccgcgctgc tgggtgctgcg	2280
cgcctccttc gacgagcgc agccctacgc ccacatgaac ggaggccgca agaacgagcg	2340
cgcctgccc gcggccgcat agtgatagat ctttttcct ctgccaaaa ttatggggac	2400
atcatgaagc cccttgagca tctgacttct ggctaataaa ggaaatttat tttcattgca	2460
atagtgtgtt ggaatttttt gtgtctctca ctcggaagga catatgggag ggcaaatcat	2520
ttaaaacatc agaatgagta tttggtttag agtttggcaa catatgccca ttcttcgct	2580
tcctcgctca ctgactcgt gcgctcggc gttcggctgc ggcgagcgg atcagctcac	2640
tcaaaggcgg taatacgggt atccacagaa tcaggggata acgcaggaaa gaacatgtga	2700
gcaaaaggcc agcaaaaggc caggaaacgt aaaaaggccg cgttgctggc gtttttccat	2760
aggctccgc cccctgacga gcacacaaa aatcgacgct caagtcagag gtggcgaaac	2820
ccgacaggac tataaagata ccaggcgttt cccctggaa gctccctcgt gcgctctcct	2880
gttccgacct tgccgcttac cggatacctg tccgcctttc tcccttcggg aagcgtggcg	2940
ctttctcata gctcacgctg taggtatctc agttcgggtg aggtcgttcg ctccaagctg	3000
ggctgtgtgc acgaacccc cgttcagccc gaccgctgcg ccttatccgg taactatcgt	3060

cttgagtcca acccggtaag acacgactta tcgccactgg cagcagccac tggtaacagg	3120
attagcagag cgaggtatgt aggcgggtgct acagagttct tgaagtgggtg gcctaactac	3180
ggctacacta gaagaacagt atttggatc tcgcgtctgc tgaagccagt taccttcgga	3240
aaaagagttg gtagctcttg atccggcaaa caaaccaccg ctggtagcgg tggttttttt	3300
gtttgcaagc agcagattac gcgcagaaaa aaaggatctc aagaagatcc tttgatcttt	3360
tctacgggggt ctgacgctca gtggaacgaa aactcacgtt aagggatctt ggtcatgaga	3420
ttatcaaaaa ggatcttcac ctagatcctt ttaaattaaa aatgaagttt taaatcaatc	3480
taaagtatat atgagtaaac ttggtctgac agttaccaat gcttaatcag tgaggcacct	3540
atctcagcga tctgtctatt tcgttcatcc atagttgcct gactcggggg gggggggcgc	3600
tgaggctctgc ctcgtgaaga aggtgttgct gactcatacc aggcctgaat cgcctcatca	3660
tccagccaga aagtgaggga gccacggttg atgagagctt tgttgtaggt ggaccagttg	3720
gtgattttga acttttgctt tgccacggaa cggctctgct tgtcgggaag atgcgtgac	3780
tgatccttca actcagcaaa agttcgattt attcaacaaa gccgcctgcc cgtcaagtca	3840
gcgtaatgct ctgccagtgt tacaaccaat taaccaattc tgattagaaa aactcatcga	3900
gcatcaaatg aaactgcaat ttattcatat caggattatc aataccatat ttttgaaaaa	3960
gccgtttctg taatgaagga gaaaactcac cgaggcagtt ccataggatg gcaagatcct	4020
ggtatcggtc tgcgattccg actcgtccaa catcaataca acctattaat ttccctcgt	4080
caaaaataag gttatcaagt gagaaatcac catgagtgac gactgaatcc ggtgagaatg	4140
gcaaaagctt atgcatttct ttccagactt gttcaacagg ccagccatta cgtcgtcat	4200
caaaatcact cgcaccaacc aaaccgttat tcattcgtga ttgcgcctga gcgagacgaa	4260
atacgcgac cgtgttaaaa ggacaattac aaacaggaat cgaatgcaac cggcgcagga	4320
acactgccag cgcaccaaca atattttcac ctgaatcagg atattcttct aataacctgga	4380
atgctgtttt cccggggatc gcagtgggtga gtaaccatgc atcatcagga gtacggataa	4440
aatgcttgat ggtcgggaaga ggcataaatt ccgtcagcca gtttagtctg accatctcat	4500
ctgtaacatc attggcaacg ctacctttgc catgtttcag aaacaactct ggcgcacg	4560
gcttcccata caatcgatag attgtgcac ctgattgcc gacattatcg cgagccatt	4620
tatacccata taaatcagca tccatgttgg aatttaatcg cggcctcgag caagacgttt	4680
cccgttgaat atggctcata acacccttg tattactgtt tatgtaagca gacagtttta	4740
ttgttcatga tgatatattt ttatcttgtg caatgtaaca tcagagattt tgagacacaa	4800
cgtggctttc ccccccccc cattattgaa gcatttatca gggttattgt ctcatgagcg	4860
gatacatatt tgaatgtatt tagaaaaata aacaatatag ggttcgcgc acatttccc	4920
gaaaagtgcc acctgacgtc taagaaacca ttattatcat gacattaacc tataaaaata	4980
ggcgatcac gaggccttt cgtctcgcgc gtttcgggtga tgacggtgaa aacctctgac	5040
acatgcagct cccggagacg gtcacagctt gtctgtaagc ggatgccggg agcagacaag	5100
cccgtcaggg cgcgtcagcg ggtgttggcg ggtgtcgggg ctggcttaac tatcggcat	5160
cagagcagat tgtactgaga gtgcaccata tgcggtgtga aataccgcac agatgcgtaa	5220
ggagaaaata ccgcatcaga ttggctat	5248

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- [WO0102556A2 \[0003\]](#)
- [WO0050590A1 \[0004\]](#)
- [WO2008073660A1 \[0005\]](#)
- [US2009170767A1 \[0006\]](#)
- [US2012135033A1 \[0007\]](#)
- [US2007083334A1 \[0008\]](#)
- [US2012128584A1 \[0009\]](#)
- [US2013034566A1 \[0010\]](#)
- [US2010150918A1 \[0011\]](#)
- [US2011008347A1 \[0012\]](#)
- [US5593972A \[0208\]](#)
- [US5962428A \[0208\]](#)
- [WO94016737A \[0208\]](#)
- [US5644048A \[0272\]](#)
- [US5386023A \[0272\]](#)
- [US5637684A \[0272\]](#)
- [US5602240A \[0272\]](#)
- [US5216141A \[0272\]](#)
- [US4469663A \[0272\]](#)
- [US5235033A \[0272\]](#)
- [US5034506A \[0272\]](#)
- [WO9400153A \[0282\] \[0291\]](#)
- [WO9633739A \[0282\] \[0290\] \[0291\]](#)
- [WO9517210A \[0282\] \[0282\]](#)
- [WO9602555A \[0282\]](#)
- [GB2122204B \[0285\]](#)
- [WO9421292A \[0286\]](#)
- [WO9843670A2 \[0286\]](#)
- [GB2220211A \[0286\]](#)
- [US4912094A \[0286\]](#)
- [EP0549074B1 \[0286\]](#)
- [US5057540A \[0289\] \[0290\]](#)
- [EP0362279B1 \[0289\] \[0290\]](#)
- [EP0109942B1 \[0290\]](#)
- [WO9611711A \[0290\]](#)
- [US4897268A \[0318\]](#)
- [US5075109A \[0318\]](#)
- [US5928647A \[0318\]](#)
- [US5611126A \[0318\]](#)
- [US5820883A \[0318\]](#)
- [US5853763A \[0318\]](#)
- [US5814344A \[0318\]](#)
- [US5942252A \[0318\]](#)
- [US4789734A \[0319\]](#)
- [US4906474A \[0320\]](#)
- [US4925673A \[0320\]](#)
- [US3625214A \[0320\]](#)
- [US5023252A \[0339\]](#)
- [US4992445A \[0339\]](#)
- [US5001139A \[0339\]](#)
- [US5376359A \[0359\]](#)
- [US5190029A \[0359\]](#)
- [US5776434A \[0359\]](#)
- [US4886499A \[0382\]](#)
- [US5190521A \[0382\]](#)
- [US5328483A \[0382\]](#)
- [US5527288A \[0382\]](#)
- [US4270537A \[0382\]](#)
- [US5015235A \[0382\]](#)

- [US5141496A \[0382\]](#)
- [US5417662A \[0382\]](#)
- [WO9934850A \[0382\]](#)
- [US5480381A \[0382\]](#)
- [US5599302A \[0382\]](#)
- [US5334144A \[0382\]](#)
- [US5993412A \[0382\]](#)
- [US5649912A \[0382\]](#)
- [US5569189A \[0382\]](#)
- [US5704911A \[0382\]](#)
- [US5383651A \[0382\]](#)
- [US5693397A \[0382\]](#)
- [US5466220A \[0382\]](#)
- [US5339163A \[0382\]](#)
- [US5312335A \[0382\]](#)
- [US5503627A \[0382\]](#)
- [US5064413A \[0382\]](#)
- [US5520A \[0382\]](#)
- [US639A \[0382\]](#)
- [US4596556A \[0382\]](#)
- [US4790824A \[0382\]](#)
- [US4941860A \[0382\]](#)
- [US4940460A \[0382\]](#)
- [WC9737705A \[0382\]](#)
- [WC9713537A \[0382\]](#)
- [US61972176B \[0567\]](#)

Non-patent literature cited in the description

- **VIEHL et al.**Breast Cancer Res Treat, 2008, vol. 109, 305- [\[0013\]](#)
- **SEON et al.**Curr Drug Deliv, 2011, vol. 8, 1 [\[0014\]](#)
- **BEAUCAGE et al.**Tetrahedron, 1993, vol. 49, 101925- [\[0272\]](#)
- **LETSINGER**J. Org. Chem., 1970, vol. 35, 3800- [\[0272\]](#)
- **SPRINZL et al.**Eur. J. Biochem., 1977, vol. 81, 579- [\[0272\]](#)
- **LETSINGER et al.**Nucl. Acids Res., 1986, vol. 14, 3487- [\[0272\]](#)
- **SAWAI et al.**Chem. Lett., 1984, vol. 805, [\[0272\]](#)
- **LETSINGER et al.**J. Am. Chem. Soc., 1988, vol. 110, 4470- [\[0272\]](#) [\[0272\]](#)
- **PAUWELS et al.**Chemica Scripta, 1986, vol. 26, 141- [\[0272\]](#)
- **MAG et al.**Nucleic Acids Res., 1991, vol. 19, 1437- [\[0272\]](#)
- **BRIU et al.**J. Am. Chem. Soc., 1989, vol. 111, 2321- [\[0272\]](#)
- **ECKSTEIN**Oligonucleotides and Analogues: A Practical ApproachOxford University Press [\[0272\]](#)
- **EGHOLM**J. Am. Chem. Soc., 1992, vol. 114, 1895- [\[0272\]](#)
- **MEIER et al.**Chem. Int. Ed. Engl., 1992, vol. 31, 1008- [\[0272\]](#)
- **NIELSEN**Nature, 1993, vol. 365, 566- [\[0272\]](#)
- **CARLSSON et al.**Nature, 1996, vol. 380, 207- [\[0272\]](#)
- **KOSHKIN et al.**J. Am. Chem. Soc., 1998, vol. 120, 13252-3 [\[0272\]](#)
- **DENPCY et al.**Proc. Natl. Acad. Sci. USA, 1995, vol. 92, 6097- [\[0272\]](#)
- **KIEDROWSHI et al.**Angew. Chem. Intl. Ed. English, 1991, vol. 30, 423- [\[0272\]](#)
- **LETSINGER et al.**Nucleoside & Nucleotide, 1994, vol. 13, 1597- [\[0272\]](#)
- Carbohydrate Modifications in Antisense ResearchASC Symposium Seriesvol. 580, [\[0272\]](#) [\[0272\]](#)
- **MESMAEKER et al.**Bioorganic & Medicinal Chem. Lett., 1994, vol. 4, 395- [\[0272\]](#)
- **JEFFS et al.**J. Biomolecular NMR, 1994, vol. 34, 17- [\[0272\]](#)
- Tetrahedron Lett., 1996, vol. 37, 743- [\[0272\]](#)
- **JENKINS et al.**Chem. Soc. Rev., 1995, 169-176 [\[0272\]](#)
- **RAWLS, CE NEWS**Locked nucleic acids, 1997, 35- [\[0272\]](#)

- **RIBI et al.** Immunology and hnmunopharmacology of bacterial endotoxins Plenum Publ. Corp. 19860000407-419 [0284]
- **HILGERS et al.** Int. ArchAllergy. Immunol, 1986, vol. 79, 4392-6 [0286]
- **HILGERS et al.** Immunology, 1987, vol. 60, 1141-6 [0286]
- **LACAILLE-DUBOIS, MWAGNER H.** A review of the biological and pharmacological activities of saponins Phytomedicine, 1996, vol. 2, 363-386 [0288]
- Saponins as vaccine adjuvants CritRev TherDrug Carrier Syst 19960000vol. 12, 55- [0289]
- **BOMFORD et al.** Vaccine, 1992, vol. 10, 9572-577 [0290]
- **ANSEL et al.** Pharmaceutical Dosage Forms and Drug Delivery Systems Lippencott Williams & Wilkins 19990000 [0310] [0370]
- Surfactant Systems Chapman and Hall 19830000 [0311]
- Merck Index Entry 6858 Merck & Co. Inc. 1162- [0311]
- Merck Index Entry 7742 Merck & Co. Inc. 1308- [0311]
- CHEMICAL ABSTRACTS, 9002-92-0 [0313]
- Merck index Merck & Co. Inc. [0313]
- Liposomes **G. GREGORIADIS** Drug Carriers in Biology and Medicine Academic Press 197900002- [0319]
- **JEINTIPS**, 1998, vol. 19, 155-157 [0320]
- Remington "The Science and Practice of Pharmacy Lippincott Williams & Wilkins [0328]
- Remington's Pharmaceutical Sciences Mack Publishing Co. [0335]
- Dermatological Formulations: Percutaneous absorption Marcel Dekker Incl 19830000 [0337]
- **BANGHAM et al.** J. Mol. Biol., 1965, vol. 23, 238-252 [0345]
- **SZOKA et al.** Proc. Natl. Acad. Sci. USA, 1978, vol. 75, 4194-4198 [0345]
- Novel gastroretentive dosage forms: evaluation of gastroretentivity and its effect on levodopa in humans **KLAUSNER, E. A. LAVY, EBARTA, MCSEREPES, E. FRIEDMAN, MHOFFMAN, A** Pharm. Res. 20030000vol. 20, 1466-73 [0351]
- **HOFFMAN, A. STEPENSKY, D. LAVY, EEYAL, S. KLAUSNER, E. FRIEDMAN, M.** Pharmacokinetic and pharmacodynamic aspects of gastroretentive dosage forms Int. J. Pharm., 2004, vol. 11, 141-53 [0351]
- **STREUBEL, A. SIEPMANN, JBODMEIER, R.** Gastroretentive drug delivery systems Expert Opin. Drug Deliver., 2006, vol. 3, 217-3 [0351]
- **CHAVANPATIL, M. D. JAIN, P. CHAUDHARI, S. SHEAR, R. VAVIA, P. R** Novel sustained release, swellable and bioadhesive gastroretentive drug delivery system for ofloxacin Int. J. Pharm., 2006, [0351]
- Remington's Pharmaceutical Sciences Mack Publishing Co. 19900000 [0384]

PATENTKRAV

1. Sammensætning omfattende en nukleotidsekvens, der koder for et fusionspeptid af 5 epitoper, hvor nukleotidsekvensen koder for en
5 aminosyresekvens, der har mindst 90 % sekvensidentitet med aminosyresekvensen ifølge SEQ ID NO 39, hvor sammensætningen er virksom til at frembringe et immunrespons hos et individ.

2. Sammensætning ifølge krav 1, der omfatter et plasmid omfattende en nukleotidsekvens, hvor sekvensen koder for et polypeptid med mindst 90 %
10 sekvensidentitet med aminosyresekvensen ifølge SEQ ID NO: 39.

3. Sammensætning ifølge krav 1, der omfatter et plasmid omfattende en nukleotidsekvens, hvor sekvensen koder for et polypeptid med aminosyresekvensen ifølge SEQ ID NO: 39.

4. Sammensætning ifølge et hvilket som helst af kravene 2 eller 3, hvor
15 plasmidet omfatter et pUMVC3-plasmidskelet.

5. Sammensætning ifølge et hvilket som helst af kravene 1-4, hvor sammensætningen endvidere omfatter en farmaceutisk bærer, et hjælpestof eller en kombination deraf.

6. Sammensætning ifølge krav 5, hvor hjælpestoffet er GM-CSF.

20 7. Sammensætning ifølge et hvilket som helst af kravene 1-6 til anvendelse i en fremgangsmåde til forebyggelse eller behandling af brystcancer hos et individ.

8. Sammensætning ifølge et hvilket som helst af kravene 1-6 til anvendelse i en fremgangsmåde til forebyggelse eller behandling af ovariecancer hos et individ.

25 9. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 7 eller 8, hvor fremgangsmåden omfatter indgivelse af sammensætningen til individet ved subkutan injektion, intradermal injektion, intramuskulær injektion, intravaskulær injektion, topisk påføring eller inhalation.

10. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 7-9, hvor individet er udvalgt fra gruppen bestående af et menneske med brystcancer eller ovariecancer, en mus med brystcancer eller ovariecancer og en rotte med brystcancer eller ovariecancer, eller er udvalgt fra gruppen bestående af
5 et menneske uden brystcancer eller ovariecancer, en mus uden brystcancer eller ovariecancer og en rotte uden brystcancer eller ovariecancer.

11. Sammensætning ifølge krav 1, hvor immunresponsen er et Type I-immunrespons.

12. Sammensætning ifølge krav 11, hvor:

- 10 a) immunresponsen er kendetegnet ved et forhold mellem Type I-cytokinproduktion og Type II-cytokinproduktion, der er større end 1; eller
- b) immunresponsen er kendetegnet ved et forhold mellem Type I-cytokinproduktion og Type II-cytokinproduktion, der er mindre end 1.

13. Sammensætning ifølge krav 11, hvor:

- 15 a) immunresponsen er kendetegnet ved et forhold mellem IFN γ -produktion og IL-10-produktion, der er større end 1; eller
- b) immunresponsen er kendetegnet ved et forhold mellem IFN γ -produktion og IL-10-produktion, der er mindre end 1.

DRAWINGS





FIG. 1







FIG. 2

Subject Characteristics			
Stage I/II breast cancer prior to primary Surgery	Breast Cancer (n=124)	Controls (n=100)	
Characteristic	No. of Patients %	No. of Patients %	
Age, years			
Median (Range)	52 (33-89)	51.5 (26-82)	
Gender			
Female	121	98	99
Male	3	2	1
Disease Status			
ER Positive	78	63	
HER2 Positive	31	25	
TNBC	15	12	




FIG. 3




FIG. 4

Subject Characteristics			
	Breast Cancer (n=21)	Controls (n=20)	
Characteristic	No. of Patients %	No. of Patients %	
Age, years			
Median (Range)	63 (49-87)	38(29-65)	
Stage of Breast Cancer at Enrollment			
DCIS	1 4		
Stage I	9 43		
Stage II	3 14		
Stage IIa	2 10		
Stage IIb	2 10		
Stage I-II undefined	1 4		
Stage IIIa	1 4		
Unknown stage	2 10		
HLA A2			
Positive	3 14	10 50	
Negative	9 43	8 40	
Unknown	9 43	2 10	
Gender			
Female	21 100	13 65	
Male	0 0	6 30	
Unknown	0 0	1 5	




FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9




FIG. 10






FIG. 11

Immunogenicity



Acute and Chronic Toxicity



Treatment Groups (n=5-6 each)
A= Adjuvant only (CFA/IFA)
B= Vector (empty plasmid)
C= Peptide vaccine
D= Single antigen plasmid vaccine

Efficacy





FIG. 12

DTH in TgMMTVneu



DTH in FVB






FIG. 13



Extended epitopes between 32 and 80 aa in length

FIG. 14




FIG. 15A




FIG. 15B




FIG. 15C




FIG. 16




FIG. 17




FIG. 18




FIG. 19




FIG. 20




FIG. 21




FIG. 22




FIG. 23




FIG. 24






FIG. 25




FIG. 26




FIG. 27




FIG. 28




FIG. 29





FIG. 30




FIG. 31




FIG. 32




FIG. 33




FIG. 34




FIG. 35




FIG. 36

Patient	Antigen	Th1			Th17
		IFN-g	TNF-a	IL-1b	IL-17
9	ICD				
10	ICD				
11	ICD				
12	ICD				
14	ICD				
15	ICD				
16	ICD				
17	ICD				

FIG. 37

Antigen Combinations	All BrCA (n=124)	ER+BrCA (n=78)
HIF1a, Survivin	AUC: 0.580 CI: 0.505-0.655 p=0.04	ND
HIF1a, CDC25b	ND	AUC: 0.611 CI: 0.527-0.695 p=0.011
HIF1a, Survivin CDC25b	AUC: 0.584 CI: 0.509-0.659 p=0.03	AUC: 0.621 CI: 0.538-0.705 p=0.005
HIF1a, Survivin CDC25b, c-met	AUC: 0.575 CI: 0.499-0.650 p=0.054	AUC: 0.607 CI: 0.523-0.691 p=0.014
HIF1a, Survivin CDC25b, c-met, MDM2	AUC: 0.572 CI: 0.496-0.647 p=0.085	AUC: 0.610 CI: 0.526-0.693 p=0.012

FIG. 38

PROTEIN	STEM CELL	EMT	POOR PROGNOSIS	HOMOLOGY TO MOUSE
CD105				72%
Cripto				67%
Cyclin B1				82%
GLI1				85%
HIF-1α				87%
JAG-1				96%
c-met				88%
NRP2				94%
PRAME				50%
PRL3				96%
SATB1				97%
IGF-1R				95%

FIG. 39




FIG. 40




FIG. 41




FIG. 42A




FIG. 42B




FIG. 42C




FIG. 42D




FIG. 43A




FIG. 43B




FIG. 44A




FIG. 44C




FIG. 44B




FIG. 44D